

ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE

Field of the invention

5 The present invention relates to compounds and their use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response, and to related compositions, methods and intermediate compounds.

Background of the invention

10 Chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis, psoriasis, Crohn's disease, ulcerative colitis, uveitis and chronic obstructive pulmonary disease (COPD) represent a significant burden to society because of life-long debilitating illness, increased mortality and high costs for therapy and care (Straub R.H. and
15 Schradin C., 2016). Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widespread medicines employed for treating inflammatory disorders, but these agents do not prevent the progression of the inflammation and only treat the accompanying symptoms. Glucocorticoids are powerful anti-inflammatory agents, making them emergency treatments for acute inflammatory flares, but given longer term these medicines give rise to a plethora of unwanted side-effects and
20 may also be subject to resistance (Straub R. H. and Cutolo M., 2016). Thus, considerable unmet medical need still exists for the treatment of inflammatory disorders and extensive efforts to discover new medicines to alleviate the burden of these diseases is ongoing (Hanke T. *et al.*, 2016).

25 Dimethyl fumarate (DMF), a diester of the citric acid cycle (CAC) intermediate fumaric acid, is utilised as an oral therapy for treating psoriasis (Brück J. *et al.*, 2018) and multiple sclerosis (Mills E. A. *et al.*, 2018). Importantly, following oral administration, none of this agent is detected in plasma (Dibbert S. *et al.*, 2013), the only drug-related compounds observed being the hydrolysis product monomethyl fumarate (MMF) and glutathione (GSH) conjugates of both the parent (DMF)
30 and metabolite (MMF). DMF's mechanism of action is complex and controversial. This compound's efficacy has been attributed to a multiplicity of different phenomena involving covalent modification of proteins and the conversion of "prodrug" DMF to MMF. In particular, the following pathways have been highlighted as being of relevance to DMF's anti-inflammatory effects: 1) activation of the anti-oxidant, anti-inflammatory, nuclear factor (erythroid-derived 2)-
35 like 2 (NRF2) pathway as a consequence of reaction of the electrophilic α,β -unsaturated ester moiety with nucleophilic cysteine residues on kelch-like ECH-associated protein 1 (KEAP1) (Brennan M. S. *et al.*, 2015); 2) induction of activating transcription factor 3 (ATF3), leading to

suppression of pro-inflammatory cytokines interleukin (IL)-6 and IL-8 (Müller S. *et al.*, 2017); 3) inactivation of the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) through succination of its catalytic cysteine residue with a Michael accepting unsaturated ester (Kornberg M. D. *et al.*, 2018; Angiari S. and O'Neill L. A., 2018); 4) inhibition of nuclear factor-kappaB (NF- κ B)-driven cytokine production (Gillard G. O. *et al.*, 2015); 5) preventing the association of PKC θ with the costimulatory receptor CD28 to reduce the production of IL-2 and block T-cell activation (Blewett M. M. *et al.*, 2016); 6) reaction of the electrophilic α,β -unsaturated ester with the nucleophilic thiol group of anti-oxidant GSH, impacting cellular responses to oxidative stress (Lehmann J. C. U. *et al.*, 2007); 7) agonism of the hydroxycarboxylic acid receptor 2 (HCA2) by the MMF generated *in vivo* through DMF hydrolysis (von Glehn F. *et al.*, 2018); 8) allosteric covalent inhibition of the p90 ribosomal S6 kinases (Andersen J. L. *et al.*, 2018); 9) inhibition of the expression and function of hypoxia-inducible factor-1 α (HIF-1 α) and its target genes, such as IL-8 (Zhao G. *et al.*, 2014); and 10) inhibition of Toll-like receptor (TLR)-induced M1 and K63 ubiquitin chain formation (McGuire V. A. *et al.*, 2016). In general, with the exception of HCA2 agonism (Tang H. *et al.*, 2008), membrane permeable diester DMF tends to exhibit much more profound biological effects in cells compared to its monoester counterpart MMF. However, the lack of systemic exposure of DMF *in vivo* has led some researchers to assert that MMF is, in fact, the principal active component following oral DMF administration (Mrowietz U. *et al.*, 2018). As such, it is evident that some of the profound biology exerted by DMF in cells is lost because of hydrolysis *in vivo* to MMF.

Recently, it has been discovered that, during inflammatory macrophage activation, the CAC becomes anaplerotic and is diverted such that the unsaturated diacid itaconic acid, "itaconate", is generated (Murphy M. P. and O'Neill L. A. J., 2018; O'Neill L. A. J. and Artyomov M. N., 2019; Yu X.-H. *et al.*, 2019). Instead of being hydrated to isocitrate by aconitate hydratase, the CAC intermediate aconitate is decarboxylated by the protein product of immune-responsive gene 1 (IRG1), one of the most highly upregulated genes in macrophages under proinflammatory conditions, subsequently named aconitate decarboxylase 1, to produce itaconic acid (Michelucci A. *et al.*, 2013). This unsaturated diacid is an inhibitor of the bacterial enzyme isocitrate lyase and, as such, it exerts anti-bacterial activity. In addition, itaconic acid has been shown to inhibit the CAC enzyme succinate dehydrogenase (SDH) (Ackermann *et al.*, 1949), leading accordingly to succinate accumulation (Cordes T. *et al.*, 2016). By inhibiting SDH, an enzyme critical for the inflammatory response (E. L. Mills *et al.*, 2016), itaconate ameliorates inflammation *in vitro* and *in vivo* during macrophage activation and ischemia-reperfusion injury (Lampropoulou V. *et al.*, 2016).

Like fumaric acid, itaconic acid is an α,β -unsaturated carboxylic acid. As such, it is a Michael

acceptor which induces a global electrophilic stress response. In this regard, the itaconic acid diester dimethyl itaconate (DMI), like DMF, produces an anti-inflammatory response, reducing the expression levels of pro-inflammatory cytokines IL-1 β , IL-6, IL-12 and IL-18 in lipopolysaccharide (LPS)-stimulated bone marrow-derived macrophages (WO2017/142855A1, incorporated herein
5 by reference). This response appears to be mediated, in part, by NRF2 activation, via alkylation of KEAP1 cysteine residues by the electrophilic α,β -unsaturated ester moiety (Mills E. L. *et al.*, 2018), which enhances the expression of downstream genes with anti-oxidant and anti-inflammatory capacities. Nevertheless, not all of the pronounced immunoregulatory effects engendered by DMI can be attributed to NRF2 activation. In particular, the modulation of I κ B ζ by
10 DMI is independent of NRF2 and is mediated via upregulation of ATF3, a global negative regulator of immune activation that downregulates various cytokines, such as IL-6 (Bambouskova M. *et al.*, 2018). Moreover, by inhibiting I κ B ζ protein production, DMI ameliorates IL-17-mediated pathologies, highlighting the therapeutic potential of this regulatory pathway (WO2019/036509A1, incorporated herein by reference). Further highlighting its pharmacologic potential, DMI has
15 recently been reported to 1) demonstrate a protective effect on cerebral ischemia/reperfusion injury, thereby offering potential for the treatment of ischemic stroke (Zhang D. *et al.*, 2019); 2) provide protection from the cardiotoxic effects of doxorubicin (Shan Q. *et al.*, 2019); and 3) protect against lipopolysacchride-induced mastitis in mice by activating MAPKs and NRF2 while inhibiting NF- κ B signaling pathways (Zhao C. *et al.*, 2019). Furthermore, DMI is said to have utility in
20 preventing and treating ulcerative colitis and canceration thereof (CN110731955, Sun Yat-sen University Cancer Center); and has been reported to protect against fungal keratitis by activating the NRF2/HO-1 signalling pathway (Gu L. *et al.*, 2020). Nevertheless, it should be noted that DMI is not metabolised to itaconic acid intracellularly (ElAzzouny M. *et al.*, 2017). Other α,β -unsaturated esters exhibit IL-1 β -lowering effects in macrophages by inhibiting the NLRP3
25 inflammasome (Cocco M. *et al.*, 2017 and 2014), and have been demonstrated to inhibit the TLR4 pathway, leading ultimately to suppression of LPS-induced stimulation of NF- κ B, tumour necrosis factor (TNF)- α , IL-1 β and nitric oxide release (Zhang S. *et al.*, 2012).

Other itaconic acid derivatives have been demonstrated to elicit anti-inflammatory effects
30 (Bagavant G. *et al.*, 1994). A notable example is 4-octyl itaconic acid (4OI), an itaconate derivative with improved cellular uptake. Since the α,β -unsaturated carboxylic acid is not esterified in 4OI, this electrophile exhibits low reactivity with biological thiols (Schmidt T. J. *et al.*, 2007), much like the situation encountered with itaconic acid itself. As a result of its low reactivity/electrophilicity, the NRF2-activating effects of 4OI are not attenuated by GSH, in contrast to the findings with the
35 much more reactive DMI. In this latter case, the α,β -unsaturated carboxylic acid is esterified and, as a consequence, the IL-6-lowering and NRF2-activating effects of DMI are reversed by the thiols N-acetylcysteine and GSH, respectively. Through the reaction with KEAP1 and the resulting


NRF2 activation, as well as GAPDH inhibition (Liao S.-T. *et al.*, 2019), 4OI has been demonstrated to produce a wide range of interesting biological effects, including: 1) protection of neuronal cells from hydrogen peroxide (Liu H. *et al.*, 2018); 2) inhibition of proinflammatory cytokine production in peripheral blood mononuclear cells of SLE patients (Tang C. *et al.*, 2018); and 3) protection of human umbilical vein endothelial cells from high glucose (Tang C. *et al.*, 2019); 4) inhibition of osteoclastogenesis by suppressing the E3 ubiquitin ligase Hrd1 and activating NRF2 signaling (Sun X. *et al.*, 2019); 5) induction of repression of STING by NRF2 and type I IFN production in cells from patients with STING-dependent interferonopathies (Olagnier D. *et al.*, 2018); 6) protection against renal fibrosis via inhibiting the TGF-beta/Smad pathway, autophagy and reducing generation of reactive oxygen species (Tian F. *et al.*, 2020); 7) reduction of brain viral burden in mice intracranially injected with Zika virus (Daniels B. P. *et al.* 2019); and 8) protection against liver ischemia–reperfusion injury (Yi F. *et al.* 2020). Furthermore, itaconate has been reported to modulate tricarboxylic acid and redox metabolism to mitigate reperfusion injury (Cordes T. *et al.*, 2020). In addition, raised plasma itaconate levels demonstrate a clear correlation with reduction in rheumatoid arthritis disease activity scores following commencement of therapy with conventional disease modifying anti-rheumatic drug (cDMARD) therapy (Daly R. *et al.* 2019).

Artyomov *et al.* (WO2017/142855; WO2019/036509) disclose the use of itaconate, malonate or a derivative thereof as an immunomodulatory agent.

In spite of the above findings, there remains a need to identify and develop new itaconate derivatives possessing enhanced properties compared to currently marketed anti-inflammatory agents, such as DMF. The present inventors have now discovered, surprisingly, that certain itaconate diesters are highly effective at reducing cytokine release in cells and/or in activating NRF2-driven effects. These properties, amongst others, make them potentially more effective than DMI and/or dimethyl fumarate. Such compounds therefore possess excellent anti-inflammatory properties.

Summary

The present disclosure provides a compound of formula (IW-1):



wherein,

R^A is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl, 6–10 membered heterospirocyclyl and 4–10 membered heterocyclyl; wherein R^A is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1A} , OR^{2A} , $NR^{2A}R^{3A}$, SR^{2A} , SOR^{9A} , SO_2R^{9A} , $SO_2NR^{2A}R^{3A}$, $C(O)R^{2A}$ and $CONR^{2A}R^{3A}$;

5 R^{1A} is selected from the group consisting of fluoro, methyl, CO_2H , cyano, $SiR^{4A}R^{5A}R^{6A}$, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl; wherein methyl, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl are optionally substituted by R^{7A} and/or R^{8A} ;

10 R^{4A} , R^{5A} and R^{6A} are independently selected from the group consisting of C_{1-4} alkyl and phenyl; wherein phenyl is optionally substituted by one or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

15 R^{7A} and R^{8A} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

or, taken together, R^{7A} and R^{8A} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring;

20 R^{2A} and R^{3A} are independently H, C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{2A} and R^{3A} are independently optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qA}W^A$;

or, taken together, R^{2A} and R^{3A} form a 4–7 membered heterocyclic ring optionally independently substituted by one or more substituents selected from the group consisting of C_{1-2} alkyl, hydroxy and oxo;

25 R^{9A} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9A} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qA}W^A$;

qA is 0 or 1;

30 W^A is selected from the group consisting of C_{3-8} cycloalkyl, phenyl and 5–6 membered heteroaryl; wherein W^A is optionally substituted by one or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

wherein

35 R^B is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^B is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$, $CONR^{2B}R^{3B}$, $C(O)NHSO_2R^{9B}$ and $C(O)NHSO_2NR^{2B}R^{3B}$;

R^{1B} is selected from the group consisting of halo, trifluoromethyl, methyl, CO_2H , cyano,

SiR^{4B}R^{5B}R^{6B}, C₃₋₈ cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl; wherein methyl, C₃₋₈ cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl are optionally substituted by R^{7B} and/or R^{8B};

R^{4B}, R^{5B} and R^{6B} are independently selected from the group consisting of C₁₋₄ alkyl and phenyl; wherein phenyl is optionally substituted by one or more substituents selected from the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxy, CO₂H, cyano, methanesulfonyl and halo;

R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxy, CO₂H, CO₂(C₁₋₆ alkyl), cyano, methanesulfonyl and halo;

or, taken together, R^{7B} and R^{8B} form a C₃₋₈ cycloalkyl or 4-7 membered heterocyclic ring;

R^{2B} and R^{3B} are independently H, C₁₋₈ alkyl, C₃₋₈ cycloalkyl or phenyl; wherein R^{2B} and R^{3B} are independently optionally substituted by one or more substituents selected from the group consisting of C₁₋₈ alkyl, C₁₋₄ alkoxy, fluoro, hydroxy, oxo and -(CH₂)_{qB}W^B;

or, taken together, R^{2B} and R^{3B} form a 4-7 membered heterocyclic ring optionally independently substituted by one or more substituents selected from the group consisting of C₁₋₂ alkyl, hydroxy and oxo;

R^{9B} is C₁₋₈ alkyl, C₃₋₈ cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C₁₋₈ alkyl, C₁₋₄ alkoxy, halo, CO₂H, hydroxy, oxo and -(CH₂)_{qB}W^B;

q_B is 0 or 1;

W^B is selected from the group consisting of C₃₋₈ cycloalkyl, phenyl and 5-6 membered heteroaryl; wherein W^B is optionally substituted by one or more substituents selected from the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxy, CO₂H, cyano, methanesulfonyl and halo;


R^C and R^D are independently selected from the group consisting of H, C₁₋₂ alkyl, hydroxy, methoxy and fluoro;

and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;

or a pharmaceutically acceptable salt and/or solvate thereof.

The present disclosure, in one aspect, provides a compound which is a compound of formula (IW-1):



5 wherein,

R^A is selected from the group consisting of C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{5-10} spirocycloalkyl and 4–7 membered heterocyclyl; wherein R^A is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1A} , OR^{2A} , $NR^{2A}R^{3A}$, SR^{2A} , SOR^{9A} , SO_2R^{9A} , $SO_2NR^{2A}R^{3A}$, $C(O)R^{2A}$ and $CONR^{2A}R^{3A}$;

10 R^{1A} is selected from the group consisting of fluoro, methyl, cyano, $SiR^{4A}R^{5A}R^{6A}$, C_{3-8} cycloalkyl, phenyl and 5-6 membered heteroaryl; wherein methyl, C_{3-8} cycloalkyl, phenyl and 5-6 membered heteroaryl are optionally substituted by R^{7A} and/or R^{8A} ;

R^{4A} , R^{5A} and R^{6A} are independently selected from the group consisting of C_{1-4} alkyl and phenyl; wherein phenyl is optionally substituted by one or more substituents selected from the group

15 consisting of C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

R^{7A} and R^{8A} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

or, taken together, R^{7A} and R^{8A} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring;

R^{2A} and R^{3A} are independently H, C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{2A} and R^{3A} are

20 independently optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qA}W^A$;

or, taken together, R^{2A} and R^{3A} form a 4–7 membered heterocyclic ring optionally independently substituted by one or more substituents selected from the group consisting of C_{1-2} alkyl, hydroxy and oxo;

25 R^{9A} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9A} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qA}W^A$;

qA is 0 or 1;

W^A is selected from the group consisting of C_{3-8} cycloalkyl, phenyl and 5–6 membered heteroaryl;

30 wherein W^A is optionally substituted by one or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

wherein

R^B is C_{1-2} alkyl substituted by CO_2H optionally substituted by at least one other substituent selected from the group consisting of halo, trifluoromethyl and methyl;

35 R^C and R^D are independently selected from the group consisting of H, C_{1-2} alkyl, hydroxy, methoxy

and fluoro;

and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;

- 5 or a pharmaceutically acceptable salt and/or solvate thereof;
or a compound selected from the group consisting of:
1-(2-cyanoethyl) 4-octyl 2-methylenesuccinate;
1-(2-(methylsulfonyl)ethyl) 4-octyl 2-methylenesuccinate;
4-octyl 1-(3,3,3-trifluoropropyl) 2-methylenesuccinate;
10 4-octyl 1-(oxetan-3-yl) 2-methylenesuccinate;
4-octyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
1-(3-(dimethylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;
4-butyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
1-(2-cyanoethyl) 4-butyl 2-methylenesuccinate;
15 1-(2-(2,5-dioxopyrrolidin-1-yl)ethyl) 4-octyl 2-methylenesuccinate;
1-(2-cyanoethyl) 4-methyl 2-methylenesuccinate;
1-(2-cyanoethyl) 4-hexyl 2-methylenesuccinate;
4-methyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
4-octyl 1-(2-(trifluoromethoxy)ethyl) 2-methylenesuccinate;
20 4-hexyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
4-methyl 1-(oxetan-3-yl) 2-methylenesuccinate;
1-(2-(N,N-dimethylsulfamoyl)ethyl) 4-octyl 2-methylenesuccinate;
1-(2-(dimethylamino)ethyl) 4-octyl 2-methylenesuccinate;
1-(3-(methylsulfonyl)propyl) 4-octyl 2-methylenesuccinate;
25 1-(1-(methylsulfonyl)propan-2-yl) 4-octyl 2-methylenesuccinate;
1-(2-(methylsulfonyl)ethyl) 4-(3-phenoxypropyl) 2-methylenesuccinate;
1-(2-(dimethylamino)-2-oxoethyl) 4-octyl 2-methylenesuccinate;
4-isopropyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
(S)-4-octyl 1-(tetrahydrofuran-3-yl) 2-methylenesuccinate;
30 (R)-4-octyl 1-(tetrahydrofuran-3-yl) 2-methylenesuccinate;
4-cyclooctyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
4-octyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
1-(1-cyanopropan-2-yl) 4-octyl 2-methylenesuccinate;
1-(1-(methylsulfonyl)piperidin-4-yl) 4-octyl 2-methylenesuccinate;
35 1-(2-methoxyethyl) 4-octyl 2-methylenesuccinate;
1-(2-cyano-2-methylpropyl) 4-octyl 2-methylenesuccinate;
1-(1-methoxypropan-2-yl) 4-octyl 2-methylenesuccinate;
1-((1-cyanocyclopropyl)methyl) 4-octyl 2-methylenesuccinate;

- 1-(2-methoxypropyl) 4-octyl 2-methylenesuccinate;
 1-(2-methoxy-2-methylpropyl) 4-octyl 2-methylenesuccinate;
 1-(2-morpholinoethyl) 4-octyl 2-methylenesuccinate;
 4-(2-(2-ethoxyethoxy)ethyl) 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 5 4-butyl 1-(oxetan-3-yl) 2-methylenesuccinate;
 4-hexyl 1-(oxetan-3-yl) 2-methylenesuccinate;
 4-butyl 1-(2-tosylethyl) 2-methylenesuccinate;
 4-octyl 1-(2-tosylethyl) 2-methylenesuccinate;
 4-cyclooctyl 1-methyl 2-methylenesuccinate;
 10 1-methyl 4-octyl 2-methylenesuccinate;
 dicyclobutyl 2-methylenesuccinate;
 di(oxetan-3-yl) 2-methylenesuccinate;
 1-cyclobutyl 4-octyl 2-methylenesuccinate;
 1-(1-acetoxyethyl) 4-octyl 2-methylenesuccinate;
 15 1-(1,1-dioxidothietan-3-yl) 4-octyl 2-methylenesuccinate;
 1-(2-(tert-butoxy)-2-oxoethyl) 4-octyl 2-methylenesuccinate;
 1-(1-acetylazetidin-3-yl) 4-octyl 2-methylenesuccinate;
 1-(2-(4-methylpiperazin-1-yl)ethyl) 4-octyl 2-methylenesuccinate;
 1-(2-(1,1-dioxidothiomorpholino)ethyl) 4-octyl 2-methylenesuccinate;
 20 1-(2-(methylsulfonamido)ethyl) 4-octyl 2-methylenesuccinate;
 4-cyclooctyl 1-(1,1-dioxidothietan-3-yl) 2-methylenesuccinate;
 (R)-1-(2-(methylsulfonyl)ethyl) 4-(octan-2-yl) 2-methylenesuccinate;
 1-(1-(methylsulfonyl)propan-2-yl) 4-((R)-octan-2-yl) 2-methylenesuccinate;
 (R)-1-(1,1-dioxidothietan-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
 25 (R)-1-(1-acetylazetidin-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-(1-(methylsulfonyl)propan-2-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-(1,1-dioxidothietan-3-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 4-cyclooctyl 1-(1-(methylsulfonyl)propan-2-yl) 2-methylenesuccinate;
 30 1-(1-acetylazetidin-3-yl) 4-cyclooctyl 2-methylenesuccinate;
 4-cyclohexyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 (S)-1-(1-acetylazetidin-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
 (S)-1-(1,1-dioxidothietan-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
 35 1-(3-methyloxetan-3-yl) 4-octyl 2-methylenesuccinate;
 4-cyclooctyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
 4-cyclooctyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
 4-cyclooctyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;

- (R)-4-(octan-2-yl) 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 (R)-4-(octan-2-yl) 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
 1-(1-acetylazetidin-3-yl) 4-cyclohexyl 2-methylenesuccinate;
 4-cyclohexyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
 5 4-hexyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
 4-hexyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 1-(2-(1H-tetrazol-5-yl)ethyl) 4-hexyl 2-methylenesuccinate;
 2-(N-methyl-2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetamido)acetic acid;
 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetyl)-L-proline;
 10 N-methyl-N-(2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)glycine;
 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)-L-proline;
 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)glycine;
 N-(2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetyl)-N-methylglycine;
 (2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetyl)-L-proline;
 15 (S)-N-methyl-N-(2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetyl)glycine;
 (S)-(2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetyl)glycine;
 1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl) 4-octyl 2-methylenesuccinate;
 1-(3-morpholino-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 1-(3-(diethylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 20 1-(3-(methylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 1-(2-((N,N-dimethylsulfamoyl)amino)-2-oxoethyl) 4-hexyl 2-methylenesuccinate;
 4-hexyl 1-(2-(methylsulfonamido)-2-oxoethyl) 2-methylenesuccinate;
 4-hexyl 1-(3-(methylsulfonamido)-2-oxoethyl) 2-methylenesuccinate;
 (E)-4-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)but-2-enoic acid;
 25 3-((2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)ethyl)sulfonyl)propanoic acid;
 1-((2H-tetrazol-5-yl)methyl) 4-cyclohexyl 2-methylenesuccinate;
 2-((3-((2-((3-chlorophenyl)sulfonyl)ethoxy)carbonyl)but-3-enoyl)oxy)acetic acid;
 (R)-2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)-2-phenylacetic acid;
 1-(2-(1H-tetrazol-5-yl)ethyl) 4-cyclohexyl 2-methylenesuccinate;
 30 (S)-1-(2-(1H-tetrazol-5-yl)ethyl) 4-octan-2-yl 2-methylenesuccinate;
 1-(2-(1H-tetrazol-5-yl)ethyl) 4-cyclooctyl 2-methylenesuccinate;
 1-(2-((3-chlorophenyl)sulfonyl)-2-methylpropyl) 4-cyclooctyl 2-methylenesuccinate;
 4-cyclooctyl 1-(2-methyl-2-(methylsulfonyl)propyl) 2-methylenesuccinate;
 1-(1-(1H-tetrazol-5-yl)ethyl) 4-cyclooctyl 2-methylenesuccinate;
 35 1-((1H-tetrazol-5-yl)methyl) 4-cyclooctyl 2-methylenesuccinate;
 (R)-1-(2-(1H-tetrazol-5-yl)ethyl) 4-octan-2-yl 2-methylenesuccinate;
 (2R,3S)-2-acetamido-3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)butanoic acid;
 4-cyclooctyl 1-(3-(2-ethoxy-2-oxoethyl)oxetan-3-yl) 2-methylenesuccinate;

- 4-(2-(methylsulfonyl)ethyl) 1-octyl 2-methyl-3-methylenesuccinate;
 1-octyl 4-((S)-tetrahydrofuran-3-yl) 2-methyl-3-methylenesuccinate;
 1-(1-(1H-tetrazol-5-yl)propan-2-yl) 4-((R)-octan-2-yl) 2-methylenesuccinate;
 1-(1-(1H-tetrazol-5-yl)propan-2-yl) 4-((S)-octan-2-yl) 2-methylenesuccinate;
 5 4-cyclohexyl 1-((2-methyl-2H-tetrazol-5-yl)methyl) 2-methylenesuccinate;
 4-cyclohexyl 1-((1-methyl-1H-tetrazol-5-yl)methyl) 2-methylenesuccinate;
 2-((4-((adamantan-2-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 bis((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-methylenesuccinate;
 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-(2-oxaspiro[3.3]heptan-6-yl) 2-
 10 methylenesuccinate;
 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-(oxepan-4-yl) 2-
 methylenesuccinate;
 4-(1-butoxypropan-2-yl) 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-
 methylenesuccinate;
 15 4-spiro[3.3]heptan-2-yl 1-(3,3,3-trifluoro-2,2-dihydroxypropyl) 2-methylenesuccinate hydrate; (R)-
 1-((2H-tetrazol-5-yl)methyl) 4-(octan-2-yl) 2-methylenesuccinate;
 1-(2H-tetrazol-5-yl)methyl 4-cycloheptyl 2-methylenesuccinate;
 1-(2H-tetrazol-5-yl)methyl 4-spiro[3.3]heptan-2-yl 2-methylenesuccinate;
 (S)-1-(2H-tetrazol-5-yl)methyl 4-octan-2-yl 2-methylenesuccinate;
 20 1-(1-(1H-tetrazol-5-yl)ethyl) 4-((S)-octan-2-yl) 2-methylenesuccinate;
 1-(cyclopropyl(1H-tetrazol-5-yl)methyl) 4-((S)-octan-2-yl) 2-methylenesuccinate;
 dicyclohexyl 2-methylenesuccinate; 2-((4-((adamantan-1-yl)oxy)-2-methylene-4-
 oxobutanoyl)oxy)acetic acid; 2-((4-(bicyclo[3.3.1]nonan-9-yloxy)-2-methylene-4-
 oxobutanoyl)oxy)acetic acid;
 25 1-(3,3-difluorocyclobutyl) 4-octyl 2-methylenesuccinate;
 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-((R)-octan-2-yl) 2-
 methylenesuccinate; and
 (R)-4-(octan-2-yl) 1-((3-oxo-2,3-dihydroisoxazol-5-yl)methyl) 2-methylenesuccinate;
 or a pharmaceutically acceptable salt and/or solvate thereof.

30 The present disclosure, in another aspect, provides a pharmaceutical composition comprising a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof.

The present disclosure, in another aspect, provides a compound of formula (IW-1) or a
 35 pharmaceutically acceptable

salt and/or solvate thereof or a pharmaceutical composition as defined above for use as a medicament.

The present disclosure, in another aspect, provides a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof or a pharmaceutical composition as defined above for use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response, wherein the inflammatory disease or disease associated with an undesirable immune response is, or is associated with, a disease selected from the group consisting of: psoriasis (including chronic plaque, erythrodermic, pustular, guttate, inverse and nail variants), asthma, chronic obstructive pulmonary disease (COPD, including chronic bronchitis and emphysema), heart failure (including left ventricular failure), myocardial infarction, angina pectoris, other atherosclerosis and/or atherothrombosis-related disorders (including peripheral vascular disease and ischaemic stroke), a mitochondrial and neurodegenerative disease (such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, retinitis pigmentosa or mitochondrial encephalomyopathy), autoimmune paraneoplastic retinopathy, transplantation rejection (including antibody-mediated and T cell-mediated forms), multiple sclerosis, transverse myelitis, ischaemia-reperfusion injury (e.g. during elective surgery such as cardiopulmonary bypass for coronary artery bypass grafting or other cardiac surgery, following percutaneous coronary intervention, following treatment of acute ST-elevation myocardial infarction or ischaemic stroke, organ transplantation, or acute compartment syndrome), AGE-induced genome damage, an inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), primary sclerosing cholangitis (PSC), PSC-autoimmune hepatitis overlap syndrome, non-alcoholic fatty liver disease (non-alcoholic steatohepatitis), rheumatica, granuloma annulare, cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), lupus nephritis, drug-induced lupus, autoimmune myocarditis or myopericarditis, Dressler's syndrome, giant cell myocarditis, post-pericardiotomy syndrome, drug-induced hypersensitivity syndromes (including hypersensitivity myocarditis), eczema, sarcoidosis, erythema nodosum, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorders, MOG (myelin oligodendrocyte glycoprotein) antibody-associated disorders (including MOG-EM), optic neuritis, CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids), diffuse myelinoclastic sclerosis, Addison's disease, alopecia areata, ankylosing spondylitis, other spondyloarthritides (including peripheral spondyloarthritis, that is associated with psoriasis, inflammatory bowel disease, reactive arthritis or juvenile onset forms), antiphospholipid antibody syndrome, autoimmune hemolytic anaemia, autoimmune hepatitis, autoimmune inner ear disease, pemphigoid (including bullous pemphigoid, mucous membrane pemphigoid, cicatricial pemphigoid, herpes gestationis or pemphigoid gestationis, ocular cicatricial pemphigoid), linear IgA disease, Behçet's disease, celiac disease, Chagas disease, dermatomyositis, diabetes mellitus type I, endometriosis, Goodpasture's

syndrome, Graves' disease, Guillain-Barre syndrome and its subtypes (including acute inflammatory demyelinating polyneuropathy, AIDP, acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), pharyngeal-cervical-brachial variant, Miller-Fisher variant and Bickerstaff's brainstem encephalitis), progressive inflammatory

5 neuropathy, Hashimoto's disease, hidradenitis suppurativa, inclusion body myositis, necrotising myopathy, Kawasaki disease, IgA nephropathy, Henoch-Schonlein purpura, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura (TTP), Evans' syndrome, interstitial cystitis, mixed connective tissue disease, undifferentiated connective tissue disease, morphea, myasthenia gravis (including MuSK antibody positive and seronegative variants),

10 narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, psoriatic arthritis, polymyositis, primary biliary cholangitis (also known as primary biliary cirrhosis), rheumatoid arthritis, palindromic rheumatism, schizophrenia, autoimmune (meningo-)encephalitis syndromes, scleroderma, Sjogren's syndrome, stiff person syndrome, polymyalgia rheumatica, giant cell arteritis (temporal arteritis), Takayasu arteritis, polyarteritis nodosa, Kawasaki disease,

15 granulomatosis with polyangiitis (GPA; formerly known as Wegener's granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome), microscopic polyarteritis/polyangiitis, hypocomplementaemic urticarial vasculitis, hypersensitivity vasculitis, cryoglobulinemia, thromboangiitis obliterans (Buerger's disease), vasculitis, leukocytoclastic vasculitis, vitiligo, acute disseminated encephalomyelitis,

20 adrenoleukodystrophy, Alexander's disease, Alper's disease, balo concentric sclerosis or Marburg disease, cryptogenic organising pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia), Canavan disease, central nervous system vasculitic syndrome, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic inflammatory demyelinating polyneuropathy (CIDP), diabetic retinopathy, globoid cell

25 leukodystrophy (Krabbe disease), graft-versus-host disease (GVHD) (including acute and chronic forms, as well as intestinal GVHD), hepatitis C (HCV) infection or complication, herpes simplex viral infection or complication, human immunodeficiency virus (HIV) infection or complication, lichen planus, monomelic amyotrophy, cystic fibrosis, pulmonary arterial hypertension (PAH, including idiopathic PAH), lung sarcoidosis, idiopathic pulmonary fibrosis, paediatric asthma,

30 atopic dermatitis, allergic dermatitis, contact dermatitis, allergic rhinitis, rhinitis, sinusitis, conjunctivitis, allergic conjunctivitis, keratoconjunctivitis sicca, dry eye, xerophthalmia, glaucoma, macular oedema, diabetic macular oedema, central retinal vein occlusion (CRVO), macular degeneration (including dry and/or wet age related macular degeneration, AMD), post-operative cataract inflammation, uveitis (including posterior, anterior, intermediate and pan uveitis),

35 iridocyclitis, scleritis, corneal graft and limbal cell transplant rejection, gluten sensitive enteropathy (coeliac disease), dermatitis herpetiformis, eosinophilic esophagitis, achalasia, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, aortitis and periaortitis, autoimmune retinopathy, autoimmune urticaria,

Behcet's disease, (idiopathic) Castleman's disease, Cogan's syndrome, IgG4-related disease, retroperitoneal fibrosis, juvenile idiopathic arthritis including systemic juvenile idiopathic arthritis (Still's disease), adult-onset Still's disease, ligneous conjunctivitis, Mooren's ulcer, pityriasis lichenoides et varioliformis acuta (PLEVA, also known as Mucha-Habermann disease), multifocal motor neuropathy (MMN), paediatric acute-onset neuropsychiatric syndrome (PANS) (including paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)), paraneoplastic syndromes (including paraneoplastic cerebellar degeneration, Lambert-Eaton myasthenic syndrome, limbic encephalitis, brainstem encephalitis, opsoclonus myoclonus ataxia syndrome, anti-NMDA receptor encephalitis, thymoma-associated multiorgan autoimmunity), perivenous encephalomyelitis, reflex sympathetic dystrophy, relapsing polychondritis, sperm & testicular autoimmunity, Susac's syndrome, Tolosa-Hunt syndrome, Vogt-Koyanagi-Harada Disease, anti-synthetase syndrome, autoimmune enteropathy, immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX), microscopic colitis, autoimmune lymphoproliferative syndrome (ALPS), autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APEX), gout, pseudogout, amyloid (including AA or secondary amyloidosis), eosinophilic fasciitis (Shulman syndrome) progesterone hypersensitivity (including progesterone dermatitis), familial Mediterranean fever (FMF), tumour necrosis factor (TNF) receptor-associated periodic fever syndrome (TRAPS), hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS), PAPA (pyogenic arthritis, pyoderma gangrenosum, severe cystic acne) syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), deficiency of the interleukin-36-receptor antagonist (DITRA), cryopyrin-associated periodic syndromes (CAPS) (including familial cold autoinflammatory syndrome [FCAS], Muckle-Wells syndrome, neonatal onset multisystem inflammatory disease [NOMID]), NLRP12-associated autoinflammatory disorders (NLRP12AD), periodic fever aphthous stomatitis (PFAPA), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), Majeed syndrome, Blau syndrome (also known as juvenile systemic granulomatosis), macrophage activation syndrome, chronic recurrent multifocal osteomyelitis (CRMO), familial cold autoinflammatory syndrome, mutant adenosine deaminase 2 and monogenic interferonopathies (including Aicardi-Goutières syndrome, retinal vasculopathy with cerebral leukodystrophy, spondyloenchondrodysplasia, STING [stimulator of interferon genes]-associated vasculopathy with onset in infancy, proteasome associated autoinflammatory syndromes, familial chilblain lupus, dyschromatosis symmetrica hereditaria), Schnitzler syndrome; familial cylindromatosis, congenital B cell lymphocytosis, OTULIN-related autoinflammatory syndrome, type 2 diabetes mellitus, insulin resistance and the metabolic syndrome (including obesity-associated inflammation), atherosclerotic disorders (e.g. myocardial infarction, angina, ischaemic heart failure, ischaemic nephropathy, ischaemic stroke, peripheral vascular disease, aortic aneurysm), renal inflammatory disorders (e.g. diabetic nephropathy, membranous nephropathy, minimal change disease, crescentic glomerulonephritis, acute kidney injury, renal transplantation).

The present disclosure, in another aspect, provides the use of a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof or a pharmaceutical composition as defined above in the manufacture of a medicament for treating or preventing an inflammatory disease or a disease associated with an immune response, wherein the inflammatory disease or disease associated with an undesirable immune response is, or is associated with, a disease selected from the group consisting of: psoriasis (including chronic plaque, erythrodermic, pustular, guttate, inverse and nail variants), asthma, chronic obstructive pulmonary disease (COPD, including chronic bronchitis and emphysema), heart failure (including left ventricular failure), myocardial infarction, angina pectoris, other atherosclerosis and/or atherothrombosis-related disorders (including peripheral vascular disease and ischaemic stroke), a mitochondrial and neurodegenerative disease (such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, retinitis pigmentosa or mitochondrial encephalomyopathy), autoimmune paraneoplastic retinopathy, transplantation rejection (including antibody-mediated and T cell-mediated forms), multiple sclerosis, transverse myelitis, ischaemia-reperfusion injury (e.g. during elective surgery such as cardiopulmonary bypass for coronary artery bypass grafting or other cardiac surgery, following percutaneous coronary intervention, following treatment of acute ST-elevation myocardial infarction or ischaemic stroke, organ transplantation, or acute compartment syndrome), AGE-induced genome damage, an inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), primary sclerosing cholangitis (PSC), PSC-autoimmune hepatitis overlap syndrome, non-alcoholic fatty liver disease (non-alcoholic steatohepatitis), rheumatica, granuloma annulare, cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), lupus nephritis, drug-induced lupus, autoimmune myocarditis or myopericarditis, Dressler's syndrome, giant cell myocarditis, post-pericardiotomy syndrome, drug-induced hypersensitivity syndromes (including hypersensitivity myocarditis), eczema, sarcoidosis, erythema nodosum, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorders, MOG (myelin oligodendrocyte glycoprotein) antibody-associated disorders (including MOG-EM), optic neuritis, CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids), diffuse myelinoclastic sclerosis, Addison's disease, alopecia areata, ankylosing spondylitis, other spondyloarthritides (including peripheral spondyloarthritis, that is associated with psoriasis, inflammatory bowel disease, reactive arthritis or juvenile onset forms), antiphospholipid antibody syndrome, autoimmune hemolytic anaemia, autoimmune hepatitis, autoimmune inner ear disease, pemphigoid (including bullous pemphigoid, mucous membrane pemphigoid, cicatricial pemphigoid, herpes gestationis or pemphigoid gestationis, ocular cicatricial pemphigoid), linear IgA disease, Behçet's disease, celiac disease, Chagas disease, dermatomyositis, diabetes mellitus type I, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome and its subtypes (including acute inflammatory demyelinating polyneuropathy, AIDP, acute motor axonal neuropathy

(AMAN), acute motor and sensory axonal neuropathy (AMSAN), pharyngeal-cervical-brachial variant, Miller-Fisher variant and Bickerstaff's brainstem encephalitis), progressive inflammatory neuropathy, Hashimoto's disease, hidradenitis suppurativa, inclusion body myositis, necrotising myopathy, Kawasaki disease, IgA nephropathy, Henoch-Schonlein purpura, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura (TTP), Evans' syndrome, interstitial cystitis, mixed connective tissue disease, undifferentiated connective tissue disease, morphea, myasthenia gravis (including MuSK antibody positive and seronegative variants), narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, psoriatic arthritis, polymyositis, primary biliary cholangitis (also known as primary biliary cirrhosis), rheumatoid arthritis, palindromic rheumatism, schizophrenia, autoimmune (meningo-)encephalitis syndromes, scleroderma, Sjogren's syndrome, stiff person syndrome, polymyalgia rheumatica, giant cell arteritis (temporal arteritis), Takayasu arteritis, polyarteritis nodosa, Kawasaki disease, granulomatosis with polyangiitis (GPA; formerly known as Wegener's granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome), microscopic polyarteritis/polyangiitis, hypocomplementaemic urticarial vasculitis, hypersensitivity vasculitis, cryoglobulinemia, thromboangiitis obliterans (Buerger's disease), vasculitis, leukocytoclastic vasculitis, vitiligo, acute disseminated encephalomyelitis, adrenoleukodystrophy, Alexander's disease, Alper's disease, Baló concentric sclerosis or Marburg disease, cryptogenic organising pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia), Canavan disease, central nervous system vasculitic syndrome, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic inflammatory demyelinating polyneuropathy (CIDP), diabetic retinopathy, globoid cell leukodystrophy (Krabbe disease), graft-versus-host disease (GVHD) (including acute and chronic forms, as well as intestinal GVHD), hepatitis C (HCV) infection or complication, herpes simplex viral infection or complication, human immunodeficiency virus (HIV) infection or complication, lichen planus, monomelic amyotrophy, cystic fibrosis, pulmonary arterial hypertension (PAH, including idiopathic PAH), lung sarcoidosis, idiopathic pulmonary fibrosis, paediatric asthma, atopic dermatitis, allergic dermatitis, contact dermatitis, allergic rhinitis, rhinitis, sinusitis, conjunctivitis, allergic conjunctivitis, keratoconjunctivitis sicca, dry eye, xerophthalmia, glaucoma, macular oedema, diabetic macular oedema, central retinal vein occlusion (CRVO), macular degeneration (including dry and/or wet age related macular degeneration, AMD), post-operative cataract inflammation, uveitis (including posterior, anterior, intermediate and pan uveitis), iridocyclitis, scleritis, corneal graft and limbal cell transplant rejection, gluten sensitive enteropathy (coeliac disease), dermatitis herpetiformis, eosinophilic esophagitis, achalasia, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, aortitis and periaortitis, autoimmune retinopathy, autoimmune urticaria, Behcet's disease, (idiopathic) Castleman's disease, Cogan's syndrome, IgG4-related disease, retroperitoneal fibrosis, juvenile idiopathic arthritis including systemic juvenile idiopathic arthritis

(Still's disease), adult-onset Still's disease, ligneous conjunctivitis, Mooren's ulcer, pityriasis lichenoides et varioliformis acuta (PLEVA, also known as Mucha-Habermann disease), multifocal motor neuropathy (MMN), paediatric acute-onset neuropsychiatric syndrome (PANS) (including paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)), paraneoplastic syndromes (including paraneoplastic cerebellar degeneration, Lambert-Eaton myasthenic syndrome, limbic encephalitis, brainstem encephalitis, opsoclonus myoclonus ataxia syndrome, anti-NMDA receptor encephalitis, thymoma-associated multiorgan autoimmunity), perivenous encephalomyelitis, reflex sympathetic dystrophy, relapsing polychondritis, sperm & testicular autoimmunity, Susac's syndrome, Tolosa-Hunt syndrome, Vogt-Koyanagi-Harada Disease, anti-synthetase syndrome, autoimmune enteropathy, immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX), microscopic colitis, autoimmune lymphoproliferative syndrome (ALPS), autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APEX), gout, pseudogout, amyloid (including AA or secondary amyloidosis), eosinophilic fasciitis (Shulman syndrome) progesterone hypersensitivity (including progesterone dermatitis), familial Mediterranean fever (FMF), tumour necrosis factor (TNF) receptor-associated periodic fever syndrome (TRAPS), hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS), PAPA (pyogenic arthritis, pyoderma gangrenosum, severe cystic acne) syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), deficiency of the interleukin-36-receptor antagonist (DITRA), cryopyrin-associated periodic syndromes (CAPS) (including familial cold autoinflammatory syndrome [FCAS], Muckle-Wells syndrome, neonatal onset multisystem inflammatory disease [NOMID]), NLRP12-associated autoinflammatory disorders (NLRP12AD), periodic fever aphthous stomatitis (PFAPA), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), Majeed syndrome, Blau syndrome (also known as juvenile systemic granulomatosis), macrophage activation syndrome, chronic recurrent multifocal osteomyelitis (CRMO), familial cold autoinflammatory syndrome, mutant adenosine deaminase 2 and monogenic interferonopathies (including Aicardi-Goutières syndrome, retinal vasculopathy with cerebral leukodystrophy, spondyloenchondrodysplasia, STING [stimulator of interferon genes]-associated vasculopathy with onset in infancy, proteasome associated autoinflammatory syndromes, familial chilblain lupus, dyschromatosis symmetrica hereditaria), Schnitzler syndrome; familial cylindromatosis, congenital B cell lymphocytosis, OTULIN-related autoinflammatory syndrome, type 2 diabetes mellitus, insulin resistance and the metabolic syndrome (including obesity-associated inflammation), atherosclerotic disorders (e.g. myocardial infarction, angina, ischaemic heart failure, ischaemic nephropathy, ischaemic stroke, peripheral vascular disease, aortic aneurysm), renal inflammatory disorders (e.g. diabetic nephropathy, membranous nephropathy, minimal change disease, crescentic glomerulonephritis, acute kidney injury, renal transplantation).


The present disclosure, in another aspect, provides the compound of pharmaceutical composition as defined above for use in combination with a further therapeutic agent, such as a corticosteroid (glucocorticoid), retinoid (e.g. acitretin, isotretinoin, tazarotene), anthralin, vitamin D analogue (e.g. calcitriol, calcipotriol), calcineurin inhibitors (e.g. tacrolimus, pimecrolimus), phototherapy or photochemotherapy (e.g. psoralen ultraviolet irradiation, PUVA) or other form of ultraviolet light irradiation therapy, ciclosporine, a thiopurine (e.g. azathioprine, 6-mercaptopurine), methotrexate, an anti-TNF α agents (e.g. infliximab, etanercept, adalimumab, certolizumab, golimumab or a biosimilar), phosphodiesterase-4 (PDE4) inhibition (e.g. apremilast, crisaborole), anti-IL-17 agent (e.g. brodalumab, ixekizumab, secukinumab), anti-IL12/IL-23 agent (e.g. ustekinumab, briakinumab), anti-IL-23 agent (e.g. guselkumab, tildrakizumab), JAK (Janus Kinase) inhibitor (e.g. tofacitinib, ruxolitinib, baricitinib, filgotinib, upadacitinib), plasma exchange, intravenous immune globulin (IVIG), cyclophosphamide, anti-CD20 B cell depleting agent (e.g. rituximab, ocrelizumab, ofatumumab, obinutuzumab), anthracycline analogue (e.g. mitoxantrone), cladribine, sphingosine 1-phosphate receptor modulator or sphingosine analogue (e.g. fingolimod, siponimod, ozanimod, etrasimod), interferon beta preparation (including interferon beta 1b/1a), glatiramer, anti-CD3 therapy (e.g. OKT3), anti-CD52 targeting agent (e.g. alemtuzumab), leflunomide, teriflunomide, gold compound, laquinimod, potassium channel blocker (e.g. dalfampridine/4-aminopyridine), mycophenolic acid, mycophenolate mofetil, purine analogue (e.g. pentostatin), mTOR (mechanistic target of rapamycin) pathway inhibitor (e.g. sirolimus, everolimus), anti-thymocyte globulin (ATG), IL-2 receptor (CD25) inhibitor (e.g. basiliximab, daclizumab), anti-IL-6 receptor or anti-IL-6 agent (e.g. tocilizumab, siltuximab), Bruton's tyrosine kinase (BTK) inhibitor (e.g. ibrutinib), tyrosine kinase inhibitor (e.g. imatinib), ursodeoxycholic acid, hydroxychloroquine, chloroquine, B cell activating factor (BAFF, also known as BLyS, B lymphocyte stimulator) inhibitor (e.g. belimumab, blisibimod), other B cell targeted therapy including a fusion protein targeting both APRIL (A Proliferation-Inducing Ligand) and BLyS (e.g. atacicept), PI3K inhibitor including pan-inhibitor or one targeting the p110 δ and/or p110 γ containing isoforms (e.g. idelalisib, copanlisib, duvelisib), an interferon α receptor inhibitor (e.g. anifrolumab, sifalimumab), T cell co-stimulation blocker (e.g. abatacept, belatacept), thalidomide and its derivatives (e.g. lenalidomide), dapsone, clofazimine, a leukotriene antagonist (e.g. montelukast), theophylline, anti-IgE therapy (e.g. omalizumab), an anti-IL-5 agent (e.g. mepolizumab, reslizumab), a long-acting muscarinic agent (e.g. tiotropium, aclidinium, umeclidinium), a PDE4 inhibitor (e.g. roflumilast), riluzole, a free radical scavenger (e.g. edaravone), a proteasome inhibitor (e.g. bortezomib), a complement cascade inhibitor including one directed against C5 (e.g. eculizumab), immunoabsorbent, antithymocyte globulin, 5-aminosalicylates and their derivatives (e.g. sulfasalazine, balsalazide, mesalamine), an anti-integrin agent including one targeting $\alpha 4\beta 1$ and/or $\alpha 4\beta 7$ integrins (e.g. natalizumab, vedolizumab), an anti-CD11- α agent (e.g. efalizumab), a non-steroidal anti-inflammatory drug (NSAID) including a salicylate (e.g. aspirin), a propionic acid (e.g. ibuprofen, naproxen), an acetic

acid (e.g. indomethacin, diclofenac, etodolac), an oxicam (e.g. meloxicam) a fenamate (e.g. mefenamic acid), a selective or relatively selective COX-2 inhibitor (e.g. celecoxib, etroxicoxib, valdecoxib and etodolac, meloxicam, nabumetone), colchicine, an IL-4 receptor inhibitor (e.g. dupilumab), topical/contact immunotherapy (e.g. diphenylcyclopropenone, squaric acid dibutyl ester), anti-IL-1 receptor therapy (e.g. anakinra), IL-1 β inhibitor (e.g. canakinumab), IL-1 neutralising therapy (e.g. rilonacept), chlorambucil, a specific antibiotic with immunomodulatory properties and/or ability to modulate NRF2 (e.g. tetracyclines including minocycline, clindamycin, macrolide antibiotics), anti-androgenic therapy (e.g. cyproterone, spironolactone, finasteride), pentoxifylline, ursodeoxycholic acid, obeticholic acid, fibrate, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, a VEGF (vascular endothelial growth factor) inhibitor (e.g. bevacizumab, ranibizumab, pegaptanib, aflibercept), pirfenidone or mizoribine.

The present disclosure provides a method of treating or preventing an inflammatory disease or a disease associated with an undesirable immune response, which comprises administering a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof.

Also provided are intermediate compounds of use in the preparation of compounds of formula (IW-1).

The present disclosure, in another aspect, provides a compound which is:




wherein:

$R^{A'}$ is a protected derivative of R^A , or $R^{A'}$ is R^A wherein R^A is selected from the group consisting of C₃₋₈ cycloalkyl, C₅₋₁₀ spirocycloalkyl and 4–7 membered heterocyclyl, wherein R^A is optionally substituted as defined herein, or R^A is C₁₋₈ alkyl which is substituted by one or more substituents as defined herein;


R^C and R^D are as defined herein;

or a salt thereof

The present disclosure, in another aspect, provides a compound which is selected from the group consisting of:



; and



wherein:

R^B is as defined herein;

5 R^C and R^D are as defined herein; and

PG is an oxygen protecting group;

or a salt thereof.

Detailed description of the invention

10

Compounds of formula (IW-1)

Embodiments and preferences set out herein with respect to the compound of formula (IW-1) apply equally to the pharmaceutical composition, compound for use, use and method aspects of

15 the invention.

20

25

The term “ C_{1-10} alkyl” refers to a straight or branched fully saturated hydrocarbon group having from 1 to 10 carbon atoms. The term encompasses methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, n-hexyl and n-octyl. Other branched variants such as heptyl- $CH(CH_3)-$ and hexyl- $CH(CH_3)-$ are also included. Further branched variants include n-pentyl- $CH(CH_2CH_3)-$ and (n-Bu) $_2CH-$. Other branched variants include n-pentyl- $C(CH_3)_2-$ or n-hexyl- $C(CH_3)_2-$. Another branched variant is $-CH(t-Bu)_2$. Other alkyl groups, for example C_{1-9} alkyl, C_{1-8} alkyl, C_{1-7} alkyl, C_{1-6} alkyl, C_{1-5} alkyl, C_{1-4} alkyl, C_{1-3} alkyl, C_{1-2} alkyl, C_{2-10} alkyl, C_{2-9} alkyl, C_{2-8} alkyl, C_{2-7} alkyl, C_{2-6} alkyl, C_{2-5} alkyl, C_{2-4} alkyl, C_{2-3} alkyl, C_{3-10} alkyl, C_{3-9} alkyl, C_{3-8} alkyl, C_{3-7} alkyl, C_{3-6} alkyl, C_{3-5} alkyl, C_{3-4} alkyl, C_{4-10} alkyl, C_{4-9} alkyl, C_{4-8} alkyl, C_{4-7} alkyl, C_{4-6} alkyl, C_{4-5} alkyl, C_{5-10} alkyl, C_{5-9} alkyl, C_{5-8} alkyl, C_{5-7} alkyl, C_{5-6} alkyl, C_{6-10} alkyl, C_{6-9} alkyl, C_{6-8} alkyl, C_{7-10} alkyl, C_{7-9} alkyl, C_{7-8} alkyl, C_{8-10} alkyl, C_{8-9} alkyl and C_{9-10} alkyl are as defined above but contain different numbers of carbon atoms. The term “ C_{1-10} alkyl” also encompasses “ C_{1-10} alkylene” which is a

bifunctional straight or branched fully saturated hydrocarbon group having from 1 to 10 carbon atoms. Example “C₁₋₁₀ alkylene” groups include methylene, ethylene, n-propylene, n-butylene, n-pentylene, n-heptylene, n-hexylene and n-octylene.

- 5 The term “C₂₋₁₀ alkenyl” refers to a straight or branched hydrocarbon group having from 2 to 10 carbon atoms and at least one carbon-carbon double bond. The term encompasses, CH=CH₂, CH₂CH=CH₂, CH=CHCH₃, CH₂CH₂CH=CH₂, CH=CHCH₂CH₃, CH₂CH=CHCH₃, CH₂CH₂CH₂CH=CH₂, CH=CHCH₂CH₂CH₃, CH₂CH=CHCH₂CH₃, CH₂CH₂CH=CHCH₃, CH=CHCH=CHCH₃ and CH₂CH=CHCH=CH₂. Branched variants such as CH(CH₃)CH=CH₂ and
- 10 CH=C(CH₃)CH₂ are also included. Other alkenyl groups, for example C₂₋₉ alkenyl, C₂₋₈ alkenyl, C₂₋₇ alkenyl, C₂₋₆ alkenyl, C₂₋₅ alkenyl, C₂₋₄ alkenyl, C₂₋₃ alkenyl, C₃₋₁₀ alkenyl, C₃₋₉ alkenyl, C₃₋₈ alkenyl, C₃₋₇ alkenyl, C₃₋₆ alkenyl, C₃₋₅ alkenyl, C₃₋₄ alkenyl, C₄₋₁₀ alkenyl, C₄₋₉ alkenyl, C₄₋₈ alkenyl, C₄₋₇ alkenyl, C₄₋₆ alkenyl, C₄₋₅ alkenyl, C₅₋₁₀ alkenyl, C₅₋₉ alkenyl, C₅₋₈ alkenyl, C₅₋₇ alkenyl, C₅₋₆ alkenyl, C₆₋₁₀ alkenyl, C₆₋₉ alkenyl, C₆₋₈ alkenyl, C₇₋₁₀ alkenyl, C₇₋₉ alkenyl, C₇₋₈ alkenyl, C₈₋₁₀
- 15 alkenyl, C₈₋₉ alkenyl and C₉₋₁₀ alkenyl are as defined above but contain different numbers of carbon atoms.

The term “C₁₋₄ alkoxy” refers to a C₁₋₄ alkyl group (e.g. C₁₋₃ alkyl group, C₁₋₂ alkyl group or C₁ alkyl group) as defined above, singularly bonded to oxygen. The term encompasses methoxy, ethoxy,

20 1-propoxy and 2-propoxy, and is suitably methoxy.

The term “C₁₋₄ haloalkyl” (e.g. C₁₋₃ haloalkyl group, C₁₋₂ haloalkyl group or C₁ haloalkyl group) as used herein refers to a straight or a branched fully saturated hydrocarbon chain containing the specified number of carbon atoms and at least one halogen atom, such as fluoro or chloro,

25 especially fluoro. An example of haloalkyl is CF₃. Further examples of haloalkyl are CHF₂ and CH₂CF₃.

The term “C₁₋₄ haloalkoxy” refers to a C₁₋₄ haloalkyl group (e.g. C₁₋₃ haloalkyl group, C₁₋₂ haloalkyl group or C₁ haloalkyl group) as defined above, singularly bonded to oxygen. Examples of C₁₋₄

30 haloalkoxy include OCF₃, OCHF₂ and OCH₂CF₃.

The term “C₃₋₁₀ cycloalkyl” refers to a fully saturated cyclic hydrocarbon group having from 3 to 10 carbon atoms. The term encompasses cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl as well as bridged systems such as

35 bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl and adamantyl. Other cycloalkyl groups, for example C₃₋₉ cycloalkyl, C₃₋₈ cycloalkyl, C₃₋₇ cycloalkyl, C₃₋₆ cycloalkyl, C₃₋₅ cycloalkyl, C₃₋₄ cycloalkyl, C₄₋₁₀ cycloalkyl, C₄₋₉ cycloalkyl, C₄₋₈ cycloalkyl, C₄₋₇ cycloalkyl, C₄₋₆ cycloalkyl, C₄₋₅

cycloalkyl, C₅₋₁₀ cycloalkyl, C₅₋₉ cycloalkyl, C₅₋₈ cycloalkyl, C₅₋₇ cycloalkyl, C₅₋₆ cycloalkyl, C₆₋₁₀ cycloalkyl, C₆₋₉ cycloalkyl, C₆₋₈ cycloalkyl, C₆₋₇ cycloalkyl, C₇₋₁₀ cycloalkyl, C₇₋₉ cycloalkyl, C₇₋₈ cycloalkyl, C₈₋₁₀ cycloalkyl, C₈₋₉ cycloalkyl and C₉₋₁₀ cycloalkyl are as defined above but contain different numbers of carbon atoms.

5


The term “C₅₋₁₀ spirocycloalkyl” refers to a bicyclic cycloalkyl group wherein the two rings are connected through just one atom. The rings can be different or identical. The term encompasses spiro[3.3]heptyl. Other spirocycloalkyl groups, for example C₅₋₉ spirocycloalkyl, C₅₋₈ spirocycloalkyl and C₅₋₇ spirocycloalkyl are as defined above but contain different numbers of carbon atoms.

10

The term “4–10 membered heterocyclyl” refers to a non-aromatic cyclic group having 4 to 10 ring atoms and at least one heteroatom selected from N, O, S and B. The term “heterocyclyl” is interchangeable with “heterocyclic ring”. The term encompasses oxetanyl, thietanyl, azetidyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and homomorpholinyl. Other heterocyclyl groups, for example, 4–9 membered heterocyclyl, 4–8 membered heterocyclyl, 4–7 membered heterocyclyl, 4–6 membered heterocyclyl and 4–5 membered heterocyclyl are as defined above but contain different numbers of ring atoms. 4–10 membered (e.g. 4–7 membered or 4-6 membered) heterocyclyl groups can typically be substituted by one or more oxo groups. Suitably, thietanyl is substituted by one or two oxo groups. Bicyclic heterocyclic compounds are also encompassed, such as the following:

15

20



25

The term “6–10 membered heterospirocyclyl” refers to a bicyclic non aromatic group having 6-10 ring atoms and at least one heteroatom selected from N, O, S and B, wherein the two rings are connected through just one atom. The term encompasses the following group



30

. Other heterospirocyclyl groups, for example 6–9 membered heterospirocyclyl, 6–8 membered heterospirocyclyl, 7–10 membered heterospirocyclyl, 7–9 membered heterospirocyclyl and 7–8 membered heterospirocyclyl are as defined above but contain different numbers of ring atoms.

The term “hydroxy” (which may also be referred to as “hydroxyl”) refers to an -OH group.

The term “oxo” refers to a =O substituent, whereby an oxygen atom is doubly bonded to carbon (e.g. C=O) or another element (e.g. S=O, S(=O)₂). The carbon or other element is suitably an atom of an alkyl, cycloalkyl, spirocycloalkyl or heterocyclyl group.

- 5 The term “5-6 membered heteroaryl” refers to a cyclic group with aromatic character having 5-6 ring atoms, at least one of which is a heteroatom independently selected from N, O and S. The term encompasses pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, oxazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyradiziny and pyrazinyl.
- 10 The term “halo” as used herein, refers to fluorine, chlorine, bromine or iodine. Particular examples of halo are fluorine and chlorine, especially fluorine.

Where substituents are indicated as being *optionally substituted* in formulae (IW-1), (IW), (IW-a), (IW-b), (IW-c), (IW-d), (IW-e), (IY), (I), (IWA), (IYA), (IA), (IWB), (IYB), (IB), (IWC), (IC), (IWD-1), (IYD-1), (ID-1), (IWD-2), (IYD-2), (ID-2) and (IWE) in the embodiments and preferences set out
 15 below, said substituents are optionally substituted as specified in the given formula unless stated otherwise, even if the possible substitution is not explicitly listed in the embodiment.

In one embodiment, R^A is selected from the group consisting of C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₃₋₁₀ cycloalkyl, C₅₋₁₀ spirocycloalkyl, 6–10 membered heterospirocyclyl and 4–10 membered heterocyclyl.

20

Suitably, R^A is selected from the group consisting of C₁₋₈ alkyl, C₂₋₈ alkenyl, C₃₋₈ cycloalkyl, C₅₋₈ spirocycloalkyl, 6–9 membered heterospirocyclyl and 4–7 membered heterocyclyl. Suitably, R^A is
 25 selected from the group consisting of C₁₋₈ alkyl, C₃₋₈ cycloalkyl and 4–7 membered heterocyclyl.

Suitably, R^A is selected from the group consisting of C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₃₋₁₀ cycloalkyl and C₅₋₁₀ spirocycloalkyl. Suitably, R^A is selected from the group consisting of C₆₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₆₋₁₀ cycloalkyl and C₅₋₁₀ spirocycloalkyl, such as R^A is selected from the group consisting of C₆₋₁₀ alkyl and C₆₋₁₀ cycloalkyl. Alternatively, R^A is selected from the group consisting of methyl,
 30 ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, heptyl-CH(CH₃)-, hexyl-CH(CH₃)- and C₈ cycloalkyl.

Suitably, R^A is C₁₋₁₀ alkyl, in particular C₁₋₈ alkyl.

35

Suitably, R^A is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl and n-octyl, and in particular is selected from the group consisting of

methyl, ethyl, n-propyl, iso-propyl, n-butyl, n-hexyl and n-octyl.


Suitably, R^A is C_{6-10} alkyl, in particular n-heptyl, n-octyl, heptyl-CH(CH₃)– and hexyl-CH(CH₃)–, such as hexyl-CH(CH₃)–.

5

Suitably, R^A is n-pentyl-C(CH₃)₂– or n-hexyl-C(CH₃)₂–.

Suitably, R^A is n-hexyl-CH(CH₃)–, n-pentyl-C(CH₃)₂– or n-hexyl-C(CH₃)₂–.

10 Most suitably, R^A is hexyl-CH(CH₃)– and has the following structure:




In one embodiment, R^A is C_{2-10} alkenyl, e.g. C_{3-10} alkenyl, in particular CH₂CH=CH₂ or CH=CHCH₃. Alternatively, R^A is C_{2-8} alkenyl.

15

In one embodiment, R^A is C_{3-10} cycloalkyl, in particular C_{3-8} cycloalkyl. Suitably, R^A is C_{6-10} cycloalkyl, in particular C_8 cycloalkyl.

Suitably, R^A is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, 20 cyclohexyl, cycloheptyl, cyclooctyl and bicyclo[2.2.1]heptyl; and in particular is cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl or bicyclo[2.2.1]heptyl. Alternatively, R^A is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, and in particular is cyclobutyl or cyclooctyl. Suitably, R^A is cyclooctyl. Alternatively R^A is cyclobutyl.

25 Suitably, R^A is 1-adamantyl:




In one embodiment, R^A is C_{5-10} spirocycloalkyl, such as C_{5-8} spirocycloalkyl, and in particular is spiro[3.3]heptyl.

30

In one embodiment, R^A is 4–10 membered heterocyclyl, in particular 4–7 membered or 4-6 membered heterocyclyl, such as 4-7 membered heterocyclyl. Suitably, R^A is 4-10 membered (e.g. 4–7 membered or 4-6 membered, such as 4-7 membered heterocyclyl) heterocyclyl containing one or two heteroatoms independently selected from N, O and S. Suitably, R^A is selected from

the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, thiomorpholinyl and morpholinyl. In one embodiment, R^A is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperazinyl, piperidinyl, thiomorpholinyl and morpholinyl, all of which are optionally substituted by one or more oxo groups. Suitably, R^A is 4 membered heterocyclyl e.g. selected from the group consisting of azetidiny, oxetanyl and thietanyl. Suitably, thietanyl is substituted by one or two oxo groups.

In one embodiment, R^A is 6–10 membered heterospirocyclyl, e.g. 7-10 membered heterospirocyclyl or 6-9 membered heterospirocyclyl, such as 6-9 membered heterospirocyclyl and in particular is:




In one embodiment, R^A e.g. as defined above, is not substituted. Suitably, R^A is hexyl-CH(CH₃)- and is not substituted.

In another embodiment, R^A e.g. as defined above, is substituted.

In one embodiment, R^A is substituted by one or more substituents selected from the group consisting of oxo, R^{1A} , $NR^{2A}R^{3A}$, SR^{2A} , SOR^{9A} , SO_2R^{9A} , $SO_2NR^{2A}R^{3A}$, $C(O)R^{2A}$ and $CONR^{2A}R^{3A}$. Suitably, the one or more substituent is R^{1A} . Suitably, R^A is substituted by one R^{1A} . Alternatively, R^A is substituted by two R^{1A} . Alternatively, R^A is substituted by three R^{1A} . In any one of the above embodiments, R^{1A} may be the same or different.

When R^A is substituted by at least one R^{1A} group the substituent may replace any C-H bond present in R^A . When R^A is substituted by at least two R^{1A} groups, the R^{1A} groups may be on the same carbon atom or different carbon atoms. When R^A is a cyclic group, such as C_{3–10} cycloalkyl, C_{5–10} spirocycloalkyl, 6–10 membered heterospirocyclyl and 4–10 membered heterocyclyl, the group may be substituted at the point of attachment of R^A to the oxygen atom such that the following structures form:



In one embodiment, R^{1A} is selected from the group consisting of fluoro, methyl, CO₂H, cyano, SiR^{4A}R^{5A}R^{6A}, 4–7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl; and in particular

is selected from the group consisting of fluoro, methyl, cyano, $\text{SiR}^{4\text{A}}\text{R}^{5\text{A}}\text{R}^{6\text{A}}$ and phenyl. In a second embodiment, $\text{R}^{1\text{A}}$ is selected from the group consisting of methyl, cyano, $\text{SiR}^{4\text{A}}\text{R}^{5\text{A}}\text{R}^{6\text{A}}$, C_{3-8} cycloalkyl, phenyl and 5-6 membered heteroaryl.

5 Suitably, $\text{R}^{1\text{A}}$ is fluoro. Alternatively, $\text{R}^{1\text{A}}$ is methyl. Alternatively, $\text{R}^{1\text{A}}$ is COOH . Alternatively, $\text{R}^{1\text{A}}$ is cyano. Alternatively, $\text{R}^{1\text{A}}$ is $\text{SiR}^{4\text{A}}\text{R}^{5\text{A}}\text{R}^{6\text{A}}$. Alternatively, $\text{R}^{1\text{A}}$ is C_{3-8} cycloalkyl. Alternatively, $\text{R}^{1\text{A}}$ is 4–7 membered heterocyclyl. Alternatively, $\text{R}^{1\text{A}}$ is phenyl. Alternatively, $\text{R}^{1\text{A}}$ is 5-6 membered heteroaryl.

10 Most suitably, $\text{R}^{1\text{A}}$ is selected from fluoro, methyl, C_{3-8} cycloalkyl and phenyl, such as fluoro and phenyl, especially fluoro.

In another embodiment, R^{A} is substituted by one phenyl group. In another embodiment, R^{A} is substituted by three fluoro groups. Suitably the three fluoro groups are attached to the same
15 terminal carbon atom to form a CF_3 group.

In one embodiment, $\text{R}^{4\text{A}}$, $\text{R}^{5\text{A}}$ and $\text{R}^{6\text{A}}$ are independently selected from the group consisting of C_{1-4} alkyl and phenyl. Suitably, $\text{R}^{4\text{A}}$, $\text{R}^{5\text{A}}$ and $\text{R}^{6\text{A}}$ are independently selected from the group consisting of methyl, ethyl, isopropyl, tert-butyl and phenyl. In one embodiment, the phenyl group
20 is not substituted. In another embodiment the phenyl group is substituted by one or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo. Suitably the substituent is C_{1-4} alkyl. Alternatively, the substituent is C_{1-4} alkoxy. Alternatively, the substituent is hydroxy. Alternatively, the substituent is CO_2H . Alternatively, the substituent is cyano. Alternatively, the substituent is methanesulfonyl.
25 Alternatively, the substituent is halo. In one embodiment, the phenyl group is substituted by one substituent as defined above. In one embodiment, the phenyl group is substituted by two substituents as defined above. In one embodiment, the phenyl group is substituted by three substituents as defined above. In any one of the above embodiments, the substituents may be the same or different.

30 In one embodiment, $\text{R}^{1\text{A}}$ is substituted by $\text{R}^{7\text{A}}$ and/or $\text{R}^{8\text{A}}$ when $\text{R}^{1\text{A}}$ is methyl, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, such as methyl or phenyl. Suitably, $\text{R}^{1\text{A}}$ is substituted by $\text{R}^{7\text{A}}$ and $\text{R}^{8\text{A}}$. Alternatively, $\text{R}^{1\text{A}}$ is substituted by $\text{R}^{7\text{A}}$ or $\text{R}^{8\text{A}}$. In one embodiment, $\text{R}^{1\text{A}}$ is not substituted by $\text{R}^{7\text{A}}$ and/or $\text{R}^{8\text{A}}$ when $\text{R}^{1\text{A}}$ is methyl, C_{3-8} cycloalkyl, 4–7
35 membered heterocyclyl, phenyl or 5-6 membered heteroaryl. In one embodiment $\text{R}^{1\text{A}}$ is substituted by $\text{R}^{7\text{A}}$ and $\text{R}^{8\text{A}}$ is absent.

In one embodiment, R^{7A} and R^{8A} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo; or, taken together, R^{7A} and R^{8A} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring.

5 Suitably, R^{7A} and R^{8A} are independently selected from the group consisting of oxo, methyl, ethyl, methoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo (e.g. fluoro) such as oxo, methyl, ethyl, methoxy, hydroxy, cyano, methanesulfonyl and halo (e.g. fluoro); or, taken together, R^{7A} and R^{8A} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring. In one embodiment, R^{7A} and R^{8A} are fluoro. In one embodiment, R^{7A} and R^{8A} are chloro. In one embodiment, R^{7A} and R^{8A} are
10 independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, cyano, methanesulfonyl and halo.

Suitably, R^{7A} is oxo. Alternatively, R^{7A} is C_{1-4} alkyl, such as methyl. Alternatively, R^{7A} is C_{1-4} alkoxy such as methoxy. Alternatively, R^{7A} is C_{1-4} haloalkyl such as CF_3 . Alternatively, R^{7A} is C_{1-4}
15 haloalkoxy such as OCF_3 . Alternatively, R^{7A} is hydroxy. Alternatively, R^{7A} is CO_2H . Alternatively, R^{7A} is cyano. Alternatively, R^{7A} is methanesulfonyl. Alternatively, R^{7A} is halo such as chloro or fluoro, e.g., chloro. In any one of the above embodiments, suitably R^{8A} is absent. Most suitably, R^{7A} is halo such as chloro or fluoro, e.g., chloro, or C_{1-4} haloalkyl such as CF_3 and R^{8A} is absent.

20 Suitably, R^{8A} is oxo. Alternatively, R^{8A} is C_{1-4} alkyl, such as methyl. Alternatively, R^{8A} is C_{1-4} alkoxy such as methoxy. Alternatively, R^{8A} is C_{1-4} haloalkyl such as CF_3 . Alternatively, R^{8A} is C_{1-4} haloalkoxy such as OCF_3 . Alternatively, R^{8A} is hydroxy. Alternatively, R^{8A} is CO_2H . Alternatively, R^{8A} is cyano. Alternatively, R^{8A} is methanesulfonyl. Alternatively, R^{8A} is halo such as chloro or fluoro, e.g., chloro. In any one of the above embodiments, suitably R^{7A} is absent.

25 In another embodiment, taken together, R^{7A} and R^{8A} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring. Suitably, R^{7A} and R^{8A} form a C_{3-8} cycloalkyl ring such as a C_{3-6} cycloalkyl ring. Suitably, R^{7A} and R^{8A} form a 4–7 membered heterocyclic ring such as a 4–6 membered heterocyclic ring.

30 In one embodiment, R^{2A} and R^{3A} are independently H, C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl. Suitably, R^{2A} and R^{3A} are independently H, C_{1-4} alkyl, C_{3-8} cycloalkyl or phenyl.

Suitably, R^{2A} is H. Alternatively, R^{2A} is C_{1-8} alkyl, such as C_{1-4} alkyl e.g. methyl. Alternatively, R^{2A}
35 is C_{3-8} cycloalkyl such as C_{3-6} cycloalkyl. Alternatively, R^{2A} is phenyl.

In one embodiment, R^{2A} is methyl or phenyl, in particular phenyl.

Suitably, R^{3A} is H. Alternatively, R^{3A} is C_{1-8} alkyl, such as C_{1-4} alkyl e.g. methyl. Alternatively, R^{3A} is C_{3-8} cycloalkyl, such as C_{3-6} cycloalkyl. Alternatively, R^{3A} is phenyl.

5 In one embodiment, R^{3A} is methyl.

In one embodiment, R^{2A} and R^{3A} are not substituted. In another embodiment, R^{2A} and R^{3A} are substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qA}W^A$. In one embodiment, R^{2A} is substituted as described
10 herein and R^{3A} is not substituted. In one embodiment, R^{2A} is not substituted and R^{3A} is substituted as described herein. Suitably, the substituent is C_{1-8} alkyl such as methyl or ethyl. Alternatively, the substituent is C_{1-4} alkoxy such as methoxy. Alternatively, the substituent is fluoro. Alternatively, the substituent is hydroxy. Alternatively, the substituent is oxo. Alternatively, the substituent is $-(CH_2)_{qA}W^A$. Suitably, R^{2A} and/or R^{3A} are substituted by one substituent.
15 Alternatively, R^{2A} and/or R^{3A} are substituted by two substituents. Alternatively, R^{2A} and/or R^{3A} are substituted by three substituents. In any one of the above embodiments, the substituents may be the same or different.

In one embodiment, R^{2A} and R^{3A} form a 4–7 membered heterocyclic ring optionally independently
20 substituted by one or more substituents selected from the group consisting of C_{1-2} alkyl, hydroxy and oxo. Suitably, the 4–7 membered heterocyclic ring is not substituted. Alternatively, the 4–7 membered heterocyclic ring is substituted by one or more substituents selected from the group consisting of C_{1-2} alkyl, hydroxy and oxo. Suitably the substituent is C_{1-2} alkyl such as methyl. Alternatively, the substituent is hydroxy. Alternatively, the substituent is oxo. Suitably, the 4–7
25 membered heterocyclic ring is substituted by one substituent. Alternatively, the 4–7 membered heterocyclic ring is substituted by two substituents. Alternatively, the 4–7 membered heterocyclic ring is substituted by three substituents. In any one of the above embodiments, the substituents may be the same or different.

30 In one embodiment, R^{9A} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl. Suitably, R^{9A} is C_{1-4} alkyl, C_{3-8} cycloalkyl or phenyl. Suitably, R^{9A} is C_{1-4} alkyl such as methyl. Alternatively, R^{9A} is C_{3-8} cycloalkyl such as C_{3-5} cycloalkyl. Alternatively, R^{9A} is phenyl.

In one embodiment, R^{9A} is methyl or phenyl, in particular phenyl.

35 In one embodiment, R^{9A} is not substituted. In another embodiment, R^{9A} is substituted by C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qA}W^A$. Suitably, the substituent is C_{1-8} alkyl such as

methyl or ethyl. Alternatively, the substituent is C₁₋₄ alkoxy such as methoxy. Alternatively, the substituent is fluoro. Alternatively, the substituent is hydroxy. Alternatively, the substituent is oxo. Alternatively, the substituent is -(CH₂)_{qA}W^A. Suitably, R^{9A} is substituted by one substituent. Alternatively, R^{9A} is substituted by two substituents. Suitably, R^{9A} is substituted by three substituents. In any one of the above embodiments, the substituents may be the same or different.

In one embodiment, W^A is selected from the group consisting of C₃₋₈ cycloalkyl, phenyl and 5-6 membered heteroaryl. Suitably, W^A is selected from the group consisting of C₃₋₈ cycloalkyl and phenyl. In one embodiment, W^A is not substituted. In another embodiment, W^A is substituted by one or more substituents selected from the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxy, CO₂H, cyano, methanesulfonyl and halo. Suitably, the substituent is C₁₋₄ alkyl such as methyl or ethyl. Alternatively, the substituent is C₁₋₄ alkoxy such as methoxy. Alternatively, the substituent is hydroxy. Alternatively, the substituent is CO₂H. Alternatively, the substituent is cyano. Alternatively, the substituent is methanesulfonyl. Alternatively, the substituent is halo such as fluoro. Suitably, W^A is substituted by one substituent. Alternatively, W^A is substituted by two substituents. Suitably, W^A is substituted by three substituents. In any one of the above embodiments, the substituents may be the same or different.

In one embodiment, q_A is 0. In one embodiment, q_A is 1.

In one embodiment, R^A contains 6 or more carbon atoms, such as 6, 7, 8, 9 or 10 carbon atoms, such as 8, 9 or 10 carbon atoms. Suitably, R^A contains 6 carbon atoms. Alternatively, R^A contains 7 carbon atoms. Alternatively, R^A contains 8 carbon atoms. Alternatively, R^A contains 9 carbon atoms. Alternatively, R^A contains 10 carbon atoms.

In one embodiment, R^B is selected from the group consisting of C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₃₋₁₀ cycloalkyl, C₅₋₁₀ spirocycloalkyl and 4-10 membered heterocyclyl. Suitably, R^B is selected from the group consisting of C₁₋₈ alkyl, C₂₋₈ alkenyl, C₃₋₈ cycloalkyl and 4-7 membered heterocyclyl. Suitably, R^B is selected from the group consisting of C₁₋₈ alkyl, C₃₋₈ cycloalkyl and 4-7 membered heterocyclyl. Alternatively, R^B is selected from the group consisting of C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₃₋₆ cycloalkyl, C₅₋₁₀ spirocycloalkyl and 4-10 membered heterocyclyl. Alternatively, R^B is selected from the group consisting of C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₅₋₁₀ spirocycloalkyl and 4-10 membered heterocyclyl.

In one embodiment, R^B is C₁₋₁₀ alkyl, in particular C₁₋₈ alkyl, C₁₋₄ alkyl, C₁₋₃ alkyl or C₁₋₂ alkyl. In one embodiment, R^B is C₁₋₂ alkyl. Suitably, R^B is C₁₋₁₀ alkyl, such as C₁₋₂ alkyl substituted by R^{1B}. When R^B is C₁₋₁₀ alkyl, in particular C₁₋₈ alkyl such as C₁₋₄ alkyl e.g. C₁₋₃ alkyl e.g. C₁₋₂ alkyl,

suitably the alkyl group is n-alkyl.

Suitably, R^B is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl and n-octyl, and in particular is selected from the group
5 consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl and tert-butyl, such as methyl and ethyl.

In one embodiment, R^B is C_{2-10} alkenyl e.g. C_{3-10} alkenyl, in particular $CH_2CH=CH_2$ or $CH=CHCH_3$.
Alternatively, R^B is C_{2-8} alkenyl.

10 In one embodiment, R^B is C_{3-10} cycloalkyl, in particular C_{3-8} cycloalkyl such as C_{3-6} cycloalkyl.

Suitably, R^B is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and bicyclo[2.2.1]heptyl; and in particular is cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl or bicyclo[2.2.1]heptyl. In another embodiment, R^B is selected
15 from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, and in particular is cyclobutyl. In another embodiment, R^B is selected from the group consisting of cyclobutyl and cyclohexyl.

In one embodiment, R^B is C_{5-10} spirocycloalkyl, such as C_{5-8} spirocycloalkyl, and in particular is
20 spiro[3.3]heptyl.

In one embodiment, R^B is 4–10 membered heterocyclyl, in particular 4–7 membered or 4-6 membered heterocyclyl, such as 4-7 membered heterocyclyl. Suitably, R^B is 4-10 membered (e.g. 4–7 membered or 4-6 membered) heterocyclyl containing one or two heteroatoms independently
25 selected from N, O and S. Alternatively, R^B is 4-10 membered (e.g. 4–7 membered or 4-6 membered) heterocyclyl containing one N atom. Alternatively, R^B is 4-10 membered (e.g. 4–7 membered or 4-6 membered) heterocyclyl containing one O atom. In one embodiment, R^B is 4-10 membered (e.g. 4–7 membered or 4-6 membered) heterocyclyl containing one S atom.
Suitably, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, thiomorpholinyl and morpholinyl. Suitably, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperazinyl, piperidinyl, thiomorpholinyl and morpholinyl, all of which are optionally substituted by one or more oxo groups. Suitably, R^B is
30 selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl and morpholinyl. Suitably, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl and morpholinyl, all of which are optionally substituted by one or more oxo groups. Suitably, R^B is
35

selected from the group consisting of oxetanyl, thietanyl optionally substituted by one or more oxo groups, azetidiny, tetrahydrofuranyl, pyrrolidiny optionally substituted by one or more oxo groups, tetrahydropyranyl, piperidiny and morpholiny. Suitably, thietanyl is substituted by one or two oxo groups (e.g. to form a ring containing S=O or S(=O)₂ functionality).


5

In one embodiment, R^B is not substituted. In another embodiment, R^B is substituted. Suitably, R^B is substituted by SO₂R^{9B}. Alternatively, R^B is substituted by R^{1B}. Suitably, R^B is substituted by one R^{1B}. Alternatively, R^B is substituted by two R^{1B}. Alternatively, R^B is substituted by three R^{1B}. In any one of the above embodiments, R^{1B} may be the same or different.

10


When R^B is substituted by at least one R^{1B} group the substituent may replace any C-H bond present in R^B. When R^B is substituted by at least two R^{1B} groups, the R^{1B} groups may be on the same carbon atom or different carbon atoms. When R^B is a cyclic group, such as C₃₋₁₀ cycloalkyl, C₅₋₁₀ spirocycloalkyl and 4-10 membered heterocyclyl, the group may be substituted at the point of attachment of R^B to the oxygen atom such that the following structures form:

15



When R^B is n-C₁₋₁₀ alkyl, in particular n-C₁₋₈ alkyl such as n-C₁₋₄ alkyl e.g. n-C₁₋₃ alkyl e.g. n-C₁₋₂ alkyl, and is substituted by at least one (such as one) R^{1B}, suitably at least one (such as one) R^{1B} is attached to the terminal carbon i.e. such that the following moiety forms:


20



wherein p is 1 to 10 in particular 1 to 8 such as 1 to 4 e.g. 1 to 3 e.g. 1 to 2.

When R^B is C₁₋₁₀ alkyl, in particular C₁₋₈ alkyl such as C₁₋₄ alkyl e.g. C₁₋₃ alkyl e.g. C₁₋₂ alkyl, and is substituted by at least one (such as one) R^{1B}, suitably the carbon atom of R^B adjacent to the ester oxygen atom is also attached to at least one (such as one) hydrogen atom i.e. such that the following moiety forms:

25



wherein p is 0 to 9 in particular 0 to 7 such as 0 to 3 e.g. 0 to 2 e.g. 0 to 1.

30

In one embodiment, R^{1B} is selected from the group consisting of halo, trifluoromethyl, methyl, CO₂H, cyano, SiR^{4B}R^{5B}R^{6B}, C₃₋₈ cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl. Suitably, R^{1B} is selected from the group consisting of trifluoromethyl,

methyl CO₂H, cyano, C₃₋₈ cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl; and in particular is selected from the group consisting of trifluoromethyl, methyl, CO₂H, cyano, C₃₋₄ cycloalkyl and phenyl, and is suitably trifluoromethyl, CO₂H, cyano or cyclopropyl.

- 5 Suitably, R^{1B} is halo e.g. fluoro. Alternatively, R^{1B} is trifluoromethyl. Alternatively, R^{1B} is methyl. Alternatively, R^{1B} is CO₂H. Alternatively, R^{1B} is cyano. Alternatively, R^{1B} is SiR^{4B}R^{5B}R^{6B}. Alternatively, R^{1B} is C₃₋₈ cycloalkyl such as C₃₋₅ cycloalkyl. Alternatively, R^{1B} is 4-7 membered heterocyclyl such as a 6 membered heterocyclyl e.g. a piperidinyl. Alternatively, R^{1B} is phenyl. Alternatively, R^{1B} is 5-6 membered heteroaryl, in particular tetrazolyl, e.g., 5-tetrazolyl.

10


Most suitably, R^{1B} is CO₂H. In one embodiment, R^B is C₁ alkyl and R^{1B} is CO₂H. Suitably, R^B is C₁ alkyl, R^{1B} is CO₂H and the carbon atom of the C₁ alkyl adjacent to the ester oxygen atom is also attached to at least one (such as one) hydrogen atom. In another embodiment, R^B is C₂ alkyl and R^{1B} is CO₂H. Suitably, R^B is C₂ alkyl and R^{1B} is CO₂H and the carbon atom of R^B adjacent to the ester oxygen atom is also attached to at least one (such as one) hydrogen atom. In any one of these embodiments, suitably R^B is not further substituted.

15

In one embodiment, R^B (in particular when R^B is C₁₋₁₀ alkyl, in particular C₁₋₈ alkyl, C₁₋₄ alkyl, C₁₋₃ alkyl or C₁₋₂ alkyl e.g. C₁₋₂ alkyl) is substituted by CO₂H. Suitably, R^B (in particular when R^B is C₁₋₁₀ alkyl, in particular C₁₋₈ alkyl, C₁₋₄ alkyl, C₁₋₃ alkyl or C₁₋₂ alkyl e.g. C₁₋₂ alkyl) is substituted by CO₂H and at least one other substituent selected from the group consisting of halo, trifluoromethyl, methyl, cyano, SiR^{4B}R^{5B}R^{6B}, C₃₋₈ cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl, such as halo, trifluoromethyl and methyl. Suitably, R^B is substituted by CO₂H and one further substituent selected from the group consisting of halo, e.g., fluoro, trifluoromethyl, methyl, cyano, SiR^{4B}R^{5B}R^{6B}, C₃₋₈ cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl, such as halo e.g. fluoro, trifluoromethyl and methyl, such as methyl and trifluoromethyl e.g. trifluoromethyl. Suitably the CO₂H is attached to the terminal carbon of the alkyl group and the one further substituent is attached to the carbon atom of R^B adjacent to the ester oxygen atom. Suitably, R^B is substituted by CO₂H and two further substituents selected from the group consisting of halo e.g. fluoro, trifluoromethyl, cyano, SiR^{4B}R^{5B}R^{6B}, C₃₋₈ cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl, such as halo, e.g., fluoro and trifluoromethyl. Suitably the CO₂H is attached to the terminal carbon of the alkyl group and one of the two further substituents is attached to the carbon atom of R^B adjacent to the ester oxygen atom.

35

By the term “one further substituent is attached to the carbon atom of R^B adjacent to the ester oxygen atom” it is meant that the following moiety forms:



wherein p is 0 to 9 in particular 0 to 7 such as 0 to 3 e.g. 0 to 2 e.g. 0 to 1.

In one embodiment, R^{4B} , R^{5B} and R^{6B} are independently selected from the group consisting of C_{1-4} alkyl and phenyl. Suitably R^{4B} , R^{5B} and R^{6B} are independently selected from the group consisting of methyl, ethyl, iso-propyl, tert-butyl and phenyl. In one embodiment, the phenyl group is not substituted. In another embodiment the phenyl group is substituted by one or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo. Suitably the substituent is C_{1-4} alkyl. Alternatively, the substituent is C_{1-4} alkoxy. Alternatively, the substituent is hydroxy. Alternatively, the substituent is CO_2H . Alternatively, the substituent is cyano. Alternatively, the substituent is methanesulfonyl. Alternatively, the substituent is halo. In one embodiment, the phenyl group is substituted by one substituent as defined above. In one embodiment, the phenyl group is substituted by two substituents as defined above. In one embodiment, the phenyl group is substituted by three substituents as defined above. In any one of the above embodiments, the substituents may be the same or different.

In one embodiment, R^{1B} is substituted by R^{7B} and/or R^{8B} when R^{1B} is methyl, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl. Suitably, R^{1B} is substituted by R^{7B} and R^{8B} . Alternatively, R^{1B} is substituted by R^{7B} or R^{8B} . In one embodiment, R^{1B} is not substituted by R^{7B} and/or R^{8B} when R^{1B} is methyl, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl. In one embodiment, R^{1B} is substituted by R^{7B} and R^{8B} is absent.

In one embodiment, R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , $CO_2(C_{1-6}$ alkyl), cyano, methanesulfonyl and halo. Suitably, R^{7B} and R^{8B} are independently selected from the group consisting of oxo, methyl, ethyl, methoxy, hydroxy, CO_2H , $CO_2(C_{1-2}$ alkyl), cyano, methanesulfonyl and halo (e.g. fluoro); or, taken together, R^{7B} and R^{8B} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring.

In one embodiment, R^{7B} and R^{8B} are independently selected from the group consisting of oxo, methyl, ethyl, methoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo (e.g. fluoro); or, taken together, R^{7B} and R^{8B} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring. In one embodiment, R^{7B} and R^{8B} are cyano or fluoro e.g. fluoro.

Suitably, R^{7B} is oxo. Alternatively, R^{7B} is C_{1-4} alkyl such as methyl and ethyl. Alternatively, R^{7B} is

C₁₋₄ alkoxy such as methoxy. Alternatively, R^{7B} is hydroxy. Alternatively, R^{7B} is CO₂H. Alternatively, R^{7B} is CO₂(C₁₋₆ alkyl) such as CO₂(C₁₋₂ alkyl). Alternatively, R^{7B} is cyano. Alternatively, R^{7B} is methanesulfonyl. Alternatively, R^{7B} is halo such as fluoro. In any one of the above embodiments, suitably R^{8B} is absent.

5

Suitably, R^{8B} is oxo. Alternatively, R^{8B} is C₁₋₄ alkyl such as methyl and ethyl. Alternatively, R^{8B} is C₁₋₄ alkoxy such as methoxy. Alternatively, R^{8B} is hydroxy. Alternatively, R^{8B} is CO₂H. Alternatively, R^{8B} is CO₂(C₁₋₆ alkyl) such as CO₂(C₁₋₂ alkyl). Alternatively, R^{8B} is cyano. Alternatively, R^{8B} is methanesulfonyl. Alternatively, R^{8B} is halo such as fluoro. In any one of the

10

In another embodiment, taken together, R^{7B} and R^{8B} form a C₃₋₈ cycloalkyl or 4-7 membered heterocyclic ring. Suitably, R^{7B} and R^{8B} form a C₃₋₈ cycloalkyl ring such as a C₃₋₅ cycloalkyl ring. Suitably, R^{7B} and R^{8B} form a 4-7 membered heterocyclic ring such as a 4-6 membered

15

In one embodiment, R^{2B} and R^{3B} are independently H, C₁₋₈ alkyl, C₃₋₈ cycloalkyl or phenyl. Suitably, R^{2B} and R^{3B} are independently H, C₁₋₄ alkyl, C₃₋₈ cycloalkyl or phenyl.

20 In one embodiment, R^{2B} and/or R^{3B} are/is independently methyl, ethyl, tert-butyl or phenyl.

In one embodiment, R^{2B} and/or R^{3B} are/is optionally independently substituted by one or more substituents selected from the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, fluoro and oxo; and particular are/is optionally substituted by one or more substituents selected from the group

25

Suitably, R^{2B} is H. Alternatively, R^{2B} is C₁₋₈ alkyl, such as C₁₋₄ alkyl, e.g., methyl. Alternatively, R^{2B} is C₃₋₈ cycloalkyl such as C₃₋₆ cycloalkyl. Alternatively, R^{2B} is phenyl.

30 In one embodiment, R^B is substituted by OR^{2B}, wherein R^{2B} is acetyl.

In one embodiment, R^{2B} is methyl or phenyl.

Suitably, R^{3B} is H. Alternatively, R^{3B} is C₁₋₈ alkyl, such as C₁₋₄ alkyl, e.g., methyl. Alternatively,

35

In one embodiment, R^{3B} is methyl.

In one embodiment, R^{2B} and R^{3B} are not substituted. In another embodiment, R^{2B} and R^{3B} are substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$. In one embodiment, R^{2B} is substituted as described herein and R^{3B} is not substituted. In one embodiment, R^{2B} is not substituted and R^{3B} is substituted as described herein. Suitably, the substituent is C_{1-8} alkyl such as methyl or ethyl. Alternatively, the substituent is C_{1-4} alkoxy such as methoxy. Alternatively, the substituent is fluoro. Alternatively, the substituent is hydroxy. Alternatively, the substituent is oxo. Alternatively, the substituent is $-(CH_2)_{qB}W^B$. Suitably, R^{2B} and/or R^{3B} are substituted by one substituent. Alternatively, R^{2B} and/or R^{3B} are substituted by two substituents. Alternatively, R^{2B} and/or R^{3B} are substituted by three substituents. In any one of the above embodiments, the substituents may be the same or different.

In one embodiment, taken together, R^{2B} and R^{3B} form a 4–7 membered heterocyclic ring.

In one embodiment, taken together, R^{2B} and R^{3B} form a 5 membered heterocyclic ring; for example, taken together, R^{2B} and R^{3B} form pyrrolidine. In one embodiment, taken together, R^{2B} and R^{3B} form a 6 membered heterocyclic ring, for example morpholine.

In one embodiment, R^{2B} and R^{3B} form a 4–7 membered heterocyclic ring optionally independently substituted by one or more substituents selected from the group consisting of C_{1-2} alkyl, hydroxy and oxo. Suitably, the 4–7 membered heterocyclic ring is not substituted. Alternatively, the 4–7 membered heterocyclic ring is substituted by one or more substituents selected from the group consisting of C_{1-2} alkyl, hydroxy and oxo. Suitably the substituent is C_{1-2} alkyl such as methyl. Alternatively, the substituent is hydroxy. Alternatively, the substituent is oxo. Suitably, the 4–7 membered heterocyclic ring is substituted by one substituent. Alternatively, the 4–7 membered heterocyclic ring is substituted by two substituents. Alternatively, the 4–7 membered heterocyclic ring is substituted by three substituents. In any one of the above embodiments, the substituents may be the same or different.

In one embodiment, R^{9B} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl. Suitably, R^{9B} is C_{1-4} alkyl or phenyl e.g. is methyl or phenyl. Suitably, R^{9B} is C_{1-4} alkyl such as methyl. Alternatively, R^{9B} is C_{3-8} cycloalkyl such as C_{3-5} cycloalkyl. Alternatively, R^{9B} is phenyl.

In one embodiment, R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$. R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4}

alkoxy, fluoro, chloro, CO₂H and oxo. In another embodiment, R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, fluoro and oxo; and particular is optionally substituted by one or more substituents selected from the group consisting of methyl, fluoro and oxo e.g. selected from the group consisting of methyl and fluoro.

5

In one embodiment, R^{9B} is not substituted. In another embodiment, R^{9B} is substituted by C₁₋₈ alkyl, C₁₋₄ alkoxy, fluoro, hydroxy, oxo and -(CH₂)_{qB}W^B. Suitably, the substituent is C₁₋₈ alkyl such as methyl or ethyl. Alternatively, the substituent is C₁₋₄ alkoxy such as methoxy. Alternatively, the substituent is fluoro. Alternatively, the substituent is hydroxy. Alternatively, the substituent is oxo. Alternatively, the substituent is -(CH₂)_{qB}W^B. Suitably, R^{9B} is substituted by one substituent. Alternatively, R^{9B} is substituted by two substituents. Suitably, R^{9B} is substituted by three substituents. In any one of the above embodiments, the substituents may be the same or different.

10

15

In one embodiment, W^B is selected from the group consisting of C₃₋₈ cycloalkyl, phenyl and 5–6 membered heteroaryl. Suitably, W^B is selected from the group consisting of C₃₋₈ cycloalkyl and phenyl. In one embodiment, W^B is not substituted. In another embodiment, W^B is substituted by one or more substituents selected from the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxy, CO₂H, cyano, methanesulfonyl and halo. Suitably, the substituent is C₁₋₄ alkyl such as methyl or ethyl. Alternatively, the substituent is C₁₋₄ alkoxy such as methoxy. Alternatively, the substituent is hydroxy. Alternatively, the substituent is CO₂H. Alternatively, the substituent is cyano. Alternatively, the substituent is methanesulfonyl. Alternatively, the substituent is halo such as fluoro. Suitably, W^B is substituted by one substituent. Alternatively, W^B is substituted by two substituents. Suitably, W^B is substituted by three substituents. In any one of the above embodiments, the substituents may be the same or different.

20

25

In one embodiment, q^B is 0. In one embodiment, q^B is 1.

For a compound of formula (IW-1), or any other embodiment described herein, when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6. According to the present invention, heteroatoms include O, N, S, F, Cl, Br, I, P, B and Si. Carbon and hydrogen atoms are not heteroatoms.

30

In one embodiment, one of R^A and R^B contains a heteroatom, for example selected from the group consisting of O, N, S, F, Cl, P and Si e.g. selected from the group consisting of O, N, S and F.

35

In one embodiment, when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 7 such as 7. In one embodiment, when

neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 8 such as 8. In one embodiment, when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 9 such as 9.

5

In one embodiment, R^A is C_{6-10} alkyl or C_{6-10} cycloalkyl and R^B is C_{1-4} alkyl substituted by at least one R^{1B} group. Suitably, R^A is C_{6-10} alkyl such as C_8 alkyl. Alternatively, R^A is C_{6-10} cycloalkyl such as cyclooctyl. Suitably, R^B is C_{1-2} alkyl substituted by at least one R^{1B} group, such as one R^{1B} group. Suitably, the at least one (e.g. one) R^{1B} group is COOH. R^B may be further substituted by an additional R^{1B} group e.g. trifluoromethyl.

10

In one embodiment, R^C and R^D are independently selected from the group consisting of H, C_{1-2} alkyl, hydroxy, methoxy and fluoro. Suitably, R^C and R^D are independently selected from the group consisting of H, C_{1-2} alkyl, hydroxy and fluoro. In one embodiment, R^C and R^D are independently selected from the group consisting of H, methoxy and fluoro.

15

In one embodiment, R^C is H. In one embodiment, R^C is C_{1-2} alkyl, in particular methyl. In one embodiment, R^C is hydroxy. In one embodiment, R^C is fluoro. In one embodiment, R^C is methoxy.

20

In one embodiment, R^D is H. In one embodiment, R^D is C_{1-2} alkyl, in particular methyl. In one embodiment, R^D is hydroxy. In one embodiment, R^D is fluoro. In one embodiment, R^D is methoxy.

In one embodiment, R^C is H, C_{1-2} alkyl (in particular methyl), hydroxy or fluoro; and R^D is H, C_{1-2} alkyl (in particular methyl), or fluoro. In one embodiment, R^C is H, C_{1-2} alkyl (in particular methyl), hydroxy or fluoro; and R^D is H, C_{1-2} alkyl (in particular methyl) or fluoro. In one embodiment, R^C is H, C_{1-2} alkyl (in particular methyl), hydroxy or fluoro; and R^D is H or C_{1-2} alkyl (in particular methyl). In one embodiment, R^C is H, C_{1-2} alkyl (in particular methyl), hydroxy or fluoro; and R^D is H or fluoro. In one embodiment, R^C is H, C_{1-2} alkyl (in particular methyl), hydroxy or fluoro; and R^D is H. In one embodiment, R^C is H and R^D is H or C_{1-2} alkyl (in particular methyl). In one embodiment, R^C is H and R^D is H or fluoro. In one embodiment, R^C is H or C_{1-2} alkyl (in particular methyl); and R^D is H, C_{1-2} alkyl (in particular methyl), or fluoro. In one embodiment, R^C is H or C_{1-2} alkyl (in particular methyl); and R^D is H or C_{1-2} alkyl (in particular methyl). In one embodiment, R^C is H or C_{1-2} alkyl (in particular methyl); and R^D is H. In one embodiment, R^C is H and R^D is H. In one embodiment, both of R^C and R^D are not hydroxy. In one embodiment, R^C is methoxy and R^D is H.


35

In one embodiment, when R^B contains 2 or more carbon atoms and 4 or more heteroatoms, then R^A must contain 6 or more carbon atoms, and the number of carbon atoms in R^A must exceed

the number of heteroatoms in R^A by at least 3 atoms.

In one embodiment, the molecular weight of the compound of formula (IW) is 150 Da – 450 Da.

5 Suitably, there is provided a compound of formula (IW):



wherein,

R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{9A} , qA and W^A are as defined for compounds of formula (IW-1); R^{7A} and R^{8A} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo; or, taken together, R^{7A} and R^{8A} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring;

wherein

R^B , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , qB and W^B are as defined for compounds of formula (IW-1);

15 R^{1B} is selected from the group consisting of trifluoromethyl, methyl, CO_2H , cyano, $SiR^{4B}R^{5B}R^{6B}$, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl; wherein methyl, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl are optionally substituted by R^{7B} and/or R^{8B} ;

R^C and R^D are as defined for compounds of formula (IW-1);


20 and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;

or a pharmaceutically acceptable salt and/or solvate thereof.

25 Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IW-1) apply equally to formula (IW).

Suitably, the present invention provides a compound of formula (IW-a):



30

wherein,

R^A is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{5-10}

spirocycloalkyl; wherein R^A is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1A} , $NR^{2A}R^{3A}$, SR^{2A} , SOR^{9A} , SO_2R^{9A} , $SO_2NR^{2A}R^{3A}$, $C(O)R^{2A}$ and $CONR^{2A}R^{3A}$;

R^{1A} is selected from the group consisting of methyl, cyano, $SiR^{4A}R^{5A}R^{6A}$, C_{3-8} cycloalkyl, phenyl and 5-6 membered heteroaryl; wherein methyl, C_{3-8} cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl are optionally substituted by R^{7A} and/or R^{8A} ;

R^{4A} , R^{5A} and R^{6A} are as defined for the compound of formula (IW-1);

R^{7A} and R^{8A} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, cyano, methanesulfonyl and halo;

or, taken together, R^{7A} and R^{8A} form a C_{3-8} cycloalkyl or 4-7 membered heterocyclic ring;

R^{2A} and R^{3A} are as defined for the compound of formula (IW-1);

R^{9A} is as defined for the compound of formula (IW-1);

q^A is 0 or 1;

W^A is as defined for the compound of formula (IW-1);

wherein R^A contains 6 or more carbon atoms;

wherein

R^B is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl, C_{5-10} spirocycloalkyl and 4-10 membered heterocyclyl; wherein R^B is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$, $CONR^{2B}R^{3B}$, $C(O)NHSO_2R^{9B}$ and $C(O)NHSO_2NR^{2B}R^{3B}$;

R^{1B} is selected from the group consisting of trifluoromethyl, methyl, CO_2H , cyano, $SiR^{4B}R^{5B}R^{6B}$, C_{3-8} cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl; wherein methyl, C_{3-8} cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl are optionally substituted by R^{7B} and/or R^{8B} ;

R^{4B} , R^{5B} and R^{6B} are as defined for the compound of formula (IW-1);

R^{7B} and R^{8B} are as defined for the compound of formula (IW-1);

R^{2B} and R^{3B} are as defined for the compound of formula (IW-1);

R^{9B} is as defined for the compound of formula (IW-1);

q^B is 0 or 1;

W^B is as defined for the compound of formula (IW-1);

R^C and R^D are independently selected from the group consisting of H, methoxy and fluoro; and wherein,


when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;

or a pharmaceutically acceptable salt and/or solvate thereof.

Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IW-1) apply equally to formula (IW-a).

5

Suitably, the present invention provides a compound of formula (IW-b):



wherein,

R^A is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl; wherein R^A is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1A} , $NR^{2A}R^{3A}$, SR^{2A} , SOR^{9A} , SO_2R^{9A} , $SO_2NR^{2A}R^{3A}$, $C(O)R^{2A}$ and $CONR^{2A}R^{3A}$;

R^{1A} is selected from the group consisting of methyl, cyano, $SiR^{4A}R^{5A}R^{6A}$, C_{3-8} cycloalkyl, phenyl and 5-6 membered heteroaryl; wherein methyl, C_{3-8} cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl are optionally substituted by R^{7A} and/or R^{8A} ;

R^{4A} , R^{5A} and R^{6A} are as defined for the compound of formula (IW-1);

R^{7A} and R^{8A} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, cyano, methanesulfonyl and halo;

or, taken together, R^{7A} and R^{8A} form a C_{3-8} cycloalkyl or 4-7 membered heterocyclic ring;

R^{2A} and R^{3A} are as defined for the compound of formula (IW-1);

R^{9A} is as defined for the compound of formula (IW-1);

qA is 0 or 1;

W^A is as defined for the compound of formula (IW-1);

wherein

R^B is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-6} cycloalkyl, C_{5-10} spirocycloalkyl and 4-10 membered heterocyclyl; wherein R^B is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$, $CONR^{2B}R^{3B}$, $C(O)NHSO_2R^{9B}$ and $C(O)NHSO_2NR^{2B}R^{3B}$;

R^{1B} is selected from the group consisting of trifluoromethyl, methyl, CO_2H , cyano, $SiR^{4B}R^{5B}R^{6B}$, C_{3-8} cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl; wherein methyl, C_{3-8} cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6

membered heteroaryl are optionally substituted by R^{7B} and/or R^{8B} ;

R^{4B} , R^{5B} and R^{6B} are as defined for the compound of formula (IW-1);

R^{7B} and R^{8B} are as defined for the compound of formula (IW-1);

R^{2B} and R^{3B} are as defined for the compound of formula (IW-1);

5 R^{9B} is as defined for the compound of formula (IW-1);

qB is 0 or 1;

W^B is as defined for the compound of formula (IW-1);

R^C and R^D are independently selected from the group consisting of H, methoxy and fluoro;

and wherein,

10 when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6; and


when R^B contains 2 or more carbon atoms and 4 or more heteroatoms, then R^A must contain 6 or more carbon atoms, and the number of carbon atoms in R^A must exceed the number of heteroatoms in R^A by at least 3 atoms;

15 or a pharmaceutically acceptable salt and/or solvate thereof.

Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IW-1) apply equally to formula (IW-b).

20

Suitably, the present invention provides a compound of formula (IW-c):



wherein:

R^A is selected from the group consisting of C_{6-10} alkyl and C_{6-10} cycloalkyl;

25 R^B is C_{1-10} alkyl substituted by R^{1B} ;


R^{1B} is selected from the group consisting of CO_2H and 5-6 membered heteroaryl;

R^C and R^D are H;

or a pharmaceutically acceptable salt and/or solvate thereof.

30 Embodiments and preferences regarding groups R^A , R^B and R^{1B} described above with respect to formula (IW-1) apply equally to formula (IW-c).

Suitably, the present invention provides a compound of formula (IW-d):



wherein:

R^A is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, heptyl-CH(CH₃)-, hexyl-CH(CH₃)- and C₈ cycloalkyl;

R^B is C₁₋₁₀ alkyl substituted by R^{1B} ;


R^{1B} is selected from the group consisting of trifluoromethyl, methyl, CO₂H, cyano, C₃₋₈ cycloalkyl, 4-7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl;

R^C and R^D are H;

or a pharmaceutically acceptable salt and/or solvate thereof.

Embodiments and preferences regarding groups R^A , R^B and R^{1B} described above with respect to formula (IW-1) apply equally to formula (IW-d).

Suitably, the present invention provides a compound of formula (IW-e):



wherein,

R^A is selected from the group consisting of C₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl and C₅₋₁₀ spirocycloalkyl; wherein R^A is not substituted or is substituted by one or more substituents selected from the group consisting of oxo, R^{1A} , OR^{2A}, NR^{2A}R^{3A}, SR^{2A}, SOR^{9A}, SO₂R^{9A}, SO₂NR^{2A}R^{3A}, C(O)R^{2A} and CONR^{2A}R^{3A};

R^{1A} is selected from the group consisting of fluoro, methyl, cyano, SiR^{4A}R^{5A}R^{6A}, C₃₋₈ cycloalkyl and phenyl; wherein methyl, C₃₋₈ cycloalkyl and phenyl are not substituted or are substituted by R^{7A} and/or R^{8A} ;

R^{4A} , R^{5A} and R^{6A} are independently selected from the group consisting of C₁₋₄ alkyl and phenyl;

R^{7A} and R^{8A} are independently selected from the group consisting of oxo, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, hydroxy, CO₂H, cyano, methanesulfonyl and halo;

or, taken together, R^{7A} and R^{8A} form a C₃₋₈ cycloalkyl or 4-7 membered heterocyclic ring;

R^{2A} and R^{3A} are independently H, C₁₋₈ alkyl, C₃₋₈ cycloalkyl or phenyl;

or, taken together, R^{2A} and R^{3A} form a 4–7 membered heterocyclic ring;


R^{9A} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; and

R^B is C_{1-2} alkyl substituted by CO_2H and is optionally further substituted by trifluoromethyl or methyl;

- 5 R^C and R^D are independently selected from the group consisting of H, C_{1-2} alkyl, hydroxy, methoxy and fluoro;
or a pharmaceutically acceptable salt and/or solvate thereof.

- 10 Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} and R^B described above with respect to formula (IW-1) apply equally to formula (IW-e).

In one embodiment, the compound of formula (IW) is a compound of formula (IY):



wherein,

- 15 R^A is selected from the group consisting of C_{1-10} alkyl, C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^A is optionally substituted as defined for compounds of formula (IW);

R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA and W^A are as defined for compounds of formula (IW);

- 20 wherein

R^B , R^{1B} , R^{4B} , R^{5B} and R^{6B} are as defined for compounds of formula (IW);

R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

- 25 or, taken together, R^{7B} and R^{8B} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring;

R^{2B} , R^{3B} , qB and W^B are as defined for compounds of formula (IW);

R^{9B} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$;


- 30 and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;

or a pharmaceutically acceptable salt and/or solvate thereof.

Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IV) apply equally to formula (IY).

- 5 In one embodiment, the compound of formula (IW) is a compound of formula (I):



wherein,

R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA , W^A are as defined for compounds of formula (IV);

- 10 wherein

R^B is selected from the group consisting of C_{1-10} alkyl, C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^B is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$;

- 15 R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , qB and W^B are as defined for compounds of formula (IV);

and wherein,


when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;

- 20 or a pharmaceutically acceptable salt and/or solvate thereof.

Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IV) apply equally to formula (I).

- 25

In one embodiment, the compound of formula (IW) is a compound of formula (IWA),



wherein,

R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA and W^A are as defined for compounds

- 30 of formula (IV);

R^B is C_{1-2} alkyl, which is substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$,

$C(O)R^{2B}$, $CONR^{2B}R^{3B}$, $C(O)NHSO_2R^{9B}$ and $C(O)NHSO_2NR^{2B}R^{3B}$; or

R^B is 4–7 membered heterocyclyl, which is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$, $CONR^{2B}R^{3B}$, $C(O)NHSO_2R^{9B}$ and $C(O)NHSO_2NR^{2B}R^{3B}$;

5 R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , qB and W^B are as defined for compounds of formula (IW);

R^C and R^D are as defined for compounds of formula (IW);

and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and

10 R^B taken together is at least 6;

or a pharmaceutically acceptable salt and/or solvate thereof.

Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B , qB , R^C and R^D described above with

15 respect to formula (IW) apply equally to formula (IWA).

In one embodiment, R^B is methyl. In one embodiment, R^B is ethyl.

In one embodiment, R^B is a 4–7 membered (e.g. 4-6 membered) heterocyclyl containing one or


20 two heteroatoms independently selected from N, O and S. In one embodiment, R^B is a 4–7 membered (e.g. 4-6 membered) heterocyclyl containing one N atom. In one embodiment, R^B is a 4–7 membered (e.g. 4-6 membered) heterocyclyl containing one O atom. In one embodiment, R^B is a 4–7 membered (e.g. 4-6 membered) heterocyclyl containing one S atom. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl,

25 pyrrolidiny, tetrahydropyranyl, piperidiny, piperaziny, thiomorpholiny and morpholiny. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidiny, tetrahydropyranyl, piperaziny, piperidiny, thiomorpholiny and morpholiny, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny,

30 tetrahydrofuranyl, pyrrolidiny, tetrahydropyranyl, piperidiny and morpholiny. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidiny, tetrahydropyranyl, piperidiny and morpholiny, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl optionally substituted by one or more oxo groups, azetidiny, tetrahydrofuranyl,

35 pyrrolidiny optionally substituted by one or more oxo groups, tetrahydropyranyl, piperidiny and morpholiny. Suitably, thietanyl is substituted by one or two oxo groups (e.g. to form a ring containing $S=O$ or $S(=O)_2$ functionality).

In one embodiment, the compound of formula (IW) is a compound of formula (IYA),



wherein,

- 5 R^A is selected from the group consisting of C_{1-10} alkyl, C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^A is optionally substituted as defined for compounds of formula (IW);

R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA and W^A are as defined for compounds of formula (IW);

- 10 wherein

R^B is C_{1-2} alkyl, which is substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$; or

- 15 R^B is 4–7 membered heterocyclyl, which is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$;

R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , qB and W^B are as defined for compounds of formula (IW);

R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

- 20 or, taken together, R^{7B} and R^{8B} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring;

R^{9B} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$;

- 25 and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;


or a pharmaceutically acceptable salt and/or solvate thereof.

- 30 Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IW) apply equally to formula (IYA).

In one embodiment, R^B is methyl. In one embodiment, R^B is ethyl.

In one embodiment, R^B is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one or two heteroatoms independently selected from N, O and S. In one embodiment, R^B is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one N atom. In one embodiment, R^B is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one O atom. In one embodiment, R^B is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one S atom. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidiny, tetrahydropyranyl, piperidiny, piperaziny, thiomorpholiny and morpholiny. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidiny, tetrahydropyranyl, piperaziny, piperidiny, thiomorpholiny and morpholiny, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidiny, tetrahydropyranyl, piperidiny and morpholiny. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidiny, tetrahydropyranyl, piperidiny and morpholiny, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl optionally substituted by one or more oxo groups, azetidiny, tetrahydrofuranyl, pyrrolidiny optionally substituted by one or more oxo groups, tetrahydropyranyl, piperidiny and morpholiny. Suitably, thietanyl is substituted by one or two oxo groups (e.g. to form a ring containing S=O or S(=O)₂ functionality).

In one embodiment, the compound of formula (IV) is a compound of formula (IA),



wherein,

R^A is selected from the group consisting of C_{1–10} alkyl, C_{3–10} cycloalkyl, C_{5–10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^A is optionally substituted as defined for compounds of formula (IV);

R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA , W^A are as defined for compounds of formula (IW);

wherein

R^B is C_{1–2} alkyl, which is substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$; or

R^B is 4–7 membered heterocyclyl, which is optionally substituted by one or more substituents

selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$;

R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , qB and W^B are as defined for compounds of formula (IW);

R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

or, taken together, R^{7B} and R^{8B} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring;

R^{9B} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$;

and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;

or a pharmaceutically acceptable salt and/or solvate thereof.


Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IW) apply equally to formula (IA).

In one embodiment, R^B is methyl. In one embodiment, R^B is ethyl.

In one embodiment, R^B is 4–7 membered (e.g. 4-6 membered) heterocyclyl containing one or two heteroatoms independently selected from N, O and S. In one embodiment, R^B is 4–7 membered (e.g. 4-6 membered) heterocyclyl containing one N atom. In one embodiment, R^B is 4–7 membered (e.g. 4-6 membered) heterocyclyl containing one O atom. In one embodiment, R^B is 4–7 membered (e.g. 4-6 membered) heterocyclyl containing one S atom. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, thiomorpholinyl and morpholinyl. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperazinyl, piperidinyl, thiomorpholinyl and morpholinyl, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl and morpholinyl. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl and morpholinyl, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^B is selected from the group consisting of oxetanyl, thietanyl optionally substituted by one or more oxo groups, azetidiny, tetrahydrofuranyl,

pyrrolidinyl optionally substituted by one or more oxo groups, tetrahydropyranyl, piperidinyl and morpholinyl. Suitably, thietanyl is substituted by one or two oxo groups (e.g. to form a ring containing S=O or S(=O)₂ functionality).

- 5 In one embodiment, the compound of formula (IW) is a compound of formula (IWB),



wherein,

R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , q^A and W^A are as defined for compounds of formula (IW);

- 10 R^W is selected from the group consisting of R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$, $CONR^{2B}R^{3B}$, $C(O)NHSO_2R^{9B}$ and $C(O)NHSO_2NR^{2B}R^{3B}$; or R^W is a 4–7 membered heterocyclyl which is optionally substituted by R^{7B} and/or R^{8B} ;

R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , q^B and W^B are as defined for compounds of formula (IW);

- 15 R^C and R^D are as defined for compounds of formula (IW);

and wherein,

when neither R^A , R^Q nor R^W contain heteroatoms, the total number of carbon atoms in groups R^A , R^Q and R^W taken together is at least 4;

or a pharmaceutically acceptable salt and/or solvate thereof.

- 20 Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , q^A , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B , q^B , R^C and R^D described above with respect to formula (IW) apply equally to formula (IWB).


- 25 In one embodiment, R^Q is H or methyl, in particular H.

In one embodiment, R^W is selected from the group consisting of R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$, $CONR^{2B}R^{3B}$, $C(O)NHSO_2R^{9B}$ and $C(O)NHSO_2NR^{2B}R^{3B}$; or R^W is a 4–7 membered heterocyclyl.

- 30 In one embodiment, R^W is a 4–7 membered (e.g. 4–6 membered) heterocyclyl. In one embodiment, R^W is a 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one or two heteroatoms independently selected from N, O and S. In one embodiment, R^W is a 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one N atom. In one embodiment, R^W is a 4–7

membered (e.g. 4–6 membered) heterocyclyl containing one O atom. In one embodiment, R^W is a 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one S atom. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, thiomorpholinyl and morpholinyl. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperazinyl, piperidinyl, thiomorpholinyl and morpholinyl, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl and morpholinyl. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl and morpholinyl, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl optionally substituted by one or more oxo groups, azetidiny, tetrahydrofuranyl, pyrrolidinyl optionally substituted by one or more oxo groups, tetrahydropyranyl, piperidinyl and morpholinyl. Suitably, thietanyl is substituted by one or two oxo groups (e.g. to form a ring containing S=O or S(=O)₂ functionality).

In one embodiment, the compound of formula (IW) is a compound of formula (IYB),



wherein,

R^A is selected from the group consisting of C_{1–10} alkyl, C_{3–10} cycloalkyl, C_{5–10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^A is optionally substituted as defined for compounds of formula (IW);

R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA and W^A are as defined for compounds of formula (IW);

wherein

R^Q is H or C_{1–2} alkyl;

R^W is selected from the group consisting of R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$; or

R^W is 4–7 membered heterocyclyl which is optionally substituted by R^{7B} and/or R^{8B} ;

R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , qB and W^B are as defined for compounds of formula (IW);

R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C_{1–4} alkyl, C_{1–4} alkoxy, hydroxy, CO₂H, cyano, methanesulfonyl and halo;

or, taken together, R^{7B} and R^{8B} form a C_{3–8} cycloalkyl or 4–7 membered heterocyclic ring;

R^{9B} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$;

and wherein,

- 5 when neither R^A , R^Q nor R^W contain heteroatoms, the total number of carbon atoms in groups R^A , R^Q and R^W taken together is at least 4;
or a pharmaceutically acceptable salt and/or solvate thereof.


10 Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IV) apply equally to formula (IYB).

In one embodiment, R^Q is H or methyl, in particular H.

- 15 In one embodiment, R^W is selected from the group consisting of R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$; or R^W is 4–7 membered heterocyclyl.

In one embodiment, R^W is 4–7 membered (e.g. 4–6 membered) heterocyclyl. In one embodiment, R^W is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one or two heteroatoms independently selected from N, O and S. In one embodiment, R^W is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one N atom. In one embodiment, R^W is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one O atom. In one embodiment, R^W is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one S atom. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, 20 tetrahydropyranyl, piperidinyl, piperazinyl, thiomorpholinyl and morpholinyl. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperazinyl, piperidinyl, thiomorpholinyl and morpholinyl, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, 30 tetrahydropyranyl, piperidinyl and morpholinyl. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl and morpholinyl, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl optionally substituted by one or more oxo groups, azetidiny, tetrahydrofuranyl, pyrrolidinyl optionally substituted by one or more oxo groups, tetrahydropyranyl, piperidinyl and morpholinyl. Suitably, thietanyl is substituted by one or two oxo groups (e.g. to form a ring containing $S=O$ or $S(=O)_2$ functionality).

In one embodiment, the compound of formula (IW) is a compound of formula (IB),



wherein,

- 5 R^A is selected from the group consisting of C_{1-10} alkyl, C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^A is optionally substituted as defined for compounds of formula (IW);

R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA and W^A are as defined for compounds of formula (IW);

- 10 wherein

R^Q is H or C_{1-2} alkyl;

R^W is selected from the group consisting of R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$; or

R^W is 4–7 membered heterocyclyl which is optionally substituted by R^{7B} and/or R^{8B} ;

- 15 R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , qB and W^B are as defined for compounds of formula (IW);

R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

or, taken together, R^{7B} and R^{8B} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring;

R^{9B} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or

- 20 more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$;

and wherein,

when neither R^A , R^Q nor R^W contain heteroatoms, the total number of carbon atoms in groups R^A , R^Q and R^W taken together is at least 4;

- 25 or a pharmaceutically acceptable salt and/or solvate thereof.

Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IW) apply equally to formula (IB).


- 30

In one embodiment, R^Q is H or methyl, in particular H.

In one embodiment, R^W is selected from the group consisting of R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$; or R^W is 4–7 membered heterocyclyl.

In one embodiment, R^W is 4–7 membered (e.g. 4–6 membered) heterocyclyl. In one embodiment, R^W is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one or two heteroatoms independently selected from N, O and S. In one embodiment, R^W is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one N atom. In one embodiment, R^W is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one O atom. In one embodiment, R^W is 4–7 membered (e.g. 4–6 membered) heterocyclyl containing one S atom. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidiny, tetrahydropyranyl, piperidiny, piperaziny, thiomorpholiny and morpholiny. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidiny, tetrahydropyranyl, piperaziny, piperidiny, thiomorpholiny and morpholiny, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidiny, tetrahydropyranyl, piperidiny and morpholiny. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl, azetidiny, tetrahydrofuranyl, pyrrolidiny, tetrahydropyranyl, piperidiny and morpholiny, all of which are optionally substituted by one or more oxo groups. In one embodiment, R^W is selected from the group consisting of oxetanyl, thietanyl optionally substituted by one or more oxo groups, azetidiny, tetrahydrofuranyl, pyrrolidiny optionally substituted by one or more oxo groups, tetrahydropyranyl, piperidiny and morpholiny. Suitably, thietanyl is substituted by one or two oxo groups (e.g. to form a ring containing $S=O$ or $S(=O)_2$ functionality).

In one embodiment, the compound of formula (IW) is a compound of formula (IWC),



R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA and W^A are as defined for compounds of formula (IW);

wherein

E is selected from the group consisting of N, O, S, $S=O$ and $S(=O)_2$;

R^E is absent, or is selected from the group consisting of H, R^{1B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$;

R^{1B} is selected from the group consisting of methyl, cyano, $SiR^{4B}R^{5B}R^{6B}$, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5–6 membered heteroaryl; wherein methyl, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5–6 membered heteroaryl are optionally substituted by R^{7B} and/or R^{8B} ;

R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , qB and W^B are as defined for compounds of formula (IW);

nE and mE are independently 1 or 2;

R^C and R^D are as defined for compounds of formula (IW);

5 or a pharmaceutically acceptable salt and/or solvate thereof.

Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B , qB , R^C and R^D described above with respect to formula (IW) apply equally to formula (IWC).

10


In one embodiment, E is selected from the group consisting of N, O and $S(=O)_2$. In one embodiment, E is N. In one embodiment, E is O. In one embodiment, E is S, $S=O$ or $S(=O)_2$. In one embodiment, E is S. In one embodiment, E is $S=O$. In one embodiment, E is $S(=O)_2$.

15 In one embodiment, E is O or S and R^E is absent.

In one embodiment, nE is 1 and mE is 1. In one embodiment, nE is 2 and mE is 1. In one embodiment, nE is 1 and mE is 2. In one embodiment, one of nE and mE is 2 and the other is 1. In one embodiment, nE is 2 and mE is 2.

20

In one embodiment, the compound of formula (IW) is a compound of formula (IC),



R^A is selected from the group consisting of C_{1-10} alkyl, C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^A is optionally substituted as defined for compounds of formula (IW);

25

R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA and W^A are as defined for compounds of formula (IW);

wherein

E is selected from the group consisting of N, O, S, $S=O$ and $S(=O)_2$;

30 R^E is absent, or is selected from the group consisting of H, R^{1B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$;

R^{1B} is selected from the group consisting of methyl, cyano, $SiR^{4B}R^{5B}R^{6B}$, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl; wherein methyl, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5-6 membered heteroaryl are

optionally substituted by R^{7B} and/or R^{8B} ;

R^{4B} , R^{5B} and R^{6B} are as defined for compounds of formula (IW);

R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

5 or, taken together, R^{7B} and R^{8B} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring;

R^{2B} and R^{3B} are as defined for compounds of formula (IW);

R^{9B} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$;

qB and W^B are as defined for compounds of formula (IW);

nE and mE are independently 1 or 2;

or a pharmaceutically acceptable salt and/or solvate thereof.


15 Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IW) apply equally to formula (IC).

In one embodiment, E is selected from the group consisting of N, O and $S(=O)_2$. In one embodiment, E is N. In one embodiment, E is O. In one embodiment, E is S, $S=O$ or $S(=O)_2$. In one embodiment, E is S. In one embodiment, E is $S=O$. In one embodiment, E is $S(=O)_2$.

In one embodiment, E is O or S and R^E is absent.

25 In one embodiment, nE is 1 and mE is 1. In one embodiment, nE is 2 and mE is 1. In one embodiment, nE is 1 and mE is 2. In one embodiment, one of nE and mE is 2 and the other is 1. In one embodiment, nE is 2 and mE is 2.

In one embodiment, the compound of formula (IW) is a compound of formula (IWD-1):



30 wherein,
 R^A is selected from the group consisting of C_{1-10} alkyl and C_{2-10} alkenyl; wherein R^A is substituted by one or more substituents selected from the group consisting of oxo, R^{1A} , OR^{2A} , SR^{2A} , SOR^{9A} , SO_2R^{9A} , $SO_2NR^{2A}R^{3A}$, $C(O)R^{2A}$ and $CONR^{2A}R^{3A}$;

R^{1A} is selected from the group consisting of fluoro, cyano and $SiR^{4A}R^{5A}R^{6A}$;

R^{4A} , R^{5A} and R^{6A} are as defined for compounds of formula (IW);

R^{2A} and R^{3A} are independently C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{2A} and R^{3A} are independently optionally substituted as defined for compounds of formula (IW);

5 or, taken together, R^{2A} and R^{3A} form a 4–7 membered heterocyclic ring optionally independently substituted by one or more substituents selected from the group consisting of C_{1-2} alkyl, hydroxy and oxo;

R^{9A} , qA and W^A are as defined for compounds of formula (IW);

wherein

10 R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , qB and W^B are as defined for compounds of formula (IW);


R^C and R^D are as defined for compounds of formula (IW);

and wherein,

15 when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;
or a pharmaceutically acceptable salt and/or solvate thereof.

Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B , qB , R^C and R^D described above with respect
20 to formula (IW) apply equally to formula (IWD-1).

In one embodiment, the compound of formula (IW) is a compound of formula (IYD-1):



wherein,

25 R^A is C_{1-10} alkyl; wherein R^A is substituted by one or more substituents selected from the group consisting of oxo, R^{1A} , OR^{2A} , SR^{2A} , SOR^{9A} , SO_2R^{9A} , $SO_2NR^{2A}R^{3A}$, $C(O)R^{2A}$ and $CONR^{2A}R^{3A}$;

R^{1A} is selected from the group consisting of fluoro, cyano and $SiR^{4A}R^{5A}R^{6A}$;

R^{4A} , R^{5A} and R^{6A} are as defined for compounds of formula (IW);

30 R^{2A} and R^{3A} are independently C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{2A} and R^{3A} are independently optionally substituted as defined for compounds of formula (IW);
or, taken together, R^{2A} and R^{3A} form a 4–7 membered heterocyclic ring optionally independently substituted by one or more substituents selected from the group consisting of C_{1-2} alkyl, hydroxy and oxo;

R^{9A} , qA and W^A are as defined for compounds of formula (IW);

wherein

R^B is selected from the group consisting of C_{1-10} alkyl, C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^B is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} ,
 5 $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$;

R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} are as defined for compounds of formula (IW);

R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

or, taken together, R^{7B} and R^{8B} form a C_{3-8} cycloalkyl or 4–7 membered
 10 heterocyclic ring;

R^{9B} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$;

qB and W^B are as defined for compounds of formula (IW);


15 and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;

or a pharmaceutically acceptable salt and/or solvate thereof.

20 Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IW) apply equally to formula (IYD-1).

In one embodiment, the compound of formula (IW) is a compound of formula (ID-1):



25 wherein,

R^A is C_{1-10} alkyl; wherein R^A is substituted by one or more substituents selected from the group consisting of oxo, R^{1A} , OR^{2A} , SR^{2A} , SOR^{9A} , SO_2R^{9A} , $SO_2NR^{2A}R^{3A}$, $C(O)R^{2A}$ and $CONR^{2A}R^{3A}$;

R^{1A} is selected from the group consisting of fluoro, cyano and $SiR^{4A}R^{5A}R^{6A}$;

30 R^{4A} , R^{5A} and R^{6A} are as defined for compounds of formula (IW);

R^{2A} and R^{3A} are independently C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{2A} and R^{3A} are independently optionally substituted as defined for compounds of formula (IW);

or, taken together, R^{2A} and R^{3A} form a 4–7 membered heterocyclic ring optionally independently substituted by one or more substituents selected from the group consisting

of C₁₋₂ alkyl, hydroxy and oxo;

R^{9A}, q^A and W^A are as defined for compounds of formula (IW);

wherein

R^B is selected from the group consisting of C₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₅₋₁₀ spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^B is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1B}, OR^{2B}, NR^{2B}R^{3B}, SR^{2B}, SOR^{9B}, SO₂R^{9B}, SO₂NR^{2B}R^{3B}, C(O)R^{2B} and CONR^{2B}R^{3B};

R^{1B}, R^{2B}, R^{3B}, R^{4B}, R^{5B}, R^{6B} are as defined for compounds of formula (IW);

R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxy, CO₂H, cyano, methanesulfonyl and halo;

or, taken together, R^{7B} and R^{8B} form a C₃₋₈ cycloalkyl or 4–7 membered heterocyclic ring;

R^{9B} is C₁₋₈ alkyl, C₃₋₈ cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C₁₋₈ alkyl, C₁₋₄ alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$;

q^B and W^B are as defined for compounds of formula (IW);


and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;

or a pharmaceutically acceptable salt and/or solvate thereof.

Embodiments and preferences regarding groups R^A, R^{1A}, R^{2A}, R^{3A}, R^{4A}, R^{5A}, R^{6A}, R^{9A}, W^A, q^A, R^B, R^{1B}, R^{2B}, R^{3B}, R^{4B}, R^{5B}, R^{6B}, R^{7B}, R^{8B}, R^{9B}, W^B and q^B described above with respect to formula (IW) apply equally to formula (ID-1).

In one embodiment, the compound of formula (IW) is a compound of formula (IWD-2):



wherein,

R^A is selected from the group consisting of C₃₋₁₀ cycloalkyl, C₅₋₁₀ spirocycloalkyl, 6–10 membered heterospirocyclyl and 4–10 membered heterocyclyl; wherein R^A is optionally substituted as defined for compounds of formula (IW);

R^{1A}, R^{2A}, R^{3A}, R^{4A}, R^{5A}, R^{6A}, R^{7A}, R^{8A}, R^{9A}, q^A and W^A are as defined for compounds of formula (IW);

wherein

R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , qB , W^B are as defined for compounds of formula (IW);


R^C and R^D are as defined for compounds of formula (IW);

and wherein,

- 5 when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;
or a pharmaceutically acceptable salt and/or solvate thereof.

- 10 Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B , qB , R^C and R^D described above with respect to formula (IW) apply equally to formula (IWD-2).

In one embodiment, the compound of formula (IW) is a compound of formula (IYD-2):



- 15 wherein,

R^A is selected from the group consisting of C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^A is optionally substituted as defined for compounds of formula (IW);

- 20 R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA and W^A are as defined for compounds of formula (IW);

wherein

- R^B is selected from the group consisting of C_{1-10} alkyl, C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^B is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} ,
25 $SO_2NR^{2B}R^{3B}$, $NR^{2B}SO_2R^{9B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$;

R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , qB and W^B are as defined for compounds of formula (IW);

R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

- 30 or, taken together, R^{7B} and R^{8B} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring;


R^{9B} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$;

and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;
or a pharmaceutically acceptable salt and/or solvate thereof.

- 5 Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IV) apply equally to formula (ID-2).

In one embodiment, the compound of formula (IV) is a compound of formula (ID-2):



wherein,

R^A is selected from the group consisting of C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^A is optionally substituted as defined for compounds of formula (IV);

R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA and W^A are as defined for compounds of formula (IV);

wherein

R^B is selected from the group consisting of C_{1-10} alkyl, C_{3-10} cycloalkyl, C_{5-10} spirocycloalkyl and 4–10 membered heterocyclyl; wherein R^B is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1B} , OR^{2B} , $NR^{2B}R^{3B}$, SR^{2B} , SOR^{9B} , SO_2R^{9B} , $SO_2NR^{2B}R^{3B}$, $C(O)R^{2B}$ and $CONR^{2B}R^{3B}$;

R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} and R^{6B} are as defined for compounds of formula (IV);

R^{7B} and R^{8B} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

or, taken together, R^{7B} and R^{8B} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring;

R^{9B} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$;

qB and W^B are as defined for compounds of formula (IV);


and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;
or a pharmaceutically acceptable salt and/or solvate thereof.

Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B and qB described above with respect to formula (IW) apply equally to formula (ID-2).

5

In one embodiment, the compound of formula (IW) is a compound of formula (IWE):



wherein,

10 R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , qA and W^A are as defined for compounds of formula (IW);

wherein

R^B is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl or C_{5-10} spirocycloalkyl; wherein C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl or C_{5-10} spirocycloalkyl are substituted by SO_2R^{9B} , CO_2H or tetrazolyl; or

15 R^B is 4–10 membered heterocyclyl which is substituted by SO_2R^{9B} or CO_2H ;

wherein R^B is optionally substituted by one or more R^{1B} ;

wherein R^{1B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , qB and W^B are as defined for compounds of formula (IW);

20 R^{9B} is a C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9B} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, halo, CO_2H , fluoro, hydroxy, oxo and $-(CH_2)_{qB}W^B$;

R^C and R^D are as defined for compounds of formula (IW);

or a pharmaceutically acceptable salt and/or solvate thereof.

25 Embodiments and preferences regarding groups R^A , R^{1A} , R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} , W^A , qA , R^B , R^{1B} , R^{2B} , R^{3B} , R^{4B} , R^{5B} , R^{6B} , R^{7B} , R^{8B} , R^{9B} , W^B , qB , R^C and R^D described above with respect to formula (IW) apply equally to formula (IWE).

In one embodiment, R^A is a C_{5-10} spirocycloalkyl, in particular spiro[3.3]heptyl.


30

In one embodiment, R^B is a C_{1-10} alkyl which is substituted by SO_2R^{9B} , CO_2H or tetrazolyl, or a 4–10 membered heterocyclyl which is substituted by SO_2R^{9B} or CO_2H .

In one embodiment, R^B is a C_{1-5} alkyl which is substituted by SO_2R^{9B} , CO_2H or tetrazolyl. Suitably,

R^B is C_{1-2} alkyl which is substituted by SO_2R^{9B} , CO_2H or tetrazolyl, for example R^B is methyl or ethyl which are substituted by SO_2R^{9B} , CO_2H or tetrazolyl.


Suitably, the tetrazolyl is 5-tetrazolyl:



5


In one embodiment, R^B is a 4–10 membered heterocyclyl which is substituted by SO_2R^{9B} or CO_2H , wherein R^{9B} is defined elsewhere herein. Suitably, R^B is a 5–6 membered heterocyclyl which is substituted by SO_2R^{9B} or CO_2H , wherein R^{9B} is defined elsewhere herein.

- 10 In one embodiment, R^B is a C_{1-10} alkyl which is substituted by SO_2R^{9B} wherein R^{9B} is defined elsewhere herein. In another embodiment, R^B is a C_{1-10} alkyl which is substituted by CO_2H . In another embodiment, R^B is a C_{1-10} alkyl which is substituted by tetrazolyl. In each embodiment, suitably C_{1-10} alkyl is C_{1-2} alkyl.




- In any one of the above embodiments, suitably when R^B is: , R^{1A} is selected from the group consisting of fluoro, methyl, cyano, $SiR^{4A}R^{5A}R^{6A}$, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5–6 membered heteroaryl; wherein methyl, C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5–6 membered heteroaryl are optionally substituted by R^{7A} and/or R^{8A} wherein R^{4A} , R^{5A} , R^{6A} , R^{7A} and R^{8A} are as defined elsewhere herein.


- 20 In any one of the above embodiments, suitably when R^B is: , R^A is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} cycloalkyl, and C_{5-10} spirocycloalkyl; R^A is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1A} , $NR^{2A}R^{3A}$, SR^{2A} , SOR^{9A} , SO_2R^{9A} , $SO_2NR^{2A}R^{3A}$, $C(O)R^{2A}$ and $CONR^{2A}R^{3A}$; and R^{1A} is selected from the group consisting of CO_2H , cyano, $SiR^{4A}R^{5A}R^{6A}$, C_{3-8} cycloalkyl, phenyl and 5–6 membered heteroaryl; wherein C_{3-8} cycloalkyl, 4–7 membered heterocyclyl, phenyl and 5–6 membered heteroaryl are optionally substituted by R^{7A} and/or R^{8A} ; and the total number of carbon atoms in R^A is at least 6, wherein R^{2A} , R^{3A} , R^{4A} , R^{5A} , R^{6A} , R^{7A} , R^{8A} , R^{9A} are as defined elsewhere herein.



25

In any one of the above embodiments, suitably when R^A is , R^A is unsubstituted.

In any one of the above embodiments, suitably when R^B is:



- 5 In one embodiment there is provided a compound of formula (IW-1), selected from the group consisting of:
- 1-(2-cyanoethyl) 4-octyl 2-methylenesuccinate;
 - 1-(2-(methylsulfonyl)ethyl) 4-octyl 2-methylenesuccinate;
 - 4-octyl 1-(3,3,3-trifluoropropyl) 2-methylenesuccinate;
 - 10 4-octyl 1-(oxetan-3-yl) 2-methylenesuccinate;
 - 4-octyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 - 1-(3-(dimethylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 - 4-butyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 - 1-(2-cyanoethyl) 4-butyl 2-methylenesuccinate;
 - 15 1-(2-(2,5-dioxopyrrolidin-1-yl)ethyl) 4-octyl 2-methylenesuccinate;
 - 1-(2-cyanoethyl) 4-methyl 2-methylenesuccinate;
 - 1-(2-cyanoethyl) 4-hexyl 2-methylenesuccinate;
 - 4-methyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 - 4-octyl 1-(2-(trifluoromethoxy)ethyl) 2-methylenesuccinate;
 - 20 4-hexyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 - 4-methyl 1-(oxetan-3-yl) 2-methylenesuccinate;
 - 1-(2-(N,N-dimethylsulfonyl)ethyl) 4-octyl 2-methylenesuccinate;
 - 1-(2-(dimethylamino)ethyl) 4-octyl 2-methylenesuccinate;
 - 1-(3-(methylsulfonyl)propyl) 4-octyl 2-methylenesuccinate;
 - 25 1-(1-(methylsulfonyl)propan-2-yl) 4-octyl 2-methylenesuccinate;
 - 1-(2-(methylsulfonyl)ethyl) 4-(3-phenoxypropyl) 2-methylenesuccinate;
 - 1-(2-(dimethylamino)-2-oxoethyl) 4-octyl 2-methylenesuccinate;
 - 4-isopropyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 - (S)-4-octyl 1-(tetrahydrofuran-3-yl) 2-methylenesuccinate;

- (R)-4-octyl 1-(tetrahydrofuran-3-yl) 2-methylenesuccinate;
4-cyclooctyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
4-octyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
1-(1-cyanopropan-2-yl) 4-octyl 2-methylenesuccinate;
5 1-(1-(methylsulfonyl)piperidin-4-yl) 4-octyl 2-methylenesuccinate;
1-(2-methoxyethyl) 4-octyl 2-methylenesuccinate;
1-(2-cyano-2-methylpropyl) 4-octyl 2-methylenesuccinate;
1-(1-methoxypropan-2-yl) 4-octyl 2-methylenesuccinate;
1-((1-cyanocyclopropyl)methyl) 4-octyl 2-methylenesuccinate;
10 1-(2-methoxypropyl) 4-octyl 2-methylenesuccinate;
1-(2-methoxy-2-methylpropyl) 4-octyl 2-methylenesuccinate;
1-(2-morpholinoethyl) 4-octyl 2-methylenesuccinate;
4-(2-(2-ethoxyethoxy)ethyl) 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
4-butyl 1-(oxetan-3-yl) 2-methylenesuccinate;
15 4-hexyl 1-(oxetan-3-yl) 2-methylenesuccinate;
4-butyl 1-(2-tosylethyl) 2-methylenesuccinate;
4-octyl 1-(2-tosylethyl) 2-methylenesuccinate;
4-cyclooctyl 1-methyl 2-methylenesuccinate;
1-methyl 4-octyl 2-methylenesuccinate;
20 dicyclobutyl 2-methylenesuccinate;
di(oxetan-3-yl) 2-methylenesuccinate;
1-cyclobutyl 4-octyl 2-methylenesuccinate;
1-(1-acetoxyethyl) 4-octyl 2-methylenesuccinate;
1-(1,1-dioxidothietan-3-yl) 4-octyl 2-methylenesuccinate;
25 1-(2-(tert-butoxy)-2-oxoethyl) 4-octyl 2-methylenesuccinate;
2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetic acid;
1-(1-acetylazetidin-3-yl) 4-octyl 2-methylenesuccinate;
1-(2-(4-methylpiperazin-1-yl)ethyl) 4-octyl 2-methylenesuccinate;
1-(2-(1,1-dioxidothiomorpholino)ethyl) 4-octyl 2-methylenesuccinate;
30 1-(2-(methylsulfonamido)ethyl) 4-octyl 2-methylenesuccinate;
4-cyclooctyl 1-(1,1-dioxidothietan-3-yl) 2-methylenesuccinate;
(R)-1-(2-(methylsulfonyl)ethyl) 4-(octan-2-yl) 2-methylenesuccinate;
1-(1-(methylsulfonyl)propan-2-yl) 4-((R)-octan-2-yl) 2-methylenesuccinate;
(R)-1-(1,1-dioxidothietan-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
35 (R)-1-(1-acetylazetidin-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
4-cyclohexyl 1-(1-(methylsulfonyl)propan-2-yl) 2-methylenesuccinate;
4-cyclohexyl 1-(1,1-dioxidothietan-3-yl) 2-methylenesuccinate;

- 4-cyclohexyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
4-cyclooctyl 1-(1-(methylsulfonyl)propan-2-yl) 2-methylenesuccinate;
1-(1-acetylazetidin-3-yl) 4-cyclooctyl 2-methylenesuccinate;
4-cyclohexyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
5 4-cyclohexyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
(S)-1-(1-acetylazetidin-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
(S)-1-(1,1-dioxidothietan-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
1-(3-methyloxetan-3-yl) 4-octyl 2-methylenesuccinate;
4-cyclooctyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
10 4-cyclooctyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
4-cyclooctyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
(R)-4-(octan-2-yl) 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
(R)-4-(octan-2-yl) 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
1-(1-acetylazetidin-3-yl) 4-cyclohexyl 2-methylenesuccinate;
15 4-cyclohexyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
4-hexyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
4-hexyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
1-(2-(1H-tetrazol-5-yl)ethyl) 4-hexyl 2-methylenesuccinate;
2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoic acid;
20 3-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoic acid;
3-((4-((4-fluorobenzyl)oxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid;
3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid;
3-((2-methylene-4-(neopentyloxy)-4-oxobutanoyl)oxy)propanoic acid;
(S)-3-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)propanoic acid;
25 3-((4-(hexyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid;
3-((2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoyl)oxy)propanoic acid;
3-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid;
(R)-3-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)propanoic acid;
(S)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid;
30 2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
2-((2-methylene-4-(neopentyloxy)-4-oxobutanoyl)oxy)acetic acid;
2-((4-((4-fluorobenzyl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
2-((4-(hexyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
35 2-((2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoyl)oxy)acetic acid;
2-((2-methylene-4-oxo-4-(spiro[3.3]heptan-2-yloxy)butanoyl)oxy)acetic acid;
2-((2-methylene-4-oxo-4-(2-tosylethoxy)butanoyl)oxy)acetic acid;

- 2-(N-methyl-2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetamido)acetic acid;
 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetyl)-L-proline;
 N-methyl-N-(2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)glycine;
 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)-L-proline;
 5 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)glycine;
 N-(2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetyl)-N-methylglycine;
 (2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetyl)-L-proline;
 (S)-N-methyl-N-(2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetyl)glycine;
 (S)-(2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetyl)glycine;
 10 1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl) 4-octyl 2-methylenesuccinate;
 1-(3-morpholino-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 1-(3-(diethylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 1-(3-(methylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid;
 15 (R)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid;
 2-((4-((4,4-difluorocyclohexyl)methoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((4-(3-ethoxypropoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((4-(bicyclo[2.2.1]heptan-2-yloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((4-cyclobutoxy-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 20 3-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)-2,2-dimethylpropanoic acid;
 1-(2-((N,N-dimethylsulfamoyl)amino)-2-oxoethyl) 4-hexyl 2-methylenesuccinate;
 4-hexyl 1-(2-(methylsulfonamido)-2-oxoethyl) 2-methylenesuccinate;
 4-hexyl 1-(3-(methylsulfonamido)-2-oxoethyl) 2-methylenesuccinate;
 2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)-3,3,3-trifluoropropanoic acid;
 25 2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)-3,3,3-trifluoropropanoic acid;
 (E)-4-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)but-2-enoic acid;
 3-((2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)ethyl)sulfonyl)propanoic acid;
 1-((2H-tetrazol-5-yl)methyl) 4-cyclohexyl 2-methylenesuccinate;
 2-((3-((2-((3-chlorophenyl)sulfonyl)ethoxy)carbonyl)but-3-enoyl)oxy)acetic acid;
 30 (R)-2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)-2-phenylacetic acid;
 1-(2-(1H-tetrazol-5-yl)ethyl) 4-cyclohexyl 2-methylenesuccinate;
 (S)-1-(2-(1H-tetrazol-5-yl)ethyl) 4-octan-2-yl 2-methylenesuccinate;
 1-(2-(1H-tetrazol-5-yl)ethyl) 4-cyclooctyl 2-methylenesuccinate;
 1-(2-((3-chlorophenyl)sulfonyl)-2-methylpropyl) 4-cyclooctyl 2-methylenesuccinate;
 35 4-cyclooctyl 1-(2-methyl-2-(methylsulfonyl)propyl) 2-methylenesuccinate;
 1-(1-(1H-tetrazol-5-yl)ethyl) 4-cyclooctyl 2-methylenesuccinate;
 1-((1H-tetrazol-5-yl)methyl) 4-cyclooctyl 2-methylenesuccinate;

- (R)-1-(2-(1H-tetrazol-5-yl)ethyl) 4-octan-2-yl 2-methylenesuccinate;
(2R,3S)-2-acetamido-3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)butanoic acid;
4-cyclooctyl 1-(3-(2-ethoxy-2-oxoethyl)oxetan-3-yl) 2-methylenesuccinate;
4-(2-(methylsulfonyl)ethyl) 1-octyl 2-methyl-3-methylenesuccinate;
5 1-octyl 4-((S)-tetrahydrofuran-3-yl) 2-methyl-3-methylenesuccinate;
1-(1-(1H-tetrazol-5-yl)propan-2-yl) 4-((R)-octan-2-yl) 2-methylenesuccinate;
1-(1-(1H-tetrazol-5-yl)propan-2-yl) 4-((S)-octan-2-yl) 2-methylenesuccinate;
4-cyclohexyl 1-((2-methyl-2H-tetrazol-5-yl)methyl) 2-methylenesuccinate;
4-cyclohexyl 1-((1-methyl-1H-tetrazol-5-yl)methyl) 2-methylenesuccinate;
10 3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)-4,4,4-trifluorobutanoic acid;
2-(4-(cycloheptyloxy)-2-methylene-4-oxobutanoyloxy)acetic acid;
2-(2-methylene-4-(octan-3-yloxy)-4-oxobutanoyloxy)acetic acid;
2-(2-methylene-4-(octan-4-yloxy)-4-oxobutanoyloxy)acetic acid;
2-((4-(heptan-4-yloxy)-2-methylene-4-oxobutanoyl)oxy) acetic acid;
15 2-((4-((adamantan-2-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
2-((4-(1-cyclohexylethoxy)-2-methylene-4-oxobutanoyl)oxy) acetic acid;
2-((4-(1-cycloheptylethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
2-(2-methylene-4-oxo-4-(spiro[3.4]octan-2-yloxy)butanoyloxy)acetic acid;
2-(2-methylene-4-oxo-4-(spiro[3.5]nonan-2-yloxy)butanoyloxy)acetic acid;
20 2-(2-methylene-4-oxo-4-(spiro[3.5]nonan-7-yloxy)butanoyloxy)acetic acid;
2-((4-((2,2-dimethylcyclohexyl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
bis((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-methylenesuccinate;
1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-(2-oxaspiro[3.3]heptan-6-yl) 2-
methylenesuccinate;
25 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-(oxepan-4-yl) 2-
methylenesuccinate;
4-(1-butoxypropan-2-yl) 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-
methylenesuccinate;
4-spiro[3.3]heptan-2-yl 1-(3,3,3-trifluoro-2,2-dihydroxypropyl) 2-methylenesuccinate hydrate;
30 (R)-1-((2H-tetrazol-5-yl)methyl) 4-(octan-2-yl) 2-methylenesuccinate;
1-(2H-tetrazol-5-yl)methyl 4-cycloheptyl 2-methylenesuccinate;
1-(2H-tetrazol-5-yl)methyl 4-spiro[3.3]heptan-2-yl 2-methylenesuccinate;
(S)-1-(2H-tetrazol-5-yl)methyl 4-octan-2-yl 2-methylenesuccinate;
1-(1-(1H-tetrazol-5-yl)ethyl) 4-((S)-octan-2-yl) 2-methylenesuccinate;
35 1-(cyclopropyl(1H-tetrazol-5-yl)methyl) 4-((S)-octan-2-yl) 2-methylenesuccinate;
dicyclohexyl 2-methylenesuccinate;
2-((4-(cyclooctyloxy)-3-methyl-2-methylene-4-oxobutanoyl)oxy)acetic acid;

- 2-((2-methylene-4-oxo-4-(2,2,4,4-tetramethylcyclobutoxy)butanoyl)oxy) acetic acid;
(S)-2-(2-methylene-4-(octan-3-yloxy)-4-oxobutanoyloxy)acetic acid;
2-((4-(cyclooctyloxy)-3-methoxy-2-methylene-4-oxobutanoyl)oxy)acetic acid; and
2-((4-((-adamantan-1-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
5 (R)-2-((4-(heptan-2-yloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
2-((2-methylene-4-(nonan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid;
2-((2-methylene-4-(nonan-5-yloxy)-4-oxobutanoyl)oxy)acetic acid;
2-((4-(1-(3,5-dichlorophenyl)ethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
2-((4-((1-(3,5-dichlorophenyl)propan-2-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
10 (R)-2-(2-methylene-4-(octan-3-yloxy)-4-oxobutanoyloxy)acetic acid;
2-((2-methylene-4-oxo-4-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)butanoyl)oxy)acetic acid;
2-((4-(1-cyclohexyl-2,2,2-trifluoroethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
2-((4-(bicyclo[3.3.1]nonan-9-yloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
15 (S)-2-((2-methylene-4-oxo-4-((1,1,1-trifluorooctan-2-yl)oxy)butanoyl)oxy)acetic acid;
(R)-2-((2-methylene-4-(nonan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid;
(R)-2-((4-(1-cyclohexylethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
1-(3,3-difluorocyclobutyl) 4-octyl 2-methylenesuccinate;
1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-((R)-octan-2-yl) 2-
20 methylenesuccinate;
(R)-4-(octan-2-yl) 1-((3-oxo-2,3-dihydroisoxazol-5-yl)methyl) 2-methylenesuccinate;
(R)-4,4,4-trifluoro-3-((2-methylene-4-(((R)-octan-2-yl)oxy)-4-oxobutanoyl)oxy)butanoic acid;
2-((4-(cyclooctyloxy)-3-hydroxy-2-methylene-4-oxobutanoyl)oxy)acetic acid;
2-(3-methylene-5-(4-methylheptan-4-yloxy)-5-oxopent-1-en-2-yloxy)acetic acid;
25 2-((4-(1-cyclohexylcyclobutoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
2-((2-methylene-4-((2-methyloctan-2-yl)oxy)-4-oxobutanoyl)oxy)acetic acid;
2-((2-methylene-4-((2-methylheptan-2-yl)oxy)-4-oxobutanoyl)oxy)acetic acid;
2-((2-methylene-4-oxo-4-(1-pentylcyclobutoxy)butanoyl)oxy) acetic acid;
2-((2-methylene-4-((2-methylspiro[3.5]nonan-2-yl)oxy)-4-oxobutanoyl)oxy)acetic acid;
30 2-((2-methylene-4-oxo-4-(((exo)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)butanoyl)oxy)acetic acid;
2-((2-methylene-4-oxo-4-((2,2,6,6-tetramethylcyclohexyl)oxy) butanoyl)oxy)acetic acid;
2-((4-(1-(3,5-dichlorophenyl)ethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (Isomer 1);
2-((4-(1-(3,5-dichlorophenyl)ethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (Isomer 2);
35 (R)-2-((2-methylene-4-oxo-4-(1-(4-(trifluoromethyl)phenyl)ethoxy)butanoyl) oxy) acetic acid);
(S)-2-((2-methylene-4-oxo-4-(1-(4-(trifluoromethyl)phenyl)ethoxy)butanoyl) oxy) acetic acid);
2-((4-(1-cyclohexylcyclopropoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;

(S)-2-((4-(1-cyclohexylethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((2-methylene-4-oxo-4-((2,2,4,4-tetramethylpentan-3-yl)oxy)butanoyl)oxy)acetic acid;
 (S)-4,4,4-trifluoro-3-((2-methylene-4-(((R)-octan-2-yl)oxy)-4-oxobutanoyl)oxy)butanoic acid;
 2-((2-methylene-4-oxo-4-(1-pentylcyclopropoxy)butanoyl)oxy)acetic acid; and
 5 3-((2-methylene-4-oxo-4-(2,2,4,4-tetramethylcyclobutoxy)butanoyl)oxy)propanoic acid;
 or a pharmaceutically acceptable salt and/or solvate of any one thereof.

Suitably, the compound is selected from the group consisting of:

(R)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid;
 10 (R)-3-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)propanoic acid; and
 2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 or a pharmaceutically acceptable salt and/or solvate of any one thereof.

Suitably, the compound is selected from the group consisting of:


15 (R)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid;
 (R)-3-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)propanoic acid;
 (S)-2-((2-methylene-4-oxo-4-((1,1,1-trifluorooctan-2-yl)oxy)butanoyl)oxy)acetic acid; and
 2-((2-methylene-4-((2-methyloctan-2-yl)oxy)-4-oxobutanoyl)oxy)acetic acid;
 or a pharmaceutically acceptable salt and/or solvate of any one thereof.

Suitably, the compound is selected from the group consisting of:

(R)-4,4,4-trifluoro-3-((2-methylene-4-(((R)-octan-2-yl)oxy)-4-oxobutanoyl)oxy)butanoic acid; and
 (S)-4,4,4-trifluoro-3-((2-methylene-4-(((R)-octan-2-yl)oxy)-4-oxobutanoyl)oxy)butanoic acid;
 or a pharmaceutically acceptable salt and/or solvate of any one thereof.

Compounds of formula (IW-1) such as (IW) may be prepared as set out in the Examples, e.g. as set out in General Procedures 1-4.

For example, compounds of formula (IW-1) such as (IW) may be prepared using the following route:




R^A , R^B , R^C and R^D are as defined elsewhere herein.

Step (i): itaconate anhydride (V) can be reacted with alcohol (IV), wherein R^A represents R^A or a protected derivative thereof, in the presence of a catalyst such as p -TsOH. H_2O in a solvent such as toluene to give monoester (III).

Step (ii): Monoester (III) and alcohol (II), where $R^{B'}$ represents R^B or a protected derivative thereof, can be condensed under standard coupling conditions as shown in the General Procedures 2 and 3 to give compounds of formula (IW) following any optional deprotection steps. Alternatively, monoester (III) can be reacted with compound (II'), wherein $R^{B'}$ represents R^B or a protected derivative thereof and X represents a leaving group such as chloro, bromo, iodo, alkanesulfonate or arenesulfonate, in the presence of a base such as potassium carbonate to give compounds of formula (IV) after any requisite deprotection steps.

Compounds of formula (IW-1) such as (IV) may also be prepared by the following route:



R^A , R^B , R^C and R^D are as defined elsewhere herein.

Step (i): itaconate anhydride (V) can be reacted with alcohol (VI), wherein PG represents a protecting group orthogonal to any protecting group present in $R^{B'}$, in the presence of a catalyst such as p -TsOH. H_2O in a solvent such as toluene to give monoester (VII).


Step (ii): Monoester (VII) and alcohol (II), wherein $R^{B'}$ represents R^B or a protected derivative thereof, can be condensed under standard coupling conditions to give diesters of formula (VIII).

Step (iii): The orthogonal protecting group PG is removed using conditions known to the person skilled in the art to give itaconate (IX) possessing a free carboxyl group at the 4-position.

Step (iv): Itaconate (IX) is coupled with alcohol (IV), wherein $R^{A'}$ represents R^A or a protected derivative thereof, under standard coupling conditions to give monoester (IW) following any deprotection steps required.

5

Compounds of formula (IW-1) such as (IW) may additionally be made by the following route:



R^A , R^B , R^C and R^D are as defined elsewhere herein.

10 Step (i): Alcohol (IV) is condensed with compound (X), wherein X^1 and X^2 represent leaving groups, such as halo e.g., chloro, bromo or iodo, and $R^{A'}$ represents R^A or a protected derivative thereof, to give monoester (XI).

Step (ii): Monoester (XI) is reacted with a trialkylphosphonoacetate of formula (XII), wherein R^{11} and R^{12} independently represent C_{1-4} alkyl optionally substituted with halo and $R^{B'}$ represents R^B or a protected derivative thereof, to provide a compound of formula (XIII).

15

Step (iii): Condensation of a compound of formula (XIII) with formaldehyde or a formaldehyde equivalent thereof e.g., paraformaldehyde, and after any optional deprotection steps, provides the compound of formula (IW-a) such as (IW).

20


The skilled person will appreciate that protecting groups may be used throughout the synthetic schemes described herein to give protected derivatives of any of the above compounds or generic formulae. Protective groups and the means for their removal are described in "*Protective Groups in Organic Synthesis*", by Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons Inc; 4th Rev Ed., 2006, ISBN-10: 0471697540. Examples of nitrogen protecting groups include trityl (Tr), tert-butyloxycarbonyl (BOC), 9-fluorenylmethyloxycarbonyl (Fmoc), acetyl (Ac), benzyl (Bn) and para-methoxy benzyl (PMB). Examples of oxygen protecting groups include acetyl (Ac), methoxymethyl (MOM), para-methoxybenzyl (PMB), benzyl, tert-butyl, methyl, ethyl,

25

tetrahydropyranyl (THP), and silyl ethers and esters (such as trimethylsilyl (TMS), tert-butyl dimethylsilyl (TBDMS), tri-iso-propylsilyloxymethyl (TOM), and triisopropylsilyl (TIPS) ethers and esters). Specific examples of carboxylic acid protecting groups include alkyl esters (such as C₁₋₆ alkyl e.g. C₁₋₄ alkyl esters), benzyl esters and silyl esters.

5


Thus, in one embodiment there is provided a process for preparing a compound of formula (IW-1) such as (IW) or a salt such as a pharmaceutically acceptable salt thereof, which comprises reacting a compound of formula (III):



(III)

10


wherein R^{A'}, R^C and R^D are defined elsewhere herein,
or a salt thereof;
with a compound of formula (II):



(II)

15 wherein R^{B'} is defined elsewhere herein,
or a salt thereof.

In one embodiment there is provided a process for preparing a compound of formula (IW-1),
such as (IW) or a salt such as a pharmaceutically acceptable salt thereof, which comprises
20 reacting a compound of formula (III):



(III)

wherein R^{A'}, R^C and R^D are defined elsewhere herein,
or a salt thereof;


25 with a compound of formula (II'):




(II')

wherein R^{B'} and X are defined elsewhere herein,
or a salt thereof.

There is also provided a process for preparing a compound of formula (III) or a salt thereof, which comprises reacting a compound of formula (V):




- 5 or a salt thereof;
with a compound of formula (IV):




wherein $R^{A'}$ is defined elsewhere herein,
or a salt thereof.

10

There is also provided a process for preparing a compound of formula (IW-1), such as (IW) or a salt such as a pharmaceutically acceptable salt thereof, which comprises reacting a compound of formula (IX):




- 15 wherein $R^{B'}$, R^C and R^D are defined elsewhere herein,
or a salt thereof;
with a compound of formula (IV)




wherein $R^{A'}$ is defined elsewhere herein,
20 or a salt thereof.

In one embodiment there is provided a process for preparing a compound of formula (VIII) or a salt thereof, which comprises reacting a compound of formula (VII):




wherein PG, R^C and R^D are defined elsewhere herein,
 or a salt thereof;
 with a compound of formula (II):




- 5 wherein R^{B'} is defined elsewhere herein,
 or a salt thereof.

In one embodiment there is provided a process for preparing a compound of formula (IW-1),
 such as (IW) or a salt such as a pharmaceutically acceptable salt thereof, which comprises
 10 reacting a compound of formula (XIII):




or a salt thereof,
 with formaldehyde or an equivalent thereof;
 wherein R^{A'}, R^{B'}, R^C, R^D, R¹¹ and R¹² are defined elsewhere herein.

- 15 In one embodiment there is provided a process for preparing a compound of formula (XIII) or a
 salt thereof, which comprises reacting a compound of formula (XI):




- wherein R^{A'}, R^C, R^D and X² are defined elsewhere herein,
 20 or a salt thereof;
 with a compound of formula (XII):



wherein R^{B'}, R¹¹ and R¹² are defined elsewhere herein,
 or a salt thereof.


- 25 In one embodiment, there is provided a compound of formula (III):



(III)

or a salt thereof, wherein $R^{A'}$, R^C and R^D are defined elsewhere herein.


In one embodiment, there is provided a compound of formula (IX):



(IX)

or a salt thereof, wherein $R^{B'}$, R^C and R^D are defined elsewhere herein. Suitably, $R^{B'}$ represents C_{1-2} alkyl substituted by CO_2H and further substituted by trifluoromethyl or methyl and e.g. represents the group $CH(CF_3)CH_2CO_2H$ or $CH(CH_3)CH_2CO_2H$, or a corresponding group in which the carboxylic acid is protected.


In one embodiment, there is provided a compound of formula (VIII):



(VIII)

or a salt thereof, wherein PG, $R^{B'}$, R^C and R^D are defined elsewhere herein. Suitably, $R^{B'}$ represents C_{1-2} alkyl substituted by CO_2H and further substituted by trifluoromethyl or methyl and e.g. represents the group $CH(CF_3)CH_2CO_2H$ or $CH(CH_3)CH_2CO_2H$, or a corresponding group in which the carboxylic acid is protected.


In one embodiment, there is provided a compound of formula (XIII):



(XIII)

or a salt thereof, wherein $R^{A'}$, $R^{B'}$, R^C , R^D , R^{11} and R^{12} are defined elsewhere herein.

In one embodiment, there is provided a compound of formula (XI):



or a salt thereof, wherein $R^{A'}$, R^C , R^D and X^2 are defined elsewhere herein.

Certain intermediates are novel and are claimed as an aspect of the invention:

- 5 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid;
 - 2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoic acid;
 - 4-(2-(2-ethoxyethoxy)ethoxy)-2-methylene-4-oxobutanoic acid;
 - 4-((4-fluorobenzyl)oxy)-2-methylene-4-oxobutanoic acid;
 - (*R*)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid;
 - 10 (*S*)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid;
 - 2-methylene-4-(neopentyloxy)-4-oxobutanoic acid;
 - 3-((2-(*tert*-butoxy)-2-oxoethoxy)carbonyl)but-3-enoic acid; and
 - 3-methyl-2-methylene-4-(octyloxy)-4-oxobutanoic acid
- or salts thereof.

15 Reference hereinbelow to compounds of formula (IW-1) is taken to include reference to all formulae disclosed herein: compounds of formula (IW), (IW-a), (IW-b), (IW-c), (IW-d), (IW-e), (IY), (I), (IWA), (IYA), (IA), (IWB), (IYB), (IB), (IWC), (IC), (IWD-1), (IYD-1), (ID-1), (IWD-2), (IYD-2), (ID-2) and (IWE).

20 It will be appreciated that for use in therapy the salts of the compounds of formula (IW-1) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art. Pharmaceutically acceptable salts include acid addition salts formed with inorganic acids e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid. Also included are salts formed with organic acids e.g. succinic acid, maleic acid, acetic acid,

25 fumaric acid, citric acid, tartaric acid, benzoic acid, p-toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid and 1,5-naphthalenedisulfonic acid. Other salts e.g. oxalates or formates, may be used, for example in the isolation of compounds of formula (IW-1) and are included within the scope of this invention, as are basic addition salts such as sodium, potassium,

30 calcium, aluminium, zinc, magnesium and other metal salts.

Pharmaceutically acceptable salts may also be formed with organic bases such as basic amines e.g. with ammonia, meglumine, tromethamine, piperazine, arginine, choline, diethylamine, benzathine or lysine. Thus, in one embodiment there is provided a compound of formula (IW-1)

in the form of a pharmaceutically acceptable salt. Alternatively, there is provided a compound of formula (IW-1) in the form of a free acid. When the compound contains a basic group as well as the free acid it may be Zwitterionic.

- 5 Suitably, the compound of formula (IW-1) is not a salt e.g. is not a pharmaceutically acceptable salt.

For compounds of formula (IW-1) which contain a carboxylic acid group, suitably, the pharmaceutically acceptable salt is a basic addition salt such as a carboxylate salt formed with a group 1 metal (e.g. a sodium or potassium salt), a group 2 metal (e.g. a magnesium or calcium salt) or an ammonium salt of a basic amine (e.g. an NH_4^+ salt), such as a sodium salt.

The compounds of formula (IW-1) may be prepared in crystalline or non-crystalline form and, if crystalline, may optionally be solvated, e.g. as the hydrate. This invention includes within its scope stoichiometric solvates (e.g. hydrates) as well as compounds containing variable amounts of solvent (e.g. water). Suitably, the compound of formula (IW-1) is not a solvate.

The invention extends to a pharmaceutically acceptable derivative thereof, such as a pharmaceutically acceptable prodrug of compounds of formula (IW-1). Typical prodrugs of compounds of formula (IW-1) which comprise a carboxylic acid include ester (e.g. C_{1-6} alkyl e.g. C_{1-4} alkyl ester) derivatives thereof. Thus, in one embodiment, the compound of formula (IW-1) is provided as a pharmaceutically acceptable prodrug. In another embodiment, the compound of formula (IW-1) is not provided as a pharmaceutically acceptable prodrug.

25 Certain compounds of formula (IW-1) may metabolise under certain conditions such as by hydrolysis of the R^{B} ester group. Certain metabolites of compounds of formula (IW-1) have activity, as described in Biological Example 8. Without wishing to be bound by theory, formation of an active metabolite (such as in vivo) of a compound of formula (IW-1) may be beneficial by contributing to the biological activity observed of the compound of formula (IW-1). Thus, in one embodiment, there is provided an active metabolite of the compound of formula (IW-1) and its use as a pharmaceutical e.g. for the treatment or prevention of the diseases mentioned herein.

It is to be understood that the present invention encompasses all isomers of compounds of formula (IW-1) (and compounds of formula (IW), (IW-a), (IW-b), (IW-c), (IW-d), (IY), (I), (IWA), (IYA), (IA), (IWB), (IYB), (IB), (IWC), (IC), (IWD-1), (IYD-1), (ID-1), (IWD-2), (IYD-2), (ID-2) and (IWE)) including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures). Where additional chiral centres are present in compounds of formula (IW-1), the

present invention includes within its scope all possible diastereoisomers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

5

The present invention also includes all isotopic forms of the compounds provided herein, whether in a form (i) wherein all atoms of a given atomic number have a mass number (or mixture of mass numbers) which predominates in nature (referred to herein as the "natural isotopic form") or (ii) wherein one or more atoms are replaced by atoms having the same atomic number, but a mass number different from the mass number of atoms which predominates in nature (referred to herein as an "unnatural variant isotopic form"). It is understood that an atom may naturally exist as a mixture of mass numbers. The term "unnatural variant isotopic form" also includes embodiments in which the proportion of an atom of given atomic number having a mass number found less commonly in nature (referred to herein as an "uncommon isotope") has been increased relative to that which is naturally occurring e.g. to the level of >20%, >50%, >75%, >90%, >95% or > 99% by number of the atoms of that atomic number (the latter embodiment referred to as an "isotopically enriched variant form"). The term "unnatural variant isotopic form" also includes embodiments in which the proportion of an uncommon isotope has been reduced relative to that which is naturally occurring. Isotopic forms may include radioactive forms (i.e. they incorporate radioisotopes) and non-radioactive forms. Radioactive forms will typically be isotopically enriched variant forms.

An unnatural variant isotopic form of a compound may thus contain one or more artificial or uncommon isotopes such as deuterium (^2H or D), carbon-11 (^{11}C), carbon-13 (^{13}C), carbon-14 (^{14}C), nitrogen-13 (^{13}N), nitrogen-15 (^{15}N), oxygen-15 (^{15}O), oxygen-17 (^{17}O), oxygen-18 (^{18}O), phosphorus-32 (^{32}P), sulphur-35 (^{35}S), chlorine-36 (^{36}Cl), chlorine-37 (^{37}Cl), fluorine-18 (^{18}F), iodine-123 (^{123}I), iodine-125 (^{125}I) in one or more atoms or may contain an increased proportion of said isotopes as compared with the proportion that predominates in nature in one or more atoms.

30

Unnatural variant isotopic forms comprising radioisotopes may, for example, be used for drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. ^3H , and carbon-14, i.e. ^{14}C , are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Unnatural variant isotopic forms which incorporate deuterium i.e. ^2H or D may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Further, unnatural variant isotopic forms may be prepared which incorporate

35

positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , and would be useful in positron emission topography (PET) studies for examining substrate receptor occupancy.

In one embodiment, the compounds of formula (IW-1) are provided in a natural isotopic form. In one embodiment, the compounds of formula (IW-1) are provided in an unnatural variant isotopic form. In a specific embodiment, the unnatural variant isotopic form is a form in which deuterium (i.e. ^2H or D) is incorporated where hydrogen is specified in the chemical structure in one or more atoms of a compound of formula (IW-1). In one embodiment, the atoms of the compounds of formula (IW-1) are in an isotopic form which is not radioactive. In one embodiment, one or more atoms of the compounds of formula (IW-1) are in an isotopic form which is radioactive. Suitably radioactive isotopes are stable isotopes. Suitably the unnatural variant isotopic form is a pharmaceutically acceptable form.

In one embodiment, a compound of formula (IW-1) is provided whereby a single atom of the compound exists in an unnatural variant isotopic form. In another embodiment, a compound of formula (IW-1) is provided whereby two or more atoms exist in an unnatural variant isotopic form.

Unnatural isotopic variant forms can generally be prepared by conventional techniques known to those skilled in the art or by processes described herein e.g. processes analogous to those described in the accompanying Examples for preparing natural isotopic forms. Thus, unnatural isotopic variant forms could be prepared by using appropriate isotopically variant (or labelled) reagents in place of the normal reagents employed in the Examples. Since the compounds of formula (IW-1) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions.

Therapeutic indications

Compounds of formula (IW-1) are of use in therapy, particularly for treating or preventing an inflammatory disease or a disease associated with an undesirable immune response. As shown in Biological Example 1 below, example compounds of formula (IW-1) reduced cytokine release more effectively than dimethyl itaconate, as demonstrated by lower IC_{50} values. Cytokines are important mediators of inflammation and immune-mediated disease as evidenced by the therapeutic benefit delivered by antibodies targeting them. As shown in Biological Example 2, example compounds of formula (IW-1) also exhibited a lower EC_{50} and/or a higher E_{max} compared

with dimethyl itaconate in an NQO1 enzyme activation assay. NQO1 is an anti-oxidant target gene upregulated by increased NRF2 activity. Induction of this gene is concomitant with the inhibition of proinflammatory cytokine transcription and suppression of the inflammatory response (Kobayashi E. H. *et al.*, 2016).

5 Thus, in a first aspect, the present invention provides a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein, for use as a medicament. Also provided is a pharmaceutical composition comprising a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein. Such a
10 pharmaceutical composition contains the compound of formula (IW-1) and a pharmaceutically acceptable carrier or excipient.

In a further aspect, the present invention provides a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein, for use in treating or
15 preventing an inflammatory disease or a disease associated with an undesirable immune response. In a further aspect, the present invention provides the use of a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein, in the manufacture of a medicament for treating or preventing an inflammatory disease or a disease associated with an undesirable immune response. In a further aspect, the present invention
20 provides a method of treating or preventing an inflammatory disease or a disease associated with an undesirable immune response, which comprises administering a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein.

For all aspects of the invention, suitably the compound is administered to a subject in need
25 thereof, wherein the subject is suitably a human subject.

In one embodiment is provided a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein, for use in treating an inflammatory disease or disease associated with an undesirable immune response. In one embodiment of the invention is
30 provided the use of a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein, in the manufacture of a medicament for treating an inflammatory disease or a disease associated with an undesirable immune response. In one embodiment of the invention is provided a method of treating an inflammatory disease or a disease associated with an undesirable immune response, which comprises administering a compound of formula
35 (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein.

In one embodiment is provided a compound of formula (IW-1) or a pharmaceutically acceptable

salt and/or solvate thereof as defined herein, for use in preventing an inflammatory disease or a disease associated with an undesirable immune response. In one embodiment of the invention is provided the use of a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein, in the manufacture of a medicament for preventing an inflammatory disease or a disease associated with an undesirable immune response. In one embodiment of the invention is provided a method of preventing an inflammatory disease or a disease associated with an undesirable immune response, which comprises administering a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein.

In one embodiment is provided a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein, for use in treating or preventing an inflammatory disease. In one embodiment of the invention is provided the use of a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein, in the manufacture of a medicament for treating or preventing an inflammatory disease. In one embodiment of the invention is provided a method of treating or preventing an inflammatory disease, which comprises administering a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein.

In one embodiment is provided a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein, for use in treating or preventing a disease associated with an undesirable immune response. In one embodiment of the invention is provided the use of a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein, in the manufacture of a medicament for treating or preventing a disease associated with an undesirable immune response. In one embodiment of the invention is provided a method of treating or preventing a disease associated with an undesirable immune response, which comprises administering a compound of formula (IW-1) or a pharmaceutically acceptable salt and/or solvate thereof as defined herein.

An undesirable immune response will typically be an immune response which gives rise to a pathology i.e. is a pathological immune response or reaction.

In one embodiment, the inflammatory disease or disease associated with an undesirable immune response is an auto-immune disease.

In one embodiment, the inflammatory disease or disease associated with an undesirable immune response is, or is associated with, a disease selected from the group consisting of: psoriasis

(including chronic plaque, erythrodermic, pustular, guttate, inverse and nail variants), asthma, chronic obstructive pulmonary disease (COPD, including chronic bronchitis and emphysema), heart failure (including left ventricular failure), myocardial infarction, angina pectoris, other atherosclerosis and/or atherothrombosis-related disorders (including peripheral vascular disease and ischaemic stroke), a mitochondrial and neurodegenerative disease (such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, retinitis pigmentosa or mitochondrial encephalomyopathy), autoimmune paraneoplastic retinopathy, transplantation rejection (including antibody-mediated and T cell-mediated forms), multiple sclerosis, transverse myelitis, ischaemia-reperfusion injury (e.g. during elective surgery such as cardiopulmonary bypass for coronary artery bypass grafting or other cardiac surgery, following percutaneous coronary intervention, following treatment of acute ST-elevation myocardial infarction or ischaemic stroke, organ transplantation, or acute compartment syndrome), AGE-induced genome damage, an inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), primary sclerosing cholangitis (PSC), PSC-autoimmune hepatitis overlap syndrome, non-alcoholic fatty liver disease (non-alcoholic steatohepatitis), rheumatica, granuloma annulare, cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), lupus nephritis, drug-induced lupus, autoimmune myocarditis or myopericarditis, Dressler's syndrome, giant cell myocarditis, post-pericardiotomy syndrome, drug-induced hypersensitivity syndromes (including hypersensitivity myocarditis), eczema, sarcoidosis, erythema nodosum, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorders, MOG (myelin oligodendrocyte glycoprotein) antibody-associated disorders (including MOG-EM), optic neuritis, CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids), diffuse myelinoclastic sclerosis, Addison's disease, alopecia areata, ankylosing spondylitis, other spondyloarthritides (including peripheral spondyloarthritis, that is associated with psoriasis, inflammatory bowel disease, reactive arthritis or juvenile onset forms), antiphospholipid antibody syndrome, autoimmune hemolytic anaemia, autoimmune hepatitis, autoimmune inner ear disease, pemphigoid (including bullous pemphigoid, mucous membrane pemphigoid, cicatricial pemphigoid, herpes gestationis or pemphigoid gestationis, ocular cicatricial pemphigoid), linear IgA disease, Behçet's disease, celiac disease, Chagas disease, dermatomyositis, diabetes mellitus type I, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome and its subtypes (including acute inflammatory demyelinating polyneuropathy, AIDP, acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), pharyngeal-cervical-brachial variant, Miller-Fisher variant and Bickerstaff's brainstem encephalitis), progressive inflammatory neuropathy, Hashimoto's disease, hidradenitis suppurativa, inclusion body myositis, necrotising myopathy, Kawasaki disease, IgA nephropathy, Henoch-Schonlein purpura, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura (TTP), Evans' syndrome, interstitial cystitis, mixed connective tissue disease,

undifferentiated connective tissue disease, morphea, myasthenia gravis (including MuSK antibody positive and seronegative variants), narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, psoriatic arthritis, polymyositis, primary biliary cholangitis (also known as primary biliary cirrhosis), rheumatoid arthritis, palindromic rheumatism, schizophrenia,

5 autoimmune (meningo-)encephalitis syndromes, scleroderma, Sjogren's syndrome, stiff person syndrome, polymyalgia rheumatica, giant cell arteritis (temporal arteritis), Takayasu arteritis, polyarteritis nodosa, Kawasaki disease, granulomatosis with polyangiitis (GPA; formerly known as Wegener's granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome), microscopic polyarteritis/polyangiitis,

10 hypocomplementaemic urticarial vasculitis, hypersensitivity vasculitis, cryoglobulinemia, thromboangiitis obliterans (Buerger's disease), vasculitis, leukocytoclastic vasculitis, vitiligo, acute disseminated encephalomyelitis, adrenoleukodystrophy, Alexander's disease, Alper's disease, balo concentric sclerosis or Marburg disease, cryptogenic organising pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia), Canavan disease, central

15 nervous system vasculitic syndrome, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic inflammatory demyelinating polyneuropathy (CIDP), diabetic retinopathy, globoid cell leukodystrophy (Krabbe disease), graft-versus-host disease (GVHD) (including acute and chronic forms, as well as intestinal GVHD), hepatitis C (HCV) infection or complication, herpes simplex viral infection or complication, human immunodeficiency

20 virus (HIV) infection or complication, lichen planus, monomelic amyotrophy, cystic fibrosis, pulmonary arterial hypertension (PAH, including idiopathic PAH), lung sarcoidosis, idiopathic pulmonary fibrosis, paediatric asthma, atopic dermatitis, allergic dermatitis, contact dermatitis, allergic rhinitis, rhinitis, sinusitis, conjunctivitis, allergic conjunctivitis, keratoconjunctivitis sicca, dry eye, xerophthalmia, glaucoma, macular oedema, diabetic macular oedema, central retinal

25 vein occlusion (CRVO), macular degeneration (including dry and/or wet age related macular degeneration, AMD), post-operative cataract inflammation, uveitis (including posterior, anterior, intermediate and pan uveitis), iridocyclitis, scleritis, corneal graft and limbal cell transplant rejection, gluten sensitive enteropathy (coeliac disease), dermatitis herpetiformis, eosinophilic esophagitis, achalasia, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune

30 oophoritis, autoimmune orchitis, autoimmune pancreatitis, aortitis and periaortitis, autoimmune retinopathy, autoimmune urticaria, Behcet's disease, (idiopathic) Castleman's disease, Cogan's syndrome, IgG4-related disease, retroperitoneal fibrosis, juvenile idiopathic arthritis including systemic juvenile idiopathic arthritis (Still's disease), adult-onset Still's disease, ligneous conjunctivitis, Mooren's ulcer, pityriasis lichenoides et varioliformis acuta (PLEVA, also known as

35 Mucha-Habermann disease), multifocal motor neuropathy (MMN), paediatric acute-onset neuropsychiatric syndrome (PANS) (including paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)), paraneoplastic syndromes (including

paraneoplastic cerebellar degeneration, Lambert-Eaton myasthenic syndrome, limbic encephalitis, brainstem encephalitis, opsoclonus myoclonus ataxia syndrome, anti-NMDA receptor encephalitis, thymoma-associated multiorgan autoimmunity), perivenous encephalomyelitis, reflex sympathetic dystrophy, relapsing polychondritis, sperm & testicular autoimmunity, Susac's syndrome, Tolosa-Hunt syndrome, Vogt-Koyanagi-Harada Disease, anti-synthetase syndrome, autoimmune enteropathy, immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX), microscopic colitis, autoimmune lymphoproliferative syndrome (ALPS), autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APEX), gout, pseudogout, amyloid (including AA or secondary amyloidosis), eosinophilic fasciitis (Shulman syndrome) progesterone hypersensitivity (including progesterone dermatitis), familial Mediterranean fever (FMF), tumour necrosis factor (TNF) receptor-associated periodic fever syndrome (TRAPS), hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS), PAPA (pyogenic arthritis, pyoderma gangrenosum, severe cystic acne) syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), deficiency of the interleukin-36-receptor antagonist (DITRA), cryopyrin-associated periodic syndromes (CAPS) (including familial cold autoinflammatory syndrome [FCAS], Muckle-Wells syndrome, neonatal onset multisystem inflammatory disease [NOMID]), NLRP12-associated autoinflammatory disorders (NLRP12AD), periodic fever aphthous stomatitis (PFAPA), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), Majeed syndrome, Blau syndrome (also known as juvenile systemic granulomatosis), macrophage activation syndrome, chronic recurrent multifocal osteomyelitis (CRMO), familial cold autoinflammatory syndrome, mutant adenosine deaminase 2 and monogenic interferonopathies (including Aicardi-Goutières syndrome, retinal vasculopathy with cerebral leukodystrophy, spondyloenchondrodysplasia, STING [stimulator of interferon genes]-associated vasculopathy with onset in infancy, proteasome associated autoinflammatory syndromes, familial chilblain lupus, dyschromatosis symmetrica hereditaria), Schnitzler syndrome; familial cylindromatosis, congenital B cell lymphocytosis, OTULIN-related autoinflammatory syndrome, type 2 diabetes mellitus, insulin resistance and the metabolic syndrome (including obesity-associated inflammation), atherosclerotic disorders (e.g. myocardial infarction, angina, ischaemic heart failure, ischaemic nephropathy, ischaemic stroke, peripheral vascular disease, aortic aneurysm), renal inflammatory disorders (e.g. diabetic nephropathy, membranous nephropathy, minimal change disease, crescentic glomerulonephritis, acute kidney injury, renal transplantation).

In one embodiment, the inflammatory disease or disease associated with an undesirable immune response is, or is associated with, a disease selected from the following autoinflammatory diseases: familial Mediterranean fever (FMF), tumour necrosis factor (TNF) receptor-associated periodic fever syndrome (TRAPS), hyperimmunoglobulinaemia D with periodic fever syndrome

(HIDS), PAPA (pyogenic arthritis, pyoderma gangrenosum, and severe cystic acne) syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), deficiency of the interleukin-36-receptor antagonist (DITRA), cryopyrin-associated periodic syndromes (CAPS) (including familial cold autoinflammatory syndrome [FCAS], Muckle-Wells syndrome, and neonatal onset multisystem inflammatory disease [NOMID]), NLRP12-associated autoinflammatory disorders (NLRP12AD),
5 periodic fever aphthous stomatitis (PFAPA), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), Majeed syndrome, Blau syndrome (also known as juvenile systemic granulomatosis), macrophage activation syndrome, chronic recurrent multifocal osteomyelitis (CRMO), familial cold autoinflammatory syndrome, mutant adenosine
10 deaminase 2 and monogenic interferonopathies (including Aicardi-Goutières syndrome, retinal vasculopathy with cerebral leukodystrophy, spondyloenchondrodysplasia, STING [stimulator of interferon genes]-associated vasculopathy with onset in infancy, proteasome associated autoinflammatory syndromes, familial chilblain lupus, dyschromatosis symmetrica hereditaria) and Schnitzler syndrome.

15 In one embodiment, the inflammatory disease or disease associated with an undesirable immune response is, or is associated with, a disease selected from the following diseases mediated by excess NF- κ B or gain of function in the NF- κ B signalling pathway or in which there is a major contribution to the abnormal pathogenesis therefrom (including non-canonical NF- κ B signalling):
20 familial cylindromatosis, congenital B cell lymphocytosis, OTULIN-related autoinflammatory syndrome, type 2 diabetes mellitus, insulin resistance and the metabolic syndrome (including obesity-associated inflammation), atherosclerotic disorders (e.g. myocardial infarction, angina, ischaemic heart failure, ischaemic nephropathy, ischaemic stroke, peripheral vascular disease, aortic aneurysm), renal inflammatory disorders (e.g. diabetic nephropathy, membranous
25 nephropathy, minimal change disease, crescentic glomerulonephritis, acute kidney injury, renal transplantation), asthma, COPD, type 1 diabetes mellitus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (including ulcerative colitis and Crohn's disease), and SLE.

In one embodiment, the disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, multiple sclerosis,
30 psoriasis, Crohn's disease, ulcerative colitis, uveitis, cryopyrin-associated periodic syndromes, Muckle-Wells syndrome, juvenile idiopathic arthritis and chronic obstructive pulmonary disease.

In one embodiment, the disease is multiple sclerosis.

35 In one embodiment, the disease is psoriasis.

In one embodiment, the compound of formula (IW-1) exhibits a lower IC₅₀ compared with dimethyl itaconate when tested in a cytokine assay e.g. as described in Biological Example 1. In one

embodiment, the compound of formula (IW-1) exhibits a lower IC_{50} compared with dimethyl fumarate when tested in a cytokine assay e.g. as described in Biological Example 1.

In one embodiment, the compound of formula (IW-1) exhibits a lower EC_{50} compared with dimethyl itaconate when tested in an NQO1 assay e.g. as described in Biological Example 2. In one embodiment, the compound of formula (IW-1) exhibits a higher E_{max} compared with dimethyl itaconate when tested in an NQO1 assay e.g. as described in Biological Example 2. In one embodiment, the compound of formula (IW-1) exhibits a lower EC_{50} and/or higher E_{max} compared with dimethyl itaconate when tested in an NQO1 assay e.g. as described in Biological Example 2. In one embodiment, the compound of formula (IW-1) exhibits a lower EC_{50} and higher E_{max} compared with dimethyl itaconate when tested in an NQO1 assay e.g. as described in Biological Example 2. In one embodiment, the compound of formula (IW-1) exhibits a lower EC_{50} compared with dimethyl fumarate when tested in an NQO1 assay e.g. as described in Biological Example 2. In one embodiment, the compound of formula (IW-1) exhibits a higher E_{max} compared with dimethyl fumarate when tested in an NQO1 assay, e.g., as described in Biological Example 2. In one embodiment, the compound of formula (IW-1) exhibits a lower EC_{50} and/or higher E_{max} compared with dimethyl fumarate when tested in an NQO1 assay e.g. as described in Biological Example 2. In one embodiment, the compound of formula (IW-1) exhibits a lower EC_{50} and higher E_{max} compared with dimethyl fumarate when tested in an NQO1 assay, e.g., as described in Biological Example 2.

In one embodiment, the compound of formula (IW-1) exhibits a lower EC_{50} compared with dimethyl itaconate when tested in an NRF2 assay e.g. as described in Biological Example 5. In one embodiment, the compound of formula (IW-1) exhibits a higher E_{max} compared with dimethyl itaconate when tested in an NRF2 assay e.g. as described in Biological Example 5. In one embodiment, the compound of formula (IW-1) exhibits a lower EC_{50} and/or higher E_{max} compared with dimethyl itaconate when tested in an NRF2 assay e.g. as described in Biological Example 5. In one embodiment, the compound of formula (IW-1) exhibits a lower EC_{50} and higher E_{max} compared with dimethyl itaconate when tested in an NRF2 assay e.g. as described in Biological Example 5.

In one embodiment, the compound of formula (I) exhibits improved oral systemic bioavailability compared with dimethyl itaconate e.g. as described in Biological Example 6. In one embodiment, the compound of formula (I) exhibits reduced plasma clearance following intravenous dosing compared with dimethyl itaconate e.g. as described in Biological Example 6.

In one embodiment, the compound of formula (IW-1) exhibits lower intrinsic clearance (Cl_{int})

compared with 4-octyl itaconate when tested in a hepatocyte stability assay, e.g., as described in Biological Example 7. In one embodiment, the compound of formula (IW-1) exhibits a longer half-life ($T_{1/2}$) compared with 4-octyl itaconate when tested in a hepatocyte stability assay, e.g. as described in Biological Example 7.

5

Administration

The compound of formula (IW-1) is usually administered as a pharmaceutical composition. Thus, in one embodiment, is provided a pharmaceutical composition comprising a compound of formula (IW-1) and one or more pharmaceutically acceptable diluents or carriers.

10

The compound of formula (IW-1) may be administered by any convenient method, e.g. by oral, parenteral, buccal, sublingual, nasal, rectal, intrathecal or transdermal administration, and the pharmaceutical compositions adapted accordingly.

15

The compound of formula (IW-1) may be administered topically to the target organ e.g. topically to the eye, lung, nose or skin. Hence the invention provides a pharmaceutical composition comprising a compound of formula (IW-1) optionally in combination with one or more topically acceptable diluents or carriers.

20

A compound of formula (IW-1) which is active when given orally can be formulated as a liquid or solid, e.g. as a syrup, suspension, emulsion, tablet, capsule or lozenge.

A liquid formulation will generally consist of a suspension or solution of the compound of formula (IW-1) in a suitable liquid carrier(s). Suitably the carrier is non-aqueous e.g. polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring and/or colouring agent.

25

A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations, such as magnesium stearate, starch, lactose, sucrose and cellulose.

30

A composition in the form of a capsule can be prepared using routine encapsulation procedures, e.g. pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatine capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), e.g. aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatine capsule.

35

Typical parenteral compositions consist of a solution or suspension of the compound of formula (IW-1) in a sterile aqueous carrier or parenterally acceptable oil, e.g. polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the compound of formula (IW-1) in a pharmaceutically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container which can take the form of a cartridge or refill for use with an atomising device. Alternatively, the sealed container may be a disposable dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas e.g. air, or an organic propellant such as a chlorofluorocarbon (CFC) or a hydrofluorocarbon (HFC). Aerosol dosage forms can also take the form of pump-atomisers.

Topical administration to the lung may be achieved by use of an aerosol formulation. Aerosol formulations typically comprise the active ingredient suspended or dissolved in a suitable aerosol propellant, such as a chlorofluorocarbon (CFC) or a hydrofluorocarbon (HFC).

Topical administration to the lung may also be achieved by use of a non-pressurised formulation such as an aqueous solution or suspension. These may be administered by means of a nebuliser e.g. one that can be hand-held and portable or for home or hospital use (i.e. non-portable). The formulation may comprise excipients such as water, buffers, tonicity adjusting agents, pH adjusting agents, surfactants and co-solvents.

Topical administration to the lung may also be achieved by use of a dry-powder formulation. The formulation will typically contain a topically acceptable diluent such as lactose, glucose or mannitol (preferably lactose).

The compound of the invention may also be administered rectally, for example in the form of suppositories or enemas, which include aqueous or oily solutions as well as suspensions and emulsions and foams. Such compositions are prepared following standard procedures, well known by those skilled in the art. For example, suppositories can be prepared by mixing the active ingredient with a conventional suppository base such as cocoa butter or other glycerides. In this case, the drug is mixed with a suitable non-irritating excipient which is solid at ordinary

temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

Generally, for compositions intended to be administered topically to the eye in the form of eye drops or eye ointments, the total amount of the compound of the present invention will be about 0.0001 to less than 4.0% (w/w).

Preferably, for topical ocular administration, the compositions administered according to the present invention will be formulated as solutions, suspensions, emulsions and other dosage forms.

The compositions administered according to the present invention may also include various other ingredients, including, but not limited to, tonicity agents, buffers, surfactants, stabilizing polymer, preservatives, co-solvents and viscosity building agents. Suitable pharmaceutical compositions of the present invention include a compound of the invention formulated with a tonicity agent and a buffer. The pharmaceutical compositions of the present invention may further optionally include a surfactant and/or a palliative agent and/or a stabilizing polymer.

Various tonicity agents may be employed to adjust the tonicity of the composition, preferably to that of natural tears for ophthalmic compositions. For example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, simple sugars such as dextrose, fructose, galactose, and/or simply polyols such as the sugar alcohols mannitol, sorbitol, xylitol, lactitol, isomaltitol, maltitol, and hydrogenated starch hydrolysates may be added to the composition to approximate physiological tonicity. Such an amount of tonicity agent will vary, depending on the particular agent to be added. In general, however, the compositions will have a tonicity agent in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality (generally about 150-450 mOsm, preferably 250-350 mOsm and most preferably at approximately 290 mOsm). In general, the tonicity agents of the invention will be present in the range of 2 to 4% w/w. Preferred tonicity agents of the invention include the simple sugars or the sugar alcohols, such as D-mannitol.

An appropriate buffer system (e.g. sodium phosphate, sodium acetate, sodium citrate, sodium borate or boric acid) may be added to the compositions to prevent pH drift under storage conditions. The particular concentration will vary, depending on the agent employed. Preferably however, the buffer will be chosen to maintain a target pH within the range of pH 5 to 8, and more preferably to a target pH of pH 5 to 7.

Surfactants may optionally be employed to deliver higher concentrations of compound of the present invention. The surfactants function to solubilise the compound and stabilise colloid dispersion, such as micellar solution, microemulsion, emulsion and suspension. Examples of surfactants which may optionally be used include polysorbate, poloxamer, polyosyl 40 stearate, polyoxyl castor oil, tyloxapol, Triton, and sorbitan monolaurate. Preferred surfactants to be employed in the invention have a hydrophile/lipophile/balance "HLB" in the range of 12.4 to 13.2 and are acceptable for ophthalmic use, such as TritonX114 and tyloxapol.

Additional agents that may be added to the ophthalmic compositions of compounds of the present invention are demulcents which function as a stabilising polymer. The stabilizing polymer should be an ionic/charged example with precedence for topical ocular use, more specifically, a polymer that carries negative charge on its surface that can exhibit a zeta-potential of (–)10–50 mV for physical stability and capable of making a dispersion in water (i.e. water soluble). A preferred stabilising polymer of the invention would be polyelectrolyte, or polyelectrolytes if more than one, from the family of cross-linked polyacrylates, such as carbomers and Pemulen(R), specifically Carbomer 974p (polyacrylic acid), at 0.1–0.5% w/w.

Other compounds may also be added to the ophthalmic compositions of the compound of the present invention to increase the viscosity of the carrier. Examples of viscosity enhancing agents include, but are not limited to: polysaccharides, such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextrans, various polymers of the cellulose family; vinyl polymers; and acrylic acid polymers.

Topical ophthalmic products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol, edentate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0% w/v. Unit dose compositions of the present invention will be sterile, but typically unpreserved. Such compositions, therefore, generally will not contain preservatives.

Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles where the compound of formula (IW-1) is formulated with a carrier such as sugar and acacia, tragacanth, or gelatine and glycerine.

Compositions suitable for transdermal administration include ointments, gels and patches.

The composition may contain from 0.1% to 100% by weight, for example from 10 to 60% by weight, of the compound of formula (IW-1), depending on the method of administration. The composition may contain from 0% to 99% by weight, for example 40% to 90% by weight, of the carrier, depending on the method of administration. The composition may contain from 0.05mg to 1000mg, for example from 1.0 mg to 500 mg, such as from 1.0 mg to 50 mg, e.g. about 10 mg of the compound of formula (IW-1), depending on the method of administration. The composition may contain from 50 mg to 1000 mg, for example from 100mg to 400mg of the carrier, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 500mg, such as from 1.0 mg to 50 mg, e.g. about 10 mg and such unit doses may be administered more than once a day, for example two or three times a day. Such therapy may extend for a number of weeks or months.

In one embodiment of the invention, the compound of formula (IW-1) is used in combination with a further therapeutic agent or agents. When the compound of formula (IW-1) is used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route. Alternatively, the compounds may be administered separately.

Therapeutic agents which may be used in combination with the present invention include: corticosteroids (glucocorticoids), retinoids (e.g. acitretin, isotretinoin, tazarotene), anthralin, vitamin D analogues (e.g. calcitriol, calcipotriol), calcineurin inhibitors (e.g. tacrolimus, pimecrolimus), phototherapy or photochemotherapy (e.g. psoralen ultraviolet irradiation, PUVA) or other form of ultraviolet light irradiation therapy, ciclosporine, thiopurines (e.g. azathioprine, 6-mercaptopurine), methotrexate, anti-TNF α agents (e.g. infliximab, etanercept, adalimumab, certolizumab, golimumab and biosimilars), phosphodiesterase-4 (PDE4) inhibition (e.g. apremilast, crisaborole), anti-IL-17 agents (e.g. brodalumab, ixekizumab, secukinumab), anti-IL12/IL-23 agents (e.g. ustekinumab, briakinumab), anti-IL-23 agents (e.g. guselkumab, tildrakizumab), JAK (Janus Kinase) inhibitors (e.g. tofacitinib, ruxolitinib, baricitinib, filgotinib, upadacitinib), plasma exchange, intravenous immune globulin (IVIG), cyclophosphamide, anti-CD20 B cell depleting agents (e.g. rituximab, ocrelizumab, ofatumumab, obinutuzumab), anthracycline analogues (e.g. mitoxantrone), cladribine, sphingosine 1-phosphate receptor modulators or sphingosine analogues (e.g. fingolimod, siponimod, ozanimod, etrasimod), interferon beta preparations (including interferon beta 1b/1a), glatiramer, anti-CD3 therapy (e.g. OKT3), anti-CD52 targeting agents (e.g. alemtuzumab), leflunomide, teriflunomide, gold compounds, laquinimod, potassium channel blockers (e.g. dalfampridine/4-aminopyridine),

mycophenolic acid, mycophenolate mofetil, purine analogues (e.g. pentostatin), mTOR (mechanistic target of rapamycin) pathway inhibitors (e.g. sirolimus, everolimus), anti-thymocyte globulin (ATG), IL-2 receptor (CD25) inhibitors (e.g. basiliximab, daclizumab), anti-IL-6 receptor or anti-IL-6 agents (e.g. tocilizumab, siltuximab), Bruton's tyrosine kinase (BTK) inhibitors (e.g. 5 ibrutinib), tyrosine kinase inhibitors (e.g. imatinib), ursodeoxycholic acid, hydroxychloroquine, chloroquine, B cell activating factor (BAFF, also known as BLyS, B lymphocyte stimulator) inhibitors (e.g. belimumab, blisibimod), other B cell targeted therapy including fusion proteins targeting both APRIL (A Proliferation-Inducing Ligand) and BLyS (e.g. atacicept), PI3K inhibitors including pan-inhibitors or those targeting the p110 δ and/or p110 γ containing isoforms (e.g. 10 idelalisib, copanlisib, duvelisib), interferon α receptor inhibitors (e.g. anifrolumab, sifalimumab), T cell co-stimulation blockers (e.g. abatacept, belatacept), thalidomide and its derivatives (e.g. lenalidomide), dapsone, clofazimine, leukotriene antagonists (e.g. montelukast), theophylline, anti-IgE therapy (e.g. omalizumab), anti-IL-5 agents (e.g. mepolizumab, reslizumab), long-acting muscarinic agents (e.g. tiotropium, aclidinium, umeclidinium), PDE4 inhibitors (e.g. roflumilast), 15 riluzole, free radical scavengers (e.g. edaravone), proteasome inhibitors (e.g. bortezomib), complement cascade inhibitors including those directed against C5 (e.g. eculizumab), immunoadsor, antithymocyte globulin, 5-aminosalicylates and their derivatives (e.g. sulfasalazine, balsalazide, mesalamine), anti-integrin agents including those targeting $\alpha 4 \beta 1$ and/or $\alpha 4 \beta 7$ integrins (e.g. natalizumab, vedolizumab), anti-CD11- α agents (e.g. efalizumab), 20 non-steroidal anti-inflammatory drugs (NSAIDs) including the salicylates (e.g. aspirin), propionic acids (e.g. ibuprofen, naproxen), acetic acids (e.g. indomethacin, diclofenac, etodolac), oxicams (e.g. meloxicam) and fenamates (e.g. mefenamic acid), selective or relatively selective COX-2 inhibitors (e.g. celecoxib, etroxicoxib, valdecoxib and etodolac, meloxicam, nabumetone), colchicine, IL-4 receptor inhibitors (e.g. dupilumab), topical/contact immunotherapy (e.g. 25 diphenylcyclopropanone, squaric acid dibutyl ester), anti-IL-1 receptor therapy (e.g. anakinra), IL-1 β inhibitor (e.g. canakinumab), IL-1 neutralising therapy (e.g. rilonacept), chlorambucil, specific antibiotics with immunomodulatory properties and/or ability to modulate NRF2 (e.g. tetracyclines including minocycline, clindamycin, macrolide antibiotics), anti-androgenic therapy (e.g. cyproterone, spironolactone, finasteride), pentoxifylline, ursodeoxycholic acid, obeticholic acid, 30 fibrate, cystic fibrosis transmembrane conductance regulator (CFTR) modulators, VEGF (vascular endothelial growth factor) inhibitors (e.g. bevacizumab, ranibizumab, pegaptanib, aflibercept), pirfenidone, and mizoribine.

Compounds of formula (IW-1) may display one or more of the following desirable properties:

- 35
- low IC₅₀ values for inhibiting release of cytokines e.g. IL-1 β and/or IL-6, from cells;
 - low EC₅₀ and/or high E_{max} values for activating the enzyme NQO1 or the NRF2 pathway;

- enhanced efficacy through improved hydrolytic stability of carboxylic acid esters and/or augmented maximum response;
- reduced dose and dosing frequency through improved pharmacokinetics;
- improved oral systemic bioavailability;
- 5 • reduced plasma clearance following intravenous dosing;
- improved metabolic stability e.g. as demonstrated by improved stability in plasma and/or hepatocytes;
- augmented cell permeability;
- enhanced aqueous solubility;
- 10 • good tolerability, for example, by limiting the flushing and/or gastrointestinal side effects provoked by oral DMF (Hunt T. *et al.*, 2015; WO2014/152494A1, incorporated herein by reference), possibly by reducing or eliminating HCA2 activity;
- low toxicity at the relevant therapeutic dose;
- distinct anti-inflammatory profiles resulting from varied electrophilicities, leading to
- 15 differential targeting of the cysteine proteome (van der Reest J. *et al.*, 2018) and, therefore, modified effects on gene activation;
- glutathione-sparing actions;
- avoiding the oncometabolite fumaric acid (Kulkarni R. A. *et al.*, 2019).

20 **Abbreviations**

	Ac ₂ O	acetic anhydride
	ADEM	acute disseminated encephalomyelitis
	AIDP	acute inflammatory demyelinating polyneuropathy
25	ALPS	autoimmune lymphoproliferative syndrome
	AMAN	acute motor axonal neuropathy
	AMD	age related macular degeneration
	AMSAN	acute motor and sensory axonal neuropathy
	APEX	autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome
30	APRIL	A PRoliferation-Inducing Ligand
	aq.	aqueous
	ATF3	activating transcription factor 3
	ATG	anti-thymocyte
	BAFF	B cell activating factor
35	BBFO	broadband fluorine observe
	BEH	ethylene bridged hybrid
	Boc	tertiary-butoxycarbonyl

	BSA	bovine serum albumin
	BTk	Bruton's tyrosine kinase
	CAC	citric acid cycle
5	CANDLE	chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature
	CAPS	cryopyrin-associated periodic syndromes
	CFC	chlorofluorocarbon
	CFTR	cystic fibrosis transmembrane conductance regulator
	CIDP	chronic inflammatory demyelinating polyneuropathy
10	CLE	cutaneous lupus erythematosus
	CLIPPERS	chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids
	CLL	chronic lymphocytic leukaemia
	COPD	chronic obstructive pulmonary disease
15	CRMO	chronic recurrent multifocal osteomyelitis
	CRVO	central retinal vein occlusion
	CSH	charged surface hybrid
	DABCO	1,4-diazabicyclo[2.2.2]octane
	DAD	diode array detector
20	DBU	1,8-diazabicyclo(5.4.0)undec-7-ene
	DCC	N,N'-dicyclohexylcarbodiimide
	DCM	dichloromethane
	DIPEA	N,N-diisopropylethylamine
	DIRA	deficiency of interleukin-1 receptor antagonist
25	DITRA	deficiency of the interleukin-36-receptor antagonist
	DLBCL	diffuse large B cell lymphoma
	DMAP	4-dimethylaminopyridine
	DMF	dimethyl fumarate
	DMI	dimethyl itaconate
30	DMP	Dess-Martin periodinane
	DMSO	dimethyl sulfoxide
	EDC	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
	EDTA	ethylenediaminetetraacetic acid
	EGPA	eosinophilic granulomatosis with polyangiitis
35	EtOAc	ethyl acetate
	FBS	fetal bovine serum
	FCAS	familial cold autoinflammatory syndrome

	FMF	familial Mediterranean fever
	GAPDH	glyceraldehyde 3-phosphate dehydrogenase
	GPA	granulomatosis with polyangiitis
	GSH	glutathione
5	GVHD	graft versus host disease
	HATU	1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
	HCA2	hydroxycarboxylic acid receptor 2
	HCV	hepatitis C
10	HFC	hydrofluorocarbon
	HIF-1 α	hypoxia-inducible factor-1 α
	HIV	human immunodeficiency virus
	HMDMs	human monocyte derived macrophages
	HOBT	1-hydroxybenzotriazole
15	IL	interleukin
	IPEX	immune dysregulation polyendocrinopathy enteropathy X-linked
	IRG1	immune-responsive gene 1
	IVIG	intravenous immune globulin
	JAK	Janus kinase
20	KEAP1	kelch-like ECH-associated protein 1
	LCMS	liquid chromatography–mass spectrometry
	LDA	lithium diisopropylamide
	LPS	lipopolysaccharide
	MALT	mucosa-associated lymphoid tissue
25	mCPBA	meta-chloroperoxybenzoic acid
	M-CSF	macrophage-colony stimulating factor
	MMF	monomethyl fumarate
	MMN	multifocal motor neuropathy
	MOG	myelin oligodendrocyte glycoprotein
30	MS	mass spectrometry
	MSD	mass selective detector
	MTBE	methyl tertiary-butyl ether
	NLRP12AD	NLRP12-associated autoinflammatory disorders
	NMM	N-methylmorpholine
35	NMR	nuclear magnetic resonance
	NOMID	neonatal onset multisystem inflammatory disease
	NQO1	NAD(P)H dehydrogenase [quinone] 1

	NRF2	nuclear factor (erythroid-derived 2)-like 2
	NSAIDs	non-steroidal anti-inflammatory drugs
	O/N	overnight
	PAH	pulmonary arterial hypertension
5	PANDAS	paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections
	PANS	paediatric acute-onset neuropsychiatric syndrome
	PAPA	pyogenic arthritis, pyoderma gangrenosum, severe cystic acne
	PMB	4-methoxybenzyl
10	PBMCs	primary peripheral blood mononuclear cells
	PBS	phosphate buffered saline
	PDA	photodiode array
	PDE4	phosphodiesterase-4
	PET	positron emission topography
15	PFAPA	periodic fever aphthous stomatitis
	PLEVA	pityriasis lichenoides et varioliformis acuta
	PMA	phorbol 12-myristate 13-acetate
	PSC	primary sclerosing cholangitis
	PUVA	psoralen ultraviolet irradiation
20	<i>p</i> -TsOH	<i>p</i> -toluenesulfonic acid
	4OI	4-octyl itaconic acid
	RT	room temperature
	sat.	saturated
	SDH	succinate dehydrogenase
25	SFC	supercritical fluid chromatography
	SLE	systemic lupus erythematosus
	STING	stimulator of interferon genes
	TFA	trifluoroacetic acid
	TLR	Toll-like receptor
30	TNF	tumour necrosis factor
	TRAPS	tumour necrosis factor receptor-associated periodic fever
	Trt	trityl, triphenylmethyl
	TTP	thrombotic thrombocytopenic purpura
	UPLC	ultra performance liquid chromatography
35	VEGF	vascular endothelial growth factor
	VWD	variable wavelength detector
	wt.	weight

EXAMPLES

Analytical Equipment

5

NMR spectra were recorded using a Bruker 400 MHz Avance III spectrometer fitted with a BBFO 5 mm probe, or a Bruker 500 MHz Avance III HD spectrometer equipped with a Bruker 5 mm SmartProbe™. Spectra were measured at 298 K, unless indicated otherwise, and were referenced relative to the solvent resonance. The chemical shifts are reported in parts per million.

10 Data were acquired using Bruker TopSpin software.

UPLC/MS analysis was carried out on a Waters Acquity UPLC system using either a Waters Acquity CSH C18 or BEH C18 column (2.1 x 30 mm) maintained at a temperature of 40 °C and eluted with a linear acetonitrile gradient appropriate for the lipophilicity of the compound over 3 or
 15 10 minutes at a constant flow rate of 0.77 mL/min. The aqueous portion of the mobile phase was either 0.1 % Formic Acid (CSH C18 column) or 10 mM Ammonium Bicarbonate (BEH C18 column). LC-UV chromatograms were recorded using a Waters Acquity PDA detector between 210 and 400 nm. Mass spectra were recorded using a Waters Acquity Qda detector with electrospray ionisation switching between positive and negative ion mode. Sample concentration
 20 was adjusted to give adequate UV response.

LCMS analysis was carried out on a Agilent LCMS system using either a Waters Acquity CSH C18 or BEH C18 column (4.6 x 30 mm) maintained at a temperature of 40 °C and eluted with a linear acetonitrile gradient appropriate for the lipophilicity of the compound over 4 or 15 minutes
 25 at a constant flow rate of 2.5 mL/min. The aqueous portion of the mobile phase was either 0.1 % Formic Acid (CSH C18 column) or 10 mM Ammonium Bicarbonate (BEH C18 column). LC-UV chromatograms were recorded using an Agilent VWD or DAD detector at 254 nm. Mass spectra were recorded using an Agilent MSD detector with electrospray ionisation switching between positive and negative ion mode. Sample concentration was adjusted to give adequate UV
 30 response.

Alternatively, the following analytical LCMS equipment and methods were also used:

LCMS/HPLC Instrument Details				
System	Instrument Name	LC Detector	ELS detector	Mass detector
1	Agilent LCMS 1200	G1315D DAD	380 ELSD	Agilent G6120B
2	Agilent LCMS 1200	G1315C DAD	380 ELSD	Agilent G6110A
LCMS/HPLC Method Details				


Method Name	Solvent System	Column	Gradient	UV range	Mass Range	Column Temp. °C	Flow Rate ml/min
A	A) water + 10 mM NH ₄ HCO ₃	Waters X-Bridge C18 (50 mm x 4.6 mm x 3.5 µm)	From 95:5 to 0:100 in 1.6 min, 0:100 for 1.4 min, from 0:100 to 95:5 in 0.1 min, 95:5 for 0.7 min	190-400 nm	100-1800 amu	40	2.0
	B) acetonitrile						
B	A) water + 0.05% TFA	Waters X-Bridge C18 (50 mm x 4.6 mm x 3.5 µm)	From 95:5 to 0:100 in 1.6 min, 0:100 for 1.4 min, from 0:100 to 95:5 in 0.05 min, 95:5 for 0.7 min	190-400 nm	100-1100 amu	40	2.0
	B) acetonitrile + 0.05% TFA						
C	A) water + 0.05% TFA	Halo C18 (30 mm x 4.6 mm x 2.7 µm)	From 95:5 to 0:100 in 0.8 min, 0:100 for 0.4 min, from 0:100 to 95:5 in 0.01 min, 95:5 for 0.2 min	190-400 nm	100-1100 amu	40	3.0

Commercial Materials

Dimethyl itaconate was purchased from Sigma-Aldrich (product number: 109533); 4-octyl itaconate was purchased from BOC biosciences (product number: B0001-007866); 4-methyl itaconate was purchased from Apollo Scientific (product number: OR10969); 4-butyl itaconate was purchased from Combi-Blocks (product number: QV-5962).

General Methods


Unless otherwise stated all reactions were stirred. Organic solutions were routinely dried over anhydrous magnesium sulfate. Hydrogenations were performed on a Thales H-cube flow reactor under the conditions stated or under pressure in a gas autoclave (bomb).

General Procedure 1 – synthesis of monoesters

A suspension of itaconic anhydride (1 eq.) in toluene was treated with *p*-TsOH.H₂O (10 mol%) followed by the appropriate alcohol (R-OH, 1 eq.) which is defined where relevant below. The resultant yellow solution was stirred at 80-110 °C. The reaction mixture was concentrated onto silica gel and the crude product was purified by chromatography on silica gel (0-5% MeOH/DCM) to afford the desired monoester.

General Procedure 2 – synthesis of diesters


A solution of the appropriate itaconic acid monoester (1 eq.) which is defined where relevant below, EDC.HCl (1.5 eq.) and DMAP (5-200 mol%) in DCM was treated with DIPEA (3 eq.) and the appropriate alcohol (R²-OH, 1.1 eq.) which is defined where relevant below. The resulting solution was stirred at RT for 20 h. The reaction mixture was concentrated onto silica and the crude product purified by chromatography on silica gel (0-5% MeOH/DCM) to afford the desired diester.

General Procedure 3 – synthesis of diesters

A solution of the appropriate alcohol (R²-OH, 1 eq.) which is defined where relevant below, HOBt.H₂O hydrate (2 eq.) and EDC.HCl (2 eq.) in DCM was treated with the appropriate itaconic acid monoester (1 eq.) which is defined where relevant below, followed by dropwise addition of DIPEA (3 eq.) at RT. The resulting mixture was stirred at RT for 16 h. The reaction mixture was

concentrated *in vacuo* and purified by column chromatography on silica gel (DCM/EtOAc 1:1) to provide the desired diester.

General Procedure 4 – synthesis of diesters




A mixture of the appropriate itaconic acid monoester (1 eq.) which is defined where relevant below, potassium carbonate (1.2 eq.) and iodomethane (1.2 eq.) in acetone was stirred for 18 h at RT. The mixture was filtered and the filtrate was concentrated onto silica gel. The crude product was purified by chromatography on silica gel (0-20% EtOAc/isohexane) to afford the desired diester.

10

In any one of the above General Procedures, suitably R¹ is R^{Ai} which is defined elsewhere herein.


Intermediate 1 – 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid



Intermediate 1 was prepared according to General Procedure 1, using cyclooctanol as R-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 12.59 (br. s, 1H), 6.13 (d, J = 1.6 Hz, 1H), 5.75 – 5.72 (m, 1H), 4.82 (tt, J = 8.2, 3.9 Hz, 1H), 3.25 (s, 2H), 1.76 – 1.40 (m, 14H). LCMS m/z 263.2 (M+Na)⁺ (ES⁺); 239.2 (M-H)⁻ (ES⁻).


20

Intermediate 2 – 2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoic acid



Intermediate 2 was prepared according to General Procedure 1, using 3-phenoxypropan-1-ol as R-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 12.65 (br. s, 1H), 7.32 – 7.26 (m, 2H), 6.95 – 6.91 (m, 3H), 6.15 (d, J = 1.6 Hz, 1H), 5.76 (br. s, 2H), 4.18 (t, J = 6.4 Hz, 2H), 4.02 (t, J = 6.3 Hz, 2H), 3.33 (br. s, 4H), 2.01 (qu, J = 6.3 Hz, 2H). LCMS m/z 287.1 (M+Na)⁺ (ES⁺); 263.1 (M-H)⁻ (ES⁻).


Intermediate 3 – 4-(hexyloxy)-2-methylene-4-oxobutanoic acid



Intermediate 3 was prepared according to General Procedure 1, using hexan-1-ol as R-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 12.57 (br. s, 1H), 6.15 (d, J = 1.6 Hz, 1H), 5.78 – 5.74 (m, 1H), 4.01


(t, J = 6.6 Hz, 2H), 3.30 (s, 2H), 1.58 – 1.51 (m, 2H), 1.35 – 1.21 (m, 6H), 0.87 (t, J = 6.8 Hz, 3H). LCMS m/z 237.2 (M+H)⁺ (ES⁺); 213.2 (M-H)⁻ (ES⁻).

Intermediate 4 – 4-isopropoxy-2-methylene-4-oxobutanoic acid




Intermediate 4 was prepared according to General Procedure 1, using propan-2-ol as R-OH. ¹H NMR (500 MHz, CDCl₃) δ 6.47 (d, J = 0.9 Hz, 1H), 5.84 (q, J = 1.1 Hz, 1H), 5.05 (hept, J = 6.3 Hz, 1H), 3.33 (s, 2H), 1.26 (d, J = 6.3 Hz, 6H). LCMS m/z 171.1 (M-H)⁻ (ES⁻).

Intermediate 5 – 4-(2-(2-ethoxyethoxy)ethoxy)-2-methylene-4-oxobutanoic acid




Intermediate 5 was prepared according to General Procedure 1, using 2-(2-ethoxyethoxy)ethan-1-ol as R-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 12.62 (s, 1H), 6.17 (d, J = 1.6 Hz, 1H), 5.78 (q, J = 1.3 Hz, 1H), 4.15 – 4.11 (m, 2H), 3.61 – 3.58 (m, 2H), 3.54 – 3.51 (m, 2H), 3.49 – 3.46 (m, 2H), 3.43 (q, J = 7.0 Hz, 2H), 3.33 (s, 2H), 1.10 (t, J = 7.0 Hz, 3H). LCMS m/z 269.1 (M+Na)⁺ (ES⁺).

Intermediate 6 – 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid




Intermediate 6 was prepared according to General Procedure 1, using cyclohexanol as R-OH. ¹H NMR (500 MHz, CDCl₃) δ 6.44 (d, J = 0.9 Hz, 1H), 5.81 (d, J = 1.2 Hz, 1H), 4.90 - 4.69 (m, 1H), 3.32 (s, 2H), 1.83 - 1.64 (m, 4H), 1.55 - 1.16 (m, 6H). ¹H NMR (500 MHz, DMSO-d₆) δ 12.62 (s, 1H), 6.17 (d, J = 1.6 Hz, 1H), 5.78 (q, J = 1.3 Hz, 1H), 4.15 – 4.11 (m, 2H), 3.61 – 3.58 (m, 2H), 3.54 – 3.51 (m, 2H), 3.49 – 3.46 (m, 2H), 3.43 (q, J = 7.0 Hz, 2H), 3.33 (s, 2H), 1.10 (t, J = 7.0 Hz, 3H). LCMS m/z 210.7 (M-H)⁻ (ES⁻).

Intermediate 7 – 4-((4-fluorobenzyl)oxy)-2-methylene-4-oxobutanoic acid




Intermediate 7 was prepared according to General Procedure 1, using (4-fluorophenyl)methanol as R-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 12.67 (s, 1H), 7.44 - 7.38 (m, 2H), 7.23 - 7.16 (m, 2H), 6.17 (d, J = 1.6 Hz, 1H), 5.81 - 5.77 (m, 1H), 5.09 (s, 2H), 3.38 (s, 2H). LCMS m/z 237.3 (M-H)⁻ (ES⁻).

Intermediate 8 – (R)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid


Intermediate 8 was prepared according to General Procedure 1, using (R)-octan-2-ol as R-OH.

5 ^1H NMR (500 MHz, CDCl_3) δ 12.58 (s, 1H), 6.13 (d, J = 1.6 Hz, 1H), 5.74 (d, J = 1.6 Hz, 1H), 4.88 - 4.58 (m, 1H), 3.26 (s, 2H), 1.54 - 1.38 (m, 2H), 1.30 - 1.20 (m, 8H), 1.13 (d, J = 6.2 Hz, 3H), 0.85 (t, J = 6.7 Hz, 3H). LCMS m/z 241.2 (M-H) $^+$ (ES $^+$).

Intermediate 9 – (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid


10 Intermediate 9 was prepared according to General Procedure 1, using (S)-octan-2-ol as R-OH.

^1H NMR (500 MHz, DMSO-d_6) δ 12.58 (s, 1H), 6.14 (d, J = 1.6 Hz, 1H), 5.75 (d, J = 1.6 Hz, 1H), 4.84 - 4.74 (m, 1H), 3.26 (s, 2H), 1.56 - 1.40 (m, 2H), 1.33 - 1.20 (m, 8H), 1.14 (d, J = 6.2 Hz, 3H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 241.0 (M-H) $^+$ (ES $^+$).

Intermediate 10 – 2-methylene-4-(neopentyloxy)-4-oxobutanoic acid

Intermediate 10 was prepared according to General Procedure 1, using 2,2-dimethylpropan-1-ol as R-OH.

20 ^1H NMR (500 MHz, DMSO-d_6) δ 12.63 (s, 1H), 6.16 (d, J = 1.6 Hz, 1H), 5.77 (d, J = 1.4 Hz, 1H), 3.72 (s, 2H), 3.34 (s, 2H), 0.88 (s, 9H). LCMS m/z 198.9 (M-H) $^+$ (ES $^+$).

Intermediate 11 – 3-((2-(tert-butoxy)-2-oxoethoxy)carbonyl)but-3-enoic acid**Step 1**

25 Boron trifluoride diethyl etherate (1.43 mL, 11.6 mmol) was added to a mixture of itaconic anhydride (10 g, 89 mmol) and 2,2,2-trichloroethanol (15.4 mL, 161 mmol) under nitrogen at RT. The reaction mixture was heated to 95 °C for 30 mins, then cooled to RT. The residue was treated with sat. aq. NaHCO_3 (400 mL) and washed with EtOAc (3 x 100 mL). The aqueous phase was acidified to pH=2 with concentrated HCl and extracted with EtOAc (3 x 120 mL). The combined

organic layers were dried (MgSO_4) and concentrated. The residue was recrystallised from a mixture of toluene and iso-hexane (1:1) (300 mL). The resulting solid was filtered, washed with iso-hexane and dried in vacuo to afford 2-methylene-4-oxo-4-(2,2,2-trichloroethoxy)butanoic acid (13.7 g, 51.3 mmol) as a white crystalline solid. ^1H NMR (400 MHz, DMSO-d_6) δ 12.70 (s, 1H), 6.21 (d, J = 1.5 Hz, 1H), 5.86 (d, J = 1.3 Hz, 1H), 4.88 (s, 2H), 3.49 (s, 2H).


Step 2

Potassium carbonate (4.16 g, 30.1 mmol) was added portionwise to a solution of 2-methylene-4-oxo-4-(2,2,2-trichloroethoxy)butanoic acid (7.50 g, 28.7 mmol) in acetone (140 mL) at RT. After 5 min tert-butyl bromoacetate (4.45 mL, 30.1 mmol) was added dropwise. The reaction mixture was stirred at RT for 16 h, then diluted with EtOAc (150 mL) and filtered. The filtrate was concentrated to afford 1-(2-(tert-butoxy)-2-oxoethyl) 4-(2,2,2-trichloroethyl) 2-methylenesuccinate (10.7 g, 28.5 mmol) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 6.36 (d, J = 1.2 Hz, 1H), 6.03 (q, J = 1.1 Hz, 1H), 4.89 (s, 2H), 4.62 (s, 2H), 3.58 (d, J = 1.0 Hz, 2H), 1.42 (s, 9H).

Step 3

Zinc (11.2 g, 171 mmol) was added portionwise over 5 min to a solution of 1-(2-(tert-butoxy)-2-oxoethyl) 4-(2,2,2-trichloroethyl) 2-methylenesuccinate (10.7 g, 28.5 mmol) in acetic acid (160 mL). The reaction mixture was stirred at RT for 18 h then diluted with water (100 mL) and EtOAc (300 mL). The mixture was carefully decanted and the phases were separated. The aqueous phase was extracted with EtOAc (3 x 200 mL). The combined organic extracts were washed with brine (3 x 150 mL), dried (Na_2SO_4) and concentrated to afford the title compound as a colourless solid (6.07 g). An analytically pure sample was obtained by recrystallisation of a small sample (300 mg) from toluene and isohexane (1:1). ^1H NMR (400 MHz, DMSO-d_6) δ 12.35 (s, 1H), 6.26 (d, J = 1.3 Hz, 1H), 5.91 - 5.85 (m, 1H), 4.62 (s, 2H), 3.32 (s, 2H), 1.42 (s, 9H). LCMS m/z 267.1 ($\text{M}+\text{Na}$) $^+$ (ES^+).


Intermediate 12 – 3-methyl-2-methylene-4-(octyloxy)-4-oxobutanoic acid



A solution of lithium diisopropylamide (2 M in THF, 4.3 mL, 8.6 mmol) was added dropwise to a solution of 4-octyl itaconate (1.00 g, 4.13 mmol) in THF (10 mL) at -78°C . The reaction mixture was stirred for 2 h at -78°C , before a solution of iodomethane (0.31 mL, 4.9 mmol) in DMF (5 mL) was added dropwise. The reaction mixture was stirred for 2 h at -78°C , then quenched with a 10% aq. citric acid solution (20 mL). The mixture was extracted with DCM (3 x 20 mL). The combined organic phases were passed through a hydrophobic phase separator and


concentrated. The crude product was purified by chromatography on silica gel (0-50% EtOAc/isohexane) to afford 3-methyl-2-methylene-4-(octyloxy)-4-oxobutanoic acid (611 mg, 2.34 mmol) as a light yellow oil. ¹H NMR (500 MHz, DMSO-d₆) δ 12.63 (s, 1H), 6.17 (d, J = 1.0 Hz, 1H), 5.70 (d, J = 1.2 Hz, 1H), 4.06 - 3.84 (m, 2H), 3.57 - 3.42 (m, 1H), 1.60 - 1.39 (m, 2H), 1.39 - 1.01 (m, 13H), 0.86 (t, J = 6.6 Hz, 3H). LCMS m/z 255.1 (M-H)⁻ (ES⁻).

Example 1 – 1-(2-cyanoethyl) 4-octyl 2-methylenesuccinate




Example 1 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 3-hydroxypropanenitrile as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.25 (d, J = 1.2 Hz, 1H), 5.90 (d, J = 1.3 Hz, 1H), 4.27 (t, J = 6.0 Hz, 2H), 4.02 (t, J = 6.6 Hz, 2H), 3.39 (s, 2H), 2.92 (t, J = 6.0 Hz, 2H), 1.58 – 1.51 (m, 2H), 1.35 – 1.21 (m, 10H), 0.89 – 0.84 (m, 3H). LCMS m/z 318.2 (M+Na)⁺ (ES⁺).

Example 2 – 1-(2-(methylsulfonyl)ethyl) 4-octyl 2-methylenesuccinate




Example 2 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 2-(methylsulfonyl)ethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.25 (d, J = 1.2 Hz, 1H), 5.89 (d, J = 1.3 Hz, 1H), 4.45 (t, J = 5.8 Hz, 2H), 4.01 (t, J = 6.6 Hz, 2H), 3.54 (t, J = 5.8 Hz, 2H), 3.38 (s, 2H), 3.03 (s, 3H), 1.59 – 1.51 (m, 2H), 1.32 – 1.21 (m, 10H), 0.89 – 0.84 (m, 3H). LCMS m/z 371.2 (M+Na)⁺ (ES⁺).

Example 3 – 4-octyl 1-(3,3,3-trifluoropropyl) 2-methylenesuccinate




Example 3 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 3,3,3-trifluoropropan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.22 (d, J = 1.3 Hz, 1H), 5.87 (q, J = 1.2 Hz, 1H), 4.32 – 4.29 (m, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.37 (d, J = 1.0 Hz, 2H), 2.75 – 2.64 (m, 2H), 1.57 – 1.50 (m, 2H), 1.34 – 1.20 (m, 10H), 0.89 – 0.83 (m, 3H). LCMS m/z 361.3 (M+Na)⁺ (ES⁺).

Example 4 – 4-octyl 1-(oxetan-3-yl) 2-methylenesuccinate




Example 4 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and oxetan-3-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.29 (d, J = 1.2 Hz, 1H), 5.92 (d, J = 1.3 Hz, 1H), 5.46 – 5.40 (m, 1H), 4.84 – 4.80 (m, 2H), 4.49 (dd, J = 7.6, 5.0 Hz, 2H), 4.02 (t, J = 6.6 Hz, 2H), 3.40 (s, 2H), 1.58 – 1.51 (m, 2H), 1.33 – 1.22 (m, 10H), 0.87 (t, J = 6.8 Hz, 3H). LCMS m/z 299.3 (M+H)⁺ (ES⁺).

Example 5 – 4-octyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate




Example 5 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 1-(2-hydroxyethyl)pyrrolidin-2-one as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.19 (d, J = 1.3 Hz, 1H), 5.84 (d, J = 1.3 Hz, 1H), 4.19 (t, J = 5.4 Hz, 2H), 4.01 (t, J = 6.6 Hz, 2H), 3.45 (t, J = 5.4 Hz, 2H), 3.39 – 3.32 (m, 4H), 2.20 (t, J = 8.1 Hz, 2H), 1.95 – 1.87 (m, 2H), 1.59 – 1.50 (m, 2H), 1.33 – 1.22 (m, 10H), 0.89 – 0.82 (m, 3H). LCMS m/z 354.3 (M+H)⁺ (ES⁺).

Example 6 – 1-(3-(dimethylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate




Example 6 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 3-hydroxy-N,N-dimethylpropanamide as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.17 (d, J = 1.4 Hz, 1H), 5.82 (d, J = 1.3 Hz, 1H), 4.28 (t, J = 6.6 Hz, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.34 (s, 2H), 2.96 (s, 3H), 2.82 (s, 3H), 2.67 (t, J = 6.6 Hz, 2H), 1.58 – 1.50 (m, 2H), 1.33 – 1.22 (m, 10H), 0.89 – 0.84 (m, 3H). LCMS m/z 342.3 (M+H)⁺ (ES⁺).

Example 7 – 4-butyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate




Example 7 was prepared according to General Procedure 2, using 4-butyl itaconate as itaconic acid monoester and 2-(methylsulfonyl)ethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.25 (d, J = 1.3 Hz, 1H), 5.90 (d, J = 1.2 Hz, 1H), 4.48 – 4.43 (m, 2H), 4.03 (t, J = 6.6 Hz, 2H), 3.57 – 3.51 (m, 2H), 3.38 (d, J = 1.0 Hz, 2H), 3.03 (s, 3H), 1.59 – 1.50 (m, 2H), 1.37 – 1.27 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H). LCMS m/z 315.2 (M+Na)⁺ (ES⁺).

Example 8 – 1-(2-cyanoethyl) 4-butyl 2-methylenesuccinate




Example 8 was prepared according to General Procedure 2, using 4-butyl itaconate as itaconic acid monoester and 3-hydroxypropanenitrile as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.26 (d, J = 1.2 Hz, 1H), 5.91 (d, J = 1.2 Hz, 1H), 4.27 (t, J = 6.0 Hz, 2H), 4.03 (t, J = 6.6 Hz, 2H), 3.39 (s, 2H), 2.92 (t, J = 6.0 Hz, 2H), 1.58 – 1.51 (m, 2H), 1.37 – 1.27 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H). LCMS m/z 240.1 (M+H)⁺ (ES⁺).

Example 9 – 1-(2-(2,5-dioxopyrrolidin-1-yl)ethyl) 4-octyl 2-methylenesuccinate




Example 9 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 1-(2-hydroxyethyl)pyrrolidine-2,5-dione as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.16 (d, J = 1.4 Hz, 1H), 5.83 (d, J = 1.3 Hz, 1H), 4.19 (t, J = 5.5 Hz, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.65 (t, J = 5.6 Hz, 2H), 3.32 (s, 2H), 2.63 (s, 4H), 1.57 – 1.50 (m, 2H), 1.32 – 1.21 (m, 10H), 0.89 – 0.84 (m, 3H). LCMS m/z 368.3 (M+H)⁺ (ES⁺).

Example 10 – 1-(2-cyanoethyl) 4-methyl 2-methylenesuccinate




Example 10 was prepared according to General Procedure 2, using 4-methyl itaconate as itaconic acid monoester and 3-hydroxypropanenitrile as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.27 (d, J = 1.2 Hz, 1H), 5.91 (d, J = 1.2 Hz, 1H), 4.28 (t, J = 5.9 Hz, 2H), 3.62 (s, 3H), 3.40 (d, J = 1.0 Hz, 2H), 2.92 (t, J = 5.9 Hz, 2H). LCMS m/z 220.1 (M+H)⁺ (ES⁺).

Example 11 – 1-(2-cyanoethyl) 4-hexyl 2-methylenesuccinate



Example 11 was prepared according to General Procedure 2, using 4-(hexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 3) as itaconic acid monoester and 3-hydroxypropanenitrile as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.26 (d, J = 1.2 Hz, 1H), 5.90 (d, J = 1.3 Hz, 1H), 4.27 (t, J = 6.0 Hz, 2H), 4.02 (t, J = 6.6 Hz, 2H), 3.39 (s, 2H), 2.91 (t, J = 6.0 Hz, 2H), 1.60 – 1.51 (m, 2H), 1.34 – 1.22 (m, 6H), 0.91 – 0.83 (m, 3H). LCMS m/z 268.1 (M+H)⁺ (ES⁺).


Example 12 – 4-methyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate



Example 12 was prepared according to General Procedure 2, using 4-methyl itaconate as itaconic acid monoester and 2-(methylsulfonyl)ethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.27 (d, J = 1.2 Hz, 1H), 5.90 (d, J = 1.3 Hz, 1H), 4.46 (t, J = 5.8 Hz, 2H), 3.61 (s, 3H), 3.54 (t, J = 5.8 Hz, 2H), 3.39 (d, J = 1.0 Hz, 2H), 3.03 (s, 3H). LCMS m/z 273.1 (M+Na)⁺ (ES⁺).

5


Example 13 – 4-octyl 1-(2-(trifluoromethoxy)ethyl) 2-methylenesuccinate



Example 13 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 2-(trifluoromethoxy)ethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.24 (d, J = 1.2 Hz, 1H), 5.89 (d, J = 1.3 Hz, 1H), 4.36 – 4.29 (m, 4H), 4.00 (t, J = 6.6 Hz, 2H), 3.38 (s, 2H), 1.58 – 1.50 (m, 2H), 1.32 – 1.21 (m, 10H), 0.86 (t, J = 6.9 Hz, 3H). LCMS m/z 355.3 (M+H)⁺ (ES⁺).

10

Example 14 – 4-hexyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate




15

Example 14 was prepared according to General Procedure 2, using 4-(hexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 3) as itaconic acid monoester and 2-(methylsulfonyl)ethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.25 (d, J = 1.2 Hz, 1H), 5.89 (d, J = 1.2 Hz, 1H), 4.48 – 4.43 (m, 2H), 4.02 (t, J = 6.6 Hz, 2H), 3.54 (t, J = 5.8 Hz, 2H), 3.38 (s, 2H), 3.03 (s, 3H), 1.58 – 1.51 (m, 2H), 1.34 – 1.22 (m, 6H), 0.92 – 0.84 (m, 3H). LCMS m/z 343.2 (M+Na)⁺ (ES⁺).

20


Example 15 – 4-methyl 1-(oxetan-3-yl) 2-methylenesuccinate



Example 15 was prepared according to General Procedure 2, using 4-methyl itaconate as itaconic acid monoester and oxetan-3-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.31 (d, J = 1.2 Hz, 1H), 5.93 (d, J = 1.1 Hz, 1H), 5.44 (tt, J = 6.3, 5.0 Hz, 1H), 4.82 (ddd, J = 7.4, 6.3, 1.0 Hz, 2H), 4.49 (ddd, J = 7.6, 5.0, 1.0 Hz, 2H), 3.62 (s, 3H), 3.41 (s, 2H). LCMS m/z 201.1 (M+H)⁺ (ES⁺).

25

Example 16 – 1-(2-(N,N-dimethylsulfamoyl)ethyl) 4-octyl 2-methylenesuccinate




30

Example 16 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 2-hydroxy-N,N-dimethylethane-1-sulfonamide as R²-OH. ¹H NMR (500 MHz,


DMSO-d₆) δ 6.26 (d, J = 1.3 Hz, 1H), 5.90 (d, J = 1.3 Hz, 1H), 4.41 (t, J = 6.0 Hz, 2H), 4.01 (t, J = 6.6 Hz, 2H), 3.45 (t, J = 6.0 Hz, 2H), 3.37 (s, 2H), 2.78 (s, 6H), 1.58 – 1.51 (m, 2H), 1.32 – 1.21 (m, 10H), 0.89 – 0.84 (m, 3H). LCMS m/z 378.3 (M+H)⁺ (ES⁺).

5 **Example 17 – 1-(2-(dimethylamino)ethyl) 4-octyl 2-methylenesuccinate**




Example 17 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 2-(dimethylamino)ethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.19 (d, J = 1.4 Hz, 1H), 5.84 – 5.81 (m, 1H), 4.16 (t, J = 5.8 Hz, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.35 (s, 2H), 2.52 – 2.47 (m, 2H), 2.17 (s, 6H), 1.58 – 1.51 (m, 2H), 1.32 – 1.23 (m, 10H), 0.89 – 0.84 (m, 3H). LCMS m/z 314.3 (M+H)⁺ (ES⁺).

Example 18 – 1-(3-(methylsulfonyl)propyl) 4-octyl 2-methylenesuccinate




Example 18 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 3-(methylsulfonyl)propan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.25 (d, J = 1.3 Hz, 1H), 5.85 (d, J = 1.3 Hz, 1H), 4.19 (t, J = 6.4 Hz, 2H), 4.01 (t, J = 6.7 Hz, 2H), 3.38 (s, 2H), 3.22 – 3.16 (m, 2H), 2.99 (s, 3H), 2.08 – 2.00 (m, 2H), 1.59 – 1.51 (m, 2H), 1.33 – 1.22 (m, 10H), 0.87 (t, J = 6.8 Hz, 3H). LCMS m/z 385.2 (M+Na)⁺ (ES⁺).

Example 19 – 1-(1-(methylsulfonyl)propan-2-yl) 4-octyl 2-methylenesuccinate




Example 19 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 1-(methylsulfonyl)propan-2-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.24 (d, J = 1.3 Hz, 1H), 5.87 (d, J = 1.3 Hz, 1H), 5.34 – 5.24 (m, 1H), 4.06 – 3.96 (m, 2H), 3.61 (dd, J = 14.8, 8.3 Hz, 1H), 3.47 (dd, J = 14.8, 3.8 Hz, 1H), 3.37 (s, 2H), 2.99 (s, 3H), 1.59 – 1.51 (m, 2H), 1.31 (d, J = 6.4 Hz, 3H), 1.29 – 1.24 (m, 10H), 0.87 (t, J = 6.8 Hz, 3H). LCMS m/z 385.2 (M+Na)⁺ (ES⁺).

Example 20 – 1-(2-(methylsulfonyl)ethyl) 4-(3-phenoxypropyl) 2-methylenesuccinate




Example 20 was prepared according to General Procedure 2, using 2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoic acid (Intermediate 2) as itaconic acid monoester and 2-(methylsulfonyl)ethan-1-ol as R²-OH. ¹H NMR (500 MHz, CDCl₃) δ 7.33 – 7.29 (m, 2H), 7.00 – 6.95 (m, 1H), 6.95 – 6.89 (m, 2H), 6.34 (s, 1H), 5.80 (d, J = 1.2 Hz, 1H), 4.62 (t, J = 5.8 Hz, 2H), 4.33 (t, J = 6.3 Hz, 2H), 4.06 (t, J = 6.1 Hz, 2H), 3.38 (s, 2H), 3.34 (t, J = 5.8 Hz, 2H), 2.98 (s, 3H), 2.18 – 2.11 (m, 2H). LCMS m/z 393.1 (M+Na)⁺ (ES⁺).

Example 21 – 1-(2-(dimethylamino)-2-oxoethyl) 4-octyl 2-methylenesuccinate




Example 21 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 2-hydroxy-N,N-dimethylacetamide as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.27 (d, J = 1.3 Hz, 1H), 5.89 (d, J = 1.3 Hz, 1H), 4.84 (s, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.37 (s, 2H), 2.93 (s, 3H), 2.82 (s, 3H), 1.58 – 1.51 (m, 2H), 1.32 – 1.22 (m, 10H), 0.89 – 0.84 (m, 3H). LCMS m/z 328.2 (M+H)⁺ (ES⁺).

Example 22 – 4-isopropyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate




Example 22 was prepared according to General Procedure 2, using 4-isopropoxy-2-methylene-4-oxobutanoic acid (intermediate 4) as itaconic acid monoester and 2-(methylsulfonyl)ethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.24 (d, J = 1.2 Hz, 1H), 5.89 – 5.87 (m, 1H), 4.89 (hept, J = 6.3 Hz, 1H), 4.47 – 4.44 (m, 2H), 3.54 (t, J = 5.7 Hz, 2H), 3.34 (s, 2H), 3.03 (s, 3H), 1.18 (d, J = 6.3 Hz, 6H). LCMS m/z 301.1 (M+Na)⁺ (ES⁺).


Example 23 – (S)-4-octyl 1-(tetrahydrofuran-3-yl) 2-methylenesuccinate




Example 23 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and (S)-tetrahydrofuran-3-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.20 (d, J = 1.3 Hz, 1H), 5.84 – 5.82 (m, 1H), 5.29 – 5.25 (m, 1H), 4.00 (t, J = 6.6 Hz, 2H), 3.82 (dd, J = 10.4, 4.6 Hz, 1H), 3.77 – 3.73 (m, 2H), 3.68 – 3.64 (m, 1H), 3.36 (s, 2H), 2.19 – 2.11 (m, 1H), 1.92 – 1.85 (m, 1H), 1.58 – 1.51 (m, 2H), 1.31 – 1.22 (m, 10H), 0.89 – 0.82 (m, 3H). LCMS m/z 313.2 (M+H)⁺ (ES⁺).

Example 24 – (R)-4-octyl 1-(tetrahydrofuran-3-yl) 2-methylenesuccinate


Example 24 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and (R)-tetrahydrofuran-3-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.20 (d, J = 1.3 Hz, 1H), 5.84 – 5.82 (m, 1H), 5.29 – 5.24 (m, 1H), 4.00 (t, J = 6.6 Hz, 2H), 3.82 (dd, J = 10.4, 4.7 Hz, 1H), 3.77 – 3.73 (m, 2H), 3.69 – 3.63 (m, 1H), 3.36 (s, 2H), 2.20 – 2.10 (m, 1H), 1.93 – 1.85 (m, 1H), 1.58 – 1.51 (m, 2H), 1.31 – 1.22 (m, 10H), 0.89 – 0.84 (m, 3H). LCMS m/z 313.2 (M+H)⁺ (ES⁺).

Example 25 – 4-cyclooctyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate

Example 25 was prepared according to General Procedure 2, using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid as itaconic acid monoester and 2-(methylsulfonyl)ethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.24 (d, J = 1.3 Hz, 1H), 5.89 – 5.86 (m, 1H), 4.83 (tt, J = 8.1, 3.9 Hz, 1H), 4.45 (t, J = 5.8 Hz, 2H), 3.53 (t, J = 5.7 Hz, 2H), 3.33 (s, 2H), 3.03 (s, 3H), 1.78 – 1.40 (m, 14H). LCMS m/z 369.1 (M+Na)⁺ (ES⁺).

Example 26 – 4-octyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate


Example 26 was prepared according to General Procedure 2, using as 4-octyl itaconate as itaconic acid monoester and tetrahydro-2H-pyran-4-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.22 (d, J = 1.4 Hz, 1H), 5.83 – 5.82 (m, 1H), 4.93 (tt, J = 8.0, 4.0 Hz, 1H), 4.01 (t, J = 6.5 Hz, 2H), 3.78 – 3.72 (m, 2H), 3.52 – 3.46 (m, 2H), 3.38 (s, 2H), 1.88 – 1.81 (m, 2H), 1.57 – 1.50 (m, 4H), 1.33 – 1.22 (m, 10H), 0.89 – 0.84 (m, 3H). LCMS m/z 349.2 (M+Na)⁺ (ES⁺).

Example 27 – 1-(1-cyanopropan-2-yl) 4-octyl 2-methylenesuccinate

Example 27 was prepared according to General Procedure 2, using as 4-octyl itaconate as itaconic acid monoester and 3-hydroxybutanenitrile as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.23 (d, J = 1.3 Hz, 1H), 5.88 (q, J = 1.2 Hz, 1H), 5.09 – 5.02 (m, 1H), 4.02 (t, J = 6.6 Hz, 2H),

3.37 (s, 2H), 2.93 – 2.89 (m, 2H), 1.59 – 1.51 (m, 2H), 1.29 (d, J = 6.3 Hz, 3H), 1.28 – 1.21 (m, 10H), 0.90 – 0.84 (m, 3H). LCMS m/z 332.5 (M+Na)⁺ (ES⁺).

Example 28 – 1-(1-(methylsulfonyl)piperidin-4-yl) 4-octyl 2-methylenesuccinate




5

Example 28 was prepared according to General Procedure 2, using as 4-octyl itaconate as itaconic acid monoester and 1-(methylsulfonyl)piperidin-4-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.25 (d, J = 1.4 Hz, 1H), 5.85 (d, J = 1.4 Hz, 1H), 4.94 – 4.88 (m, 1H), 4.01 (t, J = 6.6 Hz, 2H), 3.39 (s, 2H), 3.27 – 3.13 (m, 4H), 2.89 (s, 3H), 1.95 – 1.88 (m, 2H), 1.72 – 1.64 (m, 2H), 1.58 – 1.51 (m, 2H), 1.33 – 1.21 (m, 10H), 0.89 – 0.84 (m, 3H). LCMS m/z 426.3 (M+Na)⁺ (ES⁺).

10

Example 29 – 1-(2-methoxyethyl) 4-octyl 2-methylenesuccinate




Example 29 was prepared according to General Procedure 2, using as 4-octyl itaconate as itaconic acid monoester and 2-methoxyethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.20 (d, J = 1.4 Hz, 1H), 5.85 (q, J = 1.2 Hz, 1H), 4.22 – 4.18 (m, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.57 – 3.52 (m, 2H), 3.38 – 3.34 (m, 2H), 3.27 (s, 3H), 1.57 – 1.51 (m, 2H), 1.32 – 1.21 (m, 10H), 0.90 – 0.84 (m, 3H). LCMS m/z 323.1 (M+Na)⁺ (ES⁺).

15

20


Example 30 – 1-(2-cyano-2-methylpropyl) 4-octyl 2-methylenesuccinate



Example 30 was prepared according to General Procedure 2, using as 4-octyl itaconate as itaconic acid monoester and 3-hydroxy-2,2-dimethylpropanenitrile as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.29 (d, J = 1.3 Hz, 1H), 5.91 (q, J = 1.2 Hz, 1H), 4.14 (s, 2H), 4.01 (t, J = 6.6 Hz, 2H), 3.41 (s, 2H), 1.55 (t, J = 7.0 Hz, 2H), 1.35 (s, 6H), 1.31 – 1.22 (m, 10H), 0.89 – 0.85 (m, 3H). LCMS m/z 346.2 (M+Na)⁺ (ES⁺).

25


Example 31 – 1-(1-methoxypropan-2-yl) 4-octyl 2-methylenesuccinate



30


Example 31 was prepared according to General Procedure 2, using as 4-octyl itaconate as itaconic acid monoester and 1-methoxypropan-2-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.18 (d, J = 1.4 Hz, 1H), 5.83 – 5.81 (m, 1H), 5.02 – 4.96 (m, 1H), 4.05 – 3.96 (m, 2H), 3.45 – 3.35 (m, 2H), 3.34 (s, 2H), 3.26 (s, 3H), 1.58 – 1.51 (m, 2H), 1.33 – 1.22 (m, 10H), 1.16 (d, J = 6.5 Hz, 3H), 0.89 – 0.84 (m, 3H). LCMS m/z 337.2 (M+Na)⁺ (ES⁺).

Example 32 – 1-((1-cyanocyclopropyl)methyl) 4-octyl 2-methylenesuccinate




Example 32 was prepared according to General Procedure 2, using as 4-octyl itaconate as itaconic acid monoester and 1-(hydroxymethyl)cyclopropane-1-carbonitrile as R²-OH. ¹H NMR (500 MHz, CDCl₃) δ 6.46 (d, J = 0.8 Hz, 1H), 5.82 (q, J = 1.1 Hz, 1H), 4.18 (s, 2H), 4.12 (t, J = 6.8 Hz, 2H), 3.39 (s, 2H), 1.69 – 1.61 (m, 2H), 1.40 – 1.37 (m, 2H), 1.36 – 1.27 (m, 10H), 1.13 – 1.09 (m, 2H), 0.93 – 0.88 (m, 3H). LCMS m/z 344.2 (M+Na)⁺ (ES⁺).

Example 33 – 1-(2-methoxypropyl) 4-octyl 2-methylenesuccinate




Example 33 was prepared according to General Procedure 2, using as 4-octyl itaconate as itaconic acid monoester and 2-methoxypropan-1-ol as R²-OH. ¹H NMR (500 MHz, CDCl₃) δ 6.38 (d, J = 1.0 Hz, 1H), 5.74 (q, J = 1.1 Hz, 1H), 4.19 (dd, J = 11.5, 4.4 Hz, 1H), 4.14 (dd, J = 11.5, 5.8 Hz, 1H), 4.10 (t, J = 6.8 Hz, 2H), 3.64 – 3.58 (m, 1H), 3.41 (s, 3H), 3.37 (s, 2H), 1.68 – 1.61 (m, 2H), 1.38 – 1.26 (m, 10H), 1.21 (d, J = 6.4 Hz, 3H), 0.92 – 0.89 (m, 3H). LCMS m/z 337.3 (M+Na)⁺ (ES⁺).


Example 34 – 1-(2-methoxy-2-methylpropyl) 4-octyl 2-methylenesuccinate




Example 34 was prepared according to General Procedure 2, using as 4-octyl itaconate as itaconic acid monoester and 2-methoxy-2-methylpropan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.23 (d, J = 1.4 Hz, 1H), 5.84 (q, J = 1.2 Hz, 1H), 4.01 – 3.98 (m, 4H), 3.38 (s, 2H), 3.12 (s, 3H), 1.57 – 1.51 (m, 2H), 1.30 – 1.23 (m, 10H), 1.12 (s, 6H), 0.89 – 0.84 (m, 3H). LCMS m/z 351.2 (M+Na)⁺ (ES⁺).

Example 35 – 1-(2-morpholinoethyl) 4-octyl 2-methylenesuccinate


Example 35 was prepared according to General Procedure 2, using as 4-octyl itaconate as itaconic acid monoester and 2-morpholinoethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.20 (d, J = 1.4 Hz, 1H), 5.83 (d, J = 1.3 Hz, 1H), 4.20 (t, J = 5.8 Hz, 2H), 4.01 (t, J = 6.6 Hz, 2H), 3.57 – 3.53 (m, 4H), 3.36 (s, 2H), 2.57 (t, J = 5.8 Hz, 2H), 2.43 – 2.39 (m, 4H), 1.58 – 1.51 (m, 2H), 1.26 (d, J = 5.5 Hz, 10H), 0.89 – 0.84 (m, 3H). LCMS m/z 356.2 (M+H)⁺ (ES⁺).

Example 36 – 4-(2-(2-ethoxyethoxy)ethyl) 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate

Example 36 was prepared according to General Procedure 2, using as 4-(2-(2-ethoxyethoxy)ethoxy)-2-methylene-4-oxobutanoic acid (Intermediate 5) as itaconic acid monoester and 2-(methylsulfonyl)ethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.27 (d, J = 1.2 Hz, 1H), 5.91 (d, J = 1.2 Hz, 1H), 4.49 – 4.43 (m, 2H), 4.16 – 4.12 (m, 2H), 3.62 – 3.58 (m, 2H), 3.56 – 3.51 (m, 4H), 3.49 – 3.46 (m, 2H), 3.43 (q, J = 7.0 Hz, 2H), 3.41 (s, 2H), 3.03 (s, 3H), 1.11 (t, J = 7.0 Hz, 3H). LCMS m/z 375.1 (M+Na)⁺ (ES⁺).

Example 37 – 4-butyl 1-(oxetan-3-yl) 2-methylenesuccinate


Example 37 was prepared according to General Procedure 3, using 4-butyl itaconate as itaconic acid monoester and oxetan-3-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.30 (d, J = 1.2 Hz, 1H), 5.92 (d, J = 1.2 Hz, 1H), 5.44 (tt, J = 6.3, 5.0 Hz, 1H), 4.82 (ddd, J = 7.4, 6.3, 1.0 Hz, 2H), 4.49 (ddd, J = 7.6, 5.0, 1.0 Hz, 2H), 4.04 (t, J = 6.5 Hz, 2H), 3.40 (s, 2H), 1.58 – 1.50 (m, 2H), 1.36 – 1.27 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H). LCMS m/z 243.2 (M+H)⁺ (ES⁺).

Example 38 – 4-hexyl 1-(oxetan-3-yl) 2-methylenesuccinate

Example 38 was prepared according to General Procedure 3, using 4-(hexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 3) as itaconic acid monoester and oxetan-3-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.30 (d, J = 1.2 Hz, 1H), 5.92 (d, J = 1.2 Hz, 1H), 5.43 (tt, J = 6.3, 5.0 Hz, 1H), 4.82 (ddd, J = 7.4, 6.2, 1.0 Hz, 2H), 4.49 (ddd, J = 7.5, 5.0, 1.0 Hz, 2H), 4.02 (t, J = 6.6 Hz,


2H), 3.40 (s, 2H), 1.59 – 1.51 (m, 2H), 1.33 – 1.22 (m, 6H), 0.91 – 0.83 (m, 3H). LCMS m/z 271.2 (M+H)⁺ (ES⁺).

Example 39 – 4-butyl 1-(2-tosylethyl) 2-methylenesuccinate




Example 39 was prepared according to General Procedure 3, using 4-butyl itaconate as itaconic acid monoester and 2-tosylethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 7.81 – 7.75 (m, 2H), 7.48 – 7.43 (m, 2H), 5.76 (d, J = 1.4 Hz, 1H), 5.71 (d, J = 1.2 Hz, 1H), 4.35 – 4.31 (m, 2H), 4.00 (t, J = 6.5 Hz, 2H), 3.73 (dd, J = 6.1, 5.1 Hz, 2H), 3.19 (s, 2H), 2.41 (s, 3H), 1.55 – 1.48 (m, 2H), 1.35 – 1.25 (m, 2H), 0.90 – 0.85 (m, 3H). LCMS m/z 391.2 (M+Na)⁺ (ES⁺).

Example 40 – 4-octyl 1-(2-tosylethyl) 2-methylenesuccinate




Example 40 was prepared according to General Procedure 3, using 4-octyl itaconate as itaconic acid monoester and 2-tosylethan-1-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 7.78 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 5.77 (s, 1H), 5.71 (s, 1H), 4.33 (t, J = 5.6 Hz, 2H), 3.99 (t, J = 6.6 Hz, 2H), 3.73 (t, J = 5.6 Hz, 2H), 3.18 (s, 2H), 2.41 (s, 3H), 1.60 – 1.47 (m, 2H), 1.25 (s, 10H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 447.2 (M+Na)⁺ (ES⁺).

Example 41 – 4-cyclooctyl 1-methyl 2-methylenesuccinate



Example 41 was prepared according to General Procedure 4, using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1) as itaconic acid monoester. ¹H NMR (500 MHz, CDCl₃) δ 6.32 (d, J = 1.1 Hz, 1H), 5.72 – 5.70 (m, 1H), 4.98 (tt, J = 8.3, 3.9 Hz, 1H), 3.79 (s, 3H), 3.32 (s, 2H), 1.87 – 1.46 (m, 14H). LCMS m/z 277.2 (M+Na)⁺ (ES⁺).


Example 42 – 1-methyl 4-octyl 2-methylenesuccinate



Example 42 was prepared according to General Procedure 4, using 4-octyl itaconate as itaconic acid monoester. ¹H NMR (500 MHz, CDCl₃) δ 6.32 (d, J = 1.0 Hz, 1H), 5.70 (q, J = 1.2 Hz, 1H),

4.08 (t, $J = 6.7$ Hz, 2H), 3.76 (s, 3H), 3.33 (s, 2H), 1.66 – 1.56 (m, 2H), 1.33 – 1.23 (m, 10H), 0.90 – 0.85 (m, 3H). LCMS m/z 279.2 ($M+Na$)⁺ (ES^+).


Example 43 – dicyclobutyl 2-methylenesuccinate



A mixture of itaconic acid (0.10 g, 0.78 mmol), cyclobutanol (0.186 g, 2.58 mmol) and p -TsOH. H_2O (2 mg, 0.008 mmol) in toluene was stirred at 110 °C for 18 h. The mixture was cooled to RT and concentrated onto silica gel. The crude product was purified by chromatography on silica gel (0-20% EtOAc/isohexane), then re-purified by chromatography on silica gel (0-50% EtOAc/isohexane) to afford the title compound as a colourless oil. ¹H NMR (500 MHz, $CDCl_3$) δ 6.33 (d, $J = 1.1$ Hz, 1H), 5.70 (q, $J = 1.2$ Hz, 1H), 5.14 – 4.97 (m, 2H), 3.31 (d, $J = 1.1$ Hz, 2H), 2.45 – 2.32 (m, 4H), 2.18 – 2.03 (m, 4H), 1.89 – 1.75 (m, 2H), 1.71 – 1.57 (m, 2H). LCMS m/z 261.2 ($M+Na$)⁺ (ES^+).

10

15 Example 44 – di(oxetan-3-yl) 2-methylenesuccinate




A solution of itaconic acid (200 mg, 1.54 mmol) in DCM was treated with EDC.HCl (590 mg, 3.10 mmol) and DMAP (38 mg, 0.31 mmol). A solution of oxetan-3-ol (0.2 mL, 3.1 mmol) in DCM was added, followed by DIPEA (0.8 mL, 4.6 mmol). The mixture was stirred at RT for 24 hours, then diluted with DCM (10 mL). The solution was washed with 1 N HCl (10 mL), sat. aq. $NaHCO_3$ (10 mL) and brine (10 mL). The organic phase was dried ($MgSO_4$) and concentrated. The crude product was purified by preparative HPLC (Waters, Acidic (0.1% Formic acid), Acidic, Waters X-Select Prep-C18, 5 μ m, 19x50 mm column, 5-95% MeCN in Water) to afford the title compound as a clear colourless oil. ¹H NMR (500 MHz, MeOD) δ 6.42 (d, $J = 0.9$ Hz, 1H), 5.91 (q, $J = 1.1$ Hz, 1H), 5.51 (tt, $J = 6.3, 5.0$ Hz, 1H), 5.45 (tt, $J = 6.4, 5.0$ Hz, 1H), 4.94 (ddd, $J = 7.4, 6.3, 1.0$ Hz, 2H), 4.90 (ddd, $J = 7.4, 6.3, 1.0$ Hz, 2H), 4.65 (ddd, $J = 7.7, 5.0, 1.0$ Hz, 2H), 4.61 (ddd, $J = 7.6, 5.0, 1.0$ Hz, 2H), 3.49 (s, 2H). LCMS m/z 243.1 ($M+H$)⁺ (ES^+).

20


25

30 Example 45 – 1-cyclobutyl 4-octyl 2-methylenesuccinate




Oxalyl chloride (0.11 mL, 1.2 mmol) was added dropwise to a solution of 4-octyl itaconate (0.15 g, 0.62 mmol), cyclobutanol (0.1 mL, 1.2 mmol) and dimethylformamide (0.1 mL, 1.2 mmol) in DCM. The mixture was stirred for 16 h. Water (10 mL) was added, the phases were separated and the aqueous phase was extracted with DCM (3 × 10 mL). The combined organic extracts were washed with brine (2 × 10 mL), dried (MgSO₄) and concentrated. The crude product which was purified by chromatography on silica gel (0-10% MeOH/DCM) to afford the title compound as a pale yellow oil. ¹H NMR (500 MHz, DMSO-d₆) δ 6.19 (d, J = 1.4 Hz, 1H), 5.80 (d, J = 1.3 Hz, 1H), 4.92 – 4.85 (m, 1H), 4.08 (t, J = 6.5 Hz, 2H), 3.33 (s, 2H), 2.29 – 2.22 (m, 2H), 2.02 – 1.93 (m, 2H), 1.78 – 1.69 (m, 1H), 1.63 – 1.52 (m, 3H), 1.35 – 1.22 (m, 10H), 0.90 – 0.84 (m, 3H). LCMS m/z 319.3 (M+Na)⁺ (ES⁺).

Example 46 – 1-(1-acetoxyethyl) 4-octyl 2-methylenesuccinate




1-bromoethyl acetate (0.103 g, 0.62 mmol) was added dropwise to a suspension of 4-octyl itaconate (0.15 g, 0.62 mmol) and potassium carbonate (0.171 g, 1.24 mmol) in dimethylformamide (5 mL) at RT. The mixture was stirred for 16 h, before water (10 mL) was added and the mixture was extracted with DCM (3 × 10 mL). The combined organic extracts were washed with brine (2 × 10 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by chromatography on silica gel (0-10% MeOH/DCM) to afford the title compound as a yellow oil. ¹H NMR (500 MHz, DMSO-d₆) δ 6.78 (q, J = 5.4 Hz, 1H), 6.24 (d, J = 1.1 Hz, 1H), 5.92 (d, J = 1.3 Hz, 1H), 4.01 (t, J = 6.6 Hz, 2H), 3.36 (s, 2H), 2.04 (s, 3H), 1.58 – 1.51 (m, 2H), 1.44 (d, J = 5.4 Hz, 3H), 1.33 – 1.21 (m, 10H), 0.90 – 0.84 (m, 3H). LCMS m/z 351.3 (M+Na)⁺ (ES⁺).


Example 47 – 1-(1,1-dioxidothietan-3-yl) 4-octyl 2-methylenesuccinate




EDC (0.13 mL, 0.74 mmol) was added to a solution of 4-octyl itaconate (0.15 g, 0.62 mmol), DMAP (4 mg, 0.03 mmol) and 3-hydroxythietane 1,1-dioxide (0.11 g, 0.93 mmol) in dimethylformamide (2 mL). The mixture was stirred overnight at RT then diluted with EtOAc (10 mL) and water (10 mL). The phases were separated and the organic phase was washed with brine (2 × 10 mL), dried (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-10% MeOH/DCM) to afford the title compound as a colourless oil. ¹H NMR (500 MHz, DMSO-d₆) δ 6.78 (q, J = 5.4 Hz, 1H), 6.24 (d, J = 1.1 Hz, 1H), 5.92 (d, J = 1.3 Hz, 1H), 4.01 (t, J = 6.6 Hz, 2H), 3.36 (s, 2H), 2.04 (s, 3H), 1.58 – 1.51 (m, 2H), 1.44 (d, J = 5.4 Hz, 3H), 1.33 – 1.21 (m, 10H), 0.90 – 0.84 (m, 3H). LCMS m/z 369.2 (M+Na)⁺ (ES⁺).

Example 48 – 1-(2-(tert-butoxy)-2-oxoethyl) 4-octyl 2-methylenesuccinate

tert-Butyl bromoacetate (0.37 mL, 2.5 mmol) was added to a mixture of 4-octyl itaconate (0.50 g, 2.1 mmol) and potassium carbonate (0.35 g, 2.5 mmol) in acetone (10 mL). The mixture was stirred for 16 h at RT. The mixture was diluted with EtOAc (20 mL), filtered and concentrated onto silica gel. The crude product was purified by chromatography on silica gel (0-30% EtOAc/isohexane) to afford the title compound as a colourless oil. ¹H NMR (500 MHz, DMSO-d₆) δ 6.29 (d, J = 1.3 Hz, 1H), 5.95 - 5.92 (m, 1H), 4.61 (s, 2H), 4.01 (t, J = 6.6 Hz, 2H), 3.38 (s, 2H), 1.60 - 1.50 (m, 2H), 1.42 (s, 9H), 1.34 - 1.21 (m, 10H), 0.90 - 0.83 (m, 3H). LCMS m/z 379.3 (M+Na)⁺ (ES⁺).

Example 49 – 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetic acid


TFA (5 mL, 65 mmol) was added to a solution of 1-(2-(tert-butoxy)-2-oxoethyl) 4-octyl 2-methylenesuccinate (Example 48, 0.65 g, 1.82 mmol) in DCM (5 mL). The reaction mixture was stirred for 30 minutes, diluted with toluene (10 mL) and concentrated. The crude product was purified by chromatography on silica gel (0-4% MeOH/DCM) to afford the title compound as a colourless oil. ¹H NMR (500 MHz, DMSO-d₆) δ 13.08 (s, 1H), 6.29 (d, J = 1.2 Hz, 1H), 5.93 (q, J = 1.2 Hz, 1H), 4.64 (s, 2H), 4.01 (t, J = 6.6 Hz, 2H), 3.38 (s, 2H), 1.60 - 1.48 (m, 2H), 1.32 - 1.20 (m, 10H), 0.92 - 0.82 (m, 3H). LCMS m/z 323.2 (M+Na)⁺ (ES⁺).

Example 50 – 1-(1-acetylazetidin-3-yl) 4-octyl 2-methylenesuccinate

DCC (0.224 g, 1.08 mmol) was added to a mixture of 4-octyl itaconate (0.25 g, 1.03 mmol), DMAP (6 mg, 0.05 mmol) and 1-(3-hydroxyazetidin-1-yl)ethanone (0.143 g, 1.24 mmol) in DCM (3 mL). The mixture was stirred for 16 h at RT, before the solid was removed by filtration. The filtrate concentrated and purified by chromatography on silica gel (0-10% MeOH/DCM) to afford a colourless oil. The oil was taken up in DCM/hexane (1:5, 3 mL) and the resulting solid was removed by filtration. The filtrate was concentrated to and the residue was purified by chromatography on silica gel (0-5% MeOH/DCM) to afford the title compound as a colourless oil. ¹H NMR (500 MHz, DMSO-d₆) δ 6.29 (d, J = 1.2 Hz, 1H), 5.93 - 5.90 (m, 1H), 5.21 - 5.15 (m, 1H), 4.47 (ddd, J = 9.8, 6.7, 1.4 Hz, 1H), 4.17 (ddd, J = 10.7, 6.9, 1.4 Hz, 1H), 4.05 - 3.99 (m,


3H), 3.74 (dd, $J = 10.8, 4.0$ Hz, 1H), 3.40 (s, 2H), 1.77 (s, 3H), 1.58 – 1.50 (m, 2H), 1.32 – 1.21 (m, 10H), 0.90 – 0.84 (m, 3H). LCMS m/z 340.1 (M+H)⁺ (ES⁺).

Example 51 – 1-(2-(4-methylpiperazin-1-yl)ethyl) 4-octyl 2-methylenesuccinate




Example 51 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 2-(4-methylpiperazin-1-yl)ethanol as R²-OH. ¹H NMR (500 MHz, CDCl₃) δ 6.31 (d, $J = 1.0$ Hz, 1H), 5.70 (q, $J = 1.2$ Hz, 1H), 4.29 (t, $J = 6.1$ Hz, 2H), 4.08 (t, $J = 6.8$ Hz, 2H), 3.33 (s, 2H), 2.68 (t, $J = 6.1$ Hz, 2H), 2.65 – 2.31 (m, 8H), 2.29 (s, 3H), 1.67 – 1.56 (m, 2H), 1.32 – 1.23 (m, 10H), 0.88 (t, $J = 6.8$ Hz, 3H). LCMS m/z 369.3 (M+H)⁺ (ES⁺).

Example 52 – 1-(2-(1,1-dioxidothiomorpholino)ethyl) 4-octyl 2-methylenesuccinate




Example 52 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 4-(2-hydroxyethyl)thiomorpholine 1,1-dioxide as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.21 (d, $J = 1.3$ Hz, 1H), 5.85 (d, $J = 1.3$ Hz, 1H), 4.19 (t, $J = 5.6$ Hz, 2H), 4.01 (t, $J = 6.6$ Hz, 2H), 3.37 (s, 2H), 3.09 - 3.03 (m, 4H), 2.97 (dd, $J = 6.9, 3.5$ Hz, 4H), 2.80 (t, $J = 5.6$ Hz, 2H), 1.54 (q, $J = 6.8$ Hz, 2H), 1.32 - 1.23 (m, 10H), 0.90 - 0.83 (m, 3H). LCMS m/z 404.2 (M+H)⁺ (ES⁺).

Example 53 – 1-(2-(methylsulfonamido)ethyl) 4-octyl 2-methylenesuccinate




Example 53 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and N-(2-hydroxyethyl)methanesulfonamide as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 7.26 (t, $J = 6.0$ Hz, 1H), 6.30 (d, $J = 1.3$ Hz, 1H), 5.87 (q, $J = 1.2$ Hz, 1H), 4.12 (t, $J = 5.7$ Hz, 2H), 4.01 (t, $J = 6.6$ Hz, 2H), 3.38 (s, 2H), 3.23 (q, $J = 5.7$ Hz, 2H), 2.92 (s, 3H), 1.54 (q, $J = 6.8$ Hz, 2H), 1.32 - 1.23 (m, 10H), 0.90 - 0.83 (m, 3H). LCMS m/z 386.2 (M+Na)⁺ (ES⁺).

Example 54 – 4-cyclooctyl 1-(1,1-dioxidothietan-3-yl) 2-methylenesuccinate




Example 54 was prepared according to General Procedure 2, using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1) as itaconic acid monoester and 3-hydroxythietane 1,1-dioxide as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.28 (d, J = 1.1 Hz, 1H), 5.92 (d, J = 1.3 Hz, 1H), 5.32 (tt, J = 7.7, 2.8 Hz, 1H), 4.84 (tt, J = 8.2, 3.9 Hz, 1H), 4.79 - 4.69 (m, 2H), 4.25 - 4.16 (m, 2H), 3.36 (s, 2H), 1.78 - 1.39 (m, 14H). LCMS m/z 367.5 (M+Na)⁺ (ES⁺).

Example 55 – (R)-1-(2-(methylsulfonyl)ethyl) 4-(octan-2-yl) 2-methylenesuccinate




Example 55 was prepared according to General Procedure 2, using (R)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 8) as itaconic acid monoester and 2-(methylsulfonyl)ethanol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.24 (d, J = 1.2 Hz, 1H), 5.88 (d, J = 1.3 Hz, 1H), 4.84 - 4.63 (m, 1H), 4.44 (t, J = 5.8 Hz, 2H), 3.53 (t, J = 5.8 Hz, 2H), 3.34 (s, 2H), 3.02 (s, 3H), 1.54-1.38 (m, 2H), 1.31 - 1.20 (m, 8H), 1.14 (d, J = 6.2 Hz, 3H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 371.5 (M+Na)⁺ (ES⁺).

Example 56 – 1-(1-(methylsulfonyl)propan-2-yl) 4-((R)-octan-2-yl) 2-methylenesuccinate




Example 56 was prepared according to General Procedure 2, using (R)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 8) as itaconic acid monoester and 1-(methylsulfonyl)propan-2-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.23 (s, 1H), 5.85 (s, 1H), 5.34 - 5.21 (m, 1H), 4.84 - 4.69 (m, 1H), 3.63 - 3.54 (m, 1H), 3.50 - 3.42 (m, 1H), 3.34 - 3.32 (m, 2H), 2.98 (s, 3H), 1.52 - 1.38 (m, 2H), 1.35 - 1.19 (m, 11H), 1.16 - 1.10 (m, 3H), 0.85 (t, J = 6.8 Hz, 3H). LCMS m/z 385.6 (M+Na)⁺ (ES⁺).


Example 57 – (R)-1-(1,1-dioxidothietan-3-yl) 4-(octan-2-yl) 2-methylenesuccinate




Example 57 was prepared according to General Procedure 2, using (R)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 8) as itaconic acid monoester and 3-hydroxythietane 1,1-dioxide as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.28 (d, J = 1.1 Hz, 1H), 5.93 (d, J = 1.2 Hz, 1H), 5.36 - 5.22 (m, 1H), 4.83 - 4.66 (m, 3H), 4.23 - 4.05 (m, 2H), 3.36 (s, 2H), 1.53 - 1.41 (m, 2H), 1.30 - 1.20 (m, 8H), 1.14 (d, J = 6.3 Hz, 3H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 369.2 (M+Na)⁺ (ES⁺).

Example 58 – (R)-1-(1-acetylazetidin-3-yl) 4-(octan-2-yl) 2-methylenesuccinate


Example 58 was prepared according to General Procedure 2, using (R)-2-methylene-4-(octan-2-yl)oxy)-4-oxobutanoic acid (Intermediate 8) as itaconic acid monoester and 1-(3-hydroxyazetidin-1-yl)ethanone as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.28 (d, J = 1.2 Hz, 1H), 5.90 (d, J = 1.2 Hz, 1H), 5.21 - 5.11 (m, 1H), 4.85 - 4.73 (m, 1H), 4.53 - 4.41 (m, 1H), 4.19 - 4.13 (m, 1H), 4.06 - 3.98 (m, 1H), 3.77 - 3.67 (m, 1H), 3.37 (s, 2H), 1.77 (s, 3H), 1.52 - 1.39 (m, 2H), 1.30 - 1.18 (m, 8H), 1.14 (d, J = 6.2 Hz, 3H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 362.3 (M+Na)⁺ (ES⁺).

Example 59 – 4-cyclohexyl 1-(1-(methylsulfonyl)propan-2-yl) 2-methylenesuccinate

Example 59 was prepared according to General Procedure 2, using 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6) as itaconic acid monoester and 1-(methylsulfonyl)propan-2-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.24 (d, J = 1.3 Hz, 1H), 5.86 (d, J = 1.3 Hz, 1H), 5.36 - 5.16 (m, 1H), 4.68 - 4.58 (m, 1H), 3.70 - 3.55 (m, 1H), 3.51 - 3.42 (m, 1H), 3.35 (s, 2H), 2.99 (s, 3H), 1.78 - 1.69 (m, 2H), 1.66 - 1.54 (m, 2H), 1.51 - 1.43 (m, 1H), 1.41 - 1.13 (m, 8H). LCMS m/z 355.2 (M+Na)⁺ (ES⁺).


Example 60 – 4-cyclohexyl 1-(1,1-dioxidothietan-3-yl) 2-methylenesuccinate

Example 60 was prepared according to General Procedure 2, using 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6) as itaconic acid monoester and 3-hydroxythietane 1,1-dioxide as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.29 (d, J = 1.2 Hz, 1H), 5.93 (d, J = 1.3 Hz, 1H), 5.32 (tt, J = 7.7, 2.8 Hz, 1H), 4.80 - 4.69 (m, 2H), 4.71 - 4.58 (m, 1H), 4.26 - 4.16 (m, 2H), 3.38 (s, 2H), 1.80 - 1.72 (m, 2H), 1.70 - 1.59 (m, 2H), 1.54 - 1.44 (m, 0H), 1.44 - 1.19 (m, 6H). LCMS m/z 339.2 (M+Na)⁺ (ES⁺).

Example 61 – 4-cyclohexyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate


Example 61 was prepared according to General Procedure 2, using 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6) as itaconic acid monoester and 2-(methylsulfonyl)ethanol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.23 (d, J = 1.2 Hz, 1H), 5.87 (d, J = 1.3 Hz, 1H), 4.69 - 4.61 (m, 1H), 4.44 (t, J = 5.8 Hz, 2H), 3.52 (t, J = 5.8 Hz, 2H), 3.35 (s, 2H), 3.02 (s, 3H), 1.78 - 1.69 (m, 2H), 1.65 - 1.56 (m, 2H), 1.50 - 1.41 (m, 1H), 1.38 - 1.12 (m, 5H). LCMS m/z 341.2 (M+Na)⁺ (ES⁺).

Example 62 – 4-cyclooctyl 1-(1-(methylsulfonyl)propan-2-yl) 2-methylenesuccinate




Example 62 was prepared according to General Procedure 2, using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1) as itaconic acid monoester and 1-(methylsulfonyl)propan-2-ol as R²-OH. ¹H NMR (500 MHz, CDCl₃) δ 6.32 (s, 1H), 5.76 (d, J = 1.1 Hz, 1H), 5.49 – 5.41 (m, 1H), 5.00 – 4.94 (m, 1H), 3.47 (dd, J = 14.8, 6.6 Hz, 1H), 3.39 – 3.29 (m, 2H), 3.24 – 3.14 (m, 1H), 3.00 (s, 3H), 1.87 – 1.66 (m, 6H), 1.66 – 1.46 (m, 11H). LCMS m/z 383.5 (M+Na)⁺ (ES⁺).

Example 63 – 1-(1-acetylazetidin-3-yl) 4-cyclooctyl 2-methylenesuccinate




Example 63 was prepared according to General Procedure 2, using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1) as itaconic acid monoester and 1-(3-hydroxyazetidin-1-yl)ethanone as R²-OH. ¹H NMR (500 MHz, CDCl₃) δ 6.39 (s, 1H), 5.80 (s, 1H), 5.28 (ddd, J = 11.1, 6.9, 4.1 Hz, 1H), 4.98 (tt, J = 8.3, 3.9 Hz, 1H), 4.54 - 4.45 (m, 1H), 4.36 (dd, J = 11.2, 6.9 Hz, 1H), 4.12 (dd, J = 9.8, 4.1 Hz, 1H), 4.04 (dd, J = 11.2, 4.3 Hz, 1H), 3.34 (s, 2H), 1.91 (s, 3H), 1.85 - 1.66 (m, 6H), 1.60 - 1.52 (m, 8H). LCMS m/z 360.3 (M+Na)⁺ (ES⁺).


Example 64 – 4-cyclohexyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate




Example 64 was prepared according to General Procedure 2, using 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6) as itaconic acid monoester and tetrahydro-2H-pyran-4-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.21 (s, 1H), 5.81 (s, 1H), 4.95 - 4.88 (m, 1H), 4.72 - 4.50 (m, 1H), 3.79 - 3.70 (m, 2H), 3.53 - 3.45 (m, 2H), 3.35 (s, 2H), 1.88 - 1.80 (m, 2H), 1.76 - 1.68 (m, 2H), 1.66 - 1.59 (m, 2H), 1.57 - 1.18 (m, 8H). LCMS m/z 319.2 (M+Na)⁺ (ES⁺).

Example 65 – 4-cyclohexyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate


Example 65 was prepared according to General Procedure 2, using 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6) as itaconic acid monoester and 1-(2-hydroxyethyl)pyrrolidin-2-one as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.18 (s, 1H), 5.83 (s, 1H), 4.69 - 4.53 (m, 1H), 4.18 (t, J = 5.5 Hz, 2H), 3.44 (t, J = 5.4 Hz, 2H), 3.37 (t, J = 7.0 Hz, 2H), 3.32 (s, 2H), 2.19 (t, J = 8.1 Hz, 2H), 1.93 - 1.83 (m, 2H), 1.77 - 1.68 (m, 2H), 1.65 - 1.54 (m, 2H), 1.49 - 1.42 (m, 1H), 1.39 - 1.15 (m, 5H). LCMS m/z 346.3 (M+Na)⁺ (ES⁺).

Example 66 – (S)-1-(1-acetylazetid-3-yl) 4-(octan-2-yl) 2-methylenesuccinate


Example 66 was prepared according to General Procedure 2, using (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 9) as itaconic acid monoester and 1-(3-hydroxyazetid-1-yl)ethanone as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.28 (d, J = 1.2 Hz, 1H), 5.90 (d, J = 1.3 Hz, 1H), 5.21 - 5.14 (m, 1H), 4.83 - 4.76 (m, 1H), 4.47 (ddd, J = 9.8, 6.7, 1.4 Hz, 1H), 4.20 - 4.14 (m, 1H), 4.05 - 4.01 (m, 1H), 3.77 - 3.69 (m, 1H), 3.37 (s, 2H), 1.77 (s, 3H), 1.48 (dddt, J = 13.7, 10.5, 7.6, 5.1 Hz, 2H), 1.31 - 1.20 (m, 8H), 1.14 (d, J = 6.3 Hz, 3H), 0.86 (t, J = 6.9 Hz, 3H). LCMS m/z 340.5 (M+H)⁺ (ES⁺).

Example 67 – (S)-1-(1,1-dioxidothietan-3-yl) 4-(octan-2-yl) 2-methylenesuccinate


Example 67 was prepared according to General Procedure 2, using (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 9) as itaconic acid monoester and 3-hydroxythietane 1,1-dioxide as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.29 (d, J = 1.1 Hz, 1H), 5.93 (d, J = 1.2 Hz, 1H), 5.31 (tt, J = 7.7, 2.8 Hz, 1H), 4.83 - 4.70 (m, 3H), 4.24 - 4.17 (m, 2H), 3.37 (s, 2H), 1.49 (ddddd, J = 19.5, 14.0, 7.8, 4.7 Hz, 2H), 1.31 - 1.19 (m, 8H), 1.15 (d, J = 6.3 Hz, 3H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 369.2 (M+Na)⁺ (ES⁺).

Example 68 – 1-(3-methyloxetan-3-yl) 4-octyl 2-methylenesuccinate


Example 68 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 3-methyloxetan-3-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.23 (d, J = 1.2 Hz, 1H), 5.87 (d, J = 1.3 Hz, 1H), 4.61 (d, J = 7.1 Hz, 2H), 4.51 - 4.41 (m, 2H), 4.02 (t, J = 6.6 Hz, 2H), 3.38 (s, 2H), 1.63 (s, 3H), 1.59 - 1.50 (m, 2H), 1.31 - 1.22 (m, 10H), 0.92 - 0.83 (m, 3H). LCMS m/z 313.2 (M+H)⁺ (ES⁺).

Example 69 – 4-cyclooctyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate

Example 69 was prepared according to General Procedure 2, using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1) as itaconic acid monoester and 1-(methylsulfonyl)piperidin-4-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.24 (d, J = 1.4 Hz, 1H), 5.83 (d, J = 1.3 Hz, 1H), 4.91 (tt, J = 7.2, 3.6 Hz, 1H), 4.83 (tt, J = 8.1, 3.9 Hz, 1H), 3.35 (s, 2H), 3.25 (ddd, J = 11.7, 7.7, 3.7 Hz, 2H), 3.17 (ddd, J = 11.8, 7.4, 3.9 Hz, 2H), 2.90 (s, 3H), 1.97 - 1.88 (m, 2H), 1.76 - 1.43 (m, 16H). LCMS m/z 424.2 (M+Na)⁺ (ES⁺).


Example 70 – 4-cyclooctyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate

Example 70 was prepared according to General Procedure 2, using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1) as itaconic acid monoester and tetrahydro-2H-pyran-4-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.21 (d, J = 1.4 Hz, 1H), 5.81 (d, J = 1.4 Hz, 1H), 4.94 (tt, J = 8.0, 4.0 Hz, 1H), 4.83 (tt, J = 8.1, 3.9 Hz, 1H), 3.76 (ddd, J = 10.7, 6.2, 3.9 Hz, 2H), 3.50 (ddd, J = 11.6, 8.2, 3.3 Hz, 2H), 3.34 (s, 2H), 1.89 - 1.81 (m, 2H), 1.76 - 1.60 (m, 6H), 1.58 - 1.42 (m, 10H). LCMS m/z 347.5 (M+Na)⁺ (ES⁺).

Example 71 – 4-cyclooctyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate


Example 71 was prepared according to General Procedure 2, using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1) as itaconic acid monoester and 1-(2-hydroxyethyl)pyrrolidin-2-one as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.18 (d, J = 1.3 Hz, 1H), 5.82 (d, J = 1.3 Hz, 1H), 4.83 (tt, J = 8.2, 3.9 Hz, 1H), 4.19 (t, J = 5.4 Hz, 2H), 3.45 (t, J = 5.4 Hz, 2H), 3.38 (t, J = 7.0 Hz, 2H), 3.31 (s, 2H), 2.20 (t, J = 8.1 Hz, 2H), 1.91 (ddd, J = 15.2, 8.1, 6.8 Hz, 2H), 1.77 - 1.43 (m, 14H). LCMS m/z 374.4 (M+Na)⁺ (ES⁺).

Example 72 – (R)-4-(octan-2-yl) 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate




Example 72 was prepared according to General Procedure 2, using (R)-4-(octan-2-yl) 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate (Intermediate 8) as itaconic acid monoester and 1-(2-hydroxyethyl)pyrrolidin-2-one as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.17 (d, J = 1.3 Hz, 1H), 5.82 (d, J = 1.4 Hz, 1H), 4.81 - 4.66 (m, 1H), 4.23 - 4.11 (m, 2H), 3.44 (t, J = 5.4 Hz, 2H), 3.37 (t, J = 7.0 Hz, 2H), 3.31 (s, 2H), 2.19 (t, J = 8.1 Hz, 2H), 1.95 - 1.84 (m, 2H), 1.52 - 1.40 (m, 2H), 1.27 - 1.18 (m, 8H), 1.13 (d, J = 6.3 Hz, 3H), 0.85 (t, J = 6.8 Hz, 3H). LCMS m/z 354.3 (M+H)⁺ (ES⁺).

Example 73 – (R)-4-(octan-2-yl) 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate



Example 73 was prepared according to General Procedure 2, using (R)-4-(octan-2-yl) 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate (Intermediate 8) as itaconic acid monoester and tetrahydro-2H-pyran-4-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.21 (d, J = 1.4 Hz, 1H), 5.81 (d, J = 1.4 Hz, 1H), 4.96 - 4.88 (m, 1H), 4.81 - 4.72 (m, 1H), 3.79 - 3.72 (m, 2H), 3.52 - 3.44 (m, 2H), 3.35 - 3.33 (m, 2H), 1.87 - 1.78 (m, 2H), 1.59 - 1.39 (m, 4H), 1.29 - 1.19 (m, 8H), 1.13 (d, J = 6.3 Hz, 3H), 0.85 (t, J = 6.8 Hz, 3H). LCMS m/z 349.3 (M+H)⁺ (ES⁺).


Example 74 – 1-(1-acetylazetidin-3-yl) 4-cyclohexyl 2-methylenesuccinate



Example 74 was prepared according to General Procedure 2, using 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6) as itaconic acid monoester and 1-(3-hydroxyazetidin-1-yl)ethanone as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.28 (d, J = 1.2 Hz, 1H), 5.90 (d, J = 1.2 Hz, 1H), 5.20 - 5.11 (m, 1H), 4.70 - 4.62 (m, 1H), 4.52 - 4.41 (m, 1H), 4.20 -


4.09 (m, 1H), 4.06 - 3.93 (m, 1H), 3.79 - 3.68 (m, 1H), 3.38 (s, 2H), 1.80 - 1.70 (m, 5H), 1.65 - 1.58 (m, 2H), 1.49 - 1.12 (m, 6H). LCMS m/z 310.3 (M+H)⁺ (ES⁺).

Example 75 – 4-cyclohexyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate




Example 75 was prepared according to General Procedure 2, using 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6) as itaconic acid monoester and 1-(methylsulfonyl)piperidin-4-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.24 (d, J = 1.3 Hz, 1H), 5.84 (d, J = 1.4 Hz, 1H), 4.95 - 4.86 (m, 1H), 4.69 - 4.58 (m, 1H), 3.37 (s, 2H), 3.28 - 3.21 (m, 2H), 3.19 - 3.08 (m, 2H), 2.89 (s, 3H), 1.96 - 1.82 (m, 2H), 1.78 - 1.57 (m, 6H), 1.49 - 1.19 (m, 6H). LCMS m/z 395.9 (M+Na)⁺ (ES⁺).

Example 76 – 4-hexyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate




Example 76 was prepared according to General Procedure 2, using 4-(hexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 3) as itaconic acid monoester and 1-(methylsulfonyl)piperidin-4-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.24 (d, J = 1.4 Hz, 1H), 5.84 (d, J = 1.3 Hz, 1H), 4.95 - 4.79 (m, 1H), 4.01 (t, J = 6.6 Hz, 2H), 3.38 (s, 2H), 3.27 - 3.10 (m, 4H), 2.88 (s, 3H), 1.97 - 1.84 (m, 2H), 1.73 - 1.60 (m, 2H), 1.58 - 1.44 (m, 2H), 1.37 - 1.17 (m, 6H), 0.86 (t, J = 7.1 Hz, 3H). LCMS m/z 398.4 (M+Na)⁺ (ES⁺).


Example 77 – 4-hexyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate



Example 77 was prepared according to General Procedure 2, using 4-(hexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 3) as itaconic acid monoester and 1-(2-hydroxyethyl)pyrrolidin-2-one as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.19 (d, J = 1.3 Hz, 1H), 5.84 (d, J = 1.3 Hz, 1H), 4.18 (t, J = 5.4 Hz, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.44 (t, J = 5.4 Hz, 2H), 3.39 - 3.34 (m, 4H), 2.19 (t, J = 8.1 Hz, 2H), 1.97 - 1.81 (m, 2H), 1.60 - 1.47 (m, 2H), 1.37 - 1.19 (m, 6H), 0.93 - 0.71 (m, 3H). LCMS m/z 348.3 (M+H)⁺ (ES⁺).

Example 78 – 1-(2-(1H-tetrazol-5-yl)ethyl) 4-hexyl 2-methylenesuccinate


Example 78 was prepared according to General Procedure 2, using 4-(hexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 3) as itaconic acid monoester and 2-(1H-tetrazol-5-yl)ethanol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.13 (d, J = 1.3 Hz, 1H), 5.81 (d, J = 1.2 Hz, 1H), 4.45 (t, J = 6.3 Hz, 2H), 3.94 (t, J = 6.6 Hz, 2H), 3.31 (s, 2H), 3.27 (t, J = 6.3 Hz, 2H), 1.59 - 1.47 (m, 2H), 1.30 - 1.21 (m, 6H), 0.90 - 0.83 (m, 3H) (1 exchangeable proton not seen). LCMS m/z 311.0 (M+H)⁺ (ES⁺).

Example 79 – 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoic acid**Step 1**

tert-Butyl 2-bromopropanoate (1.03 g, 4.95 mmol) was added to a suspension of 4-octyl itaconate (1.00 g, 4.13 mmol) and potassium carbonate (0.696 g, 5.03 mmol) in acetone (20 mL). The reaction mixture was stirred at RT for 18 h, then heated to 50 °C and stirred for a further 5 h. The reaction mixture was diluted with ethyl acetate (40 mL), filtered and concentrated to afford 1-(1-(tert-butoxy)-1-oxopropan-2-yl) 4-octyl 2-methylenesuccinate (1.7 g, 3.07 mmol). ¹H NMR (500 MHz, DMSO-d₆) δ 6.27 (d, J = 1.3 Hz, 1H), 5.95 - 5.88 (m, 1H), 4.88 (q, J = 7.0 Hz, 1H), 4.00 (t, J = 6.6 Hz, 2H), 3.41 - 3.32 (m, 2H), 1.59 - 1.51 (m, 2H), 1.43 - 1.35 (m, 12H), 1.32 - 1.18 (m, 10H), 0.89 - 0.84 (m, 3H). LCMS m/z 393.2 (M+Na)⁺ (ES⁺).

Step 2


TFA (11 mL) was added to a solution of 1-(1-(tert-butoxy)-1-oxopropan-2-yl) 4-octyl 2-methylenesuccinate (1.53 g, 4.13 mmol) in DCM (11 mL) and the mixture was stirred for 30 min at RT. The reaction was diluted with toluene (20 mL) and concentrated. The residue was dissolved in ethyl acetate (40 mL) and washed with water (10 x 25 mL). The organic phase was dried (MgSO₄) and concentrated to afford the title compound (1.00 g, 3.15 mmol) as a colourless oil. ¹H NMR (500 MHz, DMSO-d₆) δ 13.06 (s, 1H), 6.27 (d, J = 1.3 Hz, 1H), 5.90 (d, J = 1.3 Hz, 1H), 4.96 (q, J = 7.1 Hz, 1H), 4.00 (t, J = 6.6 Hz, 2H), 3.36 (s, 2H), 1.59 - 1.50 (m, 2H), 1.42 (d, J = 7.0 Hz, 3H), 1.31 - 1.22 (m, 10H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 337.2 (M+Na)⁺ (ES⁺).

Example 80 – 3-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoic acid**Step 1**

A solution of 4-octyl itaconate (2.00 g, 8.25 mmol), tert-butyl 3-hydroxypropanoate (1.49 mL, 9.90 mmol), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (3.16 g, 16.5 mmol) and DMAP (0.101 g, 0.83 mmol) in DCM (60 mL) was treated with DIPEA (2.88 mL, 16.5 mmol). The resulting solution was stirred at RT for 20 h. The reaction mixture was concentrated onto silica gel and the crude product purified by chromatography on silica gel (0-20% EtOAc/DCM or 0-20% EtOAc/DCM) to afford 1-(3-(tert-butoxy)-3-oxopropyl) 4-octyl 2-methylenesuccinate (1.56 g, 4.13 mmol) as a clear colourless oil. ¹H NMR (500 MHz, DMSO-d₆) δ 6.30 (d, J = 1.0 Hz, 1H), 5.70 (d, J = 1.2 Hz, 1H), 4.39 (t, J = 6.5 Hz, 2H), 4.08 (t, J = 6.8 Hz, 2H), 3.32 (s, 2H), 2.59 (t, J = 6.5 Hz, 2H), 1.63 – 1.51 (m, 2H), 1.45 (s, 9H), 1.32 – 1.13 (m, 10H), 0.88 (t, J = 6.9 Hz, 3H). LCMS m/z 392.9 (M+Na)⁺ (ES⁺).

Step 2


TFA (15 mL) was added to a solution of 1-(3-(tert-butoxy)-3-oxopropyl) 4-octyl 2-methylenesuccinate (1.56 g, 4.21 mmol) in DCM (15 mL) and the mixture was stirred for 2 h at RT. The reaction was diluted with toluene (50 mL) and concentrated. The residue was co-evaporated with toluene (2 x 20 mL) and dried in vacuo to afford the title compound (1.546 g, 4.87 mmol) as a colourless solid. ¹H NMR (500 MHz, DMSO-d₆) δ 12.37 (s, 1H), 6.16 (d, J = 1.3 Hz, 1H), 5.82 (d, J = 1.4 Hz, 1H), 4.25 (t, J = 6.2 Hz, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.32 (s, 2H), 2.59 (t, J = 6.2 Hz, 2H), 1.58 - 1.47 (m, 2H), 1.36 - 1.16 (m, 10H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 337.2 (M+Na)⁺ (ES⁺).

Example 81 – 3-((4-((4-fluorobenzyl)oxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid

Example 81 was prepared according to the procedure of Example 80, but using 4-isopropoxy-2-methylene-4-oxobutanoic acid (Intermediate 7) instead of 4-octyl itaconate. ¹H NMR (500 MHz, DMSO-d₆) δ 12.39 (br s, 1H), 7.44 - 7.38 (m, 2H), 7.25 - 7.17 (m, 2H), 6.18 (d, J = 1.3 Hz, 1H),


5.85 (d, J = 1.3 Hz, 1H), 5.08 (s, 2H), 4.24 (t, J = 6.2 Hz, 2H), 3.41 (s, 2H), 2.57 (t, J = 6.2 Hz, 2H). LCMS m/z 333.3 (M+Na)⁺ (ES⁺).

Example 82 – 3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid




Example 82 was prepared according to the procedure of Example 80, but using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1) instead of 4-octyl itaconate. ¹H NMR (500 MHz, DMSO-d₆) δ 12.39 (s, 1H), 6.15 (d, J = 1.4 Hz, 1H), 5.85 - 5.74 (m, 1H), 4.83 (tt, J = 8.1, 3.9 Hz, 1H), 4.26 (t, J = 6.2 Hz, 2H), 3.30 (s, 2H), 2.60 (t, J = 6.2 Hz, 2H), 1.77 - 1.41 (m, 14H). LCMS m/z 335.3 (M+Na)⁺ (ES⁺).

Example 83 – 3-((2-methylene-4-(neopentyloxy)-4-oxobutanoyl)oxy)propanoic acid




Example 83 was prepared according to the procedure of Example 80, but using 2-methylene-4-(neopentyloxy)-4-oxobutanoic acid (Intermediate 10) instead of 4-octyl itaconate. ¹H NMR (400 MHz, DMSO-d₆) δ 12.38 (s, 1H), 6.18 (d, J = 1.4 Hz, 1H), 5.88 - 5.82 (m, 1H), 4.26 (t, J = 6.2 Hz, 2H), 3.72 (s, 2H), 3.38 (s, 2H), 2.59 (t, J = 6.2 Hz, 2H), 0.88 (s, 9H). LCMS m/z 295.7 (M+Na)⁺ (ES⁺).

Example 84 – (S)-3-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)propanoic acid




Example 84 was prepared according to the procedure of Example 80, but using (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 9) instead of 4-octyl itaconate. ¹H NMR (400 MHz, DMSO-d₆) δ 12.39 (s, 1H), 6.15 (d, J = 1.3 Hz, 1H), 5.81 (d, J = 1.3 Hz, 1H), 4.84 - 4.70 (m, 1H), 4.25 (t, J = 6.2 Hz, 2H), 3.30 (s, 2H), 2.59 (t, J = 6.2 Hz, 2H), 1.54 - 1.37 (m, 2H), 1.25 (dd, J = 10.7, 5.2 Hz, 8H), 1.13 (d, J = 6.2 Hz, 3H), 0.85 (t, J = 6.4 Hz, 3H). LCMS m/z 336.9 (M+Na)⁺ (ES⁺).

Example 85 – 3-((4-(hexyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid




Example 85 was prepared according to the procedure of Example 80, but using 4-(hexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 3) instead of 4-octyl itaconate. ¹H NMR (400 MHz, DMSO-d₆) δ 12.39 (s, 1H), 6.16 (d, J = 1.4 Hz, 1H), 5.82 (d, J = 1.3 Hz, 1H), 4.25 (t, J = 6.2 Hz, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.33 (s, 2H), 2.59 (t, J = 6.2 Hz, 2H), 1.61 - 1.47 (m, 2H), 1.32 - 1.19 (m, 6H), 0.93 - 0.78 (m, 3H). LCMS m/z 309.7 (M+Na)⁺ (ES⁺).

Example 86 – 3-((2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoyl)oxy)propanoic acid




Example 86 was prepared according to the procedure of Example 80, but using 2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoic acid (Intermediate 2) instead of 4-octyl itaconate. ¹H NMR (400 MHz, DMSO-d₆) δ 12.41 (s, 1H), 7.35 - 7.24 (m, 2H), 6.99 - 6.88 (m, 3H), 6.17 (d, J = 1.3 Hz, 1H), 5.83 (q, J = 1.2 Hz, 1H), 4.24 (t, J = 6.2 Hz, 2H), 4.19 (t, J = 6.4 Hz, 2H), 4.01 (t, J = 6.3 Hz, 2H), 3.37 (s, 2H), 2.58 (t, J = 6.2 Hz, 2H), 2.06 - 1.97 (m, 2H). LCMS m/z 359.3 (M+Na)⁺ (ES⁺).

Example 87 – 3-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid




Example 87 was prepared according to the procedure of Example 80, but using 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6) instead of 4-octyl itaconate. ¹H NMR (400 MHz, DMSO-d₆) δ 12.40 (s, 1H), 6.15 (d, J = 1.4 Hz, 1H), 5.81 (d, J = 1.3 Hz, 1H), 4.70 - 4.59 (m, 1H), 4.25 (t, J = 6.2 Hz, 2H), 3.31 (s, 2H), 2.59 (t, J = 6.2 Hz, 2H), 1.77 - 1.70 (m, 2H), 1.65 - 1.55 (m, 2H), 1.49 - 1.16 (m, 6H). LCMS m/z 307.4 (M+Na)⁺ (ES⁺).

Example 88 – (R)-3-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)propanoic acid




Example 88 was prepared according to the procedure of Example 80, but using (R)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 8) instead of 4-octyl itaconate. ¹H NMR (400 MHz, DMSO-d₆) δ 12.38 (s, 1H), 6.15 (d, J = 1.4 Hz, 1H), 5.81 (d, J = 1.4 Hz, 1H), 4.83 - 4.72 (m, 1H), 4.25 (t, J = 6.2 Hz, 2H), 3.30 (s, 2H), 2.59 (t, J = 6.3 Hz, 2H), 1.54 - 1.39 (m, 2H), 1.29 - 1.16 (m, 8H), 1.13 (d, J = 6.3 Hz, 3H), 0.85 (t, J = 6.4 Hz, 3H). LCMS m/z 337.4 (M+Na)⁺ (ES⁺).

Example 89 – (S)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid**Step 1**

A mixture of (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 9, 1 g, 4.13 mmol), tert-butyl bromoacetate (0.64 mL, 4.3 mmol) and potassium carbonate (0.684 g, 4.95 mmol) in acetone (20 mL) was stirred at RT overnight. The reaction mixture was concentrated and the residue was partitioned between water (20 mL) and EtOAc (10 mL). The phases were separated and the aqueous phase was extracted with EtOAc (10 mL). The combined organic phases were washed with brine (10 mL), dried (MgSO₄) and concentrated to afford (S)-1-(2-(tert-butoxy)-2-oxoethyl) 4-octan-2-yl 2-methylenesuccinate (1.56 g, 4.07 mmol) as a colourless oil. ¹H NMR (500 MHz, DMSO-d₆) δ 6.28 (s, 1H), 5.92 (s, 1H), 4.82 – 4.75 (m, 1H), 4.60 (s, 2H), 3.35 (s, 2H), 1.42 (s, 9H), 1.31 – 1.20 (m, 10H), 1.14 (d, J = 6.3 Hz, 3H), 0.88 – 0.84 (m, 3H).

Step 2


TFA (7.5 mL) was added to a solution of (S)-1-(2-(tert-butoxy)-2-oxoethyl) 4-octan-2-yl 2-methylenesuccinate (1.5 g, 3.79 mmol) in DCM (7.5 mL). The reaction mixture was stirred for 2 h, partitioned between EtOAc (50 mL) and water (50 mL) and the phases separated. The organic phase was washed with water (2 x 20 mL), brine (20 mL), dried (MgSO₄) and concentrated. The residue was redissolved in DCM (10 mL), washed with water (2 x 10 mL), dried (MgSO₄) and concentrated to afford the title compound (0.922 g, 3.04 mmol) as a colourless oil. ¹H NMR (500 MHz, DMSO-d₆) δ 13.08 (br. s, 1H), 6.28 (d, J = 1.2 Hz, 1H), 5.92 (d, J = 1.3 Hz, 1H), 4.83 - 4.74 (m, 1H), 4.64 (s, 2H), 3.35 (s, 2H), 1.55 - 1.40 (m, 2H), 1.31 - 1.18 (m, 8H), 1.14 (d, J = 6.2 Hz, 3H), 0.86 (t, J = 6.9 Hz, 3H). LCMS m/z 323.2 (M+H)⁺ (ES⁺).

Example 90 – 2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid

Example 90 was prepared according to the procedure of Example 89, but using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1) instead of (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid. ¹H NMR (500 MHz, DMSO-d₆) δ 13.11 (s, 1H), 6.27 (d, J = 1.2 Hz, 1H), 5.91


(d, $J = 1.4$ Hz, 1H), 4.82 (tt, $J = 8.1, 3.9$ Hz, 1H), 4.63 (s, 2H), 3.33 (s, 2H), 1.75 - 1.42 (m, 14H). LCMS m/z 321.3 ($M+Na$)⁺ (ES^+).

Example 91 – 2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid




Example 91 was prepared according to the procedure of Example 89, but using 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6) instead of (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid. ¹H NMR (500 MHz, DMSO- d_6) δ 13.09 (s, 1H), 6.27 (d, $J = 1.3$ Hz, 1H), 5.91 (d, $J = 1.3$ Hz, 1H), 4.68 - 4.59 (m, 3H), 3.35 (s, 2H), 1.77 - 1.70 (m, 2H), 1.65 - 1.58 (m, 2H), 1.50 - 1.17 (m, 6H). LCMS m/z 293.6 ($M+Na$)⁺ (ES^+).

Example 92 – 2-((2-methylene-4-(neopentyloxy)-4-oxobutanoyl)oxy)acetic acid




Example 92 was prepared according to the procedure of Example 89, but using 2-methylene-4-(neopentyloxy)-4-oxobutanoic acid (Intermediate 10) instead of (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid. ¹H NMR (500 MHz, DMSO- d_6) δ 13.08 (s, 1H), 6.30 (d, $J = 1.2$ Hz, 1H), 5.95 (d, $J = 1.2$ Hz, 1H), 4.64 (s, 2H), 3.73 (s, 2H), 3.42 (s, 2H), 0.88 (s, 9H). LCMS m/z 280.7 ($M+Na$)⁺ (ES^+).

Example 93 – 2-((4-((4-fluorobenzyl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid



Example 93 was prepared according to the procedure of Example 89, but using 4-isopropoxy-2-methylene-4-oxobutanoic acid (Intermediate 7) instead of (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid. ¹H NMR (400 MHz, DMSO- d_6) δ 13.10 (br. s, 1H), 7.44 - 7.37 (m, 2H), 7.25 - 7.17 (m, 2H), 6.30 (d, $J = 1.2$ Hz, 1H), 5.95 (d, $J = 1.2$ Hz, 1H), 5.09 (s, 2H), 4.63 (s, 2H), 3.45 (s, 2H). LCMS m/z 297.3 ($M+H$)⁺ (ES^+).


Example 94 – 2-((4-(hexyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid



Example 94 was prepared according to the procedure of Example 89, but using 4-(hexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 3) instead of (S)-2-methylene-4-(octan-2-yloxy)-4-


oxobutanoic acid. ^1H NMR (400 MHz, DMSO- d_6) δ 13.10 (s, 1H), 6.28 (d, J = 1.2 Hz, 1H), 5.92 (d, J = 1.2 Hz, 1H), 4.63 (s, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.37 (s, 2H), 1.58 - 1.42 (m, 2H), 1.31 - 1.11 (m, 6H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 295.3 ($M+\text{Na}$) $^+$ (ES^+).

5 Example 95 – 2-((2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoyl)oxy)acetic acid



Example 95 was prepared according to the procedure of Example 89, but using 2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoic acid (Intermediate 2) instead of (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid. ^1H NMR (400 MHz, DMSO- d_6) δ 13.09 (s, 1H), 7.33 - 7.25 (m, 2H), 6.98 - 6.90 (m, 3H), 6.29 (d, J = 1.2 Hz, 1H), 5.97 - 5.90 (m, 1H), 4.62 (s, 2H), 4.19 (t, J = 6.4 Hz, 2H), 4.01 (t, J = 6.3 Hz, 2H), 3.41 (s, 2H), 2.07 - 1.97 (m, 2H). LCMS m/z 345.3 ($M+\text{Na}$) $^+$ (ES^+).

Example 96 – 2-((2-methylene-4-oxo-4-(spiro[3.3]heptan-2-yloxy)butanoyl)oxy)acetic acid



15 Step 1


N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.471 g, 2.46 mmol) was added to a solution of 3-((2-(tert-butoxy)-2-oxoethoxy)carbonyl)but-3-enoic acid (Intermediate 11, 0.400 g, 1.64 mmol), spiro[3.3]heptan-2-ol (0.220 g, 1.97 mmol) and DMAP (0.300 g, 2.46 mmol) in DCM (10 mL). The reaction mixture was stirred at RT for 18 h. The reaction mixture was concentrated and the crude product was purified by chromatography on silica gel (0-10% EtOAc/DCM) to afford impure product. The crude product was purified by chromatography on silica gel (0-10% EtOAc/isohexane) to afford 1-(2-(tert-butoxy)-2-oxoethyl) 4-spiro[3.3]heptan-2-yl 2-methylenesuccinate (146 mg, 0.41 mmol) as a pale yellow oil.

25 Step 2

TFA (1 mL) was added to a solution of 1-(2-(tert-butoxy)-2-oxoethyl) 4-spiro[3.3]heptan-2-yl 2-methylenesuccinate (146 mg, 0.41 mmol) in DCM (1 mL). The reaction mixture was stirred for 1 h, diluted with toluene (5 mL) and concentrated. The residue was taken up in EtOAc (10 mL), washed with brine (10 mL), dried (MgSO_4) and concentrated to afford the title compound (90 mg, 0.316 mmol) as a colourless oil. ^1H NMR (400 MHz, DMSO- d_6) δ 13.08 (br. s, 1H), 6.28 (d, J =

1.2 Hz, 1H), 5.91 (d, $J = 1.2$ Hz, 1H), 4.82 - 4.73 (m, 1H), 4.64 (s, 2H), 3.34 (s, 2H), 2.43 - 2.34 (m, 2H), 2.02 - 1.90 (m, 6H), 1.85 - 1.74 (m, 2H). LCMS m/z 305.3 ($M+Na$)⁺ (ES^+).

Example 97 – 2-((2-methylene-4-oxo-4-(2-tosylethoxy)butanoyl)oxy)acetic acid




Step 1

N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.447 g, 2.33 mmol) was added to a solution of 3-((2-(tert-butoxy)-2-oxoethoxy)carbonyl)but-3-enoic acid (Intermediate 11, 0.475 g, 1.95 mmol) in DCM (8 mL) 2-tosylethanol (0.47 g, 2.33 mmol), DMAP (0.024 g, 0.19 mmol) followed by DIPEA (0.41 mL, 2.33 mmol). The reaction mixture was stirred for 16 h at RT, then concentrated. The crude product was purified by chromatography on silica gel (0-10% EtOAc: DCM) to afford impure product. The crude material was purified by chromatography on RP Flash C18 (0-100% MeCN/Water 0.1% Formic Acid) to afford 1-(2-(tert-butoxy)-2-oxoethyl) 4-(2-tosylethyl) 2-methylenesuccinate (0.116 g, 0.26 mmol) as a clear colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.82 - 7.76 (m, 2H), 7.50 - 7.44 (m, 2H), 6.26 (d, $J = 1.1$ Hz, 1H), 5.84 (d, $J = 1.2$ Hz, 1H), 4.61 (s, 2H), 4.26 (t, $J = 5.9$ Hz, 2H), 3.67 (t, $J = 5.9$ Hz, 2H), 3.12 (s, 2H), 2.43 (s, 3H), 1.41 (s, 9H). LCMS m/z 449.3 ($M+Na$)⁺ (ES^+).

Step 2

TFA (0.75 mL) was added to a solution of 1-(2-(tert-butoxy)-2-oxoethyl) 4-(2-tosylethyl) 2-methylenesuccinate (0.116 g, 0.27 mmol) in DCM (0.75 mL). The reaction mixture was stirred for 2 h, diluted with toluene (10 mL) and concentrated. The residue was co-evaporated with toluene (2 x 10 mL) to afford the title compound (0.054 g, 0.14 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 13.10 (s, 1H), 7.82 - 7.75 (m, 2H), 7.50 - 7.45 (m, 2H), 6.25 (d, $J = 1.1$ Hz, 1H), 5.83 (d, $J = 1.2$ Hz, 1H), 4.64 (s, 2H), 4.26 (t, $J = 5.9$ Hz, 2H), 3.68 (t, $J = 5.9$ Hz, 2H), 3.12 (s, 2H), 2.43 (s, 3H). LCMS m/z 393.3 ($M+Na$)⁺ (ES^+).

Example 98 – 2-(N-methyl-2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetamido)acetic acid




Step 1

- 5 HATU (0.209 g, 0.55 mmol) was added to a mixture of 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetic acid (Example 49, 0.15 g, 0.50 mmol), tert-butyl 2-(methylamino)acetate hydrochloride (0.100 g, 0.549 mmol) and N-methylmorpholine (0.15 mL, 1.36 mmol) in dimethylformamide (2.5 mL). The mixture was stirred for 2 h, then 1M HCl (10 mL) was added. The mixture was extracted with EtOAc (2 x 10 mL). The combined organic phases were washed
- 10 with brine (2 x 20 mL), dried (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-5% MeOH/DCM) to afford 1-(2-((2-(tert-butoxy)-2-oxoethyl)(methyl)amino)-2-oxoethyl) 4-octyl 2-methylenesuccinate (184 mg, 0.43 mmol) as a pale yellow oil. ¹H NMR (500 MHz, DMSO-d₆) δ 6.29 (d, J = 1.2 Hz, 1H), 5.93 – 5.90 (m, 1H), 5.21 – 5.15 (m, 1H), 4.47 (ddd, J = 9.8, 6.7, 1.4 Hz, 1H), 4.17 (ddd, J = 10.7, 6.9, 1.4 Hz, 1H), 4.05 –
- 15 3.99 (m, 3H), 3.74 (dd, J = 10.8, 4.0 Hz, 1H), 3.40 (s, 2H), 1.77 (s, 3H), 1.58 – 1.50 (m, 2H), 1.32 – 1.21 (m, 10H), 0.90 – 0.84 (m, 3H). LCMS m/z 450.1 (M+Na)⁺ (ES⁺).

Step 2


- TFA (1 mL, 13 mmol) was added to a solution of 1-(2-((2-(tert-butoxy)-2-oxoethyl)(methyl)amino)-2-oxoethyl) 4-octyl 2-methylenesuccinate (184 mg, 0.43 mmol) in DCM (1 mL). The reaction
- 20 mixture was stirred for 2 h, diluted with toluene (10 mL) and concentrated. The residue was co-evaporated with toluene (2 x 5 mL) and dried *in vacuo* to afford 2-(N-methyl-2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetamido)acetic acid (123 mg, 0.33 mmol) as a colourless oil. ¹H NMR (500 MHz, DMSO-d₆, 373 K) δ 12.37 (br. s, 1H), 6.28 (s, 1H), 5.86 (t, J = 1.2 Hz, 1H), 4.86
- 25 (br m, 2H), 4.12 - 3.96 (m, 4H), 3.36 (s, 2H), 3.01 (br. m, 3H), 1.65 - 1.53 (m, 2H), 1.38 - 1.23 (m, 10H), 0.89 (t, J = 6.8 Hz, 3H). LCMS m/z 372.2 (M+H)⁺ (ES⁺).

Example 99 – (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetyl)-L-proline




Example 99 was prepared according to the procedure described in Example 98, but using L-proline tert-butyl ester instead of tert-butyl 2-(methylamino)acetate hydrochloride. ¹H NMR (500 MHz, DMSO-d₆) δ 12.55 (br. s, 1H), 6.29 - 6.25 (m, 1H), 5.93 - 5.87 (m, 1H), 4.90 - 4.76 (m, 2H), 4.58 - 4.20 (m, 1H), 4.01 (t, J = 6.6 Hz, 2H), 3.58 - 3.36 (m, 4H), 2.27 - 2.08 (m, 1H), 1.97 - 1.65 (m, 3H), 1.60 - 1.50 (m, 2H), 1.34 - 1.21 (m, 10H), 0.91 - 0.81 (m, 3H). LCMS m/z 398.2 (M+H)⁺ (ES⁺).

Example 100 – N-methyl-N-(2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)glycine




Example 100 was prepared using the same procedure as described in Example 98, but using 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoic acid (Example 79) instead of 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetic acid. ¹H NMR (500 MHz, DMSO-d₆, 363 K) δ 12.30 (br. s, 1H), 6.25 (s, 1H), 5.88 - 5.80 (m, 1H), 5.49 (s, 1H), 4.18 - 3.80 (m, 4H), 2.89 (s, 5H), 1.65 - 1.52 (m, 2H), 1.40 - 1.27 (m, 13H), 0.92 - 0.85 (m, 3H). LCMS m/z 386.2 (M+H)⁺ (ES⁺).

Example 101 – (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)-L-proline



Example 101 was prepared using the same procedure as described in Example 98, but using 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoic acid (Example 79) instead of 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetic acid, and using L-proline tert-butyl ester instead of tert-butyl 2-(methylamino)acetate hydrochloride. ¹H NMR (500 MHz, DMSO-d₆) δ 12.42 (br. s, 1H), 6.28 - 6.22 (m, 1H), 5.92 - 5.86 (m, 1H), 5.37 - 4.61 (m, 1H), 4.27 - 4.17 (m, 1H), 4.05 - 3.96 (m, 2H), 3.67 - 3.39 (m, 2H), 3.36 (s, 1H), 2.24 - 2.06 (m, 1H), 2.05 - 1.66 (m, 3H), 1.60 - 1.48 (m, 2H), 1.37 - 1.21 (m, 14H), 0.92 - 0.82 (m, 3H). LCMS m/z 412.3 (M+H)⁺ (ES⁺).

Example 102 – (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)glycine




Example 102 was prepared using the same procedure as described in Example 98, but using 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoic acid (Example 79) instead of 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetic acid, and using glycine tert-butyl ester instead of tert-butyl 2-(methylamino)acetate hydrochloride. ¹H NMR (500 MHz, DMSO-d₆) δ 12.57 (s,

1H), 8.25 (t, J = 5.9 Hz, 1H), 6.32 (d, J = 1.2 Hz, 1H), 5.89 (d, J = 1.3 Hz, 1H), 5.07 (q, J = 6.8 Hz, 1H), 4.01 (td, J = 6.6, 1.6 Hz, 2H), 3.82 - 3.71 (m, 2H), 3.46 - 3.35 (m, 2H), 1.59 - 1.50 (m, 2H), 1.36 (d, J = 6.8 Hz, 3H), 1.30 - 1.22 (m, 10H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 372.4 (M+H)⁺ (ES⁺).


5

Example 103 – N-(2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetyl)-N-methylglycine




Example 103 was prepared using the same procedure as described in Example 98, but using 2-
 10 ((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (Example 90) instead of 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetic acid. ¹H NMR (500 MHz, DMSO-d₆, 363 K) δ 12.70 (s, 1H), 6.27 - 6.23 (m, 1H), 5.89 - 5.83 (m, 1H), 4.94 - 4.75 (m, 3H), 4.15 - 3.96 (m, 2H), 3.33 (s, 2H), 3.01 - 2.79 (m, 3H), 1.77 - 1.40 (m, 14H). LCMS m/z 392.2 (M+H)⁺ (ES⁺).

15 **Example 104 – (2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetyl)-L-proline**




Example 104 was prepared using the same procedure as described in Example 98, but using 2-
 ((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (Example 90) instead of 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetic acid, and using L-proline tert-butyl ester instead
 20 of tert-butyl 2-(methylamino)acetate hydrochloride. ¹H NMR (500 MHz, DMSO-d₆, 363 K) δ 12.47 (s, 1H), 6.27 - 6.23 (m, 1H), 5.91 - 5.84 (m, 1H), 4.91 - 4.57 (m, 3H), 4.54 - 4.17 (m, 1H), 3.57 - 3.36 (m, 3H), 2.23 - 1.80 (m, 5H), 1.76 - 1.43 (m, 14H). LCMS m/z 418.2 (M+Na)⁺ (ES⁺).


Example 105 – (S)-N-methyl-N-(2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetyl)glycine




Example 105 was prepared using the same procedure as described in Example 98, but using (S)-
 2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid (Example 89) instead of 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetic acid. ¹H NMR (500 MHz, DMSO-d₆, 363 K) δ
 30 6.28 (s, 1H), 5.85 (d, J = 1.3 Hz, 1H), 4.93 - 4.74 (br. m, 3H), 4.03 (br. s, 2H), 3.33 (s, 2H), 3.08 - 2.83 (br. m, 3H), 1.59 - 1.43 (m, 2H), 1.35 - 1.24 (m, 8H), 1.17 (d, J = 6.3 Hz, 3H), 0.89 (t, J = 6.7 Hz, 3H), 1 exchangeable proton not visible. LCMS m/z 394.4 (M+Na)⁺ (ES⁺).

Example 106 – (S)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetyl)glycine


Example 106 was prepared using the same procedure as described in Example 98, but using (S)-
 5 2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid (Example 89) instead of 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetic acid, and using glycine tert-butyl ester instead of tert-butyl 2-(methylamino)acetate hydrochloride. ¹H NMR (500 MHz, DMSO-d₆) δ 8.30 (t, J = 5.7 Hz, 1H), 6.34 (d, J = 1.2 Hz, 1H), 5.91 (d, J = 1.4 Hz, 1H), 4.84 - 4.74 (m, 1H), 4.59 (s, 2H), 3.80 (d, J = 5.8 Hz, 2H), 3.38 (s, 2H), 1.56 - 1.39 (m, 2H), 1.25 (d, J = 10.8 Hz, 8H), 1.14 (d, J =
 10 6.2 Hz, 3H), 0.86 (t, J = 6.8 Hz, 3H), 1 exchangeable proton not visible. LCMS m/z 380.3 (M+Na)⁺ (ES⁺).

Example 107 – 1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl) 4-octyl 2-methylenesuccinate


HATU (0.139 g, 0.37 mmol) was added to a mixture of 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetic acid (Example 49, 0.10 g, 0.33 mmol), 1-methylpiperazine (0.041 mL, 0.37 mmol) and N-methylmorpholine (0.1 mL, 0.91 mmol) in dimethylformamide (2.5 mL). The mixture was stirred for 2 h, then sat. aq. NH₄Cl (10 mL) was added. The mixture was extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with brine (2 x 20 mL), dried
 20 (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-10% MeOH/DCM) to afford the title compound (70 mg, 0.174 mmol) as a pale yellow oil. ¹H NMR (500 MHz, DMSO-d₆) δ 6.27 (d, J = 1.3 Hz, 1H), 5.90 (q, J = 1.2 Hz, 1H), 4.86 (s, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.46 - 3.34 (m, 6H), 2.34 - 2.24 (m, 4H), 2.19 (s, 3H), 1.59 - 1.51 (m, 2H), 1.26 (m, 10H), 0.89 - 0.83 (m, 3H). LCMS m/z 383.2 (M+H)⁺ (ES⁺).

Example 108 – 1-(3-morpholino-3-oxopropyl) 4-octyl 2-methylenesuccinate


Example 108 was prepared using the same procedure as described in Example 107, but using morpholine instead of 1-methylpiperazine. ¹H NMR (500 MHz, DMSO-d₆) δ 6.16 (d, J = 1.4 Hz, 1H), 5.82 (t, J = 1.3 Hz, 1H), 4.29 (t, J = 6.6 Hz, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.55 (dt, J = 12.8, 4.9 Hz, 4H), 3.46 - 3.40 (m, 4H), 3.33 (s, 2H), 2.73 - 2.67 (m, 2H), 1.57 - 1.49 (m, 2H), 1.31 - 1.22 (m, 10H), 0.86 (t, J = 6.9 Hz, 3H). LCMS m/z 384.3 (M+H)⁺ (ES⁺).

Example 109 – 1-(3-(diethylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate


Example 109 was prepared using the same procedure as described in Example 107, but using diethylamine instead of 1-methylpiperazine. ¹H NMR (500 MHz, DMSO-d₆) δ 6.15 (d, J = 1.4 Hz, 1H), 5.82 (d, J = 1.4 Hz, 1H), 4.30 (t, J = 6.5 Hz, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.33 (s, 2H), 3.30 - 3.24 (m, 4H), 2.65 (t, J = 6.5 Hz, 2H), 1.59 - 1.46 (m, 2H), 1.31 - 1.21 (m, 10H), 1.10 (t, J = 7.1 Hz, 3H), 1.01 (t, J = 7.1 Hz, 3H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 370.3 (M+H)⁺ (ES⁺).

Example 110 – 1-(3-(methylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate

Example 110 was prepared using the same procedure as described in Example 107, but using methylamine instead of 1-methylpiperazine. ¹H NMR (500 MHz, DMSO-d₆) δ 7.86 (d, J = 4.6 Hz, 1H), 6.15 (d, J = 1.4 Hz, 1H), 5.81 (d, J = 1.4 Hz, 1H), 4.25 (t, J = 6.4 Hz, 2H), 3.99 (t, J = 6.6 Hz, 2H), 3.32 (s, 2H), 2.57 (d, J = 4.6 Hz, 3H), 2.42 (t, J = 6.4 Hz, 2H), 1.57 - 1.47 (m, 2H), 1.31 - 1.18 (m, 10H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 350.3 (M+Na)⁺ (ES⁺).

Example 111 – 2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid

Example 111 was prepared using the same procedure as described in Example 79, but using 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6) instead of 4-octyl itaconate. ¹H NMR (400 MHz, DMSO-d₆) δ 13.03 (s, 1H), 6.26 (d, J = 1.3 Hz, 1H), 5.89 (d, J = 1.3 Hz, 1H), 4.96 (q, J = 7.0 Hz, 1H), 4.65 (dq, J = 8.6, 4.0 Hz, 1H), 3.40 - 3.29 (m, 2H), 1.80 - 1.70 (m, 2H), 1.64 (ddd, J = 13.0, 6.9, 3.9 Hz, 2H), 1.42 (d, J = 7.1 Hz, 3H), 1.52 - 1.19 (m, 6H). LCMS m/z 307.6 (M+Na)⁺ (ES⁺).

Example 112 – (R)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid


Example 112 was prepared according to the procedure of Example 89, but using (R)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 8) instead of (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid. ¹H NMR (400 MHz, DMSO-d₆) δ 13.09 (s, 1H), 6.28 (d, J = 1.2 Hz, 1H), 5.92 (d, J = 1.2 Hz, 1H), 4.84 - 4.74 (m, 1H), 4.64 (s, 2H), 3.35 (s, 2H), 1.58 - 1.39

(m, 2H), 1.31 - 1.18 (m, 8H), 1.14 (d, J = 6.3 Hz, 3H), 0.91 - 0.82 (m, 3H). LCMS m/z 323.0 (M+Na)⁺ (ES⁺).

The sodium salt of Example 112 was made as follows:


5

Example 112a: (*R*)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid sodium salt




To a solution of (*R*)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid (1.0 g, 3.3 mmol) in MeCN (10 mL) was added a solution of NaHCO₃ in water (0.5 M, 6.27 mL, 3.14 mmol), and the mixture was stirred at room temperature for 10 min. The mixture was then concentrated under reduced pressure at 30 °C to remove the MeCN, and the remaining aqueous solution was washed with MTBE. The aqueous solution was then concentrated under reduced pressure at 30 °C to remove residual dissolved MTBE, and finally lyophilized to give (*R*)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid sodium salt (1.0 g, 3.1 mmol, 94 % yield) as a white solid. LCMS (System 2, Method B) m/z 323.2 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 6.18 (d, J = 0.8 Hz, 1H), 5.75 (d, J = 0.8 Hz, 1H), 4.82-4.74 (m, 1H), 4.14 (d, J = 1.2 Hz, 2H), 3.25 (s, 2H), 1.52-1.38 (m, 2H), 1.27-1.23 (m, 8H), 1.13 (d, J = 6.4 Hz, 3H), 0.85 (t, J = 6.4 Hz, 3H).

Example 113 – 2-((4-((4,4-difluorocyclohexyl)methoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid



Example 113 was prepared according to the procedure of Example 96, but using 4,4-difluorocyclohexanol instead of spiro[3.3]heptan-2-ol. ¹H NMR (400 MHz, DMSO-d₆) δ 13.08 (s, 1H), 6.30 (d, J = 1.2 Hz, 1H), 5.94 (d, J = 1.3 Hz, 1H), 4.65 (s, 2H), 3.92 (d, J = 6.1 Hz, 2H), 3.41 (s, 2H), 2.07 - 1.93 (m, 2H), 1.89 - 1.68 (m, 5H), 1.28 - 1.14 (m, 2H). LCMS m/z 319.1 (M-H)⁻ (ES⁻).


25

Example 114 – 2-((4-(3-ethoxypropoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid**Step 1**

EDC.HCl (0.371 g, 1.935 mmol) was added to a solution of 3-((2-(tert-butoxy)-2-oxoethoxy)carbonyl)but-3-enoic acid (Intermediate 11, 0.35 g, 1.29 mmol), 3-ethoxypropan-1-ol (0.18 mL, 1.56 mmol), DMAP (0.016 g, 0.13 mmol) and DIPEA (0.34 mL, 1.95 mmol) in DCM (10 mL). The reaction mixture was stirred at RT for 18 h. The reaction mixture was diluted with water (50 mL) and extracted with DCM (3 x 20 mL). The organic layers were combined and passed through a phase separator and concentrated *in vacuo*. The crude product was purified by chromatography on silica gel (0-10% EtOAc/DCM) to afford impure product. The crude product was purified by chromatography on silica gel (0-20% EtOAc/DCM) to afford 1-(2-(tert-butoxy)-2-oxoethyl) 4-(3-ethoxypropyl) 2-methylenesuccinate (260 mg, 0.71 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 6.30 (d, J = 1.2 Hz, 1H), 5.95 - 5.92 (m, 1H), 4.62 (s, 2H), 4.07 (t, J = 6.5 Hz, 2H), 3.43 - 3.35 (m, 6H), 1.82 - 1.71 (m, 2H), 1.42 (s, 9H), 1.10 (t, J = 7.0 Hz, 3H). LCMS m/z 353.3 (M+Na)⁺ (ES⁺).

Step 2


TFA (2.5 mL) was added to a solution of 1-(2-(tert-butoxy)-2-oxoethyl) 4-(3-ethoxypropyl) 2-methylenesuccinate (260 mg, 0.71 mmol) in DCM (2.5 mL). The reaction mixture was stirred for 2 h, then concentrated. The crude product was purified by chromatography on RP Flash C18 (5-75% MeCN/Water 0.1% Formic Acid) followed by chromatography on silica gel (0-10% MeOH/DCM) to afford the title compound (0.015 g, 0.052 mmol) as a clear and colourless gum. ¹H NMR (400 MHz, DMSO-d₆) δ 6.21 (d, J = 1.5 Hz, 1H), 5.82 - 5.77 (m, 1H), 4.20 (s, 2H), 4.06 (t, J = 6.5 Hz, 2H), 3.45 - 3.36 (m, 4H), 3.34 (s, 2H), 1.82 - 1.71 (m, 2H), 1.10 (t, J = 7.0 Hz, 3H). LCMS m/z 275.3 (M+H)⁺ (ES⁺).

Example 115 – 2-((4-(bicyclo[2.2.1]heptan-2-yloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid

Example 115 was prepared according to the procedure of Example 114, but using bicyclo[2.2.1]heptan-2-ol instead of 3-ethoxypropan-1-ol. ¹H NMR (400 MHz, DMSO-d₆) δ 13.10


(s, 1H), 6.27 (d, J = 1.2 Hz, 1H), 5.96 - 5.86 (m, 1H), 4.64 (s, 2H), 4.55 - 4.47 (m, 1H), 3.33 (s, 2H), 2.29 - 2.17 (m, 2H), 1.69 - 1.61 (m, 1H), 1.52 - 1.29 (m, 4H), 1.16 - 1.03 (m, 3H). LCMS m/z 305.2 (M+Na)⁺ (ES⁺).

5 Example 116 – 2-((4-cyclobutoxy-2-methylene-4-oxobutanoyl)oxy)acetic acid



Example 116 was prepared according to the procedure of Example 114, but using cyclobutanol instead of 3-ethoxypropan-1-ol. ¹H NMR (400 MHz, DMSO-d₆) δ 13.08 (s, 1H), 6.29 (s, 1H), 5.92 (d, J = 1.5 Hz, 1H), 4.89 (p, J = 7.4 Hz, 1H), 4.65 (s, 2H), 3.36 (s, 2H), 2.30 - 2.19 (m, 2H), 2.06 - 1.92 (m, 2H), 1.79 - 1.68 (m, 1H), 1.65 - 1.50 (m, 1H). LCMS m/z 265.1 (M+Na)⁺ (ES⁺).

Example 117 – 3-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)-2,2-dimethylpropanoic acid



15 Step 1

1-(chloromethyl)-4-methoxybenzene (1 mL, 7.4 mmol) was added to a mixture of 3-hydroxy-2,2-dimethylpropanoic acid (1.00 g, 8.47 mmol) and cesium carbonate (2.76 g, 8.47 mmol) in dimethylformamide (40 mL). The mixture was stirred at RT for 3 h, then heated to 70 °C for 2 h, then cooled to RT and stirred for 18 h. The mixture was poured onto water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with brine (100 mL), dried (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-50% EtOAc/isohexane) to afford 4-methoxybenzyl 3-hydroxy-2,2-dimethylpropanoate (1.45 g, 5.78 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.32 - 7.27 (m, 2H), 6.97 - 6.90 (m, 2H), 5.01 (s, 2H), 4.85 (t, J = 5.5 Hz, 1H), 3.76 (s, 3H), 3.42 (d, J = 5.5 Hz, 2H), 1.08 (s, 6H).

25

Step 2

EDC·HCl (0.248 g, 1.30 mmol) was added to a solution of 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6, 250 mg, 1.18 mmol), 4-methoxybenzyl 3-hydroxy-2,2-dimethylpropanoate (337 mg, 1.41 mmol), DMAP (0.014 g, 0.12 mmol) and DIPEA (0.31 mL, 1.77 mmol) in DCM (5 mL). The reaction mixture was stirred at RT for 18 h. The reaction mixture was diluted with 1 M HCl (30 mL). The phases were separated and the aqueous phase was extracted with DCM (10 mL). The combined organic phases were washed with brine (30 mL), dried (MgSO₄)

30

and concentrated. The crude product was purified by chromatography on silica gel (0-30% EtOAc/isohexane) to afford 4-cyclohexyl 1-(3-((4-methoxybenzyl)oxy)-2,2-dimethyl-3-oxopropyl) 2-methylenesuccinate (213 mg, 0.47 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.31 - 7.24 (m, 2H), 6.94 - 6.89 (m, 2H), 6.08 (d, J = 1.4 Hz, 1H), 5.78 (d, J = 1.3 Hz, 1H), 5.04 (s, 2H), 4.68 - 4.61 (m, 1H), 4.11 (s, 2H), 3.75 (s, 3H), 3.28 (s, 2H), 1.78 - 1.70 (m, 2H), 1.66 - 1.57 (m, 2H), 1.51 - 1.41 (m, 1H), 1.40 - 1.21 (m, 5H), 1.17 (s, 6H).

Step 3

TFA (1.5 mL) was added to a solution of 4-cyclohexyl 1-(3-((4-methoxybenzyl)oxy)-2,2-dimethyl-3-oxopropyl) 2-methylenesuccinate (213 mg, 0.47 mmol) in DCM (3 mL). The reaction mixture was stirred for 1 h, diluted with toluene (5 mL) and concentrated. The crude product was purified by chromatography on silica gel (0-60% EtOAc/isohexane) to afford the title compound (87 mg, 0.28 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 12.45 (s, 1H), 6.18 (d, J = 1.4 Hz, 1H), 5.83 (d, J = 1.3 Hz, 1H), 4.65 (td, J = 8.5, 3.9 Hz, 1H), 4.08 (s, 2H), 3.33 (s, 2H), 1.80 - 1.70 (m, 2H), 1.69 - 1.57 (m, 2H), 1.52 - 1.17 (m, 6H), 1.14 (s, 6H). LCMS m/z 335.3 (M+Na)⁺ (ES⁺).

Example 118 – 1-(2-((N,N-dimethylsulfamoyl)amino)-2-oxoethyl) 4-hexyl 2-methylenesuccinate



To a solution of 2-((4-(hexyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (Example 94, 498 mg, 1.83 mmol) in DCM (13 mL), was added HATU (696 mg, 1.83 mmol), DIPEA (0.64 mL, 3.66 mmol), followed by dimethylsulfamide (273 mg, 2.20 mmol). The resulting solution was stirred at RT for 16 h. Water (50 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (50 mL), dried (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isohexane) to afford the title compound (221 mg, 0.53 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 11.70 (s, 1H), 6.29 (d, J = 1.2 Hz, 1H), 5.93 (d, J = 1.2 Hz, 1H), 4.68 (s, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.38 (s, 2H), 2.79 (s, 6H), 1.59 - 1.47 (m, 2H), 1.33 - 1.15 (m, 6H), 0.86 (t, J = 6.4 Hz, 3H). LCMS m/z 401.4 (M+Na)⁺ (ES⁺).


Example 119 – 4-hexyl 1-(2-(methylsulfonamido)-2-oxoethyl) 2-methylenesuccinate



To a solution of 2-((4-(hexyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (Example 94, 477 mg, 1.75 mmol) in DCM (13 mL), was added HATU (666 mg, 1.75 mmol), DIPEA (0.61 mL, 3.50


mmol), followed by methanesulfonamide (200 mg, 2.10 mmol). The resulting solution was stirred at RT for 72 h. Water (50 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (50 mL), dried (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isohexane) to afford the title compound (221 mg, 0.53 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 12.06 (s, 1H), 6.30 (d, J = 1.2 Hz, 1H), 5.94 (d, J = 1.2 Hz, 1H), 4.70 (s, 2H), 4.01 (t, J = 6.6 Hz, 2H), 3.39 (s, 2H), 3.24 (s, 3H), 1.58 - 1.45 (m, 2H), 1.33 - 1.19 (m, 6H), 0.86 (t, J = 6.2 Hz, 3H). LCMS m/z 372.3 (M+Na)⁺ (ES⁺).

10 Example 120 – 4-hexyl 1-(3-(methylsulfonamido)-2-oxoethyl) 2-methylenesuccinate



Example 120 was prepared according to the procedure of Example 119, but using 3-((4-(hexyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid (Example 85) instead of 2-((4-(hexyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid. ¹H NMR (400 MHz, DMSO-d₆) δ 11.83 (s, 1H), 6.17 (d, J = 1.4 Hz, 1H), 5.83 (d, J = 1.2 Hz, 1H), 4.28 (t, J = 6.1 Hz, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.33 (s, 2H), 3.22 (s, 3H), 2.65 (t, J = 6.1 Hz, 2H), 1.58 - 1.49 (m, 2H), 1.34 - 1.18 (m, 6H), 0.86 (t, J = 6.0 Hz, 3H). LCMS m/z 386.3 (M+H)⁺ (ES⁺).

20 Example 121 – 2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)-3,3,3-trifluoropropanoic acid



Step 1

1-(chloromethyl)-4-methoxybenzene (0.90 mL, 6.64 mmol) was added to a mixture of 3,3,3-trifluoro-2-hydroxypropanoic acid (1.00 g, 6.94 mmol) and cesium carbonate (2.26 g, 6.94 mmol) in dimethylformamide (30 mL). The mixture was stirred at RT for 3 h, then heated to 70 °C for 2 h, then cooled to RT and stirred for 18 h. The mixture was poured onto water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with brine (100 mL), dried (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-50% EtOAc/isohexane) to afford 4-methoxybenzyl 3,3,3-trifluoro-2-hydroxypropanoate (640 mg, 2.30 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ

7.36 – 7.30 (m, 2H), 7.14 (d, J = 7.4 Hz, 1H), 7.00 – 6.91 (m, 2H), 5.22 – 5.14 (m, 2H), 4.92 – 4.83 (m, 1H), 3.76 (s, 3H).


Step 2

5 EDC.HCl (0.348 g, 1.81 mmol) was added to a solution of 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6, 0.35 g, 1.65 mmol), 4-methoxybenzyl 3,3,3-trifluoro-2-hydroxypropanoate (0.523 g, 1.98 mmol), DMAP (0.020 g, 0.17 mmol) and DIPEA (0.43 mL, 2.47 mmol) in DCM (8 mL) at 0 °C. The reaction mixture was allowed to warm to RT and stirred for 72 h. The reaction mixture was diluted with 1 M HCl (30 mL). The phases were separated and the
10 aqueous phase was extracted with DCM (10 mL). The combined organic phases were washed with brine (30 mL), dried (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-20% EtOAc/isohehexane) to afford 4-cyclohexyl 1-(1,1,1-trifluoro-3-((4-methoxybenzyl)oxy)-3-oxopropan-2-yl) 2-methylenesuccinate (302 mg, 0.593 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.34 - 7.29 (m, 2H), 6.98 - 6.92 (m, 2H), 6.36 (d, J = 0.9 Hz, 1H), 6.15 (q, J = 7.3 Hz, 1H), 6.06 (d, J = 1.1 Hz, 1H), 5.23 (s, 2H), 4.70 - 4.61 (m, 1H), 3.76 (s, 3H), 3.41 (s, 2H), 1.79 - 1.71 (m, 2H), 1.68 - 1.59 (m, 2H), 1.54 - 1.42 (m, 1H), 1.41 - 1.21 (m, 5H). LCMS m/z 481.3 (M+Na)⁺ (ES⁺).


Step 3

20 TFA (1 mL) was added to a solution of 4-cyclohexyl 1-(1,1,1-trifluoro-3-((4-methoxybenzyl)oxy)-3-oxopropan-2-yl) 2-methylenesuccinate (302 mg, 0.659 mmol) in DCM (2 mL). The reaction mixture was stirred for 1 h, diluted with toluene (5 mL) and concentrated. The crude product was purified by chromatography on silica gel (0-60% EtOAc/isohehexane) to afford the title compound
25 (38 mg, 0.107 mmol, 16.20 % yield) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 14.49 (br. s, 1H), 6.35 (d, J = 0.9 Hz, 1H), 6.04 (d, J = 1.1 Hz, 1H), 5.87 (q, J = 7.6 Hz, 1H), 4.70 - 4.60 (m, 1H), 3.47 - 3.35 (m, 2H), 1.80 - 1.71 (m, 2H), 1.69 - 1.58 (m, 2H), 1.52 - 1.43 (m, 1H), 1.42 - 1.18 (m, 5H). LCMS m/z 337.2 (M-H)⁻ (ES⁻).

30 **Example 122 – 2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)-3,3,3-trifluoropropanoic acid**



Example 122 was prepared according to the procedure of Example 121, but using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1) instead of 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid. ¹H NMR (400 MHz, DMSO-d₆) δ 14.47 (s, 1H), 6.34 (s, 1H), 6.03 (s, 1H), 5.86 (q, J = 7.6 Hz, 1H), 4.82 (tt, J = 8.2, 4.0 Hz, 1H), 3.37 (d, J = 2.1 Hz, 2H), 1.80 - 1.32 (m, 12H). LCMS m/z 390.0 (M+H)⁺ (ES⁺).

Example 123 – (E)-4-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)but-2-enoic acidStep 1

- 5 DCC (1.87 g, 9.06 mmol) was added to a stirred solution of (E)-4-bromobut-2-enoic acid (1.00 g, 6.06 mmol), 4-methoxybenzyl alcohol (0.90 mL, 7.2 mmol) and DMAP (0.074 g, 0.61 mmol) in DCM (30 mL) at 0 °C. The mixture was allowed to warm to RT and stirred for 18 h. The precipitate was removed by filtration and the filtrate concentrated. The crude product was purified by chromatography on silica gel (0-100% DCM/isohexane) to afford (E)-4-methoxybenzyl 4-bromobut-2-enoate (1.07 g, 3.49 mmol) as a colourless gum. ¹H NMR (400 MHz, DMSO-d₆) δ 7.37 – 7.30 (m, 2H), 7.00 – 6.88 (m, 3H), 6.23 – 6.15 (m, 1H), 5.10 (s, 2H), 4.32 – 4.23 (m, 2H), 3.76 (s, 3H).

Step 2

- 15 (E)-4-methoxybenzyl 4-bromobut-2-enoate (1.00 g, 3.26 mmol) was added to a mixture of 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6, 0.923 g, 3.91 mmol) and potassium carbonate (0.586 g, 4.24 mmol) in acetone (20 mL). The reaction mixture was stirred for 20 h at RT then concentrated *in vacuo*. The residue was taken up in EtOAc (80 mL), then washed with a saturated solution of NaHCO₃ (3 x 50 mL). The organic layer was dried (phase separator) and concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isohexane) to afford (E)-4-cyclohexyl 1-(4-((4-methoxybenzyl)oxy)-4-oxobut-2-en-1-yl) 2-methylenesuccinate (1.57 g, 3.26 mmol, 85% purity) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.33 (d, J = 8.2 Hz, 2H), 6.99 - 6.88 (m, 3H), 6.28 (s, 1H), 6.06 - 5.97 (m, 1H), 5.88 (s, 1H), 5.10 (s, 2H), 4.87 - 4.81 (m, 2H), 4.69 - 4.59 (m, 1H), 3.76 (s, 3H), 3.39 (s, 2H), 1.76 - 1.65 (m, 2H), 1.62 - 1.52 (m, 2H), 1.48 - 1.39 (m, 1H), 1.38 - 1.14 (m, 5H). LCMS m/z 439.3 (M+Na)⁺ (ES⁺).


Step 3

- 30 TFA (0.8 mL, 10.4 mmol) was added dropwise to a solution of (E)-4-cyclohexyl 1-(4-((4-methoxybenzyl)oxy)-4-oxobut-2-en-1-yl) 2-methylenesuccinate (1.57 g, 3.26 mmol) in DCM (30 mL) at 0 °C. The mixture was warmed to RT and stirred for 20 h, then concentrated *in vacuo*. The crude product was purified by chromatography on RP Flash C18 (5-75% MeCN/Water 0.1%

Formic Acid) to afford the title compound (0.54 g, 1.73 mmol) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 12.47 (s, br. 1H), 6.88 - 6.78 (m, 1H), 6.28 (d, J = 1.2 Hz, 1H), 5.96 - 5.90 (m, 1H), 5.90 - 5.88 (m, 1H), 4.84 - 4.80 (m, 2H), 4.70 - 4.62 (m, 1H), 3.39 (s, 2H), 1.81 - 1.69 (m, 2H), 1.68 - 1.57 (m, 2H), 1.51 - 1.42 (m, 1H), 1.41 - 1.16 (m, 5H). LCMS m/z 297.3 ($\text{M}+\text{H}$) $^+$ (ES^+).

5

Example 124 – 3-((2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)ethyl)sulfonyl)propanoic acid



Step 1

Tert-butyl acrylate (4.50 mL, 30.7 mmol) was added dropwise to a mixture of 2-mercaptoethanol (1.79 mL, 25.6 mmol) and potassium carbonate (0.177 g, 1.28 mmol) in DCM (24 mL) at 0 °C. The reaction mixture was warmed to RT and stirred for 48 h. The reaction was quenched with sat. aq. NH_4Cl (100 mL) and the aqueous layer was extracted with DCM (3 x 50 mL). The combined organic layers were passed through a hydrophobic phase separator and concentrated. The crude product was purified by chromatography on silica gel (0-10% MeOH/DCM) to afford tert-butyl 3-((2-hydroxyethyl)thio)propanoate (5.80 g, 23.3 mmol, 91 % yield) as a colourless oil. ^1H NMR (400 MHz, DMSO- d_6) δ 4.75 (t, J = 5.5 Hz, 1H), 3.56 - 3.46 (m, 2H), 2.68 (t, J = 6.7 Hz, 2H), 2.56 (t, J = 6.9 Hz, 2H), 2.50 - 2.44 (m, 2H), 1.40 (s, 9H). LCMS m/z 229.2 ($\text{M}+\text{Na}$) $^+$ (ES^+).

20

Step 2

3-Chlorobenzoperoxoic acid ((mCPBA) 8.15 g, 36.4 mmol) was added portionwise to a solution of tert-butyl 3-((2-hydroxyethyl)thio)propanoate (3.00 g, 14.5 mmol) in DCM (100 mL) at 0 °C. The mixture was warmed to RT and stirred for 20 h. The reaction was cooled to 0 °C and quenched with sat. aq. NaHCO_3 (300 mL). The aqueous layer was extracted with DCM (3 x 80 mL). The combined organic layers were washed with sat. aq. $\text{Na}_2\text{S}_2\text{O}_5$ (120 mL), passed through a hydrophobic phase separator and concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isohexane) to afford tert-butyl 3-((2-hydroxyethyl)sulfonyl)propanoate (1.60 g, 6.18 mmol) as a colourless oil. ^1H NMR (400 MHz, DMSO- d_6) δ 5.13 (t, J = 5.0 Hz, 1H), 3.78 (q, J = 5.4 Hz, 2H), 3.38 - 3.32 (m, 2H), 3.24 (t, J = 5.7 Hz, 2H), 2.65 (t, J = 7.5 Hz, 2H), 1.41 (d, J = 1.2 Hz, 9H).


30

Step 3

EDC.HCl (1.20 g, 6.3 mmol) was added to a solution of 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6, 663 mg, 3.12 mmol), tert-butyl 3-((2-hydroxyethyl)sulfonyl)propanoate (809 mg, 3.12 mmol), DMAP (38 mg, 0.31 mmol) and DIPEA (1.1 mL, 6.3 mmol) in DCM (16 mL). The mixture was stirred at RT for 20 h. The reaction mixture was concentrated onto silica and purified by chromatography on silica gel (0-30% EtOAc/isohexane) to afford 1-(2-((3-(tert-butoxy)-3-oxopropyl)sulfonyl)ethyl) 4-cyclohexyl 2-methylenesuccinate (405 mg, 0.84 mmol, 90% purity) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 6.22 (d, J = 1.3 Hz, 1H), 5.88 (d, J = 1.2 Hz, 1H), 4.71 - 4.56 (m, 1H), 4.44 (t, J = 6.2, 5.2, 4.4 Hz, 2H), 3.57 (t, J = 5.7 Hz, 2H), 3.41 - 3.32 (m, 4H), 2.67 (t, J = 7.5 Hz, 2H), 1.80 - 1.68 (m, 2H), 1.66 - 1.58 (m, 2H), 1.53 - 1.09 (m, 15H). LCMS m/z 455.3 (M+Na)⁺ (ES⁺).

Step 4

TFA (3.0 mL, 39 mmol) was added to a solution of 1-(2-((3-(tert-butoxy)-3-oxopropyl)sulfonyl)ethyl) 4-cyclohexyl 2-methylenesuccinate (405 mg, 0.84 mmol) in DCM (3 mL) at RT. The mixture was stirred for 1 h, diluted with toluene (20 mL) and concentrated. The residue was taken up in EtOAc (50 mL), washed with brine (20 mL), dried (MgSO₄) and concentrated to afford the title compound (278 mg, 0.716 mmol) as a yellow gum. ¹H NMR (400 MHz, DMSO-d₆) δ 6.23 (d, J = 1.2 Hz, 1H), 5.87 (d, J = 1.3 Hz, 1H), 4.69 - 4.61 (m, 1H), 4.44 (t, J = 5.7 Hz, 2H), 3.58 (t, J = 5.7 Hz, 2H), 3.45 - 3.32 (m, 4H), 2.68 (t, J = 7.5 Hz, 2H), 1.79 - 1.71 (m, 2H), 1.66 - 1.55 (m, 2H), 1.50 - 1.16 (m, 6H) (1 exchangeable proton not visible). LCMS m/z 375.3 (M+Na)⁺ (ES⁺).

Example 125 – 1-((2H-tetrazol-5-yl)methyl) 4-cyclohexyl 2-methylenesuccinateStep 1

To a solution of (2H-tetrazol-5-yl)methanol (0.50 g, 5.0 mmol) in DCM (10 mL) and DMF (2.5 mL) were added triethylamine (0.78 mL, 5.6 mmol) and trityl chloride (1.39 g, 5.00 mmol). The resulting mixture was stirred at RT for 1 h, diluted with water (50 mL), and extracted with DCM (3 x 40 mL). The combined organic phases were dried (phase separator) and concentrated. The crude product

was purified by chromatography on silica gel (0-50% EtOAc/isohexane) to afford (2-trityl-2H-tetrazol-5-yl)methanol (1.40 g, 3.76 mmol) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 7.48 – 7.33 (m, 10H), 7.09 – 6.95 (m, 5H), 5.66 (t, J = 6.0 Hz, 1H), 4.71 (d, J = 5.9 Hz, 2H).

5 Step 2

DCC (0.583 g, 2.83 mmol) was added to a stirred solution of 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6, 0.400 g, 1.88 mmol), (2-trityl-2H-tetrazol-5-yl)methanol (0.772 g, 2.07 mmol) and DMAP (0.023 g, 0.19 mmol) in DCM (12 mL) at 0 °C. The mixture was warmed to RT and stirred for 18 h. The precipitate was removed by filtration and filtrate was concentrated.

10 The crude product was purified by chromatography on silica gel (0-50% EtOAc/isohexane) to afford 4-cyclohexyl 1-((2-trityl-2H-tetrazol-5-yl)methyl) 2-methylenesuccinate (0.16 g, 0.27 mmol) as a colourless gum. ^1H NMR (400 MHz, DMSO- d_6) δ 7.41 (m, 10H), 7.04 - 6.98 (m, 5H), 6.22 (d, J = 1.2 Hz, 1H), 5.90 - 5.86 (m, 1H), 5.46 (s, 2H), 4.58 (m, 1H), 3.32 (s, 2H), 1.60 (m, 5H), 1.48 - 1.35 (m, 1H), 1.32 - 1.08 (m, 4H). LCMS m/z 559.2 ($M+\text{Na}$) $^+$ (ES^+).


15

Step 3

TFA (0.55 mL, 7.1 mmol) was added dropwise to a solution of 4-cyclohexyl 1-((2-trityl-2H-tetrazol-5-yl)methyl) 2-methylenesuccinate (0.16 g, 0.27 mmol) in DCM (3 mL) at 0 °C. The mixture was stirred at RT for 20 h, before 4 N HCl in 1,4-dioxane (0.2 mL, 0.8 mmol) was added and the reaction mixture stirred for a further 18 h then concentrated. The crude product was purified by chromatography on RP Flash C18 (5-75% MeCN/Water 0.1% Formic Acid) to afford the title compound as a colourless gum. ^1H NMR (400 MHz, DMSO- d_6) δ 6.31 (d, J = 1.2 Hz, 1H), 5.95 - 5.90 (m, 1H), 5.49 (s, 2H), 4.70 - 4.53 (m, 1H), 3.38 (s, 2H), 1.74 - 1.52 (m, 4H), 1.51 - 1.39 (m, 1H), 1.35 - 1.16 (m, 5H) (1 exchangeable proton not visible). LCMS m/z 295.2 ($M+\text{H}$) $^+$ (ES^+).

25

Example 126 – 2-((3-((2-((3-chlorophenyl)sulfonyl)ethoxy)carbonyl)but-3-enoyl)oxy)acetic acid



Step 1

A mixture of (4-methoxyphenyl)methanol (17.3 g, 125 mmol) and itaconic anhydride (16.8 g, 150 mmol) in toluene/iso-hexane (1:1, 300 mL) was heated at 70 °C for 16 h. The mixture was cooled to RT and the precipitate was filtered. The solid was taken up in EtOAc (200 mL) and washed with water (3 x 100 mL), brine (100 mL), dried (MgSO₄) and concentrated. The crude product was recrystallized from a mixture of toluene/iso-hexane (200 mL/200 mL) to afford 4-((4-methoxybenzyl)oxy)-2-methylene-4-oxobutanoic acid (19.1 g, 73.4 mmol) as a colourless solid. ¹H NMR (400 MHz, DMSO-d₆) δ 12.63 (s, 1H), 7.29 (d, J = 8.7 Hz, 2H), 6.92 (d, J = 8.6 Hz, 2H), 6.16 (d, J = 1.6 Hz, 1H), 5.77 (d, J = 1.4 Hz, 1H), 5.02 (s, 2H), 3.76 (s, 3H), 3.34 (s, 2H). LCMS m/z 272.9 (M+Na)⁺ (ES⁺).

Step 2

A slurry of EDC.HCl (0.920 g, 4.80 mmol) in DCM (1 mL) was added dropwise to a solution of 4-((4-methoxybenzyl)oxy)-2-methylene-4-oxobutanoic acid (1.00 g, 4.00 mmol), 2-((3-chlorophenyl)sulfonyl)ethanol (1.06 g, 4.80 mmol) and DMAP (0.586 g, 4.80 mmol) in DCM (6 mL) at 0 °C. The mixture was allowed to slowly warm to RT and stirred for 16 h. The reaction mixture was poured into 1M HCl (5 mL) and extracted with EtOAc (3 x 15 mL). The combined organic extracts were washed with brine (20 mL), dried (Na₂SO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-10% EtOAc/DCM) to afford 1-(2-((3-chlorophenyl)sulfonyl)ethyl) 4-(4-methoxybenzyl) 2-methylenesuccinate (0.439 g, 0.960 mmol) as a colourless oil. LCMS m/z 475.1 (M+Na)⁺ (ES⁺).

Step 3

TFA (0.22 mL, 2.9 mmol) was added dropwise to a solution of 1-(2-((3-chlorophenyl)sulfonyl)ethyl) 4-(4-methoxybenzyl) 2-methylenesuccinate (0.439 g, 0.97 mmol) in DCM (11 mL) at 0 °C. The mixture was slowly warmed to RT and stirred for 16 h. The solvent was removed and the residue was co-evaporated with toluene (2 x 10 mL). The crude product was purified by chromatography on silica gel (0-10% MeOH/DCM) to afford 3-((2-((3-chlorophenyl)sulfonyl)ethoxy)carbonyl)but-3-enoic acid (0.274 g, 0.81 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 12.33 (s, 1H), 7.96 (t, J = 1.9 Hz, 1H), 7.88 (dt, J = 7.8, 1.4 Hz, 1H), 7.83 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H), 7.68 (t, J = 7.9 Hz, 1H), 5.71 (d, J = 1.3 Hz, 1H), 5.67 (d, J = 1.3 Hz, 1H), 4.42 - 4.35 (m, 2H), 3.93 - 3.86 (m, 2H), 3.13 - 3.08 (m, 2H). LCMS m/z 355.1 (M+Na)⁺ (ES⁺).

Step 4


Tert-butyl bromoacetate (0.13 mL, 0.87 mmol) was added dropwise to a mixture of 3-((2-((3-chlorophenyl)sulfonyl)ethoxy)carbonyl)but-3-enoic acid (0.274 g, 0.82 mmol) and potassium

carbonate (0.12 g, 0.87 mmol) in acetone (3.5 mL). The reaction was stirred at RT for 16 h. The mixture was filtered and concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isohexane) to afford 4-(2-(tert-butoxy)-2-oxoethyl) 1-(2-((3-chlorophenyl)sulfonyl)ethyl) 2-methylenesuccinate (0.294 g, 0.65 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.96 (t, J = 1.9 Hz, 1H), 7.88 (ddd, J = 7.8, 1.8, 1.0 Hz, 1H), 7.83 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H), 7.69 (t, J = 7.9 Hz, 1H), 5.83 (d, J = 1.2 Hz, 1H), 5.81 - 5.76 (m, 1H), 4.52 (s, 2H), 4.42 - 4.36 (m, 2H), 3.94 - 3.87 (m, 2H), 3.27 (s, 2H), 1.41 (s, 9H). LCMS m/z 469.1 (M+Na)⁺ (ES⁺).

10 Step 5

TFA (1.8 mL) was added to a solution of 4-(2-(tert-butoxy)-2-oxoethyl) 1-(2-((3-chlorophenyl)sulfonyl)ethyl) 2-methylenesuccinate (0.294 g, 0.65 mmol) in DCM (1.8 mL). The mixture was stirred for 30 min. The solvent was removed and the residue was co-evaporated with toluene (2 x 10 mL). The crude product was purified by chromatography on silica gel (0-10% MeOH/DCM) to afford the title compound (0.132 g, 0.33 mmol) as a colourless gum. ¹H NMR (400 MHz, DMSO-d₆) δ 13.07 (s, 1H), 7.96 (t, J = 1.9 Hz, 1H), 7.88 (ddd, J = 7.8, 1.7, 1.0 Hz, 1H), 7.83 (ddd, J = 8.1, 2.2, 1.0 Hz, 1H), 7.69 (t, J = 7.9 Hz, 1H), 5.83 (d, J = 1.2 Hz, 1H), 5.81 - 5.77 (m, 1H), 4.56 (s, 2H), 4.41 - 4.35 (m, 2H), 3.93 - 3.87 (m, 2H), 3.25 (s, 2H). LCMS m/z 389.0 (M-Na)⁻ (ES⁻).

Example 127 – (R)-2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)-2-phenylacetic acid



Step 1

Cesium carbonate (1.07 g, 3.29 mmol) was added to a solution of (R)-mandelic acid (1.00 g, 6.57 mmol) in methanol (8 mL) at 0 °C. The suspension was stirred for 1 h at 0 °C, then concentrated. Dimethylformamide (4 mL) was added and the mixture was cooled to 0 °C, 4-methoxybenzyl chloride (1.1 mL, 8.1 mmol) was added dropwise. The mixture was warmed to RT and stirred for 18 h. EtOAc (100 mL) was added and the organic layer was washed with sat. aq. NH₄Cl (2 x 100 mL) followed by sat. aq. NaHCO₃ (100 mL). The organic layer was dried (phase separator) and concentrated. The resulting oil was cooled in an ice-bath which initiated precipitation of a white solid. Isohexane (50 mL) was added and the resulting suspension filtered. The solid was washed with isohexane (3 x 20 mL) and dried to afford (R)-4-methoxybenzyl 2-hydroxy-2-phenylacetate

(1.61 g, 5.32 mmol) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 7.45 – 7.26 (m, 5H), 7.25 – 7.15 (m, 2H), 6.92 – 6.85 (m, 2H), 6.11 – 6.04 (m, 1H), 5.16 (d, J = 5.4 Hz, 1H), 5.04 (q, J = 12.1 Hz, 2H), 3.74 (s, 3H).


5 Step 2

DCC (0.583 g, 2.83 mmol) was added to a stirred solution of (R)-4-methoxybenzyl 2-hydroxy-2-phenylacetate (0.570 g, 1.89 mmol), 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6, 0.40 g, 1.89 mmol) and DMAP (0.023 g, 0.19 mmol) in DCM (10 mL) at 0°C. The mixture was allowed to warm to RT and stirred for 18 h. The mixture was filtered, washing with toluene (3 x 5 mL) and the filtrate was concentrated. The residue was suspended in toluene (20 mL) and filtered, washing with toluene (3 x 5 mL) and the filtrate was concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isohexane) followed by chromatography on RP Flash C18 (5-75% MeCN/Water 0.1% Formic Acid) to afford (R)-4-cyclohexyl 1-(2-((4-methoxybenzyl)oxy)-2-oxo-1-phenylethyl) 2-methylenesuccinate (0.47 g, 0.85 mmol, 84 % purity) as a colourless oil. ^1H NMR (400 MHz, DMSO- d_6) δ 7.50 - 7.45 (m, 2H), 7.44 - 7.38 (m, 3H), 7.21 - 7.14 (m, 2H), 6.90 - 6.84 (m, 2H), 6.34 (d, J = 1.2 Hz, 1H), 6.06 (s, 1H), 5.97 - 5.92 (m, 1H), 5.15 - 5.01 (m, 2H), 4.63 - 4.53 (m, 1H), 3.74 (s, 3H), 3.39 (s, 2H), 1.73 - 1.51 (m, 3H), 1.49 - 1.37 (m, 1H), 1.34 - 1.13 (m, 6H). LCMS m/z 489.1 ($M+\text{Na}$) $^+$ (ES^+).

20 Step 3

TFA (0.15 mL, 1.9 mmol) was added dropwise to a solution of (R)-4-cyclohexyl 1-(2-((4-methoxybenzyl)oxy)-2-oxo-1-phenylethyl) 2-methylenesuccinate (0.47 g, 0.85 mmol) in DCM (8 mL) at 0 °C. The mixture was stirred at RT for 20 h, then concentrated. The crude product was purified by chromatography on RP Flash C18 (5-75% MeCN/Water 0.1% Formic Acid) to afford the title compound (0.209 g, 0.54 mmol) as a colourless gum. ^1H NMR (400 MHz, DMSO- d_6) δ 13.29 (s, 1H), 7.53 - 7.46 (m, 2H), 7.46 - 7.39 (m, 3H), 6.33 (d, J = 1.2 Hz, 1H), 5.95 - 5.91 (m, 1H), 5.89 (s, 1H), 4.64 - 4.52 (m, 1H), 3.39 (s, 2H), 1.74 - 1.51 (m, 4H), 1.51 - 1.38 (m, 1H), 1.34 - 1.13 (m, 5H). LCMS m/z 369.1 ($M+\text{Na}$) $^+$ (ES^+).


30 **Example 128 – 1-(2-(1H-tetrazol-5-yl)ethyl) 4-cyclohexyl 2-methylenesuccinate**



A slurry of EDC.HCl (297 mg, 1.55 mmol) in DCM (3 mL) was added slowly to a solution of 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 6, 219 mg, 1.03 mmol), 2-(1H-tetrazol-5-yl)ethanol (141 mg, 1.24 mmol) and DMAP (189 mg, 1.55 mmol) in DCM (3 mL) at 0 °C. The mixture was allowed to warm slowly to RT and stirred for 16 h. The reaction mixture was diluted with 1 M HCl (5 mL) and the phases were separated. The aqueous phase was extracted


with DCM (2 x 5 mL). The combined organic phases were dried (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isoohexane) to afford the title compound (77 mg, 0.25 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 6.13 (d, J = 1.3 Hz, 1H), 5.81 (d, J = 1.3 Hz, 1H), 4.64 - 4.56 (m, 1H), 4.45 (t, J = 6.4 Hz, 2H), 3.30 (s, 2H), 3.27 (t, J = 6.4 Hz, 2H), 1.77 - 1.57 (m, 4H), 1.51 - 1.42 (m, 1H), 1.38 - 1.19 (m, 5H) (1 exchangeable proton not visible). LCMS m/z 309.2 (M+H)⁺ (ES⁺).

Example 129 – (S)-1-(2-(1H-tetrazol-5-yl)ethyl) 4-octan-2-yl 2-methylenesuccinate




Example 129 was prepared according to the procedure of Example 128, but using (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 9) instead of 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid. ¹H NMR (400 MHz, DMSO-d₆) δ 6.12 (d, J = 1.3 Hz, 1H), 5.80 (d, J = 1.3 Hz, 1H), 4.78 - 4.68 (m, 1H), 4.44 (t, J = 6.4 Hz, 2H), 3.30 - 3.24 (m, 4H), 1.52 - 1.37 (m, 2H), 1.30 - 1.15 (m, 8H), 1.10 (d, J = 6.3 Hz, 3H), 0.89 - 0.81 (m, 3H) (1 exchangeable proton not visible). LCMS m/z 339.2 (M+H)⁺ (ES⁺).

Example 130 – 1-(2-(1H-tetrazol-5-yl)ethyl) 4-cyclooctyl 2-methylenesuccinate



Example 130 was prepared according to the procedure of Example 128, but using 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1) instead of 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid. ¹H NMR (400 MHz, DMSO-d₆) δ 6.12 (d, J = 1.4 Hz, 1H), 5.80 (d, J = 1.2 Hz, 1H), 4.80 - 4.73 (m, 1H), 4.45 (t, J = 6.3 Hz, 2H), 3.30 - 3.25 (m, 4H), 1.73 - 1.38 (m, 14H) (1 exchangeable proton not visible). LCMS m/z 337.2 (M+H)⁺ (ES⁺).

Example 131 – 1-(2-((3-chlorophenyl)sulfonyl)-2-methylpropyl) 4-cyclooctyl 2-methylenesuccinate



Step 1

3-Chlorobenzene-1-sulfonyl chloride (0.67 mL, 4.76 mmol) was added to a stirred solution of sodium sulfite (1.237 g, 9.52 mmol) and 2 M NaOH (aq.) (4.8 mL, 9.6 mmol) in water (25 mL). The reaction mixture was heated to 100 °C and stirred for 30 min, cooled to RT and concentrated.

- 5 The residue was suspended in DMF (10 mL) and pyridine (0.85 mL, 10.5 mmol) and methyl 2-bromo-2-methylpropanoate (2.5 mL, 19.3 mmol) were added. The mixture was stirred at 40 °C for 16 h. The mixture was cooled to RT and diluted with brine (100 mL). The mixture was extracted with DCM (3 x 80 mL), dried (phase separator) and concentrated. The crude product was purified by chromatography on silica gel (0-50% EtOAc/isohehexane) to afford methyl 2-((3-chlorophenyl)sulfonyl)-2-methylpropanoate (0.70 g, 2.28 mmol) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.96 - 7.89 (m, 1H), 7.81 - 7.77 (m, 2H), 7.76 - 7.69 (m, 1H), 3.62 (s, 3H), 1.53 (s, 6H). LCMS m/z 299.2 (M+Na)⁺ (ES⁺).
- 10

Step 2


- 15 Lithium borohydride (4 M in THF, 1 mL, 4 mmol) was added to a solution of methyl 2-((3-chlorophenyl)sulfonyl)-2-methylpropanoate (0.60 g, 1.95 mmol) in THF (15 mL) at 0 °C. The mixture was warmed to RT and stirred for 18 h. The reaction was quenched with acetic acid (20 mL) and concentrated. The residue was partitioned between DCM (50 mL) and water (50 mL). The phases were separated and the aqueous phase was extracted with DCM (3 x 50 mL). The combined organic phases were dried (phase separator) and concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isohehexane) to afford 2-((3-chlorophenyl)sulfonyl)-2-methylpropan-1-ol (0.57 g, 2.11 mmol) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.87 - 7.79 (m, 3H), 7.71 - 7.65 (m, 1H), 5.10 (t, J = 5.8 Hz, 1H), 3.55 - 3.50 (m, 2H), 1.22 (s, 6H). LCMS m/z 249.2 (M+H)⁺ (ES⁺).
- 20

25


Step 3

EDC.HCl (0.106 g, 0.555 mmol) was added to a solution of 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1, 0.089 g, 0.37 mmol), 2-((3-chlorophenyl)sulfonyl)-2-methylpropan-1-ol (0.1 g, 0.37 mmol) and DMAP (0.068 g, 0.56 mmol) in DCM (5 mL) at 0 °C.

- 30 The reaction was allowed to warm to RT slowly and stirred for 18 h. The mixture was diluted with 1M HCl (20 mL) and extracted with DCM (3 x 20 mL). The combined organic phases were dried (phase separator) and concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isohehexane) to afford the title compound (0.046 g, 0.093 mmol) as a colourless gum. ¹H NMR (400 MHz, DMSO-d₆) δ 7.92 - 7.86 (m, 1H), 7.84 - 7.79 (m, 2H), 7.75 - 7.67 (m, 1H), 5.91 (d, J = 1.3 Hz, 1H), 5.77 - 5.73 (m, 1H), 4.85 - 4.75 (m, 1H), 4.24 (s, 2H), 3.18 (s, 2H), 1.76 - 1.37 (m, 14H), 1.34 (s, 6H). LCMS m/z 493.2/495.2 (M+Na)⁺ (ES⁺).
- 35

Example 132 – 4-cyclooctyl 1-(2-methyl-2-(methylsulfonyl)propyl) 2-methylenesuccinate

EDC.HCl (0.156 g, 0.812 mmol) in DCM (1.1 mL) was added to a solution of 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1, 0.13 g, 0.54 mmol), 2-methyl-2-(methylsulfonyl)propan-1-ol (0.099 g, 0.65 mmol), and DMAP (0.099 g, 0.81 mmol) in DCM (1.1 mL) at 0 °C. The mixture was allowed to warm slowly to RT and stirred for 16 h. The mixture was poured into 1 M HCl (5 mL) and extracted with EtOAc (3 x 5 mL). The combined organic extracts were washed with brine (15 mL), dried (Na₂SO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isohexane) to afford the title compound (0.048 g, 0.13 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 6.27 (d, J = 1.2 Hz, 1H), 5.88 (d, J = 1.2 Hz, 1H), 4.83 (tt, J = 8.1, 4.0 Hz, 1H), 4.29 (s, 2H), 3.36 (s, 2H), 2.97 (s, 3H), 1.79 - 1.36 (m, 10H), 1.33 (s, 6H). LCMS m/z 397.3 (M+Na)⁺ (ES⁺).

Example 133 – 1-(1-(1H-tetrazol-5-yl)ethyl) 4-cyclooctyl 2-methylenesuccinate**Step 1**

Trityl-Cl (0.641 g, 2.30 mmol) was added to a solution of 1-(1H-tetrazol-5-yl)ethanol (0.25 g, 2.19 mmol) and triethylamine (0.35 mL, 2.5 mmol) in DCM (5 mL). The mixture was stirred for 2 h, then diluted with water (10 mL). The phases were separated and the aqueous phase was extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with brine (30 mL), dried (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isohexane) to afford 1-(1-trityl-1H-tetrazol-5-yl)ethanol (746 mg, 1.67 mmol) as a colourless oil that solidified on standing. ¹H NMR (400 MHz, DMSO-d₆) δ 7.46 - 7.35 (m, 9H), 7.08 - 6.98 (m, 6H), 5.69 (d, J = 5.4 Hz, 1H), 5.02 (qd, J = 6.6, 5.3 Hz, 1H), 1.48 (d, J = 6.6 Hz, 3H). LCMS m/z 243.2 (trityl)⁺ (ES⁺).

Step 2


A slurry of EDC.HCl (0.50 g, 2.6 mmol) in DCM (3 mL) was added slowly to a solution of 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1, 0.419 g, 1.74 mmol), 1-(1-trityl-

1H-tetrazol-5-yl)ethanol (0.746 g, 2.09 mmol), DIPEA (0.46 mL, 2.6 mmol) and DMAP (0.021 g, 0.17 mmol) in DCM (3 mL) at 0 °C. The mixture was allowed to warm slowly to RT and stirred for 3 days. The mixture was diluted with water (5 mL) and the phases were separated. The aqueous phase was extracted with DCM (2 x 5 mL). The combined organic phases were dried (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-50% EtOAc/isohexane) to afford 4-cyclooctyl 1-(1-(1-trityl-1H-tetrazol-5-yl)ethyl) 2-methylenesuccinate (402 mg, 0.59 mmol, 85% purity) as a colourless gum. ¹H NMR (400 MHz, DMSO-d₆) δ 7.45 - 7.36 (m, 9H), 7.03 - 6.97 (m, 6H), 6.20 (d, J = 1.3 Hz, 1H), 6.16 (q, J = 6.7 Hz, 1H), 5.85 (d, J = 1.3 Hz, 1H), 4.76 (tt, J = 8.0, 3.9 Hz, 1H), 3.31 (s, 2H), 1.64 (d, J = 6.7 Hz, 3H), 1.62 - 1.31 (m, 14H). LCMS m/z 601.1 (M+Na)⁺ (ES⁺).

Step 3


HCl (4 M in 1,4-dioxane, 1.5 mL, 6.00 mmol) was added to a solution of 4-cyclooctyl 1-(1-(1-trityl-1H-tetrazol-5-yl)ethyl) 2-methylenesuccinate (402 mg, 0.59 mmol, 85% purity) in DCM (3.5 mL). The mixture was stirred for 18 h at RT. The mixture was concentrated. The crude product was purified by chromatography on silica gel (0-5% MeOH/DCM) to afford the title compound (152 mg, 0.45 mmol) as a pale yellow oil. ¹H NMR (400 MHz, DMSO-d₆) δ 6.29 (d, J = 1.2 Hz, 1H), 6.20 (q, J = 6.7 Hz, 1H), 5.90 (d, J = 1.2 Hz, 1H), 4.78 (tt, J = 7.8, 3.8 Hz, 1H), 3.35 (s, 2H), 1.64 (d, J = 6.7 Hz, 3H), 1.63 - 1.30 (m, 14H) (1 exchangeable proton not visible). LCMS m/z 359.3 (M+Na)⁺ (ES⁺).

Example 134 – 1-((1H-tetrazol-5-yl)methyl) 4-cyclooctyl 2-methylenesuccinate



Example 134 was prepared according to the procedure of Example 133, but using (1-trityl-1H-tetrazol-5-yl)methanol instead of 1-(1-trityl-1H-tetrazol-5-yl)ethanol, in step 2. ¹H NMR (400 MHz, DMSO-d₆) δ 6.31 (d, J = 1.1 Hz, 1H), 5.92 (d, J = 1.2 Hz, 1H), 5.48 (s, 2H), 4.83 - 4.74 (m, 1H), 3.35 (s, 2H), 1.72 - 1.36 (m, 14H) (1 exchangeable proton not visible). LCMS m/z 345.3 (M+Na)⁺ (ES⁺).

Example 135 – (R)-1-(2-(1H-tetrazol-5-yl)ethyl) 4-octan-2-yl 2-methylenesuccinate




Example 135 was prepared according to the procedure of Example 133, but using 2-(1-trityl-1H-tetrazol-5-yl)ethanol, instead of 1-(1-trityl-1H-tetrazol-5-yl)ethanol, and (R)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 8) instead of 4-(cyclooctyloxy)-2-methylene-4-

oxobutanoic acid in step 2. ^1H NMR (400 MHz, DMSO- d_6) δ 6.12 (d, J = 1.3 Hz, 1H), 5.81 (d, J = 1.3 Hz, 1H), 4.78 - 4.69 (m, 1H), 4.44 (t, J = 6.4 Hz, 2H), 3.29 (s, 2H), 3.27 (t, J = 6.4 Hz, 2H), 1.52 - 1.38 (m, 2H), 1.30 - 1.16 (m, 8H), 1.11 (d, J = 6.2 Hz, 3H), 0.89 - 0.82 (m, 3H) (1 exchangeable proton not visible). LCMS m/z 339.2 ($M+H$) $^+$ (ES^+).

5

Example 136 – (2R,3S)-2-acetamido-3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)butanoic acid



Step 1

10 1-(chloromethyl)-4-methoxybenzene (0.85 mL, 6.24 mmol) was added to a mixture of (2S,3R)-2-acetamido-3-hydroxybutanoic acid (1.00 g, 6.21 mmol) and cesium carbonate (2.22 g, 6.81 mmol) in dimethylformamide (20 mL) at 0 °C. The mixture was stirred at RT for 42 h. The mixture was poured onto water (100 mL) and extracted with DCM (3 x 50 mL). The combined organic phases were dried (phase separator) and concentrated. The crude product was purified by chromatography on silica gel (0-10% MeOH/DCM) to afford (2S,3R)-4-methoxybenzyl 2-acetamido-3-hydroxybutanoate (0.95 g, 3.21 mmol) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 7.99 (d, J = 8.4 Hz, 1H), 7.35 - 7.26 (m, 2H), 6.97 - 6.89 (m, 2H), 5.11 - 4.99 (m, 2H), 4.95 (d, J = 5.5 Hz, 1H), 4.34 - 4.23 (m, 1H), 4.16 - 4.05 (m, 1H), 3.76 (s, 3H), 1.91 (s, 3H), 1.05 (d, J = 6.4 Hz, 3H). LCMS m/z 304.2 ($M+Na$) $^+$ (ES^+).

20

Step 2

DCC (0.475 g, 2.30 mmol) was added to a solution of 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (0.369 g, 1.536 mmol), (2S,3R)-4-methoxybenzyl 2-acetamido-3-hydroxybutanoate (0.48 g, 1.54 mmol), DMAP (0.019 g, 0.15 mmol) in DCM (15 mL) at 0 °C. The reaction mixture was allowed to warm to RT and stirred for 18 h. The reaction mixture was filtered, washing with toluene (3 x 5 mL) and the filtrate was concentrated. The residue was suspended in toluene (20 mL) and filtered, washing with toluene (3 x 5 mL) and the filtrate was concentrated. The crude product was purified by chromatography on RP Flash C18 (5-100% MeCN/Water 0.1% Formic Acid, eluting at 100%) to afford a residue which was treated with toluene (20 mL). The


25

solid was removed by filtration and the filtrate was concentrated to afford 1-((2S,3R)-3-acetamido-4-((4-methoxybenzyl)oxy)-4-oxobutan-2-yl) 4-cyclooctyl 2-methylenesuccinate (0.23 g, 0.41 mmol) as a colourless gum. ¹H NMR (400 MHz, DMSO-d₆) δ 8.34 (d, J = 9.0 Hz, 1H), 7.30 - 7.23 (m, 2H), 6.94 - 6.86 (m, 2H), 6.24 (d, J = 1.4 Hz, 1H), 5.81 - 5.77 (m, 1H), 5.32 - 5.23 (m, 1H), 5.07 - 4.96 (m, 2H), 4.87 - 4.77 (m, 1H), 4.75 - 4.68 (m, 1H), 3.75 (s, 3H), 3.28 (s, 2H), 1.96 (s, 3H), 1.80 - 1.34 (m, 14H), 1.15 (d, J = 6.4 Hz, 3H). LCMS m/z 526.3 (M+Na)⁺ (ES⁺).


Step 3

TFA (0.2 mL) was added to a solution of 1-((2S,3R)-3-acetamido-4-((4-methoxybenzyl)oxy)-4-oxobutan-2-yl) 4-cyclooctyl 2-methylenesuccinate (0.23 g, 0.41 mmol) in DCM (5 mL). The reaction mixture was stirred for 20 h and concentrated. The crude product was purified by chromatography on silica gel (0-10% MeOH/DCM) to afford the title compound (0.044 g, 0.11 mmol) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 12.91 (s, br. 1H), 8.18 (d, J = 9.1 Hz, 1H), 6.32 (d, J = 1.4 Hz, 1H), 5.86 - 5.77 (m, 1H), 5.34 - 5.20 (m, 1H), 4.88 - 4.76 (m, 1H), 4.64 - 4.53 (m, 1H), 3.31 (s, 2H), 1.95 (s, 3H), 1.79 - 1.35 (m, 14H), 1.15 (d, J = 6.4 Hz, 3H). LCMS m/z 406.2 (M+Na)⁺ (ES⁺).


Example 137 – 4-cyclooctyl 1-(3-(2-ethoxy-2-oxoethyl)oxetan-3-yl) 2-methylenesuccinate




1-Chloro-N,N,2-trimethylprop-1-en-1-amine (0.27 mL, 2.01 mmol) was added to a solution of 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1, 0.44 g, 1.83 mmol) in DCM (5 mL). The mixture was stirred for 2 h and concentrated. The residue was dissolved in DCM (2 mL) and added dropwise to a solution of ethyl 2-(3-hydroxyoxetan-3-yl)acetate (0.323 g, 2.01 mmol) and NMM (0.28 mL, 2.6 mmol) in DCM (3 mL). The mixture was stirred for 16 h at RT, then poured into water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic extracts were washed with brine (20 mL), dried (Na₂SO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-100% EtOAc/isohexane) to afford the title compound (0.072 g, 0.19 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 6.20 (d, J = 1.3 Hz, 1H), 5.87 (d, J = 1.3 Hz, 1H), 4.84 (tt, J = 8.2, 3.9 Hz, 1H), 4.71 - 4.65 (m, 2H), 4.64 (d, J = 7.7 Hz, 2H), 4.06 (q, J = 7.1 Hz, 2H), 3.32 (s, 2H), 3.20 (s, 2H), 1.79 - 1.42 (m, 14H), 1.16 (t, J = 7.1 Hz, 3H). LCMS m/z 383.3 (M+H)⁺ (ES⁺).

Example 138 – 4-(2-(methylsulfonyl)ethyl) 1-octyl 2-methyl-3-methylenesuccinate


Example 138 was prepared according to General Procedure 2, using 3-methyl-2-methylene-4-(octyloxy)-4-oxobutanoic acid (Intermediate 12) as itaconic acid monoester and 2-(methylsulfonyl)ethanol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.28 (s, 1H), 5.85 (s, 1H), 4.45 (t, J = 5.8 Hz, 2H), 4.00 (t, J = 6.6 Hz, 2H), 3.61 - 3.52 (m, 3H), 3.03 (s, 3H), 1.55 - 1.49 (m, 2H), 1.30 - 1.23 (m, 13H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 385.5 (M+Na)⁺ (ES⁺).

Example 139 – 1-octyl 4-((S)-tetrahydrofuran-3-yl) 2-methyl-3-methylenesuccinate


Example 139 was prepared according to General Procedure 2, using 3-methyl-2-methylene-4-(octyloxy)-4-oxobutanoic acid (Intermediate 12) as itaconic acid monoester and (S)-tetrahydrofuran-3-ol as R²-OH. ¹H NMR (500 MHz, DMSO-d₆) δ 6.23 (s, 1H), 5.79 (s, 1H), 5.29 - 5.25 (m, 1H), 3.98 (t, J = 6.5 Hz, 2H), 3.84 - 3.72 (m, 3H), 3.65 (dd, J = 10.5, 3.7 Hz, 1H), 3.56 (q, J = 7.2 Hz, 1H), 2.20 - 2.08 (m, 1H), 1.93 - 1.84 (m, 1H), 1.57 - 1.48 (m, 2H), 1.29 - 1.23 (m, 13H), 0.86 (t, J = 6.8 Hz, 3H). LCMS m/z 349.2 (M+Na)⁺ (ES⁺).

Example 140 – 1-(1-(1H-tetrazol-5-yl)propan-2-yl) 4-((R)-octan-2-yl) 2-methylenesuccinate


Example 140 was prepared according to General Procedure 2, using Intermediate 8 as itaconic acid monoester and 1-(1H-tetrazol-5-yl)propan-2-ol as R²-OH. ¹H NMR (400 MHz, DMSO-d₆) δ 6.11 (d, J = 1.4 Hz, 1H), 5.78 (d, J = 1.4 Hz, 1H), 5.30 - 5.13 (m, 1H), 4.75 (h, J = 6.2 Hz, 1H), 3.37 - 3.13 (m, 4H), 1.54 - 1.35 (m, 2H), 1.34 - 1.16 (m, 11H), 1.11 (dd, J = 6.3, 2.4 Hz, 3H), 0.85 (t, J = 6.6 Hz, 3H) (1 exchangeable proton not visible). LCMS m/z 353.4 (M+H)⁺ (ES⁺).

Example 141 – 1-(1-(1H-tetrazol-5-yl)propan-2-yl) 4-((S)-octan-2-yl) 2-methylenesuccinate


Example 141 was prepared according to General Procedure 2, using Intermediate 9 as itaconic acid monoester and 1-(1H-tetrazol-5-yl)propan-2-ol as R²-OH. ¹H NMR (400 MHz, DMSO-d₆) δ 6.11 (d, J = 1.4 Hz, 1H), 5.78 (d, J = 1.4 Hz, 1H), 5.21 (h, J = 6.7 Hz, 1H), 4.75 (h, J = 6.3 Hz, 1H), 3.40 - 3.13 (m, 4H), 1.53 - 1.35 (m, 2H), 1.33 - 1.16 (m, 11H), 1.11 (dd, J = 6.2, 2.4 Hz, 3H), 0.85 (t, J = 6.6 Hz, 3H) (1 exchangeable proton not visible). LCMS m/z 375.4 (M+Na)⁺ (ES⁺).

Example 142 – 4-cyclohexyl 1-((2-methyl-2H-tetrazol-5-yl)methyl) 2-methylenesuccinate

Example 142 was prepared according to the procedure of Example 130, but using Intermediate 6 instead of 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1). ¹H NMR (400 MHz, DMSO-d₆) δ 6.23 (d, J = 1.2 Hz, 1H), 5.91 - 5.87 (m, 1H), 5.41 (s, 2H), 4.69 - 4.57 (m, 1H), 4.38 (s, 3H), 3.36 (s, 2H), 1.76 - 1.55 (m, 4H), 1.52 - 1.40 (m, 1H), 1.38 - 1.14 (m, 5H). LCMS m/z 309 (M+H)⁺ (ES⁺).

Example 143 – 4-cyclohexyl 1-((1-methyl-1H-tetrazol-5-yl)methyl) 2-methylenesuccinate

Example 143 was prepared according to the procedure of Example 130, but using Intermediate 6 instead of 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (Intermediate 1). ¹H NMR (400 MHz, DMSO-d₆) δ 6.30 (d, J = 1.1 Hz, 1H), 5.95 - 5.90 (m, 1H), 5.52 (s, 2H), 4.66 - 4.54 (m, 1H), 4.10 (s, 3H), 3.38 (s, 2H), 1.73 - 1.40 (m, 5H), 1.37 - 1.12 (m, 5H). LCMS m/z 309 (M+H)⁺ (ES⁺).

Example 144 – 3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)-4,4,4-trifluorobutanoic acid**Step 1**

1-(chloromethyl)-4-methoxybenzene (0.86 ml, 6.3 mmol) was added to a mixture of 4,4,4-trifluoro-3-hydroxybutanoic acid (1.00 g, 6.33 mmol) and cesium carbonate (2.06 g, 6.33 mmol) in DMF (27 mL). The mixture was stirred at RT for 1 h, then heated to 70 °C for 2 h. The mixture was cooled to RT and stirred for 18 h. The mixture was poured onto water (50 mL) and extracted with EtOAc (3x50 mL). The combined organic phases were washed with brine (100 mL), dried (MgSO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-

100% EtOAc/isohehexane) to afford 4-methoxybenzyl 4,4,4-trifluoro-3-hydroxybutanoate (0.283 g, 0.97 mmol) as a colourless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.37 - 7.26 (m, 2H), 6.98 - 6.87 (m, 2H), 6.58 (d, J = 6.7 Hz, 1H), 5.08 (d, J = 13.5 Hz, 1H), 5.05 (d, J = 13.6 Hz, 1H), 4.35 (dt, J = 17.3, 7.2, 3.3 Hz, 1H), 3.75 (s, 3H), 2.77 (dd, J = 15.8, 3.3 Hz, 1H), 2.57 - 2.52 (m, 1H).

5

Step 2


A slurry of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.28 g, 1.5 mmol) in DCM (1.6 mL) was added slowly to a solution of 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (0.233 g, 0.97 mmol), 4-methoxybenzyl 4,4,4-trifluoro-3-hydroxybutanoate (0.283 g, 0.97 mmol), DIPEA (0.25 mL, 1.5 mmol) and DMAP (0.012 g, 0.097 mmol) in DCM (1.6 mL) at 0 °C. The mixture was allowed to warm slowly to RT and stirred for 18 h. The mixture was diluted with 1 M HCl (10 mL) and extracted with EtOAc (3x10 mL). The combined organic phases were washed with brine (15 mL), dried (Na₂SO₄) and concentrated. The crude product was purified by chromatography on silica gel (0-50% EtOAc/isohehexane) to afford 4-cyclooctyl 1-(1,1,1-trifluoro-4-((4-methoxybenzyl)oxy)-4-oxobutan-2-yl) 2-methylenesuccinate (0.304 g, 0.56 mmol) as a colourless oil. LCMS m/z 523.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ 7.34 - 7.22 (m, 2H), 6.96 - 6.85 (m, 2H), 6.23 (d, J = 1.0 Hz, 1H), 5.93 (d, J = 1.1 Hz, 1H), 5.81 (dq, J = 10.3, 6.7, 3.6 Hz, 1H), 5.04 (s, 2H), 4.80 (tt, J = 8.2, 4.0 Hz, 1H), 3.75 (s, 3H), 3.31 (s, 2H), 3.10 (dd, J = 16.8, 3.6 Hz, 1H), 2.87 (dd, J = 16.8, 9.5 Hz, 1H), 1.78 - 1.33 (m, 14H).

20

Step 3

Trifluoroacetic acid (1.4 mL) was added to a solution of 4-cyclooctyl 1-(1,1,1-trifluoro-4-((4-methoxybenzyl)oxy)-4-oxobutan-2-yl) 2-methylenesuccinate (0.304 g, 0.56 mmol) in DCM (5 mL) at 0 °C. The reaction mixture was warmed to RT, stirred for 30 min and concentrated. The residue was co-evaporated with toluene (2x10 mL). The crude product was purified by chromatography on silica gel (0-50% EtOAc/DCM) to afford 3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)-4,4,4-trifluorobutanoic acid (0.127 g, 0.32 mmol) as a colourless oil. LCMS m/z 403.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ 12.84 (s, 1H), 6.29 (d, J = 1.1 Hz, 1H), 5.96 (d, J = 1.2 Hz, 1H), 5.83 - 5.71 (m, 1H), 4.82 (tt, J = 8.1, 3.9 Hz, 1H), 3.35 (s, 2H), 2.96 (dd, J = 16.9, 3.8 Hz, 1H), 2.74 (dd, J = 16.9, 9.2 Hz, 1H), 1.79 - 1.34 (m, 14H).

30

Example 145 – 2-(4-(cycloheptyloxy)-2-methylene-4-oxobutanoyloxy)acetic acid**Step 1**





To a solution of 3-((2-*tert*-butoxy-2-oxoethoxy)carbonyl)but-3-enoic acid (234 mg, 0.96 mmol), cycloheptanol (110 mg, 0.96 mmol) and DMAP (117 mg, 0.96 mmol) in DCM (4 mL) was added EDC·HCl (276 mg, 1.44 mmol) at 0 °C, and the resulting mixture was stirred at room temperature for 1 h. The mixture was quenched with aqueous NH₄Cl (2 mL), the phases were separated, and the aqueous phase was extracted with DCM (2 x 3 mL). The combined organic phases were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at 40 °C, and the residue was purified by flash column chromatography (25 g silica, 0-10% MTBE/petroleum ether) to give 1-(2-*tert*-butoxy-2-oxoethyl) 4-cycloheptyl 2-methylenesuccinate (130 mg, 0.38 mmol, 40 %) as a pale-yellow oil. LCMS (System 2, Method B) *m/z* 363.3 (M+Na)⁺ (ES⁺).





Step 2





A mixture of 1-(2-*tert*-butoxy-2-oxoethyl) 4-cycloheptyl 2-methylenesuccinate (130 mg, 0.38 mmol) and HCl solution in 1,4-dioxane (4 M, 3 mL, 12 mmol) in DCM (2 mL) was stirred at room temperature for 4 h. The mixture was concentrated under reduced pressure at 40 °C and the residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10 μm 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.05% TFA/water); gradient: 15-95% MeCN; collection wavelength: 214 nm). The collected fractions were concentrated at 40 °C under reduced pressure to remove MeCN, and the residue was lyophilized to give 2-(4-(cycloheptyloxy)-2-methylene-4-oxobutanoyloxy)acetic acid (76 mg, 0.27 mmol, 70 %) as a pale-yellow oil. LCMS (System 2, Method B) *m/z* 307.1 (M+Na)⁺ (ES⁺).





¹H NMR (400 MHz, DMSO-*d*₆) δ: 13.06 (br, 1H), 6.27 (d, *J* = 0.8 Hz, 1H), 5.91 (d, *J* = 0.8 Hz, 1H), 4.83-4.78 (m, 1H), 4.63 (s, 2H), 3.33 (s, 2H), 1.83-1.76 (m, 2H), 1.62-1.51 (m, 4H), 1.50-1.48 (m, 4H), 1.42-1.37 (m, 2H).




The following compounds were made using a similar procedure:






Example No.	Alcohol Intermediate / Example Structure / Name	LCMS / ¹ H NMR data
146	octan-3-ol  2-(2-methylene-4-(octan-3-yloxy)-4-oxobutanoyloxy)acetic acid	LCMS (System 2, Method B) m/z 323.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.09 (br, 1H), 6.28 (d, J = 0.8 Hz, 1H), 5.93 (d, J = 0.8 Hz, 1H), 4.73-4.66 (m, 1H), 4.62 (s, 2H), 3.37 (s, 2H), 1.56-1.40 (m, 4H), 1.25-1.14 (m, 6H), 0.84 (t, J = 6.4 Hz, 3H), 0.80 (d, J = 7.2 Hz, 3H).
147	octan-4-ol  2-(2-methylene-4-(octan-4-yloxy)-4-oxobutanoyloxy)acetic acid	LCMS (System 2, Method B) m/z 323.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.09 (br, 1H), 6.28 (d, J = 1.2 Hz, 1H), 5.92 (d, J = 1.2 Hz, 1H), 4.81-4.74 (m, 1H), 4.62 (s, 2H), 3.36 (s, 2H), 1.49-1.42 (m, 4H), 1.32-1.14 (m, 6H), 0.84 (t, J = 7.2 Hz, 6H).
148	heptan-4-ol  2-((4-(heptan-4-yloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 309.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.09 (br, 1H), 6.28 (d, J = 1.2 Hz, 1H), 5.93 (d, J = 0.8 Hz, 1H), 4.82-4.77 (m, 1H), 4.62 (s, 2H), 3.37 (s, 2H), 1.48-1.42 (m, 4H), 1.32-1.16 (m, 4H), 0.85 (t, J = 7.2 Hz, 6H).
149	adamantan-2-ol  2-((4-((adamantan-2-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 323.2 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.01 (br, 1H), 6.29 (s, 1H), 5.94 (s, 1H), 4.80 (m, 1H), 4.63 (s, 2H), 3.41 (s, 2H), 1.89-1.86 (m, 4H), 1.80-1.78 (m, 4H), 1.72-1.68 (m, 4H), 1.49 (d, J = 12.4 Hz, 2H).

150	1-cyclohexylethan-1-ol  2-((4-(1-cyclohexylethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 321.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.11 (br, 1H), 6.28 (s, 1H), 5.92 (s, 1H), 4.64-4.58 (m, 1H), 4.62 (s, 2H), 3.40 (s, 2H), 1.68 (d, J = 10.0 Hz, 3H), 1.59 (t, J = 10.8 Hz, 2H), 1.42-1.35 (m, 1H), 1.21-1.12 (m, 3H), 1.09 (d, J = 6.0 Hz, 3H), 1.06-0.84 (m, 2H).
151	1-cycloheptylethan-1-ol  2-((4-(1-cycloheptylethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 335.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.08 (br, 1H), 6.27 (s, 1H), 5.92 (s, 1H), 4.70-4.65 (m, 1H), 4.63 (s, 2H), 3.34 (s, 2H), 1.63-1.61 (m, 5H), 1.57-1.33 (m, 6H), 1.22-1.14 (m, 2H), 1.07 (d, J = 6.0 Hz, 3H).
152	spiro[3.4]octan-2-ol  2-(2-methylene-4-oxo-4-(spiro[3.4]octan-2-yloxy)butanoyloxy)acetic acid	LCMS (System 2, Method B) m/z 319.1 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.08 (br, 1H), 6.28 (d, J = 0.8 Hz, 1H), 5.91 (d, J = 0.8 Hz, 1H), 4.90-4.83 (m, 1H), 4.64 (s, 2H), 3.35 (s, 2H), 2.23-2.18 (m, 2H), 1.92-1.87 (m, 2H), 1.57-1.47 (m, 8H).
153	spiro[3.5]nonan-2-ol  2-(2-methylene-4-oxo-4-(spiro[3.5]nonan-2-yloxy)butanoyloxy)acetic acid	LCMS (System 2, Method B) m/z 333.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.08 (br, 1H), 6.28 (s, 1H), 5.91 (s, 1H), 4.91-4.83 (m, 1H), 4.64 (s, 2H), 3.35 (s, 2H), 2.19-2.14 (m, 2H), 1.68-1.63 (m, 2H), 1.40-1.30 (m, 10H).

154	spiro[3.5]nonan-7-ol  2-(2-methylene-4-oxo-4-(spiro[3.5]nonan-7-yloxy)butanoyloxy)acetic acid	LCMS (System 2, Method B) m/z 333.3 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.10 (br, 1H), 6.26 (s, 1H), 5.90 (s, 1H), 4.62 (s, 3H), 3.34 (s, 2H), 1.83-1.77 (m, 2H), 1.70-1.61 (m, 8H), 1.37-1.34 (m, 4H).
155	2,2-dimethylcyclohexan-1-ol  2-((4-((2,2-dimethylcyclohexyl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 321.3 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.09 (br, 1H), 6.28 (s, 1H), 5.93 (s, 1H), 4.62 (s, 2H), 4.47-4.44 (m, 1H), 3.38 (s, 2H), 1.62-1.58 (m, 2H), 1.42-1.34 (m, 4H), 1.29-1.18 (m, 2H), 0.84 (s, 6H).
169	2,2,4,4-tetramethylcyclobutan-1-ol  2-((2-methylene-4-oxo-4-(2,2,4,4-tetramethylcyclobutoxy)butanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 321.2 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.11 (br, 1H), 6.29 (s, 1H), 5.95 (s, 1H), 4.63 (s, 2H), 4.35 (s, 1H), 3.43 (s, 2H), 1.51 (d, J = 11.6 Hz, 1H), 1.41 (d, J = 11.6 Hz, 1H), 1.10 (s, 6H), 1.00 (s, 6H).
170	(S)-octan-3-ol  (S)-2-(2-methylene-4-(octan-3-yloxy)-4-oxobutanoyloxy)acetic acid	LCMS (System 2, Method B) m/z 323.2 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.09 (br, 1H), 6.28 (d, J = 0.8 Hz, 1H), 5.93 (d, J = 0.8 Hz, 1H), 4.73-4.66 (m, 1H), 4.62 (s, 2H), 3.37 (s, 2H), 1.56-1.40 (m, 4H), 1.25-1.14 (m, 6H), 0.84 (t, J = 6.4 Hz, 3H), 0.80 (d, J = 7.2 Hz, 3H).


173	(<i>R</i>)-heptan-2-ol  (<i>R</i>)-2-((4-(heptan-2-yloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 309.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.14 (br, 1H), 6.27 (d, J = 0.8 Hz, 1H), 5.91 (d, J = 0.8 Hz, 1H), 4.80-4.75 (m, 1H), 4.63 (s, 2H), 3.34 (s, 2H), 1.49-1.43 (m, 2H), 1.29-1.23 (m, 6H), 1.13 (d, J = 6.4 Hz, 3H), 0.85 (t, J = 6.4 Hz, 3H).
174	nonan-2-ol  2-((2-methylene-4-(nonan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 337.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.09 (br, 1H), 6.27 (d, J = 1.2 Hz, 1H), 5.91 (d, J = 1.2 Hz, 1H), 4.82-4.74 (m, 1H), 4.62 (s, 2H), 3.50 (s, 2H), 1.48-1.43 (m, 2H), 1.29-1.23 (m, 10H), 1.13 (d, J = 6.4 Hz, 3H), 0.86 (t, J = 6.8 Hz, 3H).
175	nonan-5-ol  2-((2-methylene-4-(nonan-5-yloxy)-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 337.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.14 (br, 1H), 6.28 (d, J = 1.2 Hz, 1H), 5.92 (d, J = 0.8 Hz, 1H), 4.79-4.74 (m, 1H), 4.62 (s, 2H), 3.37 (s, 2H), 1.52-1.42 (m, 4H), 1.31-1.14 (m, 8H), 0.85 (t, J = 6.8 Hz, 6H).
176	1-(3,5-dichlorophenyl)ethan-1-ol  2-((4-(1-(3,5-dichlorophenyl)ethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 383.0 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.12 (br, 1H), 7.54 (t, J = 2.0 Hz, 1H), 7.41 (d, J = 1.6 Hz, 2H), 6.31 (d, J = 0.8 Hz, 1H), 5.96 (d, J = 0.8 Hz, 1H),

	methylene-4-oxobutanoyl)oxy)acetic acid	5.77 (q, J = 6.4 Hz, 1H), 4.63 (s, 2H), 3.47 (s, 2H), 1.44 (d, J = 6.4 Hz, 3H).
177	1-(3,5-dichlorophenyl)propan-2-ol  2-((4-((1-(3,5-dichlorophenyl)propan-2-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 397.1 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.07 (br, 1H), 7.46 (t, J = 2.0 Hz, 1H), 7.29 (d, J = 1.6 Hz, 2H), 6.27 (s, 1H), 5.87 (d, J = 0.8 Hz, 1H), 4.99 (q, J = 6.4 Hz, 1H), 4.61 (d, J = 1.6 Hz, 2H), 3.31 (s, 2H), 2.88-2.78 (m, 2H), 1.14 (d, J = 6.4 Hz, 3H).
178	(R)-octan-3-ol  (R)-2-(2-methylene-4-(octan-3-yloxy)-4-oxobutanoyloxy)acetic acid	LCMS (System 2, Method B) m/z 323.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.11 (br, 1H), 6.28 (d, J = 0.8 Hz, 1H), 5.93 (d, J = 0.8 Hz, 1H), 4.73-4.66 (m, 1H), 4.62 (s, 2H), 3.37 (s, 2H), 1.56-1.40 (m, 4H), 1.25-1.14 (m, 6H), 0.84 (t, J = 6.4 Hz, 3H), 0.80 (d, J = 7.2 Hz, 3H).
179	(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol (CAS No. 464-43-7)  2-((2-methylene-4-oxo-4-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)butanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 347.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.13 (br, 1H), 6.29 (s, 1H), 5.94 (d, J = 0.8 Hz, 1H), 4.79-4.77 (m, 1H), 4.64 (s, 2H), 3.40 (s, 2H), 2.27-2.20 (m, 1H), 1.84-1.77 (m, 1H), 1.72-1.63 (m, 2H), 1.27-1.12 (m, 2H), 0.91 (dd, J = 13.6, 3.6 Hz, 1H), 0.84 (d, J = 8.8 Hz, 6H), 0.76 (s, 3H).
180	1-cyclohexyl-2,2,2-trifluoroethan-1-ol	LCMS (System 2, Method B) m/z 375.3 (M+Na) ⁺ (ES ⁺).

	 2-((4-(1-cyclohexyl-2,2,2-trifluoroethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.08 (br, 1H), 6.33 (s, 1H), 6.01 (s, 1H), 5.27-5.18 (m, 1H), 4.63 (s, 2H), 3.56 (s, 2H), 1.88-1.75 (m, 1H), 1.71-1.51 (m, 5H), 1.29-0.96 (m, 5H).
181	bicyclo[3.3.1]nonan-9-ol  2-((4-(bicyclo[3.3.1]nonan-9-yloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 333.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.08 (br, 1H), 6.29 (d, J = 1.2 Hz, 1H), 5.94 (d, J = 1.2 Hz, 1H), 4.66 (s, 1H), 4.63 (s, 2H), 3.41 (s, 2H), 1.83-1.75 (m, 6H), 1.73 (d, J = 13.2 Hz, 4H), 1.45 (d, J = 6.0 Hz, 4H).
182	(S)-1,1,1-trifluorooctan-2-ol  (S)-2-((2-methylene-4-oxo-4-((1,1,1-trifluorooctan-2-yl)oxy)butanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 377.1 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.10 (br, 1H), 6.34 (s, 1H), 6.02 (s, 1H), 5.41-5.36 (m, 1H), 4.62 (s, 2H), 3.54 (s, 2H), 1.75-1.62 (m, 2H), 1.26-1.24 (m, 8H), 0.86 (t, J = 6.4 Hz, 3H).
183	(R)-nonan-2-ol  (R)-2-((2-methylene-4-(nonan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 337.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.06 (br, 1H), 6.27 (d, J = 1.2 Hz, 1H), 5.91 (d, J = 1.2 Hz, 1H), 4.82-4.74 (m, 1H), 4.62 (s, 2H), 3.50 (s, 2H), 1.48-1.43 (m, 2H), 1.29-1.23 (m, 10H), 1.13 (d, J = 6.4 Hz, 3H), 0.86 (t, J = 6.8 Hz, 3H).
184	(R)-1-cyclohexylethan-1-ol 	LCMS (System 2, Method B) m/z 321.3 (M+Na)⁺ (ES⁺).

	(R)-2-((4-(1-cyclohexylethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.14 (br, 1H), 6.28 (s, 1H), 5.92 (s, 1H), 4.62 (s, 2H), 4.66-4.58 (m, 1H), 3.26 (s, 2H), 1.69-1.67 (m, 3H), 1.62-1.53 (m, 2H), 1.42-1.35 (m, 1H), 1.25-1.08 (m, 3H), 1.15 (d, J = 6.4 Hz, 3H), 1.04-0.82 (m, 2H).
--	--	---

Example 156 – bis((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-methylenesuccinate



5 Step 1

To a solution of (endo)-3-azabicyclo[3.2.1]octan-8-ol hydrochloride (3.8 g, 23.2 mmol) in a mixture of THF (40 mL) and H₂O (10 mL) was added Na₂CO₃ (7.38 g, 69.7 mmol), followed by Boc₂O (10.1 g, 46.4 mmol) added portionwise at 0 °C. The reaction mixture was stirred at room temperature for 3 h, then diluted with water (100 mL) and extracted with MTBE. The separated organic layers were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at 30 °C, and the residue was purified by flash column chromatography (120 g silica, 0-50% ethyl acetate/petroleum ether) to give *tert*-butyl (endo)-8-hydroxy-3-azabicyclo[3.2.1]octane-3-carboxylate (4.7g, 20.7 mmol, 89 %) as a colorless oil.

¹H NMR (400 MHz, CDCl₃) δ: 4.03 (t, *d* = 5.2 Hz, 1H), 3.67 (d, *d* = 12.0 Hz, 1H), 3.54 (d, *d* = 12.0 Hz, 1H), 3.33(dd, *d* = 32.8, 12.4 Hz, 2H), 2.01 (d, *d* = 20.0 Hz, 1H), 1.70-1.54 (m, 4H), 1.43 (s, 9H).

Step 2

To a solution of *tert*-butyl (endo)-8-hydroxy-3-azabicyclo[3.2.1]octane-3-carboxylate (4.7 g, 20.7 mmol) in DCM (50 mL) was added triethylamine (6.3 g, 62.1 mmol) and acetic

anhydride (6.3 g, 62.1 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 3 h, then washed with water (2 x 50 mL) and brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at 30 °C to give *tert*-butyl (endo)-8-acetoxy-3-azabicyclo[3.2.1]octane-3-carboxylate (5.5 g, 20.4 mmol, 99 %) as a pale-yellow oil. LCMS (System 2, Method C) m/z 214.4 (M-56+H)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ: 4.77 (t, *d* = 4.8 Hz, 1H), 3.70 (d, *d* = 12.8 Hz, 1H), 3.56 (d, *d* = 12.0 Hz, 1H), 3.15 (dd, *d* = 29.2, 12.8 Hz, 2H), 2.20 (d, *d* = 20.0 Hz, 1H), 2.10 (s, 3H), 1.73-1.70 (m, 2H), 1.62-1.56 (m, 2H), 1.45 (s, 9H).

Step 3

To a solution of *tert*-butyl (endo)-8-acetoxy-3-azabicyclo[3.2.1]octane-3-carboxylate (5.5 g, 20.4 mmol) in DCM (50 mL) was added HCl solution in 1,4-dioxane (3 M, 20.4 mL, 61.2 mmol), and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was then concentrated under reduced pressure at 40 °C to give (endo)-3-azabicyclo[3.2.1]octan-8-yl acetate hydrochloride (4.2 g, 20.4 mmol, 98 %) as a pale-yellow solid. LCMS (System 2, Method C) m/z 170.3 (M+H)⁺ (ES⁺).

Step 4

To a mixture of (endo)-3-azabicyclo[3.2.1]octan-8-yl acetate hydrochloride (4.2 g, 20.4 mmol) and triethylamine (6.2 g, 61.2 mmol) in DCM (50 mL) was added methanesulfonyl chloride (4.7 g, 40.8 mmol) at 0 °C, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then washed with water (2 x 50 mL) and brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at 30 °C to give (endo)-3-(methanesulfonyl)-3-azabicyclo[3.2.1]octan-8-yl acetate (4.8 g, 19.4 mmol, 95 %) as pale-brown oil. LCMS (System 2, Method C) m/z 248.3 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ: 4.82 (t, *d* = 5.2 Hz, 1H), 3.65 (dd, *d* = 11.6, 3.6 Hz, 2H), 3.13 (d, *d* = 11.2 Hz, 2H), 2.80 (s, 3H), 2.33 (s, 2H), 2.12 (s, 3H), 1.78 (d, *d* = 1.6 Hz, 4H).

Step 5

To a mixture of (endo)-3-(methanesulfonyl)-3-azabicyclo[3.2.1]octan-8-yl acetate (4.8 g, 19.4 mmol) and 1,4-dioxane (50 mL) was added aqueous NaOH solution (2.5 M, 19.4 mL, 48.5 mmol) at 0 °C, and the reaction mixture was stirred at room temperature for 5 h. The reaction mixture was then acidified with conc. aqueous HCl to pH ~ 7 and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under reduced pressure at 40 °C to give (endo)-3-(methanesulfonyl)-3-azabicyclo[3.2.1]octan-8-ol (4 g, 19.5 mmol, 100 %) as a pale-brown solid. LCMS (System 1, Method A) m/z 206.3 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ: 4.07 (t, *d* = 5.2 Hz, 1H), 3.31 (d, *d* = 2.4 Hz, 4H), 2.79 (s, 3H), 2.33 (s, 2H), 2.11 (q, *d* = 2.4 Hz, 3H), 1.79-1.71 (m, 4H).

Step 6

To a solution of 4-(4-methoxybenzyloxy)-2-methylene-4-oxobutanoic acid (1.70 g, 6.82 mmol), (endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-ol (1.40 g, 6.82 mmol), DMAP (832 mg, 6.82 mmol) and DIPEA (2.64 g, 20.46 mmol) in DCM (20 mL) was added EDC.HCl (1.96 g, 10.23 mmol) at 0 °C, and the resulting pale-yellow mixture was stirred at room temperature overnight. The mixture was then quenched with dilute aqueous HCl (0.5 M, 10 mL), the phases were separated, and the aqueous phase extracted with DCM (2 x 20 mL). The combined organic phases were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at 40 °C, and the residue was purified by flash column chromatography (80 g silica, 30-60% MTBE/petroleum ether) to give 4-(4-methoxybenzyl) 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-methylenesuccinate (2.40 g, 5.49 mmol, 80 %) as a colorless oil. LCMS (System 2, Method B) m/z 460.1 (M+Na)⁺ (ES⁺).

Step 7

A mixture of 4-(4-methoxybenzyl) 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-methylenesuccinate (2.40 g, 5.49 mmol), HCl solution in 1,4-dioxane (4 M, 5 mL, 20 mmol) and DCM (5 mL) was stirred at room temperature for 2 h. The mixture was then concentrated under reduced pressure at 40 °C and the residue was purified by reversed phase column chromatography (120 g C18 silica; flow rate: 40 mL/min; 40-75% MeCN/(10 mM HCl/water); collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 3-(((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yloxy)carbonyl)but-3-enoic acid (1.00 g, 3.15 mmol, 57 %) as a white solid. LCMS (System 2, Method B) m/z 318.3 (M+H)⁺ (ES⁺).



Step 8


To a solution of 3-(((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yloxy)carbonyl)but-3-enoic acid (200 mg, 0.63 mmol), (endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-ol (129 mg, 0.63 mmol), and DMAP (76 mg, 0.63 mmol) in DCM (3 mL) was added EDC.HCl (182 mg, 0.94 mmol) at 0 °C, and the resulting clear colorless mixture was stirred at room temperature for 2 h. The mixture was then quenched with dilute aqueous HCl (0.5 M, 1 mL), the phases were separated, and the aqueous phase was extracted with DCM (2 x 2 mL). The combined organic phases were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at 40 °C, and the residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10 μm 19x250 mm; Flow Rate: 20 mL/min; solvent

system: MeCN/(0.05% TFA/water); gradient: 50-95% MeCN; collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give bis((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-methylenesuccinate (145 mg, 0.29 mmol, 45 %)


5 % as a white solid. LCMS (System 2, Method B) m/z 505.3 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ : 6.36 (s, 1H), 5.95 (s, 1H), 4.82 (t, J = 5.2 Hz, 1H), 4.72 (t, J = 4.8 Hz, 1H), 3.55 (s, 2H), 3.17-3.09 (m, 6H), 3.01 (d, J = 11.2 Hz, 2H), 2.90 (s, 3H), 2.86 (s, 3H), 2.29-2.26 (m, 4H), 1.76-1.70 (m, 4H), 1.61-1.54 (m, 4H).

10 The following compounds were made using a similar procedure:

Example No.	Alcohol used in Step 8 / Example Structure / Name	LCMS / ¹ H NMR data
157	2-oxaspiro[3.3]heptan-6-ol  1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-(2-oxaspiro[3.3]heptan-6-yl) 2-methylenesuccinate	LCMS (System 2, Method B) m/z 414.3 (M+H) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ : 6.32 (s, 1H), 5.88 (s, 1H), 4.81-4.75 (m, 2H), 4.56 (s, 2H), 4.49 (s, 2H), 3.40 (s, 2H), 3.18-3.15 (m, 2H), 3.08-3.06 (m, 2H), 2.89 (s, 3H), 2.64-2.59 (m, 2H), 2.29 (m, 2H), 2.17-2.11 (m, 2H), 1.76-1.73 (m, 2H), 1.62-1.57 (m, 2H).
158	oxepan-4-ol  1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-(oxepan-4-yl) 2-methylenesuccinate	LCMS (System 2, Method B) m/z 438.2 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ : 6.33 (s, 1H), 5.90 (s, 1H), 4.94-4.88 (m, 1H), 4.80 (t, J = 5.2 Hz, 1H), 3.65-3.52 (m, 4H), 3.38 (s, 2H), 3.17 (dd, J = 11.2, 2.8 Hz, 2H), 3.09 (d, J = 11.2 Hz, 2H), 2.90 (s, 3H), 2.30 (m, 2H), 1.94-1.89 (m, 1H), 1.84-1.80 (m, 1H), 1.76-1.62 (m, 5H), 1.60-1.55 (m, 3H).
159	1-butoxypropan-2-ol	LCMS (System 2, Method B) m/z 432.3 (M+H) ⁺ (ES ⁺).

	 4-(1-butoxypropan-2-yl) 1-((endo)-3-(methylsulfonyl)-azabicyclo[3.2.1]octan-8-yl) 2-methylenesuccinate	¹ H NMR (400 MHz, DMSO-d ₆) δ: 6.32 (s, 1H), 5.89 (s, 1H), 4.94-4.90 (m, 1H), 4.79 (t, J = 5.2 Hz, 1H), 3.41 (s, 2H), 3.40-3.39 (m, 2H), 3.36-3.32 (m, 2H), 3.18-3.15 (m, 2H), 3.11-3.08 (m, 2H), 2.89 (s, 3H), 2.30 (m, 2H), 1.76-1.73 (m, 2H), 1.62-1.57 (m, 2H), 1.49-1.42 (m, 2H), 1.34-1.25 (m, 2H), 1.12 (d, J = 6.4 Hz, 3H), 0.87 (t, J = 7.6 Hz, 3H).
--	---	--

Example 160 – 4-spiro[3.3]heptan-2-yl 1-(3,3,3-trifluoro-2,2-dihydroxypropyl) 2-methylenesuccinate hydrate



5 Step 1


A mixture of 3-methylenedihydrofuran-2,5-dione (300 mg, 2.68 mmol), spiro[3.3]heptan-2-ol (250 mg, 2.23 mmol) and *p*-toluenesulfonic acid monohydrate (26 mg, 0.13 mmol) in toluene (90 mL) was stirred at 80 °C for 16 h. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure at 50 °C. The residue was purified by reversed phase column chromatography (120 g C18 silica; flow rate: 40 mL/min; 50-80% MeCN/(10 mM HCl/water); collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 2-methylene-4-oxo-4-(spiro[3.3]heptan-2-yloxy)butanoic acid (450 mg, 90 %) as a white solid that contained 8% of the regioisomeric 3-((spiro[3.3]heptan-2-yloxy)carbonyl)but-3-enoic acid as measured by ¹H NMR. The solid was stirred in a mixture of *n*-hexane (5 mL) and MTBE (0.5 mL) at room temperature overnight, then filtered, and the wet filter cake was dried under reduced pressure at 40 °C to give pure 2-methylene-4-oxo-4-(spiro[3.3]heptan-2-yloxy)butanoic acid (400 mg, 1.78

mmol, 80%). LCMS (System 2, Method C) m/z 247.4 ($M+Na$)⁺ (ES^+). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 12.60 (br, 1H), 6.14 (d, J = 1.2 Hz, 1H), 5.74 (s, 1H), 4.79-4.72 (m, 1H), 3.25 (s, 2H), 2.40-2.35 (m, 2H), 1.99-1.89 (m, 6H), 1.81-1.74 (m, 2H).

5 Step 2

To a solution of 2-methylene-4-oxo-4-(spiro[3.3]heptan-2-yloxy)butanoic acid (200 mg, 0.89 mmol) in DMF (5 mL) was added potassium carbonate (110 mg, 0.89 mmol) and the reaction mixture was stirred at room temperature for 30 min, then 3-bromo-1,1,1-trifluoropropan-2-one (171 mg, 0.89 mmol) was added, and the resulting yellow suspension was stirred at room temperature for 6 h. More potassium carbonate (55 mg, 0.45 mmol) and 3-bromo-1,1,1-trifluoropropan-2-one (86 mg, 0.45 mmol) were added, and the mixture was stirred at room temperature overnight. The mixture was then diluted with EtOAc (10 mL) and water (10 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (2 x 5 mL). The separated organic phases were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at 40 °C, and the residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10 μ m 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.05% TFA/water); gradient: 45-95% MeCN; collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 4-spiro[3.3]heptan-2-yl 1-(3,3,3-trifluoro-2,2-dihydroxypropyl) 2-methylenesuccinate hydrate (131 mg, 0.37 mmol, 41 %) as a pale-yellow oil. LCMS (System 2, Method B) m/z 375.1 ($M+Na$)⁺ (ES^+). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 7.37 (d, J = 3.2 Hz, 2H), 6.25 (s, 1H), 5.86(s, 1H), 4.79-4.72 (m, 1H), 4.15 (s, 2H), 3.32 (s, 2H), 2.39-2.33 (m, 2H), 1.99-1.90 (m, 6H), 1.81-1.73 (m, 2H).

25 Example 161 – (R)-1-((2H-tetrazol-5-yl)methyl) 4-(octan-2-yl) 2-methylenesuccinate



Step 1

A solution of 5-(chloromethyl)-2H-tetrazole (5.5 g, 46.6 mmol) and DIPEA (1.8 g, 139.8 mmol) in dry DCM (80 mL) was stirred for 30 min at room temperature and then 1-(chloromethyl)-4-methoxy benzene (7.3 g, 46.6 mmol) was added. The resulting mixture was stirred at room temperature under a N₂ atmosphere for 16 h, then extracted with DCM (4 x 30 mL) and brine (45 mL). The combined organic layers were dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (120 g silica, 0-60% ethyl acetate/petroleum ether) to give 5-(chloromethyl)-2-(4-methoxybenzyl)-2H-tetrazole (1.25 g, 5.2 mmol, 11 %) as a yellow solid and 5-(chloromethyl)-1-(4-methoxybenzyl)-1H-tetrazole (1.0 g, 4.2 mmol, 9 %) as a yellow solid.

5-(chloromethyl)-2-(4-methoxybenzyl)-2H-tetrazole: ¹H NMR (400 MHz, DMSO-d₆) δ: 7.33 (d, *J* = 8.4 Hz, 2H), 6.93 (d, *J* = 8.8 Hz, 2H), 5.84 (s, 2H), 4.97 (s, 2H), 3.72 (s, 3H).

5-(chloromethyl)-1-(4-methoxybenzyl)-1H-tetrazole: ¹H NMR (400 MHz, DMSO-d₆) δ: 7.31 (d, *J* = 8.8 Hz, 2H), 6.93 (d, *J* = 8.8 Hz, 2H), 5.63 (s, 2H), 5.20 (s, 2H), 3.72 (s, 3H).

Step 2

A solution of 4-(4-methoxybenzyloxy)-2-methylene-4-oxobutanoic acid (1.33 g, 5.3 mmol) and potassium carbonate (731 mg, 5.3 mmol) in dry DMF (20 mL) was stirred for 30 min at room temperature and then 5-(chloromethyl)-2-(4-methoxybenzyl)-2H-tetrazole (1.25 g, 5.3 mmol) was added. The reaction mixture was stirred at room temperature under a N₂ atmosphere for 16 h, then quenched with water (45 mL) and extracted with EtOAc (4 x 30 mL). The organic layer was dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (80 g silica, 0-60% ethyl acetate/petroleum ether) to give 4-(4-methoxybenzyl) 1-(2-(4-methoxybenzyl)-2H-tetrazol-5-yl)methyl 2-methylenesuccinate (1.9 g, 4.2 mmol, 81 %) as a white solid. LCMS (System 2, Method B) *m/z* 453.3 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 7.31 (d, *J* = 8.4 Hz, 2H), 7.21 (d, *J* = 8.4 Hz, 2H), 6.90 (m, 4H), 6.20 (s, 1H), 5.87 (s, 1H), 5.83 (m, 2H), 5.36 (s, 2H), 4.93 (s, 2H), 3.73 (s, 3H), 3.71 (s, 3H), 3.38 (s, 2H).

Step 3

To a solution of 4-(4-methoxybenzyl) 1-(2-(4-methoxybenzyl)-2H-tetrazol-5-yl)methyl 2-methylenesuccinate (1.9 g, 4.2 mmol) in dry DCM (20 mL) was added HCl solution in 1,4-dioxane (4 M, 42 mL, 168 mmol) and the mixture was stirred at room temperature for 4 h. The mixture was then concentrated under reduced pressure at 40 °C and the residue was purified by reversed phase column chromatography (120 g C18 silica; flow rate: 40 mL/min; 0-60%

MeCN/(10 mM HCl/water); collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 3-(((2-(4-methoxybenzyl)-2H-tetrazol-5-yl)methoxy)-carbonyl)but-3-enoic acid (1.0 g, 3.0 mmol, 75 %) as a colorless oil. LCMS (System 2, Method B) m/z 333.3 ($M+H$)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 12.48 (s, 1H), 7.34 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 6.17 (d, J = 1.2 Hz, 1H), 5.84 (s, 3H), 5.39 (s, 2H), 3.73 (s, 3H), 3.29 (s, 2H).



Step 4

To a solution of 3-(((2-(4-methoxybenzyl)-2H-tetrazol-5-yl)methoxy)carbonyl)but-3-enoic acid (180 mg, 0.54 mmol), (R)-octan-2-ol (70 mg, 0.54 mmol) and DMAP (66 mg, 0.54 mmol) in DCM (3 mL) at 0 °C was added EDC.HCl (156 mg, 0.81 mmol), and the resulting colorless clear mixture was stirred at room temperature for 2 h. The mixture was then quenched with dilute aqueous HCl (0.5 M, 1 mL), the phases were separated, and the aqueous phase was extracted with DCM (2 x 2 mL). The separated organic phases were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at 40 °C, and the residue was purified by flash column chromatography (25 g silica, 0-27% MTBE/petroleum ether) to give (R)-1-((2-(4-methoxybenzyl)-2H-tetrazol-5-yl)methyl) 4-(octan-2-yl) 2-methylenesuccinate (130 mg, 0.29 mmol, 54 %) as a yellow oil. LCMS (System 2, Method B) m/z 445.3 ($M+H$)⁺ (ES⁺).


Step 5

A solution of (R)-1-((2-(4-methoxybenzyl)-2H-tetrazol-5-yl)methyl) 4-(octan-2-yl) 2-methylenesuccinate (130 mg, 0.29 mmol) in TFA (4 mL) was stirred at 45 °C for 2 h and then concentrated under reduced pressure at 40 °C. The residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10 μ m 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.05% TFA/water); gradient: 50-95% MeCN; collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give (R)-1-((2H-tetrazol-5-yl)methyl) 4-(octan-2-yl) 2-methylenesuccinate (65 mg, 0.20 mmol, 68 %) as a white solid. LCMS (System 2, Method B) m/z 325.3 ($M+H$)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 16.75 (br, 1H), 6.29 (s, 1H), 5.91 (s, 1H), 5.46 (s, 2H), 4.74-4.69 (m, 1H), 3.35 (s, 2H), 1.43-1.37 (m, 2H), 1.25-1.19 (m, 8H), 1.05 (d, J = 6.0 Hz, 3H), 0.83 (t, J = 6.8 Hz, 3H).

The following compounds were made using a similar procedure:

Example No.	Alcohol used in Step 4 / Example Structure / Name	LCMS / ¹ H NMR data
162	cycloheptanol  1-(2H-tetrazol-5-yl)methyl 4-cycloheptyl 2-methylenesuccinate	LCMS (System 2, Method B) m/z 309.3 (M+H) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 16.78 (br, 1H), 6.28 (s, 1H), 5.90 (s, 1H), 5.46 (s, 2H), 4.78-4.71 (m, 1H), 3.33 (s, 2H), 1.74-1.67 (m, 2H), 1.51-1.44 (m, 8H), 1.5-1.31 (m, 2H).
163	spiro[3.3]heptan-2-ol  1-(2H-tetrazol-5-yl)methyl 4-spiro[3.3]heptan-2-yl 2-methylenesuccinate	LCMS (System 2, Method B) m/z 307.1 (M+H) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 16.80 (br, 1H), 6.29 (s, 1H), 5.90 (s, 1H), 5.46 (s, 2H), 4.73-4.65 (m, 1H), 3.33 (s, 2H), 2.33-2.29 (m, 2H), 1.94-1.87 (m, 4H), 1.85-1.80 (m, 2H), 1.76-1.73 (m, 2H).

Example 164 – (S)-1-(2H-tetrazol-5-yl)methyl 4-octan-2-yl 2-methylenesuccinate



Step 1

To a solution of (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (150 mg, 0.62 mmol) in DMF (2 mL) was added potassium carbonate (86 mg, 0.62 mmol) and the mixture was stirred at room temperature for 30 min. 5-(Chloromethyl)-2-(4-methoxybenzyl)-2H-tetrazole (148 mg, 0.62 mmol) was added, and the mixture was stirred at room temperature for 2 h, then diluted with EtOAc (2 mL) and water (2 mL). The phases were separated, and the aqueous phase was extracted with EtOAc (2 x 2 mL). The combined organic phases were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at


40 °C, and the residue was purified by flash column chromatography (25 g silica, 0-40% MTBE/petroleum ether) to give (S)-1-(2-(4-methoxybenzyl)-2H-tetrazol-5-yl)methyl 4-octan-2-yl 2-methylenesuccinate (220 mg, 0.49 mmol, 80 %) as a colorless oil. LCMS (System 2, Method B) m/z 445.3 (M+H)⁺ (ES⁺).

5

Step 2

A mixture of (S)-1-(2-(4-methoxybenzyl)-2*H*-tetrazol-5-yl)methyl 4-octan-2-yl 2-methylenesuccinate (220 mg, 0.49 mmol) in TFA (1 mL) and DCM (1 mL) was stirred at 45 °C for 4 h, then concentrated under reduced pressure at 40 °C. The residue was purified by reversed phase column chromatography (120 g C18 silica; flow rate: 40 mL/min; 50-80% MeCN/(10 mM HCl/water); collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40°C to remove MeCN, and the residue was lyophilized to give a solid (116 mg), which was twice triturated in a mixture of *n*-hexane (4 mL) and MTBE (0.5 mL) to give (S)-1-(2*H*-tetrazol-5-yl)methyl 4-octan-2-yl 2-methylenesuccinate (90 mg, 0.28 mmol, 57 %) as a white solid. LCMS (System 2, Method B) *m/z* 325.3 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 16.75 (br, 1H), 6.29 (s, 1H), 5.90 (s, 1H), 5.45 (s, 2H), 4.74-4.69 (m, 1H), 3.34 (s, 2H), 1.43-1.38 (m, 2H), 1.25-1.19 (m, 8H), 1.05 (d, *J* = 6.4 Hz, 3H), 0.83 (t, *J* = 6.8 Hz, 3H).

20 **Example 165 – 1-(1-(1H-tetrazol-5-yl)ethyl) 4-((S)-octan-2-yl) 2-methylenesuccinate**



Step 1

A mixture of ethyl 1H-tetrazole-5-carboxylate (4.6 g, 32.4 mmol), 1-(chloromethyl)-4-methoxybenzene (5.1 g, 32.4 mmol) and potassium carbonate (4.5 g, 32.4 mmol) in DMF (50 mL) was stirred at room temperature overnight. The reaction mixture was then diluted with H₂O (150 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure at 40 °C. The residue was purified by flash column chromatography (120 g silica, 0-40% ethyl acetate/petroleum ether) to give ethyl 2-(4-methoxybenzyl)-2H-tetrazole-5-carboxylate (2.1 g, 8.0 mmol, 25 %) as a white solid and a mixture of ethyl 2-(4-methoxybenzyl)-2H-tetrazole-5-carboxylate and ethyl 1-(4-methoxybenzyl)-1H-tetrazole-5-carboxylate (2.2 g, 8.4 mmol, 26 %) as a white solid.

ethyl 2-(4-methoxybenzyl)-2H-tetrazole-5-carboxylate: LCMS (System 2, Method B) m/z 285.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 7.36 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 5.93 (s, 2H), 4.37 (q, J = 7.2 Hz, 2H), 3.71 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H).

Step 2

To a solution of ethyl 2-(4-methoxybenzyl)-2H-tetrazole-5-carboxylate (1.4 g, 5.35 mmol) in methanol (40 mL) at 0 °C was added lithium borohydride solution in THF (2 M, 5.35 mL, 10.7 mmol) and the reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was quenched with dilute aqueous HCl (0.5 M, 20 mL), and concentrated under reduced pressure at 35 °C to remove methanol. The aqueous residue was extracted with EtOAc (2 x 20 mL), and the combined organic layers were dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (120 g silica, 0-60% ethyl acetate/petroleum ether) to give (2-(4-methoxybenzyl)-2H-tetrazol-5-yl)methanol (800 mg, 3.63 mmol, 68 %) as a yellow oil. LCMS (System 2, Method B) m/z 243.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 7.32 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.4 Hz, 3H), 5.79 (s, 2H), 4.61 (s, 2H), 3.72 (s, 3H).

Step 3

To a solution of (2-(4-methoxybenzyl)-2H-tetrazol-5-yl)methanol (800 mg, 3.63 mmol) in dichloromethane (20 mL) was added Dess-Martin periodinane (2.31 g, 5.45 mmol) at 0 °C, and the reaction mixture was stirred at room temperature for 0.5 h. The reaction mixture was quenched by the addition of aqueous Na₂S₂O₃/NaHCO₃ mixture (20 mL) and then extracted with DCM (2 x 20 mL). The combined organic layers were dried over Na₂SO₄, filtered and the filtrate was concentrated to give crude 2-(4-methoxybenzyl)-2H-tetrazole-5-carbaldehyde (750 mg, 3.44 mmol, 94 %) as a yellow oil, which was used directly in the next step.

LCMS (System 2, Method B) m/z 259.3 2 ($M+H_2O+Na$)⁺ (ES^+). ¹H NMR (400 MHz, DMSO- d_6) δ : 10.08 (s, 1H), 7.38 (d, J = 8.4 Hz, 2H), 6.94 (d, J = 8.4 Hz, 2H), 5.97 (s, 2H), 3.72 (s, 3H).

Step 4

5 To a solution of 2-(4-methoxybenzyl)-2H-tetrazole-5-carbaldehyde (400 mg, 1.83 mmol) in THF (10 mL) at -40 °C was added a solution of methyl magnesium bromide in THF (1 M, 5.46 mL, 5.46 mmol) and the resulting mixture was stirred at room temperature for 2 h. The reaction mixture was then quenched with dilute aqueous HCl (0.5 M, 10 mL) and extracted with EtOAc (2 x 10 mL). The combined organic layers were dried over Na₂SO₄, filtered and the filtrate was
10 concentrated under reduced pressure. The residue was purified by flash column chromatography (120 g silica, 0-50% ethyl acetate/petroleum ether) to give crude 1-(2-(4-methoxybenzyl)-2H-tetrazol-5-yl)ethan-1-ol (300 mg, 1.28 mmol, 70 %) as a yellow oil. LCMS (System 2, Method B) m/z 235.3 ($M+H$)⁺ (ES^+). ¹H NMR (400 MHz, DMSO- d_6) δ : 7.34 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.4 Hz, 3H), 5.81 (s, 2H), 4.96 (q, J = 6.4 Hz,
15 1H), 3.74 (s, 3H), 1.45 (d, J = 6.4 Hz, 3H).

Step 5

To a solution of (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (300 mg, 1.28 mmol), 1-(2-(4-methoxybenzyl)-2H-tetrazol-5-yl)ethan-1-ol (300 mg, 1.28 mmol) and DMAP (156
20 mg, 1.28 mmol) in DCM (7 mL) at 0 °C was added EDC.HCl (369 mg, 1.92 mmol), and the resulting colorless clear mixture was stirred at room temperature for 3 h. The mixture was quenched with dilute aqueous HCl (0.5 M, 1 mL), the phases were separated, and the aqueous phase was extracted with DCM (2 x 2 mL). The combined organic phases were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at
25 40 °C, and the residue was purified by flash column chromatography (25 g silica, 0-40% MTBE/petroleum ether) to give 1-(1-(2-(4-methoxybenzyl)-2H-tetrazol-5-yl)ethyl) 4-((S)-octan-2-yl) 2-methylenesuccinate (400 mg, 0.87 mmol, 68 %) as a yellow oil. LCMS (System 2, Method B) m/z 459.3 ($M+H$)⁺ (ES^+).


Step 6

A solution of 1-(1-(2-(4-methoxybenzyl)-2H-tetrazol-5-yl)ethyl) 4-((S)-octan-2-yl) 2-methylenesuccinate (400 mg, 0.87 mmol) in TFA (8 mL) was stirred at 45 °C for 2 h, then concentrated at 40 °C under reduced pressure and the residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10 μ m 19x250 mm; Flow Rate: 20 mL/min; solvent
35 system: MeCN/(0.05% TFA/water); gradient: 30-95% MeCN; collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 1-(1-(1H-tetrazol-5-yl)ethyl) 4-((S)-octan-2-yl) 2-

methylenesuccinate (120 mg, 0.35 mmol, 40 %) as a pale-yellow oil. LCMS (System 2, Method B) m/z 339.3 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ : 16.75 (br, 1H), 6.29 (s, 1H), 6.19 (q, J = 6.4 Hz, 1H), 5.91 (s, 1H), 4.76-4.71 (m, 1H), 3.35 (s, 2H), 1.63 (d, J = 6.4 Hz, 3H), 1.44-1.41 (m, 2H), 1.25-1.19 (m, 8H), 1.08 (t, J = 5.6 Hz, 3H), 0.85 (t, J = 5.6 Hz, 3H).

5

Example 166 – 1-(cyclopropyl(1H-tetrazol-5-yl)methyl) 4-((S)-octan-2-yl) 2-methylenesuccinate



10 **Step 1**

A mixture of ethyl 1H-tetrazole-5-carboxylate (4.6 g, 32.4 mmol), triphenylmethyl chloride (9.0 g, 32.4 mmol) and potassium carbonate (4.5 g, 32.4 mmol) in DMF (50 mL) was stirred at room temperature overnight. The reaction mixture was diluted with saturated aqueous NH₄Cl solution (150 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with
 15 brine (100 mL), dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure at 40 °C. The residual solid was purified by trituration in a mixture of petroleum ether (30 mL) and ethyl acetate (3 mL) to give ethyl 2-trityl-2H-tetrazole-5-carboxylate (6.4 g, 16.6 mmol, 51 %) as a white solid. LCMS (System 2, Method C) m/z 407.4 (M+Na)⁺ (ES⁺).

20 **Step 2**

To a solution of 2-trityl-2H-tetrazole-5-carboxylate (2.1 g, 5.8 mmol) in THF (50 mL) at 0 °C was added lithium aluminium hydride (416 mg, 10.9 mmol), and the reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was quenched by adding Na₂SO₄·10H₂O (2.1 g, 6.5 mmol) in portions, then the mixture was filtered and the filtrate was concentrated under reduced pressure
 25 at 35 °C to give (2-trityl-2H-tetrazol-5-yl)methanol (1.4 g, 4.1 mmol, 75 %) as a white solid. LCMS (System 2, Method C) m/z 365.4 (M+Na)⁺ (ES⁺).

Step 3

To a solution of (2-trityl-2H-tetrazol-5-yl)methanol (1.4 g, 4.1 mmol) in DCM (1 mL) at 0 °C was added Dess-Martin periodinane (2.6 g, 6.1 mmol), and the reaction mixture was stirred at room temperature for 0.5 h. The reaction mixture was quenched by the addition of aqueous Na₂S₂O₃/NaHCO₃ mixture (20 mL) and then extracted with DCM (2 x 50 mL). The combined organic layer was dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure at 30 °C. The residue was purified by flash column chromatography (120 g silica, 0-5% ethyl acetate/petroleum ether) to give 2-trityl-2H-tetrazole-5-carbaldehyde (720 mg, 2.1 mmol, 51 %) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.15 (s, 1H), 7.44-7.41 (m, 9H), 7.08-7.05 (m, 6H).

Step 4

To a solution of 2-trityl-2H-tetrazole-5-carbaldehyde (720 mg, 2.12 mmol) in THF (20 mL) at 0 °C was added cyclopropyl magnesium bromide solution in THF (1 M, 3.2 mL, 3.2 mmol), and the reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was quenched by the addition of saturated aqueous NH₄Cl solution (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layers were dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure at 40 °C. The residue was purified by basic silica flash column chromatography (0-10% ethyl acetate/petroleum ether) to give cyclopropyl(2-trityl-2H-tetrazol-5-yl) methanol (540 mg, 68 %) as a yellow solid. LCMS (System 2, Method C) m/z 405.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 7.19-7.15 (m, 9H), 6.80-6.76 (m, 6H), 5.52 (br, 1H), 4.10 (d, J = 7.6 Hz, 1H), 1.08-1.05 (m, 1H), 0.29-0.26 (m, 1H), 0.18-0.12 (m, 2H), 0.01-0.00 (m, 1H).

Step 5


To a solution of (S)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (126 mg, 0.52 mmol), cyclopropyl(2-trityl-2H-tetrazol-5-yl) methanol (200 mg, 0.52 mmol) and DMAP (63 mg, 0.52 mmol) in DCM (7 mL) at 0 °C was added dicyclohexylcarbodiimide (150 mg, 0.78 mmol), and the resulting mixture was stirred at room temperature for 3 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure at 30 °C. The residue was purified by flash column chromatography (40 g silica, 0-40% MTBE/petroleum ether) to give 1-(cyclopropyl(2-trityl-2H-tetrazol-5-yl)methyl) 4-((S)-octan-2-yl) 2-methylenesuccinate (240 mg, 0.40 mmol, 76%) as a yellow oil. LCMS (System 2, Method C) m/z 629.2 (M+Na)⁺ (ES⁺).

Step 6

A mixture of 1-(cyclopropyl(2-trityl-2H-tetrazol-5-yl)methyl) 4-((S)-octan-2-yl) 2-methylenesuccinate (200 mg, 0.33 mmol) and HCl solution in 1,4-dioxane (4 M, 1 mL, 4 mmol) in

DCM (4 mL) was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure at 30 °C and the residue was purified by flash column chromatography (80 g silica, 0-40% ethyl acetate/petroleum ether) to give the crude product, which was further purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10 µm 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.05% TFA/water); gradient: 30-95% MeCN; collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 1-(cyclopropyl(1H-tetrazol-5-yl)methyl) 4-((S)-octan-2-yl) 2-methylenesuccinate (27 mg, 0.074 mmol, 22%) as a pale-yellow oil. LCMS (System 2, Method B) m/z 365.2 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 6.28 (s, 1H), 5.90 (s, 1H), 5.58 (d, J = 9.2 Hz, 1H), 4.76-4.73 (m, 1H), 3.41 (s, 2H), 1.50-1.41 (m, 3H), 1.26 (m, 9H), 1.09 (dd, J = 9.6, 6.4 Hz, 3H), 0.85 (t, J = 5.6 Hz, 3H), 0.62-0.58 (m, 2H), 0.47 (m, 2H).

Example 167 – dicyclohexyl 2-methylenesuccinate



A mixture of 3-methylenedihydrofuran-2,5-dione (3.00 g, 26.8 mmol), cyclohexanol (2.44 g, 24.3 mmol) and *p*-toluenesulfonic acid monohydrate (255 mg, 1.34 mmol) in toluene (30 mL) was stirred at 80 °C for 16 hours, then cooled to room temperature and concentrated under reduced pressure at 50 °C. The residue was purified by reversed phase column chromatography (120 g C18 silica; flow rate: 40 mL/min; 50-70% then 80-90% MeCN/(10 mM HCl/water); collection wavelength: 214 nm).


The first set of fractions that were collected were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 4-(cyclohexyloxy)-2-methylene-4-oxobutanoic acid that contained ~ 5% (by ¹H-NMR) of the regioisomeric 3-((cyclohexyloxy)carbonyl)but-3-enoic acid (3.00 g, 14.1 mmol, 58%) as a white solid.

The second set of fractions that were collected were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give the crude product, which was further purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10 µm 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.05% TFA/water); gradient: 70-95% MeCN; collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give dicyclohexyl 2-methylenesuccinate (82 mg, 0.28 mmol, 1 %) as a pale-yellow oil.

dicyclohexyl 2-methylenesuccinate: LCMS (System 2, Method B) m/z 295.4 ($M+H$)⁺ (ES^+). ¹H NMR (400 MHz, DMSO- d_6) δ : 6.17 (s, 1H), 5.78 (s, 1H), 4.75-4.70 (m, 1H), 4.67-4.62 (m, 1H), 3.33 (d, J = 2.8 Hz, 2H), 1.73-1.68 (m, 4H), 1.63-1.61 (m, 4H), 1.46-1.37 (m, 4H), 1.35-1.22 (m, 8H).

5

Example 168 – 2-((4-(cyclooctyloxy)-3-methyl-2-methylene-4-oxobutanoyl)oxy)acetic acid



Step 1

10 To a solution of 4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid (570 mg, 2.38 mmol) in THF (10 mL) at -78 °C was added a solution of LDA in THF/*n*-heptane/ethyl benzene (2 M, 2.38 mL, 4.76 mmol), and the reaction mixture was stirred at -78 °C for 1 h. Iodomethane (338 mg, 2.38 mmol) was then added at -78 °C, and the reaction mixture was stirred at -78 °C for 2 h. The reaction mixture was quenched with dilute aqueous HCl (0.5 M, 20 mL) and extracted with EtOAc

15 (2 x 20 mL). The combined organic phases were dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure at 35 °C to give crude 4-(cyclooctyloxy)-3-methyl-2-methylene-4-oxobutanoic acid (550 mg, 2.16 mmol, 91%) as a colorless oil, which was used in the next step without purification. LCMS (System 2, Method C) m/z 277.4 ($M+Na$)⁺ (ES^+).

20 Step 2

To a solution of 4-(cyclooctyloxy)-3-methyl-2-methylene-4-oxobutanoic acid (550 mg, 2.16 mmol) in acetone (10 mL) was added potassium carbonate (329 mg, 2.39 mmol), and the reaction mixture was stirred at room temperature for 30 min. *tert*-Butyl 2-bromoacetate (464 mg, 2.39 mmol) was then added and the resulting mixture was stirred at room temperature overnight. The

25 reaction mixture was filtered and the filtrate was concentrated under reduced pressure at 40 °C. The residue was purified by flash column chromatography (25 g silica, 0-10% MTBE/petroleum ether) to give 1-(2-(*tert*-butoxy)-2-oxoethyl) 4-cyclooctyl 3-methyl-2-methylenesuccinate (380 mg, 1.0 mmol, 48%) as a yellow oil. LCMS (System 2, Method B) m/z 391.3 ($M+Na$)⁺ (ES^+).


30 Step 3

A mixture of 1-(2-(*tert*-butoxy)-2-oxoethyl) 4-cyclooctyl 3-methyl-2-methylenesuccinate (180 mg, 0.49 mmol) and HCl solution in 1,4-dioxane (4 M, 2 mL, 8.0 mmol) in DCM (2 mL) was stirred at room temperature for 4 h, then concentrated under reduced pressure at 40 °C. The residue was

purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10 μ m 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.05% TFA/water) gradient: 30-95% MeCN; collection wavelength: 214 nm). The fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 2-((4-(cyclooctyloxy)-3-methyl-2-methylene-4-oxobutanoyl)oxy)acetic acid (117 mg, 0.37 mmol, 77 %) as a pale-yellow oil.

LCMS (System 2, Method B) m/z 335.2 ($M+Na$)⁺ (ES^+). ¹H NMR (400 MHz, DMSO- d_6) δ : 13.10 (br, 1H), 6.28 (s, 1H), 5.85 (s, 1H), 4.82-4.76 (m, 1H), 4.64 (d, J = 1.6 Hz, 2H), 3.51 (q, J = 6.8 Hz, 1H), 1.70-1.62 (m, 6H), 1.55-1.41 (m, 8H), 1.27 (d, J = 7.2 Hz, 3H).

Example 171 – 2-((4-(cyclooctyloxy)-3-methoxy-2-methylene-4-oxobutanoyl)oxy)acetic acid



Step 1

A mixture of (2R,3R)-2,3-dihydroxysuccinic acid (3 g, 20 mmol), cyclooctanol (7.7 g, 60 mmol), anhydrous *p*-toluenesulfonic acid (344 mg, 2 mmol) and anhydrous Na₂SO₄ (6 g, 42.2 mmol) in toluene (40 mL) was stirred at 80 °C for 16 h. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure at 45 °C and the residue was purified by reversed phase column chromatography (120 g C18 silica; flow rate: 40 mL/min; 50-70% MeCN/(10 mM HCl/water); collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give dicyclooctyl (2R,3R)-2,3-dihydroxysuccinate (3.5 g, 9.4 mmol, 47 %) as a white solid. LCMS (System 2, Method B) m/z 393.3 ($M+Na$)⁺ (ES^+). ¹H NMR (400 MHz, DMSO- d_6) δ : 5.38 (d, J = 8.0 Hz, 2H), 4.90-4.86 (m, 2H), 4.32 (d, J = 7.6 Hz, 2H), 1.77-1.65 (m, 12H), 1.58-1.49 (m, 16H).

Step 2

To a solution of dicyclooctyl (2*R*,3*R*)-2,3-dihydroxysuccinate (3.5 g, 9.4 mmol) in THF:H₂O (2:1, 40 mL) was added NaIO₄ (2.3 g, 18.8 mmol) at room temperature, and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was filtered, the filtrate was diluted with EtOAc (30 mL), quenched with saturated aqueous Na₂S₂O₃ aq. and separated. The organic layer was washed with saturated aqueous NaHCO₃, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 30 °C. The residue was purified by flash column chromatography (40 g silica, 0-20% EtOAc/petroleum ether) to give crude cyclooctyl 2-oxoacetate (3 g, 16.3 mmol, 87 %) as a pale yellow oil, which was used directly in the next step. ¹H NMR (400 MHz, CDCl₃) δ: 9.39 (s, 1H), 5.08-5.03 (m, 1H), 1.91-1.68 (m, 6H), 1.60-1.58 (m, 8H).

Step 3

A mixture of cyclooctyl 2-oxoacetate (3 g, 16.3 mmol), *tert*-butyl acrylate (3.1 g, 24.4 mmol) and DABCO (914 mg, 8.1 mmol) in a solvent mixture of 1,4-dioxane/DMSO/H₂O (20 mL, 8/2/1) was stirred at room temperature for 48 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure at 50 °C. The residue was purified by reversed phase column chromatography (120 g C18 silica; flow rate: 40 mL/min; 50-70% MeCN/H₂O; collection wavelength: 214 nm). The collected fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 1-(*tert*-butyl) 4-cyclooctyl 3-hydroxy-2-methylenesuccinate (2.3 g, 7.4 mmol, 45 %) as a yellow oil. LCMS (System 2, Method B) m/z 335.2 (M+Na)⁺ (ES⁺).

Step 4

To a mixture of 1-(*tert*-butyl) 4-cyclooctyl 3-hydroxy-2-methylenesuccinate (300 mg, 0.96 mmol) and Ag₂O (445 mg, 1.92 mmol) in DCM (1 mL) was added methyl iodide (818 mg, 5.76 mmol), and the reaction mixture was stirred at 40 °C for 16 h. The mixture was filtered and the filtrate was concentrated under reduced pressure at 30 °C to give the crude product as a 5:1 mixture of 1-(*tert*-butyl) 4-cyclooctyl 3-methoxy-2-methylenesuccinate and 1-(*tert*-butyl) 4-cyclooctyl 3-methoxy-2-methylfumarate respectively. The crude product was purified by flash column chromatography (25 g silica, 0-10% MTBE/petroleum ether) to give pure 1-(*tert*-butyl) 4-cyclooctyl 3-methoxy-2-methylenesuccinate (250 mg, 0.77 mmol, 79%) as a pale yellow oil. LCMS (System 2, Method B) m/z 349.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ: 6.31 (d, *J* = 0.8 Hz, 1H), 5.88 (s, 1H), 5.02-4.98 (m, 1H), 4.58 (s, 1H), 3.44 (s, 3H), 1.86-1.64 (m, 6H), 1.63-1.52 (m, 8H), 1.48 (s, 9H).

Step 5


A mixture of 1-(*tert*-butyl) 4-cyclooctyl 3-methoxy-2-methylenesuccinate (230 mg, 0.71 mmol) and TFA (2 mL) in DCM (2 mL) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure at 40 °C to give crude 4-(cyclooctyloxy)-3-methoxy-2-methylene-4-oxobutanoic acid (200 mg, 0.71 mmol, > 100 %) as a pale yellow oil, which was used directly in the next step. LCMS (System 2, Method C) m/z 293.4 (M+Na)⁺ (ES⁺).

Step 6

To a solution of crude 4-(cyclooctyloxy)-3-methoxy-2-methylene-4-oxobutanoic acid (200 mg, 0.71 mmol) in acetone (5 mL) was added potassium carbonate (110 mg, 0.74 mmol), and the reaction mixture was stirred at room temperature for 30 min. *Tert*-butyl 2-bromoacetate (171 mg, 0.89 mmol) was added and the resulting mixture was stirred at room temperature overnight. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure at 40 °C. The residue was purified by flash column chromatography (25 g silica, 0-10% MTBE/petroleum ether) to give 1-(2-(*tert*-butoxy)-2-oxoethyl) 4-cyclooctyl 3-methoxy-2-methylenesuccinate (200 mg, 0.52 mmol, 73%) as a yellow oil. LCMS (System 2, Method B) m/z 407.3 (M+Na)⁺ (ES⁺).

Step 7

A mixture of 1-(2-(*tert*-butoxy)-2-oxoethyl) 4-cyclooctyl 3-methoxy-2-methylenesuccinate (200 mg, 0.52 mmol) and TFA (2 mL) in DCM (2 mL) was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure at 40 °C and the residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10µm 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.1% TFA/water) gradient: 45-95% MeCN; collection wavelength: 214 nm). The fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 2-((4-(cyclooctyloxy)-3-methoxy-2-methylene-4-oxobutanoyl)oxy)acetic acid (144 mg, 0.44 mmol, 84%) as a white solid. LCMS (System 2, Method B) m/z 351.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 12.97 (br, 1H), 6.40 (s, 1H), 6.03 (s, 1H), 4.90-4.84 (m, 1H), 4.65 (s, 2H), 4.60 (s, 1H), 3.33 (s, 3H), 1.77-1.54 (m, 6H), 1.49-1.38 (m, 8H).

Example 172 – 2-((4-((adamantan-1-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid**Step 1**

- 5 A mixture of adamantan-1-ol (3.1 g, 20 mmol), bromoacetic acid (5.5 g, 40 mmol) and anhydrous $p\text{-toluenesulfonic acid}$ (172 mg, 1 mmol) in toluene (100 mL) was heated at reflux overnight. The reaction mixture was cooled to room temperature, diluted with saturated aqueous NaHCO_3 , separated and the aqueous layer was extracted with EtOAc (2 x 30 mL). The combined organic layers was washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure at 40°C . The residue was purified by flash column chromatography (80 g silica, 0-5% EtOAc /petroleum ether) to give adamantan-1-yl 2-bromoacetate (4.5 g, 16.5 mmol, 83%) as a white solid. $^1\text{H NMR}$ (400 MHz, DMSO-d_6) δ : 4.02 (s, 2H), 2.50 (m, 3H), 2.05 (d, $J = 3.2$ Hz, 6H), 1.62 (t, $J = 2.8$ Hz, 6H).

Step 2

- 15 To a solution of ethyl 2-(diethoxyphosphoryl)acetate (1.2 g, 5.4 mmol) in THF (10 mL) was added NaH suspension in mineral oil (60 wt. %, 236 mg, 5.9 mmol) at 0°C , the reaction mixture was stirred at 0°C for 0.5 h, then adamantan-1-yl 2-bromoacetate (1.61 g, 5.9 mmol) was added. The reaction mixture was stirred at room temperature for 4 h, then it was quenched by the addition of dilute aqueous HCl (0.5 M, 10 mL), adjusted to $\text{pH} = 5$, and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure at 40°C . The residue was purified by flash column chromatography (40 g silica, 0-30% EtOAc /petroleum ether) to give crude 4-(adamantan-1-yl) 1-ethyl 2-(diethoxyphosphoryl)succinate (2 g, 4.8 mmol, 90%) as a yellow oil. LCMS (System 2, Method B) m/z 417.3 ($\text{M}+\text{H}^+$) (ES^+). $^1\text{H NMR}$ (400 MHz, DMSO-d_6) δ : 4.13-4.00 (m, 6H), 3.37-3.32 (m, 1H), 2.75-2.72 (m, 1H), 2.63-2.60 (m, 1H), 2.11 (m, 3H), 2.01 (s, 6H), 1.60 (m, 6H), 1.26-1.17 (m, 9H).

Step 3

To a solution of 4-(adamantan-1-yl) 1-ethyl 2-(diethoxyphosphoryl)succinate (2 g, 4.8 mmol) and potassium carbonate (1.3 g, 9.6 mmol) in DMF (20 mL) was added formaldehyde solution in water (37 wt. %, 7.8 mL, 96 mmol) at room temperature, and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with H₂O (60 mL) and extracted with MTBE (2 x 30 mL). The combined organic layers were washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 30 °C. The residue was purified by flash column chromatography (40 g silica, 0-10% MTBE/petroleum ether) to give 4-(adamantan-1-yl) 1-ethyl 2-methylenesuccinate (800 mg, 3.0 mmol, 57%) as a yellow oil. LCMS (System 2, Method B) m/z 315.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 6.14 (d, *J* = 1.2 Hz, 1H), 5.75 (d, *J* = 1.2 Hz, 1H), 4.13 (q, *J* = 7.2 Hz, 2H), 3.26 (s, 2H), 2.11 (m, 3H), 2.01 (d, *J* = 2.8 Hz, 6H), 1.60 (s, 6H), 1.21 (t, *J* = 7.8 Hz, 3H).

Step 4


To a solution of 4-(adamantan-1-yl) 1-ethyl 2-methylenesuccinate (800 mg, 3.0 mmol) in THF (10 mL) was added LiOH solution in water (2 M, 4.5 mL, 9 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure at 30 °C to remove THF. The residue was diluted with H₂O (20 mL) and washed with MTBE (2 x 10 mL). The aqueous layer was adjusted to pH = 3 using dilute aqueous HCl (0.5 M) and extracted with EtOAc (2 x 10 mL). The combined EtOAc layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 40 °C to give a 1:1 mixture of 4-((adamantan-1-yl)oxy)-2-methylene-4-oxobutanoic acid and 4-((adamantan-1-yl)oxy)-2-methyl-4-oxobut-2-enoic acid (300 mg, 1.1 mmol, 38%) as a pale yellow oil, which was used directly in the next step. LCMS (System 2, Method C) m/z 287.2 (M+Na)⁺ (ES⁺).

Step 5


To a solution of a 1:1 mixture of 4-((adamantan-1-yl)oxy)-2-methylene-4-oxobutanoic acid and 4-((adamantan-1-yl)oxy)-2-methyl-4-oxobut-2-enoic acid (300 mg, 1.1 mmol), and potassium carbonate (157 mg, 1.1 mmol) in acetone (10 mL) was added 2,2,2-trichloroethyl 2-bromoacetate (354 mg, 1.3 mmol) at room temperature, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then filtered, and the filtrate was concentrated under reduced pressure at 30 °C. The residue was purified by flash column chromatography (40 g silica, 0-10% MTBE/petroleum ether) to give 4-(adamantan-1-yl) 1-(2-oxo-2-(2,2,2-trichloroethoxy)ethyl) 2-methylenesuccinate (270 mg, 0.60 mmol, 54%) as a yellow oil. LCMS (System 2, Method B) m/z 475.3 (M+Na)⁺ (ES⁺).

Step 6

To a solution of 4-(adamantan-1-yl) 1-(2-oxo-2-(2,2,2-trichloroethoxy)ethyl) 2-methylenesuccinate (270 mg, 0.60 mmol) in AcOH (5 mL) was added zinc powder (195 mg, 3 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure at 45 °C. The residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10µm 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.05% TFA/water) gradient: 50-95% MeCN; collection wavelength: 214 nm). The fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 2-((4-((adamantan-1-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (72 mg, 37 %) as a colorless oil. LCMS (System 2, Method B) m/z 345.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.07 (br, 1H), 6.23 (s, 1H), 5.86 (s, 1H), 4.64 (s, 2H), 3.27 (s, 2H), 2.10 (s, 3H), 2.01 (d, J = 2.4 Hz, 6H), 1.60 (m, 6H).


Example 185 – 1-(3,3-difluorocyclobutyl) 4-octyl 2-methylenesuccinate

Example 185 was prepared according to General Procedure 2, using 4-octyl itaconate as itaconic acid monoester and 3,3-difluorocyclobutanol as R²-OH. LCMS m/z 333.4 (M+H)⁺ (ES⁺). ¹H NMR (500 MHz, DMSO-d₆) δ 6.25 (d, J = 1.2 Hz, 1H), 5.89 (d, J = 1.3 Hz, 1H), 4.95 (dddd, J = 12.3, 7.6, 4.7, 2.8 Hz, 1H), 4.01 (t, J = 6.6 Hz, 2H), 3.38 (s, 2H), 3.15 - 3.05 (m, 2H), 2.72 - 2.60 (m, 2H), 1.58 - 1.50 (m, 2H), 1.33 - 1.19 (m, 10H), 0.89 - 0.83 (m, 3H).

Example 186 – 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-((R)-octan-2-yl) 2-methylenesuccinate

Example 186 was prepared according to General Procedure 2, using (R)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 8) as itaconic acid monoester and (endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-ol as R²-OH. LCMS m/z 452.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ 6.31 (d, J = 0.8 Hz, 1H), 5.85 (d, J = 1.2 Hz, 1H), 4.80-4.75 (m, 2H), 3.40 (s, 2H), 3.17 (dd, J = 11.6, 3.2 Hz, 2H), 3.10 (dd, J = 10.8, 4.4 Hz, 2H), 2.89 (s, 3H), 2.30 (s, 2H), 1.76-1.74 (m, 2H), 1.62-1.57 (m, 2H), 1.48-1.45 (m, 2H), 1.27-1.23 (m, 8H), 1.13 (d, J = 6.0 Hz, 3H), 0.85 (t, J = 6.4 Hz, 3H).


Example 187 – (R)-4-(octan-2-yl) 1-((3-oxo-2,3-dihydroisoxazol-5-yl)methyl) 2-methylenesuccinate



Example 187 was prepared according to General Procedure 2, using (R)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (Intermediate 8) as itaconic acid monoester as itaconic acid monoester and 5-(hydroxymethyl)isoxazol-3(2H)-one as R²-OH. LCMS m/z 362.2 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ 11.42 (br, 1H), 6.25 (s, 1H), 6.06 (s, 1H), 5.89 (d, J = 0.8 Hz, 1H), 5.15 (s, 2H), 4.80-4.72 (m, 1H), 3.36 (s, 1H), 3.31 (s, 1H), 1.45 (bs, 2H), 1.22 (t, 8H), 1.11 (d, J = 6.4 Hz, 3H), 0.85 (t, J = 6.4 Hz, 3H).

5-(hydroxymethyl)isoxazol-3(2H)-one was prepared *via* reduction of the corresponding methyl ester with LiAlH₄ in THF. ¹H NMR (400 MHz, DMSO-d₆) δ: 5.18 (t, J = 6.0 Hz, 1H), 5.15 (s, 1H), 4.16 (d, J = 5.6 Hz, 2H), 3.17 (d, J = 5.2 Hz, 1H).

Example 188 – (R)-4,4,4-trifluoro-3-((2-methylene-4-(((R)-octan-2-yl)oxy)-4-oxobutanoyl)oxy)butanoic acid



Step 1

To a mixture of (R)-4,4,4-trifluoro-3-hydroxybutanoic acid (300 mg, 1.90 mmol) and K₂CO₃ (315 mg, 2.28 mmol) in DMF (10 mL) was added PMBCl (327 mg, 2.09 mmol) at 0 °C, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with water and extracted with EtOAc. The organic layers were washed with water and brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at 40 °C, and the residue was purified by flash column chromatography (80 g silica, 0-20% MTBE/petroleum ether) to give 4-methoxybenzyl (R)-4,4,4-trifluoro-3-hydroxybutanoate (320 mg, 1.15 mmol, 61 %) as a yellow oil. LCMS (System 2, Method B) m/z 301.1 (M+Na)⁺ (ES⁺).

Step 2


To a solution of (*R*)-2-methylene-4-(octan-2-yloxy)-4-oxobutanoic acid (228 mg, 1.15 mmol), 4-methoxybenzyl (*R*)-4,4,4-trifluoro-3-hydroxybutanoate (320 mg, 1.15 mmol) and DMAP (140 mg, 1.15 mmol) in DCM (3 mL) was added EDC.HCl (331 mg, 1.725 mmol) at 0 °C, and the resulting
 5 pale yellow mixture was stirred at room temperature for 2 h. The mixture was quenched with saturated aqueous NH₄Cl solution (1 mL), separated and the organic phase was extracted with DCM (2 x 2 mL). The separated organic phases were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure at 40 °C, and the residue was purified by flash column chromatography (25 g silica, 0-15% MTBE/petroleum ether) to give 4-
 10 ((*R*)-octan-2-yl) 1-((*R*)-1,1,1-trifluoro-4-((4-methoxybenzyl)oxy)-4-oxobutan-2-yl) 2-methylenesuccinate (300 mg, 0.60 mmol, 52 %) as a yellow oil. LCMS (System 2, Method C) m/z 525.3 (M+Na)⁺ (ES⁺).

Step 3

A solution of 4-((*R*)-octan-2-yl) 1-((*R*)-1,1,1-trifluoro-4-((4-methoxybenzyl)oxy)-4-oxobutan-2-yl) 2-methylenesuccinate (300 mg, 0.60 mmol) in HCl solution in 1,4-dioxane (4 M, 3 mL) was stirred at room temperature for 4 h. The mixture was concentrated under reduced pressure at 30 °C and the residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10µm 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.05% TFA/water) gradient: 60-95% MeCN;
 20 collection wavelength: 214 nm). The fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give (*R*)-4,4,4-trifluoro-3-((2-methylene-4-(((*R*)-octan-2-yl)oxy)-4-oxobutanoyl)oxy)butanoic acid (134 mg, 0.35 mmol 59 %) as a colourless oil. LCMS (System 2, Method B) m/z 405.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 12.85 (br, 1H), 6.28 (s, 1H), 5.96 (d, J = 0.8 Hz, 1H), 5.79-5.73 (m, 1H), 4.80-4.75 (m, 1H),
 25 3.40 (s, 2H), 2.95 (dd, J = 22.8, 4.0 Hz, 1H), 2.74 (dd, J = 16.8, 9.2 Hz, 1H), 1.48-1.33 (m, 2H), 1.29-1.23 (m, 8H), 1.12 (d, J = 6.4 Hz, 3H), 0.85 (t, J = 6.4 Hz, 3H).


The following compound was synthesised using a similar procedure but starting from (*S*)-4,4,4-trifluoro-3-hydroxybutanoic acid:

30

Example No.	Example Structure / Name	LCMS / ¹ H NMR data
205		LCMS (System 2, Method B) m/z 405.3 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 12.83 (br, 1H), 6.29 (s, 1H), 5.96 (s, 1H), 5.80-

(S)-4,4,4-trifluoro-3-((2-methylene-4-(((R)-octan-2-yl)oxy)-4-oxobutanoyl)oxy)butanoic acid	5.72 (m, 1H), 4.81-4.73 (m, 1H), 3.40 (s, 2H), 2.95 (dd, $J = 22.8, 4.0$ Hz, 1H), 2.74 (dd, $J = 16.8, 9.2$ Hz, 1H), 1.51-1.41 (m, 2H), 1.29-1.23 (m, 8H), 1.12 (d, $J = 6.4$ Hz, 3H), 0.85 (t, $J = 6.4$ Hz, 3H).
---	--

Example 189 – 2-((4-(cyclooctyloxy)-3-hydroxy-2-methylene-4-oxobutanoyl)oxy)acetic acid



5 Step 1


A mixture of 1-(*tert*-butyl) 4-cyclooctyl 3-hydroxy-2-methylenesuccinate (200 mg, 0.64 mmol) and HCl solution in 1,4-dioxane (4 M, 2 mL) in DCM (2 mL) was stirred at room temperature for 4 h. The mixture was concentrated under reduced pressure at 40 °C to give crude 2-(chloromethyl)-4-(cyclooctyloxy)-3-hydroxy-4-oxobutanoic acid (200 mg, 0.68 mmol, >100 %) as a pale yellow oil, which was used directly in the next step. LCMS (System 2, Method C) m/z 315.2 ($M+Na$)⁺ (ES^+).

Step 2

To a solution of the crude 2-(chloromethyl)-4-(cyclooctyloxy)-3-hydroxy-4-oxobutanoic acid (200 mg, 0.68 mmol) in acetone (5 mL) was added potassium carbonate (94 mg, 0.68 mmol) and the reaction mixture was stirred at room temperature for 30 min, then *tert*-butyl 2-bromoacetate (158 mg, 0.82 mmol) was added, and the resulting mixture was stirred at room temperature overnight. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure at 40 °C, and the residue was purified by flash column chromatography (25 g silica, 0-20% MTBE/petroleum ether) to give 1-(2-(*tert*-butoxy)-2-oxoethyl) 4-cyclooctyl 3-hydroxy-2-methylenesuccinate (200 mg, 0.54 mmol, 79 %) as a yellow oil. LCMS (System 2, Method B) m/z 393.3 ($M+Na$)⁺ (ES^+). ¹H NMR (400 MHz, CDCl₃) δ : 6.47 (s, 1H), 6.00 (s, 1H), 5.30 (m, 1H), 4.85 (d, $J = 6.0$ Hz, 1H), 4.66 (d, $J = 16.0$ Hz, 1H), 4.52 (d, $J = 16.0$ Hz, 1H), 3.56 (d, $J = 6.0$ Hz, 1H), 1.86-1.65 (m, 6H), 1.63-1.52 (m, 8H), 1.42 (s, 9H).

Step 3

A mixture of 1-(2-(*tert*-butoxy)-2-oxoethyl) 4-cyclooctyl 3-hydroxy-2-methylenesuccinate (200 mg, 0.54 mmol) and TFA (2 mL) in DCM (2 mL) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure at 40 °C and the residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10µm 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.1% TFA/water) gradient: 35-95% MeCN; collection wavelength: 214 nm). The fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 2-((4-(cyclooctyloxy)-3-hydroxy-2-methylene-4-oxobutanoyl)oxy)acetic acid (99 mg, 58 %) as a colorless oil. LCMS (System 2, Method B) *m/z* 337.3 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 13.10 (br, 1H), 6.30 (s, 1H), 6.07 (m, 1H), 6.03 (s, 1H), 4.85-4.79 (m, 1H), 4.83 (s, 1H), 4.64 (s, 2H), 1.71-1.53 (m, 6H), 1.49-1.36 (m, 8H).

Example 190 – 2-(3-methylene-5-(4-methylheptan-4-yloxy)-5-oxopent-1-en-2-yloxy)acetic acid**Step 1**

To a solution of 4-methylheptan-4-ol (1.50 g, 11.52 mmol) and DBU (2.62 g, 17.28 mmol) in 1-methyl-2-pyrrolidinone (25 mL) was slowly added 2-bromoacetyl bromide (3.49 g, 17.28 mmol) dropwise at 0 °C, and the mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with water (20 mL) and MTBE (20 mL), the layers were separated and the aqueous layer was extracted with MTBE (2 x 10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 40 °C. The residue was purified by flash column chromatography (25 g silica, 0-3% MTBE/petroleum ether) to give 4-methylheptan-4-yl 2-bromoacetate (2.00 g, 7.96 mmol, 69 %) as a colourless oil. ¹H NMR (400 MHz, CDCl₃) δ: 3.75 (s, 2H), 1.86-1.78 (m, 2H), 1.74-1.67 (m, 2H), 1.42 (s, 3H), 1.36-1.26 (m, 4H), 0.91 (t, *J* = 7.6 Hz, 6H).

Step 2

To a solution of methyl 2-(diethoxyphosphoryl)acetate (1.52 g, 7.24 mmol) in THF (30 mL) was added NaH suspension in mineral oil (60 wt. %, 290 mg, 7.96 mmol) at 0 °C, and the reaction mixture was stirred at 0 °C for 0.5 h. 4-Methylheptan-4-yl 2-bromoacetate (2.00 g, 7.96 mmol) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then quenched with dilute aqueous HCl (0.5 M, 10 mL) to pH = 5, and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 40 °C. The residue was purified by silica gel column chromatography (25 g silica, 1:4-1:2 EtOAc/petroleum ether) to give 1-methyl 4-(4-methylheptan-4-yl) 2-(diethoxyphosphoryl)succinate (2.30 g, 6.0 mmol, 83 %) as a light yellow oil. LCMS (System 2, Method C) m/z 403.3 (M+Na)⁺ (ES⁺).

Step 3

To a solution of 1-methyl 4-(4-methylheptan-4-yl) 2-(diethoxyphosphoryl)succinate (1.30 g, 3.42 mmol) and potassium carbonate (945 mg, 6.84 mmol) in DMF (15 mL) was added formaldehyde solution in water (37 wt. %, 5.5 mL, 68.40 mmol) at room temperature, and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with H₂O (30 mL) and extracted with MTBE (2 x 20 mL). The combined organic layers were washed with H₂O (2 x 15 mL) and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 30 °C. The residue was purified by flash column chromatography (25 g silica, 0-10% MTBE/petroleum ether) to give 1-methyl 4-(4-methylheptan-4-yl) 2-methylenesuccinate (600 mg, 2.34 mmol, 68 %) as a colourless oil. LCMS (System 2, Method C) m/z 279.4 (M+Na)⁺ (ES⁺).

Step 4

To a solution of 1-methyl 4-(4-methylheptan-4-yl) 2-methylenesuccinate (600 mg, 2.34 mmol) in THF (10 mL) was added LiOH solution in water (2 M, 4.7 mL, 9.36 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was acidified with dilute aqueous HCl (0.5 M) to pH = 3, and extracted with EtOAc (2 x 10 mL). The EtOAc layer was washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 40 °C to give a 5:1 mixture of 2-methylene-4-(4-methylheptan-4-yloxy)-4-oxobutanoic acid and 2-methyl-4-(4-methylheptan-4-yloxy)-4-oxobut-2-enoic acid (500 mg, 2.06 mmol, 88 %) as a pale yellow oil, which was used directly in the next step. LCMS (System 2, Method B) m/z 265.3 (M+Na)⁺ (ES⁺).

Step 5



To a solution of the 5:1 mixture of 2-methylene-4-(4-methylheptan-4-yloxy)-4-oxobutanoic acid and 2-methyl-4-(4-methylheptan-4-yloxy)-4-oxobut-2-enoic acid (500 mg, 2.06 mmol), and potassium carbonate (313 mg, 2.26 mmol) in acetone (10 mL) was added 2,2,2-trichloroethyl 2-





bromoacetate (558 mg, 2.06 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure at 30 °C. The residue was purified by flash column chromatography (25 g silica, 0-10% MTBE/petroleum ether) to give 4-(4-methylheptan-4-yl) 1-(2-oxo-2-(2,2,2-trichloroethoxy)ethyl) 2-methylenesuccinate (430 mg, 1.00 mmol, 48 %) as a pale yellow oil. LCMS (System 2, Method B) m/z 455.0 (M+Na)⁺ (ES⁺).

Step 6

To a solution of 4-(4-methylheptan-4-yl) 1-(2-oxo-2-(2,2,2-trichloroethoxy)ethyl) 2-methylenesuccinate (430 mg, 1.00 mmol) in AcOH (5 mL) was added zinc powder (325 mg, 4.98 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure at 30 °C. The residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10µm 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.1% TFA/water) gradient: 50-95% MeCN; collection wavelength: 214 nm). The fractions were concentrated under reduced pressure at 30 °C to remove MeCN, and the residue was lyophilized to give 2-(3-methylene-5-(4-methylheptan-4-yloxy)-5-oxopent-1-en-2-yloxy)acetic acid (72 mg, 0.24 mmol, 24 %) as a colourless oil. LCMS (System 2, Method B) m/z 323.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-d₆) δ: 13.09 (br, 1H), 6.23 (d, *J* = 1.2 Hz, 1H), 5.86 (d, *J* = 0.4 Hz, 1H), 4.61 (s, 2H), 3.28 (s, 2H), 1.76-1.68 (m, 2H), 1.64-1.56 (m, 2H), 1.30 (s, 3H), 1.28-1.18 (m, 4H), 0.85 (d, *J* = 7.2 Hz, 6H).

The following compounds were made using a similar procedure:


Example No.	Alcohol used in step 5 / Example Structure / Name	LCMS / ¹ H NMR data
191	1-cyclohexylcyclobutan-1-ol  2-((4-(1-cyclohexylcyclobutoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 347.2 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.09 (br, 1H), 6.26 (d, <i>J</i> = 1.2 Hz, 1H), 5.90 (d, <i>J</i> = 0.8 Hz, 1H), 4.63 (s, 2H), 3.23 (s, 2H), 2.28-2.15 (m, 4 H), 1.88-1.80 (m, 1H), 1.79-1.68 (m, 6H), 1.63-1.61 (m, 1H), 1.54-1.45 (m, 1H), 1.20-1.06 (m, 2H), 1.02-0.92 (m, 2H).
192	2-methyloctan-2-ol 	LCMS (System 2, Method B) m/z 337.3 (M+Na) ⁺ (ES ⁺).

	2-((2-methylene-4-((2-methyloctan-2-yl)oxy)-4-oxobutanoyl)oxy)acetic acid	¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.11 (br, 1H), 6.24 (d, J = 0.8 Hz, 1H), 5.87 (d, J = 0.8 Hz, 1H), 4.63 (s, 2H), 3.35 (s, 2H), 1.65-1.63 (m, 2H), 1.34 (s, 6H), 1.27-1.23 (m, 8H), 0.86 (t, J = 7.2 Hz, 3H).
193	2-methylheptan-2-ol  2-((2-methylene-4-((2-methylheptan-2-yl)oxy)-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 323.2 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.07 (br, 1H), 6.24 (d, J = 1.2 Hz, 1H), 5.87 (d, J = 0.8 Hz, 1H), 4.63 (s, 2H), 3.27 (s, 2H), 1.67-1.63 (m, 2H), 1.34 (s, 6H), 1.29-1.18 (m, 6H), 0.85 (d, J = 6.8 Hz, 3H).
194	1-pentylcyclobutan-1-ol  2-((2-methylene-4-oxo-4-(1-pentylcyclobutoxy)butanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 335.2 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.09 (br, 1H), 6.27 (s, 1H), 5.90 (s, 1H), 4.64 (s, 2H), 3.31 (s, 2H), 2.19-2.13 (m, 2H), 2.09-2.05 (m, 2H), 1.82-1.79 (m, 2H), 1.76-1.72 (m, 1H), 1.63-1.53 (m, 1H), 1.30-1.22 (m, 6H), 0.86 (t, J = 7.2 Hz, 3H).
195	2-methylspiro[3.5]nonan-2-ol  2-((2-methylene-4-((2-methylspiro[3.5]nonan-2-yl)oxy)-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 347.2 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.08 (br, 1H), 6.26 (s, 1H), 5.90 (s, 1H), 4.64 (s, 2H), 3.34 (s, 2H), 1.95 (q, J = 12.8 Hz, 4H), 1.46 (s, 3H), 1.40 (m, 4H), 1.31-1.30 (m, 6H).
206	1-pentylcyclopropan-1-ol  2-((2-methylene-4-oxo-4-(1-pentylcyclopropoxy)butanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 299.2 (M+H) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.07 (br, 1H), 6.27 (s, 1H), 5.90 (s, 1H), 4.62 (s, 2H), 3.33 (s, 2H), 1.68-1.64 (m, 2H), 1.37-1.24 (m, 6H), 0.86 (t, J = 6.8 Hz, 3H), 0.73 (t, J = 5.2 Hz, 2H), 0.61 (t, J = 5.2 Hz, 2H).

2-Methylspiro[3.5]nonan-2-ol was made by MeMgBr addition to the corresponding commercially available ketone in THF. ^1H NMR (400 MHz, CDCl_3) δ : 1.92 (d, $J = 14.6$ Hz, 2H), 1.89 (d, $J = 14.4$ Hz, 2H), 1.71 (m, 1H), 1.53-1.50 (m, 2H), 1.43-1.34 (m, 8H), 1.39 (s, 3H).

5

Example 196 – 2-((2-methylene-4-oxo-4-(((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)butanoyl)oxy)acetic acid



Step 1

- 10 To a solution of (*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol (CAS No. 124-76-5) (1.00 g, 6.49 mmol) and DBU (1.48 g, 9.74 mmol) in 1-methyl-2-pyrrolidinone (20 mL) was slowly added 2-bromoacetyl bromide (1.97 g, 9.74 mmol) dropwise at 0 °C, and the mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with water (20 mL) and MTBE (20 mL), separated and the aqueous layer was extracted with MTBE (2 x 10 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure at 40 °C. The residue was purified by flash column chromatography (40 g silica, 0-3% MTBE/petroleum ether) to give (*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 2-bromoacetate (1.5 g, 5.11 mmol, 79 %) as a colourless oil. ^1H NMR (400 MHz, CDCl_3) δ : 4.74-4.71 (m, 1H), 3.80 (s, 2H), 1.86-1.68 (m, 4H), 1.61-1.54 (m, 1H), 1.18-1.08 (m, 2H), 1.00 (s, 3H), 0.80 (s, 3H), 0.77 (s, 3H).

Step 2

- 25 To a solution of *tert*-butyl 2-(diethoxyphosphoryl)acetate (1.29 g, 5.11 mmol) in THF (20 mL) was added NaH suspension in mineral oil (60 wt. %, 225 mg, 5.62 mmol) at 0 °C, and the reaction mixture was stirred at 0 °C for 0.5 h, then (*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 2-

bromoacetate (1.50 g, 5.11 mmol) was added. The reaction mixture was stirred at room temperature overnight, then quenched with dilute aqueous HCl (0.5 M) to pH = 5 and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 40 °C. The residue was purified by flash column chromatography (40 g silica, 1:4-1:2 EtOAc/petroleum ether) to give 1-(*tert*-butyl) 4-((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl) 2-(diethoxyphosphoryl)succinate (1.60 g, 3.59 mmol, 70 %) as a colourless oil. LCMS (System 2, Method C) m/z 469.4 (M+Na)⁺ (ES⁺).

Step 3

To a mixture of 1-(*tert*-butyl) 4-((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl) 2-(diethoxyphosphoryl)succinate (1.60 g, 3.59 mmol) and potassium carbonate (990 mg, 7.17 mmol) in DMF (10 mL) was added formaldehyde solution in water (37 wt. %, 2.9 mL, 35.9 mmol) at room temperature, and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with H₂O (15 mL) and extracted with MTBE (2 x 20 mL). The combined organic layers were washed with H₂O (2 x 10 mL) and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 30 °C. The residue was purified by flash column chromatography (25 g silica, 0-10% MTBE/petroleum ether) to give 1-(*tert*-butyl) 4-((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl) 2-methylenesuccinate (850 mg, 2.64 mmol, 73 %) as a colourless oil. LCMS (System 2, Method C) m/z 345.4 (M+Na)⁺ (ES⁺).

Step 4

To a solution of 1-(*tert*-butyl) 4-((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl) 2-methylenesuccinate (400 mg, 1.24 mmol) in DCM (8 mL) was added HCl solution in 1,4-dioxane (4 M, 4.0 mL), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure at 40 °C to give a crude 33:20:47 mixture of 2-methylene-4-oxo-4-(((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)butanoic acid (LCMS (System 2, Method C) m/z 289.4 (M+Na)⁺ (ES⁺)), 2-methyl-4-oxo-4-(((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)but-2-enoic acid (LCMS (System 2, Method C) m/z 289.4 (M+Na)⁺ (ES⁺)) and 2-(chloromethyl)-4-oxo-4-(((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)butanoic acid (LCMS (System 2, Method C) m/z 325.2 (M+Na)⁺ (ES⁺)) (400 mg) as a pale yellow oil, which was used directly in the next step.

Step 5


To a crude 33:20:47 mixture of 2-methylene-4-oxo-4-(((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy) butanoic acid, (2-methyl-4-oxo-4-(((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)but-2-enoic acid and 2-(chloromethyl)-4-oxo-4-(((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy) butanoic acid (400 mg) and potassium carbonate (342 mg, 2.48 mmol) in acetone (10

mL) was added *tert*-butyl 2-bromoacetate (331 mg, 1.24 mmol), and the reaction mixture was stirred at room temperature overnight. The mixture was then filtered, and the filtrate was concentrated under reduced pressure at 30 °C. The residue was purified by flash column chromatography (25 g silica, 0-10% MTBE/petroleum ether) to give 1-(2-oxo-2-(2,2,2-trichloroethoxy)ethyl) 4-((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl) 2-methylenesuccinate (450 mg, 0.99 mmol, 80 % over two steps) as a pale yellow oil. LCMS (System 2, Method C) *m/z* 477.0 (M+Na)⁺ (ES⁺).

Step 6

To a solution of 1-(2-oxo-2-(2,2,2-trichloroethoxy)ethyl) 4-((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl) 2-methylenesuccinate (450 mg, 0.99 mmol) in AcOH (5 mL) was added zinc powder (322 mg, 4.96 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure at 30 °C. The residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10µm 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.05% TFA/water) gradient: 40-95% MeCN; collection wavelength: 214 nm). The fractions were concentrated under reduced pressure at 30 °C to remove MeCN, and the residue was lyophilized to give 2-((2-methylene-4-oxo-4-((*exo*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)butanoyl)oxy)acetic acid (77 mg, 0.23 mmol, 24 %) as a colourless oil. LCMS (System 2, Method B) *m/z* 347.2 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 13.06 (br, 1H), 6.27 (d, *J* = 0.8 Hz, 1H), 5.92 (d, *J* = 0.8 Hz, 1H), 4.61 (s, 2H), 4.54 (dd, *J* = 8.0, 3.6 Hz, 1H), 3.35 (s, 2H), 1.74-1.60 (m, 4H), 1.53-1.47 (m, 1H), 1.13-1.01 (m, 2H), 0.88 (s, 3H), 0.79 (s, 3H), 0.75 (s, 3H).




The following compound was made using a similar procedure:



Example No.	Alcohol / Example Structure / Name	LCMS / ¹ H NMR data
197	2,2,6,6-tetramethylcyclohexan-1-ol  2-((2-methylene-4-oxo-4-((2,2,6,6-tetramethylcyclohexyl)oxy)butanoyl)oxy)acetic acid	LCMS (System 2, Method B) <i>m/z</i> 349.3 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ: 13.09 (br, 1H), 6.31 (d, <i>J</i> = 1.2 Hz, 1H), 5.98 (s, 1H), 4.62 (s, 2H), 4.40 (s, 1H), 3.46 (s, 2H), 1.56-1.44 (1H, m), 1.45-1.37 (2H, m), 1.37-1.29 (m, 1H), 1.27-1.16 (m, 2H), 0.86 (s, 6H), 0.75 (s, 6H).

2,2,6,6-Tetramethylcyclohexan-1-ol was made by reduction of the corresponding commercially available ketone with NaBH₄ in MeOH. ¹H NMR (400 MHz, DMSO-d₆) δ: 4.40 (br, 1H), 2.83 (s, 1H), 1.56-1.48 (1H, m), 1.47-1.38 (m, 2H), 1.36-1.28 (m, 1H), 1.22-1.11 (m, 2H), 0.93 (s, 6H), 0.88 (s, 6H).

5

The following examples were prepared according to the procedure of Example 114, but using the alcohols described below instead of 3-ethoxypropan-1-ol:


Example No.	Alcohol / Example Structure / Name	LCMS / ¹ H NMR data
198	1-(3,5-dichlorophenyl)ethan-1-ol (Isomer 1)  2-((4-(1-(3,5-dichlorophenyl)ethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (Isomer 1)	LCMS (System 2, Method B) m/z 383.0 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ 13.12 (br, 1H), 7.54 (t, J = 2.0 Hz, 1H), 7.41 (d, J = 1.6 Hz, 2H), 6.31 (d, J = 0.8 Hz, 1H), 5.96 (d, J = 0.8 Hz, 1H), 5.77 (q, J = 6.4 Hz, 1H), 4.63 (s, 2H), 3.47 (s, 2H), 1.44 (d, J = 6.4 Hz, 3H).
199	1-(3,5-dichlorophenyl)ethan-1-ol (Isomer 2)  2-((4-(1-(3,5-dichlorophenyl)ethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (Isomer 2)	LCMS (System 2, Method B) m/z 383.0 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ 13.12 (br, 1H), 7.54 (t, J = 2.0 Hz, 1H), 7.41 (d, J = 1.6 Hz, 2H), 6.31 (d, J = 0.8 Hz, 1H), 5.96 (d, J = 0.8 Hz, 1H), 5.77 (q, J = 6.4 Hz, 1H), 4.63 (s, 2H), 3.47 (s, 2H), 1.44 (d, J = 6.4 Hz, 3H).
200	(R)-1-(4-(trifluoromethyl)phenyl) ethan-1-ol 	LCMS (System 2, Method B) m/z 383.0 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ 13.13 (br, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 6.30 (d, J = 0.8 Hz, 1H), 5.94 (d, J = 0.8 Hz, 1H),

	(<i>R</i>)-2-((2-methylene-4-oxo-4-(1-(4-(trifluoromethyl)phenyl)ethoxy)butanoyl oxy) acetic acid)	¹ H), 5.86 (q, J = 6.8 Hz, 1H), 4.62 (s, 2H), 3.46 (s, 2H), 1.47 (d, J = 6.4 Hz, 3H).
201	(<i>S</i>)-1-(4-(trifluoromethyl)phenyl) ethan-1-ol  (<i>S</i>)-2-((2-methylene-4-oxo-4-(1-(4-(trifluoromethyl)phenyl)ethoxy)butanoyl oxy) acetic acid)	LCMS (System 2, Method B) m/z 383.0 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ 13.06 (br, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 6.30 (d, J = 0.8 Hz, 1H), 5.94 (d, J = 0.8 Hz, 1H), 5.86 (q, J = 6.8 Hz, 1H), 4.62 (s, 2H), 3.46 (s, 2H), 1.47 (d, J = 6.4 Hz, 3H).
203	(<i>S</i>)-1-cyclohexylethan-1-ol  (<i>S</i>)-2-((4-(1-cyclohexylethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid	LCMS (System 2, Method B) m/z 321.3 (M+Na) ⁺ (ES ⁺). ¹ H NMR (400 MHz, DMSO-d ₆) δ: 13.14 (br, 1H), 6.28 (s, 1H), 5.92 (s, 1H), 4.62 (s, 2H), 4.66-4.58 (m, 1H), 3.26 (s, 2H), 1.69-1.67 (m, 3H), 1.62-1.53 (m, 2H), 1.42-1.35 (m, 1H), 1.25-1.08 (m, 3H), 1.15 (d, J = 6.4 Hz, 3H), 1.04-0.82 (m, 2H).

1-(3,5-dichlorophenyl)ethan-1-ol (Isomer 1) was prepared by the following method: Racemic 1-(3,5-dichlorophenyl)ethan-1-ol was resolved using chiral SFC (Column: CHIRALPAK AY-3 4.6x100 mm; Flow Rate: 2 mL/min; solvent system: 10% IPA/CO₂; collection wavelength: 214 nm). Isomer 1 was the first eluting peak at 1.34 min.

1-(3,5-dichlorophenyl)ethan-1-ol (Isomer 2) was prepared by the following method: Racemic 1-(3,5-dichlorophenyl)ethan-1-ol was resolved using chiral SFC (Column: CHIRALPAK AY-3 4.6x100 mm; Flow Rate: 2 mL/min; solvent system: 10% IPA/CO₂; collection wavelength: 214 nm). Isomer 2 was the second eluting peak at 1.53 min.

Example 202 – 2-((4-(1-cyclohexylcyclopropoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid



5 Step 1

To a solution of methyl cyclohexanecarboxylate (4.26 g, 30 mmol) and titanium tetraisopropoxide (11.93 g, 42 mmol) in THF (60 mL) at 0°C was slowly added a solution of ethyl magnesium bromide in diethyl ether (3M, 30 mL, 90 mmol), and the mixture was stirred at room temperature for 16 h. The reaction mixture was quenched with water (60 mL), and stirred for 1 h until a gray precipitate was formed, and then filtered. The filtrate was extracted with MTBE (3 x 40 mL), and the combined organic layers were washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure at 40°C . The residue was purified by flash column chromatography (0-3% EtOAc/petroleum ether) give 1-cyclohexylcyclopropan-1-ol (2.50 g, 17.8 mmol, 60 %) as a colourless oil. ^1H NMR (400 MHz, CDCl_3) δ : 1.80-1.75 (m, 4H), 1.69-1.66 (m, 1H), 1.26-1.17 (m, 5H), 0.94-0.92 (m, 1H), 0.70-0.67 (m, 2H), 0.45-0.42 (m, 2H). One exchangeable proton not observed.

Step 2

To a solution of 1-cyclohexylcyclopropan-1-ol (1.50 g, 10.7 mmol) and DBU (2.43 g, 16.05 mmol) in 1-methyl-2-pyrrolidinone (20 mL) was slowly added 2-bromoacetyl bromide (3.24 g, 16.05 mmol) dropwise at 0°C , and the resulting mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with water (20 mL) and MTBE (20 mL), separated and the aqueous layer was extracted with MTBE (2 x 10 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure at 40°C . The residue was purified by flash column chromatography (25 g silica, 0-3% MTBE/petroleum ether) to give 1-cyclohexylcyclopropyl 2-bromoacetate (1.70 g, 6.51 mmol, 61 %) as a colourless oil. ^1H NMR (400 MHz, CDCl_3) δ : 3.74 (s, 2H), 1.80-1.73 (m, 5H), 1.67-1.64 (m, 1H), 1.24-1.08 (m, 3H), 0.95-0.79 (m, 2H), 0.70-0.67 (m, 4H).

Step 3

To a solution of methyl 2-(diethoxyphosphoryl)acetate (1.36 g, 6.51 mmol) in THF (30 mL) was added NaH suspension in mineral oil (60 wt. %, 261 mg, 6.51 mmol) at 0 °C, and the reaction mixture was stirred at 0 °C for 0.5 h. Then 1-cyclohexylcyclopropyl 2-bromoacetate (1.70 g, 6.51 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with dilute aqueous HCl (0.5 M) to pH = 5, and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 40 °C to give 4-(1-cyclohexylcyclopropyl) 1-methyl 2-(diethoxyphosphoryl)succinate (2.70 g, 6.92 mmol, > 100 %) as a colourless oil. The crude product was used directly in next step. LCMS (System 2, Method B) m/z 413.2 (M+Na)⁺ (ES⁺).

Step 4

To a mixture of 4-(1-cyclohexylcyclopropyl) 1-methyl 2-(diethoxyphosphoryl)succinate (2.70 g, 6.92 mmol) and potassium carbonate (1.83 g, 13.8 mmol) in THF (20 mL) was added formaldehyde solution in water (37 wt. %, 11.2 mL, 138 mmol) at room temperature, and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with H₂O (20 mL) and extracted with MTBE (2 x 20 mL). The combined organic layers were washed with H₂O (2 x 15 mL) and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 30 °C. The residue was purified by flash column chromatography (25 g silica, 0-10% MTBE/petroleum ether) to give 4-(1-cyclohexylcyclopropyl) 1-methyl 2-methylenesuccinate (1.20 g, 4.51 mmol, 65 %) as a colourless oil. LCMS (System 2, Method B) m/z 267.3 (M+H)⁺ (ES⁺).

Step 5

To a solution of 4-(1-cyclohexylcyclopropyl) 1-methyl 2-methylenesuccinate (600 mg, 2.25 mmol) in THF (8 mL) was added LiOH solution in water (2 M, 3.4 mL, 6.75 mmol), and the reaction mixture was stirred at room temperature for 7 h (about 24 % of starting material remained). The reaction mixture was acidified with dilute aqueous HCl (0.5 M) to pH = 3 and extracted with EtOAc (2 x 10 mL). The EtOAc layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 40 °C to give a 2:1 mixture of 4-(1-cyclohexylcyclopropoxy)-2-methylene-4-oxobutanoic acid and 4-(1-cyclohexylcyclopropoxy)-2-methyl-4-oxobut-2-enoic acid (500 mg, 1.98 mmol, 88 %) as a pale yellow oil, which was used directly in the next step. LCMS (System 2, Method C) m/z 253.4 (M+H)⁺ (ES⁺).

Step 6


To a solution of a 2:1 mixture of 4-(1-cyclohexylcyclopropoxy)-2-methylene-4-oxobutanoic acid and 4-(1-cyclohexylcyclopropoxy)-2-methyl-4-oxobut-2-enoic acid (500 mg, 1.98 mmol), and potassium carbonate (328 mg, 2.38 mmol) in acetone (10 mL) was added 2,2,2-trichloroethyl 2-bromoacetate (530 mg, 1.98 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure at 30 °C. The residue was purified by flash column chromatography (25 g silica, 0-10% MTBE/petroleum ether) to give 4-(1-cyclohexylcyclopropyl) 1-(2-oxo-2-(2,2,2-trichloroethoxy)ethyl) 2-methylenesuccinate (300 mg, 0.68 mmol, 34 %) as a pale yellow oil.

LCMS (System 2, Method B) m/z 463.1 (M+Na)⁺ (ES⁺).

Step 7

To a solution of 4-(1-cyclohexylcyclopropyl) 1-(2-oxo-2-(2,2,2-trichloroethoxy)ethyl) 2-methylenesuccinate (100 mg, 0.22 mmol) in THF (2 mL) and water (0.5 mL) was added zinc powder (71 mg, 1.10 mmol) and sodium acetate (90 mg, 1.10 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure at 30 °C. The residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10µm 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.05% TFA/water) gradient: 30-95% MeCN; collection wavelength: 214 nm). The fractions were concentrated under reduced pressure at 30 °C to remove MeCN, and the residue was lyophilized to give 2-((4-(1-cyclohexylcyclopropoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (6 mg, 0.019 mmol, 9 %) as a colourless oil. LCMS (System 2, Method B) m/z 311.2 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ: 6.43 (s, 1H), 5.80 (s, 1H), 4.74 (s, 2H), 3.31 (s, 2H), 1.79-1.71 (m, 5H), 1.66-1.63 (m, 1H), 1.25-1.15 (m, 2H), 1.11-1.05 (m, 1H), 0.92-0.83 (m, 2H), 0.74 (d, J = 2.0 Hz, 4H). One exchangeable proton not observed.

Example 204 – 2-((2-methylene-4-oxo-4-((2,2,4,4-tetramethylpentan-3-yl)oxy)butanoyl)oxy)acetic acid



5 Step 1

To a solution of 2,2,4,4-tetramethylpentan-3-one (1.5 g, 10.6 mmol) in dry THF (40 mL) was added LiAlH_4 (802 mg, 21.1 mmol) at 0 °C, and the resulting mixture was stirred at room temperature for 1 h. To the reaction mixture was sequentially added water (1 mL), aqueous NaOH (15 wt %, 1 mL), water (2.5 mL) and Na_2SO_4 (20 g), the mixture was stirred at room temperature for 20 min, filtered, and concentrated under reduced pressure at 35 °C to give 2,2,4,4-tetramethylpentan-3-ol (1.4 g, 9.70 mmol, 90 %) as colourless crystals. ^1H NMR (400 MHz, CDCl_3) δ : 3.12 (d, J = 2.4 Hz, 1H), 1.23 (s, 18H). One exchangeable proton not observed.

Step 2

To a solution of 2,2,4,4-tetramethylpentan-3-ol (1.3 g, 9.02 mmol) and DBU (2.74 g, 18.0 mmol) in 1-methyl-2-pyrrolidinone (45 mL) was slowly added 2-bromoacetyl bromide (3.64 g, 18.0 mmol) at 0 °C dropwise and the mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with water (10 mL) and MTBE (20 mL), separated and the aqueous layer was extracted with MTBE (2 x 20 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure at 40 °C. The residue was purified by flash column chromatography (50 g silica, 0-10% EtOAc/petroleum ether) to give 2,2,4,4-tetramethylpentan-3-yl 2-bromoacetate (1.50 g, 5.68 mmol, 62 %) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ : 4.63 (s, 1H), 3.87 (s, 2H), 1.04 (s, 18H).

25 Step 3

To a solution of *tert*-butyl 2-(diethoxyphosphoryl)acetate (1.43 g, 5.68 mmol) in THF (15 mL) was added NaH suspension in mineral oil (60 wt. %, 227 mg, 5.68 mmol) at 0 °C, and the reaction

mixture was stirred at 0 °C for 0.5 h. 2,2,4,4-Tetramethylpentan-3-yl 2-bromoacetate (1.5 g, 5.68 mmol) was then added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with dilute aqueous HCl (0.5 M) to pH = 5, and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over Na₂SO₄,
5 filtered and concentrated under reduced pressure at 40 °C to give crude 1-(*tert*-butyl) 4-(2,2,4,4-tetramethylpentan-3-yl) 2-(diethoxyphosphoryl)succinate (3.00 g, 6.87 mmol, > 100 %) as a colourless oil. The crude product was used directly in next step. LCMS (System 2, Method B) m/z 459.3 (M+Na)⁺ (ES⁺).

10 Step 4

To a solution of 1-(*tert*-butyl) 4-(2,2,4,4-tetramethylpentan-3-yl) 2-(diethoxyphosphoryl)succinate (3.00 g, ~ 6.87 mmol, crude) and potassium carbonate (1.90 g, 13.8 mmol) in THF (24 mL) and H₂O (6 mL) was added formaldehyde solution in water (37 wt. %, 11.15 mL, 138 mmol) at room temperature, and the reaction mixture was stirred at room temperature for 4 h. The reaction
15 mixture was diluted with H₂O (15 mL) and extracted with MTBE (3 x 30 mL). The combined organic layers were washed with H₂O (2 x 10 mL) and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure at 40 °C. The residue was purified by flash column chromatography (25 g silica, 0-20% MTBE/petroleum ether) to give 1-(*tert*-butyl) 4-(2,2,4,4-tetramethylpentan-3-yl) 2-methylenesuccinate (1.45 g, 4.64 mmol, 68 %) as a colourless oil.
20 LCMS (System 2, Method B) m/z 335.4 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ: 6.24 (d, J = 1.2 Hz, 1H), 5.63 (d, J = 1.2 Hz, 1H), 4.57 (s, 1H), 3.35 (d, J = 0.8 Hz, 2H), 1.48 (s, 9H), 0.98 (s, 18H).

Step 5

25 A solution of 1-(*tert*-butyl) 4-(2,2,4,4-tetramethylpentan-3-yl) 2-methylenesuccinate (450 mg, 1.44 mmol) in TFA/DCM (2:1, 7 mL) was stirred at room temperature for 4 h. The mixture was concentrated under reduced pressure at 40 °C to give 2-methylene-4-oxo-4-((2,2,4,4-tetramethylpentan-3-yl)oxy)butanoic acid (400 mg, 1.56 mmol, > 100 %) as a colourless oil, which was used directly in the next step. LCMS (System 2, Method C) m/z 279.4 (M+Na)⁺ (ES⁺).

Step 6


To a solution of 2-methylene-4-oxo-4-((2,2,4,4-tetramethylpentan-3-yl)oxy)butanoic acid (400 mg, 1.56 mmol), and potassium carbonate (645 mg, 4.68 mmol) in acetone (10 mL) was added *tert*-butyl 2-bromoacetate (608 mg, 3.12 mmol), and the reaction mixture was stirred at room
35 temperature for 2 days. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure at 40 °C. The residue was purified by flash column chromatography (25 g silica, 0-20% MTBE/petroleum ether) to give 1-(2-(*tert*-butoxy)-2-oxoethyl) 4-(2,2,4,4-

tetramethylpentan-3-yl) 2-methylenesuccinate (430 mg, 1.16 mmol, 81 %) as a colourless oil. LCMS (System 2, Method C) m/z 393.4 ($M+Na$)⁺ (ES^+).

Step 7

- 5 A solution of 1-(2-(*tert*-butoxy)-2-oxoethyl) 4-(2,2,4,4-tetramethylpentan-3-yl) 2-methylenesuccinate (430 mg, 1.16 mmol) in TFA/DCM (2:1, 6 mL) was stirred at room temperature for 1 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure at 40 °C. The residue was purified by preparative HPLC (Column: Waters X-Bridge C18 OBD 10µm 19x250 mm; Flow Rate: 20 mL/min; solvent system: MeCN/(0.05% TFA/water) gradient: 50-95% MeCN; collection wavelength: 214 nm). The fractions were concentrated under reduced pressure at 40 °C to remove MeCN, and the residue was lyophilized to give 2-((2-methylene-4-oxo-4-((2,2,4,4-tetramethylpentan-3-yl)oxy)butanoyl)oxy)acetic acid (302 mg, 0.96 mmol, 83 %) as a white solid. LCMS (System 2, Method B) m/z 337.3 ($M+Na$)⁺ (ES^+). ¹H NMR (400 MHz, CDCl₃) δ: 13.01 (br, 1H), 6.30 (d, J = 1.2 Hz, 1H), 5.97 (s, J = 1.2 Hz, 1H), 4.62 (s, 2H), 4.45 (s, 1H), 3.45 (s, 2H), 0.93 (s, 18H).

Example 207 – 3-((2-methylene-4-oxo-4-(2,2,4,4-tetramethylcyclobutoxy)butanoyl)oxy)propanoic acid



- 20 Example 207 was prepared according to the procedure of Example 80, but using 2,2,4,4-tetramethylcyclobutan-1-ol instead of 4-octyl itaconate. LCMS (System 2, Method B) m/z 335.2 ($M+Na$)⁺ (ES^+). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.41 (br, 1H), 6.17 (d, J = 1.2 Hz, 1H), 5.85 (d, J = 0.8 Hz, 1H), 4.36 (s, 1H), 4.25 (t, J = 2.0 Hz, 2H), 3.39 (s, 2H), 2.59 (t, J = 2.0 Hz, 2H), 1.51 (d, J = 11.6 Hz, 1H), 1.41 (d, J = 11.6 Hz, 1H), 1.10 (s, 6H), 1.00 (s, 6H).

Biological Example 1 – THP-1 AlphaLISA IL-1β and IL-6 Cytokine Assay

Measuring inhibitory effects on IL-1β and IL-6 cytokine output from THP-1s

- 30 The cytokine inhibition profiles of compounds of formula (IW-1) were determined in a differentiated THP-1 cell assay. All assays were performed in RPMI-1640 growth medium (Gibco), supplemented with 10% fetal bovine serum (FBS; Gibco), 1% penicillin-streptomycin and 1% sodium pyruvate unless specified otherwise. The IL-1β and IL-6 cytokine inhibition assays were each run in a background of differentiated THP-1 cells as described below. All reagents described

were from Sigma-Aldrich unless specified otherwise. Compounds were prepared as 10mM DMSO stocks.

Assay Procedure

5

THP-1 cells were expanded as a suspension up to 80% confluence in appropriate growth medium. Cells were harvested, suspended, and treated with an appropriate concentration of phorbol 12-myristate 13-acetate (PMA) over a 72hr period (37°C/5% CO₂).

10 Following 72hrs of THP-1 cell incubation, cellular medium was removed and replaced with fresh growth media containing 1% of FBS. Working concentrations of compounds were prepared separately in 10% FBS treated growth medium and pre-incubated with the cells for 30 minutes (37°C/5% CO₂). Following the 30 minute compound pre-incubation, THP-1s were treated with an appropriate concentration of LPS and the THP-1s were subsequently incubated for a 24hr period
15 (37°C/5% CO₂). An appropriate final concentration of Nigericin was then dispensed into the THP-1 plates and incubated for 1 hour (37°C/5% CO₂) before THP-1 supernatants were harvested and collected in separate polypropylene 96-well holding plates.

Reagents from each of the IL-1 β and IL-6 commercial kits (Perkin Elmer) were prepared and run
20 according to the manufacturer's instructions. Subsequently, fluorescence signal detection in a microplate reader was measured (EnVision® Multilabel Reader, Perkin Elmer).

Percentage inhibition was calculated per cytokine by normalising the sample data to the high and low controls used within each plate (+/- LPS respectively). Percentage inhibition was then plotted
25 against compound concentration and the 50% inhibitory concentration (IC₅₀) was determined from the resultant concentration-response curve.

A number of Example compounds of formula (IW-1) were tested and the results are shown in Table 1 below. Dimethyl itaconate and dimethyl fumarate were included as comparator
30 compounds. All compounds of formula (IW-1) shown in Table 1 exhibited comparable or improved cytokine-lowering potencies compared to dimethyl itaconate and/or dimethyl fumarate for IL-1 β and/or IL-6. Certain compounds shown in Table 1 exhibited improved cytokine-lowering potencies compared to dimethyl itaconate and/or dimethyl fumarate for IL-1 β and/or IL-6.

Table 1 – THP-1 cell IL-1 β and IL-6 IC₅₀ values (μ M)

Compound	IL-1 β (IC ₅₀)	IL-6 (IC ₅₀)
dimethyl fumarate	14.4	9.3
dimethyl itaconate	>100	100.0
Example 1	9.3	6.0
Example 2	5.0	2.9
Example 3	15.6	56.2
Example 4	9.3	3.6
Example 5	6.5	2.0
Example 6	12.8	12.1
Example 7	16.7	12.0
Example 9	4.7	2.2
Example 10	27.9	7.6
Example 11	3.7	NT*
Example 12	28.2	11.3
Example 14	1.6	2.1
Example 15	15.4	8.9
Example 16	1.7	1.1
Example 17	1.5	1.4
Example 19	3.6	1.9
Example 20	5.6	3.4
Example 21	2.9	2.4
Example 22	15.4	7.0
Example 23	8.2	4.5
Example 24	15.0	4.2
Example 25	1.9	1.9
Example 26	16.1	NT*
Example 27	12.2	6.4
Example 28	5.2	2.2
Example 29	18.4	7.9
Example 30	11.3	4.8
Example 31	12.9	15.5
Example 32	18.9	9.5
Example 33	14.1	11.7
Example 34	31.8	16.1
Example 35	6.7	3.7

Compound	IL-1 β (IC ₅₀)	IL-6 (IC ₅₀)
dimethyl fumarate	14.4	9.3
dimethyl itaconate	>100	100.0
Example 36	20.5	8.9
Example 38	7.4	6.8
Example 39	5.1	7.3
Example 40	1.7	3.4
Example 46	6.7	3.0
Example 47	3.3	3.0
Example 48	10.1	5.1
Example 49	7.2	5.5
Example 50	2.7	1.7
Example 51	7.3	4
Example 52	8.5	2.5
Example 53	9.3	5.4
Example 54	3.9	1.5
Example 55	5.1	3.8
Example 56	7.9	3.5
Example 57	4.4	2.6
Example 58	6.5	3.8
Example 59	13.3	8.8
Example 60	1.9	1.4
Example 61	6.1	5
Example 62	3.5	2.8
Example 63	1.3	2.5
Example 64	10.2	12.6
Example 65	22.6	22.4
Example 66	2.3	2.5
Example 67	5.7	4.8
Example 68	24	9.1
Example 69	1.7	2.2
Example 70	6.1	9.4
Example 71	8.7	9.6
Example 72	11.4	8.2
Example 73	24.1	23.5
Example 74	4.2	NT*

Compound	IL-1 β (IC ₅₀)	IL-6 (IC ₅₀)
dimethyl fumarate	14.4	9.3
dimethyl itaconate	>100	100.0
Example 75	11.2	NT*
Example 76	4.1	NT*
Example 77	14.5	NT*
Example 78	4.2	NT*
Example 79	11.9	13.5
Example 80	9.6	5.3
Example 81	100	52.1
Example 82	25.7	18.9
Example 83	34.2	96.9
Example 84	14.3	22
Example 85	22.6	18.6
Example 86	100	15.7
Example 87	28.1	100
Example 88	25.2	20.4
Example 89	17.5	12.6
Example 90	16.4	9.8
Example 91	48.1	33.8
Example 92	75.3	21.2
Example 93	73.8	28.1
Example 94	5.3	NT*
Example 95	80.6	NT*
Example 96	15.7	47.1
Example 97	29.3	30.3
Example 98	2.1	4.3
Example 99	1.9	2.5
Example 100	11	5.1
Example 101	15.2	4.7
Example 102	1.5	1.1
Example 103	55.5	NT*
Example 104	14.4	NT*
Example 105	27.9	NT*
Example 106	15.6	NT*
Example 107	10	2.7

Compound	IL-1 β (IC ₅₀)	IL-6 (IC ₅₀)
dimethyl fumarate	14.4	9.3
dimethyl itaconate	>100	100.0
Example 108	11.1	3.1
Example 109	10.6	6.8
Example 110	8.5	4.4
Example 111	100	70.9
Example 112	14.6	NT*
Example 113	100	48.5
Example 114	100	56.2
Example 115	59.5	36.3
Example 116	100	60.4
Example 117	100	43.9
Example 118	16.2	14
Example 119	82.4	47.5
Example 120	26.9	7.7
Example 121	54.2	NT*
Example 122	13	NT*
Example 123	19.5	NT*
Example 124	52.4	NT*
Example 125	17	NT*
Example 126	0.7	NT*
Example 127	44.9	NT*
Example 128	32.7	NT*
Example 129	5.5	NT*
Example 130	16	NT*
Example 131	4.4	NT*
Example 132	4.3	NT*
Example 133	14.8	NT*
Example 134	9.8	NT*
Example 135	4.2	NT*
Example 136	54.2	NT*
Example 137	5.7	NT*
Example 138	6.8	5.2
Example 139	21.7	15.1
Example 140	7.8	NT

Compound	IL-1 β (IC ₅₀)	IL-6 (IC ₅₀)
dimethyl fumarate	14.4	9.3
dimethyl itaconate	>100	100.0
Example 141	6.5	NT
Example 142	6.2	NT
Example 143	2.0	NT
Example 144	1.7	NT
Example 145	19.3	NT
Example 146	8.5	NT
Example 147	13.4	NT
Example 148	29.6	NT
Example 149	12.1	NT
Example 150	11.7	NT
Example 151	10.3	NT
Example 152	10.3	NT
Example 153	7.0	NT
Example 154	8.4	NT
Example 155	16.5	NT
Example 156	27.9	NT
Example 157	41.6	NT
Example 158	24.2	NT
Example 159	31.9	NT
Example 160	8.1	NT
Example 161	6.8	NT
Example 162	14.7	NT
Example 163	23.9	NT
Example 164	2.0	NT
Example 165	15.8	NT
Example 166	67.4	NT
Example 167	29.1	NT
Example 168	49.3	NT
Example 169	15.6	NT
Example 170	14.7	NT
Example 171	21.8	NT
Example 172	23.8	NT
Example 173	27.6	NT

Compound	IL-1 β (IC ₅₀)	IL-6 (IC ₅₀)
dimethyl fumarate	14.4	9.3
dimethyl itaconate	>100	100.0
Example 174	10.9	NT
Example 175	7.6	NT
Example 176	12.0	NT
Example 177	20.5	NT
Example 178	24.6	NT
Example 179	11.0	NT
Example 180	8.2	NT
Example 181	32.8	NT
Example 182	6.1	NT
Example 183	9.6	NT
Example 184	33.9	NT
Example 185	21.6	8.8
Example 186	3.5	NT
Example 187	2.9	NT
Example 188	3.5	NT
Example 189	57.9	NT
Example 190	58.4	NT
Example 191	26.6	NT
Example 192	10.6	NT
Example 193	17.6	NT
Example 194	24.8	NT
Example 195	24.3	NT
Example 196	18.8	NT
Example 197	21.4	NT
Example 198	22.0	NT
Example 199	18.3	NT
Example 200	11.5	NT
Example 201	24.6	NT
Example 202	36.7	NT
Example 203	22.0	NT
Example 204	41.7	NT
Example 205	1.7	NT
Example 206	19.1	NT

Compound	IL-1 β (IC ₅₀)	IL-6 (IC ₅₀)
dimethyl fumarate	14.4	9.3
dimethyl itaconate	>100	100.0
Example 207	100	NT

NT* = not tested

Biological Example 2 – NQO1 Enzyme Activation Assay

5 NQO1 Enzyme Activation Assay as a readout of NRF2 Activation in THP-1 cellular background

NAD(P)H dehydrogenase [quinone] 1 (NQO1) is an anti-oxidant target gene upregulated by increased NRF2 activity. Induction of this gene is concomitant with the inhibition of proinflammatory cytokine transcription and suppression of the inflammatory response (Kobayashi
 10 E. H. *et al.*, 2016). The NQO1 enzyme activation activities of compounds of formula (IW-1) were determined using a cellular based NQO1 activation assay (Abcam). The NQO1 activation assay was run in differentiated THP-1 cells (a human monocyte-like cell line) as described below. All reagents described are from Sigma-Aldrich unless specified otherwise. Compounds were prepared as 10mM DMSO stocks.

15 Assay Procedure

THP-1 cells were expanded as a suspension up to 80% confluence in appropriate growth medium. Cells were harvested, suspended, treated with phorbol 12-myristate 13-acetate (PMA) and plated
 20 according to the cell density required for each plate format over a 72hr period (37°C/5% CO₂).

Following 72hrs of THP-1 cell incubation, cellular medium was removed and replaced with fresh media. Working concentrations of compounds were prepared and pre-incubated for 30 minutes (37°C/5% CO₂). Compound treatment was then applied to the PMA treated THP-1 cell plate
 25 followed by LPS treatment. A 'low' (DMSO vehicle only) control and 'high' (designated concentration of dimethyl fumarate) was applied to each plate at the point of compound treatment. Cells were subsequently incubated for a 48hr period (37°C/5% CO₂) after which all NQO1 assay reagents were prepared according to the manufacturer's instructions. NQO1 extraction buffer was applied to PBS washed THP-1 cells and incubated on ice for 15 minutes to prepare THP-1 lysates
 30 for the NQO1 activity assay. THP-1 lysates were diluted 1:5 with PBS and treated with a 1:1 volume of kit prepared NQO1 Reaction Buffer. Absorbance was subsequently measured kinetically on an appropriate reader over a 6 minute period.

For activation determination, the fold change in response per well was determined by first calculating the average NQO1 activation data for the vehicle control and then dividing the individual well response by the averaged NQO1 response for the vehicle control as shown below:

$$5 \quad \text{Fold change} = \frac{\text{(Sample value)}}{\text{Mean}_{\text{Min}}}$$

Where 'Min' = vehicle control only

10 The relative 50% activation concentration (EC_{50}) was determined from the resulting fold change response curve. The maximum efficacy (E_{max}) was reported as the percentage activation calculated at the top concentration of compound used in the titration applied. If a full curve was unattainable preventing a correct curve fit, the E_{max} value was extrapolated using existing curve data. All percentage activation data were normalised to the DMF and vehicle controls, meaning the E_{max} represents the percentage inhibition achieved by a compound at a particular
15 concentration relative to that achieved by DMF (set as the 'High' control and therefore representative of 100% activation).

A number of compounds of formula (IW-1) were tested, and the results are shown in Table 2 below. Dimethyl itaconate and dimethyl fumarate were included as comparator compounds. All
20 compounds of formula (IW-1) shown in Table 2 (except Example 185) exhibited a lower EC_{50} and/or a higher E_{max} compared with dimethyl itaconate and/or dimethyl fumarate.

Table 2 - NQO1 enzyme activation

Compound	EC_{50} (μM)	E_{max} (%)
dimethyl itaconate	74.1	144
dimethyl fumarate	12.9	126
Example 1	6.9	167
Example 2	4.6	213
Example 3	14.7	91
Example 4	13.6	171
Example 5	5.9	81
Example 6	30.6	154
Example 7	7.3	78
Example 8	35.4	152
Example 9	9.8	98
Example 10	15.2	107

Compound	EC ₅₀ (μM)	E _{max} (%)
dimethyl itaconate	74.1	144
dimethyl fumarate	12.9	126
Example 11	10.4	124
Example 12	22.7	88
Example 13	2.8	45
Example 14	14.4	180
Example 16	19.8	108
Example 17	2.6	68
Example 18	5.4	67
Example 19	51.0	44
Example 20	20.0	224
Example 21	12.1	150
Example 37	21.0	105
Example 38	8.5	111
Example 39	1.3	59
Example 40	16.6	56
Example 41	38.1	129
Example 42	24.3	66
Example 43	169.8	150
Example 44	64.6	217
Example 45	1.6	72

Biological Example 3 – Primary human monocyte AlphaLISA IL-1β and IL-6 Cytokine Assay

Measuring inhibitory effects on IL-1β and IL-6 cytokine output from isolated primary human monocytes

5

10

The cytokine inhibition profiles of compounds of formula (IW-1) were determined in a CD14⁺ isolated primary human monocyte cell assay. All assays were performed in RPMI-1640 growth medium (Gibco), supplemented with heat-inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin unless specified otherwise. The IL-1β and IL-6 cytokine inhibition assays were each run in a background of isolated primary human monocyte cells as described below. All reagents described were from Sigma-Aldrich unless specified otherwise. Compounds were prepared as 100mM DMSO stocks.

Assay Procedure

Primary peripheral blood mononuclear cells (PBMCs) were isolated from human whole blood. Following PBMC isolation, a CD14⁺ monocyte isolation step was conducted whereby CD14⁺ magnetic beads (Miltenyi Biotec) were incubated for 15 minutes with the PBMC suspension that was previously treated with ice cold T-cell isolation buffer (PBS, 0.5% BSA, 2mM EDTA). Following bead incubation, the treated cell suspension was passed through a magnetic separation column designed to positively select for magnetically labelled cells. The isolated CD14⁺ monocytes were subsequently plated at the appropriate cell density for the assay, prior to compound treatment on the day of plating. Working concentrations of compounds were prepared separately in RPMI-1640 only growth medium and pre-incubated with the cells for 30 minutes (37°C/5% CO₂). Following the 30 minute compound pre-incubation, primary monocytes were treated with an appropriate concentration of LPS and subsequently incubated for a 24hr period (37°C/5% CO₂). An appropriate final concentration of Nigericin was then dispensed into the primary monocyte plates and incubated for 1 hour (37°C/5% CO₂) before monocyte supernatants were harvested and collected in separate polypropylene 96-well holding plates prior to commencing the AlphaLISA cytokine assay.

Reagents from each of the IL-1 β and IL-6 commercial kits (Perkin Elmer) were prepared and run according to the manufacturer's instructions. Subsequently, fluorescence signal was measured in a microplate reader (EnVision® Multilabel Reader, Perkin Elmer).

Percentage inhibition was calculated per cytokine by normalising the sample data to the high and low controls used within each plate (+/- LPS respectively). Percentage inhibition was then plotted against compound concentration and the 50% inhibitory concentration (IC₅₀) was determined from the resultant concentration-response curve.

A number of Example compounds of formula (IW-1) were tested and the results are shown in Table 3 below. Dimethyl fumarate and 4-octyl itaconate were included as comparator compounds. Examples 2, 3 and 9 exhibited lower IC_{50s} than dimethyl fumarate. All compounds which were tested exhibited lower IC_{50s} than 4-octyl itaconate.

Table 3 – primary monocyte IL-1 β and IL-6 IC₅₀ values (μ M)

Compound	IL-1 β (IC ₅₀)	IL-6 (IC ₅₀)
dimethyl fumarate	8.5	15.7
4-octyl itaconate	>100	NT*
Example 1	8.9	26.9

Compound	IL-1 β (IC ₅₀)	IL-6 (IC ₅₀)
dimethyl fumarate	8.5	15.7
4-octyl itaconate	>100	NT*
Example 2	3.6	13.2
Example 3	3.9	NT
Example 9	3.3	10.7
Example 88	17.3	NT
Example 90	81.3	NT
Example 112	13.7	NT

NT* = not tested

Biological Example 4 – Primary human monocyte derived macrophages (HMDMs) **AlphaLISA IL-1 β Cytokine Assay**

5

Measuring inhibitory effects on IL-1 β cytokine output from isolated primary HMDMs

The cytokine inhibition profiles of compounds of formula (IW-1) were determined in a monocyte differentiated macrophage cell assay. All assays were performed in RPMI-1640 growth medium (Gibco), supplemented with heat-inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin unless specified otherwise. The IL-1 β cytokine inhibition assay was run in a background of isolated primary HMDM cells as described below. All reagents described were from Sigma-Aldrich unless specified otherwise. Compounds were prepared as 100mM DMSO stocks.

15

Assay Procedure

Primary peripheral blood mononuclear cells (PBMCs) were isolated from human whole blood. Following PBMC isolation, a CD14⁺ monocyte isolation step was conducted whereby CD14⁺ magnetic beads (Miltenyi Biotec) were incubated for 15 minutes with the PBMC suspension that was previously treated with ice cold T-cell isolation buffer (PBS, 0.5% BSA, 2mM EDTA). Following bead incubation, the treated cell suspension was passed through a magnetic separation column designed to positively select for magnetically labelled cells. The isolated CD14⁺ monocytes were subsequently plated at an appropriate cell density and treated for a 7 day period with M-CSF (BioLegend) to drive macrophage differentiation. Following the differentiation period, working concentrations of compounds were prepared separately in RPMI-1640 only growth medium and pre-incubated with the cells for 30 minutes (37°C/5% CO₂). Following the 30 minute compound pre-incubation, primary HMDMs were treated with an appropriate concentration of LPS and subsequently incubated for a 24hr period (37°C/5% CO₂). Nigericin was

added and incubated for 1 hour prior to harvesting primary HMDM supernatants and collected in separate polypropylene 96-well holding plates prior to commencing the AlphaLISA cytokine assay.

- 5 Reagents from the IL-1 β commercial kit (Perkin Elmer) was prepared and run according to the manufacturer's instructions. Subsequently, fluorescence signal was measured in a microplate reader (EnVision® Multilabel Reader, Perkin Elmer).

Percentage inhibition was calculated per cytokine by normalising the sample data to the high and
 10 low controls used within each plate (+/- LPS respectively). Percentage inhibition was then plotted against compound concentration and the 50% inhibitory concentration (IC₅₀) was determined from the resultant concentration-response curve.

A number of Example compounds of formula (IW-1) were tested and the results are shown in
 15 Table 4 below. Dimethyl fumarate was included as a comparator compound. All compounds of formula (IW-1) shown in Table 4 exhibited lower IC₅₀ than the comparator compound.

Table 4 – HMDM IL-1 β IC₅₀ values (μ M)

Compound	IL-1 β (IC ₅₀)
dimethyl fumarate	2.0
Example 1	0.4
Example 2	0.3
Example 3	0.7
Example 4	0.4
Example 9	1.2

20 **Biological Example 5 – NRF2 +/- GSH activation assay**

Measuring compound activation effects on the anti-inflammatory transcription factor NRF2 in DiscoverX PathHunter NRF2 translocation kit

- 25 Potency and efficacy of compounds of formula (IW-1) against the target of interest to activate NRF2 (nuclear factor erythroid 2-related factor 2) were determined using the PathHunter NRF2 translocation kit (DiscoverX). The NRF2 translocation assay was run using an engineered recombinant cell line, utilising enzyme fragment complementation to determine activation of the Keap1-NRF2 protein complex and subsequent translocation of NRF2 into the nucleus. Enzyme

activity was quantified using a chemiluminescent substrate consumed following the formation of a functional enzyme upon PK-tagged NRF2 translocation into the nucleus.

The assay was run under either +/- GSH (glutathione) conditions to determine the attenuating activities of GSH against target compounds.

Additionally, a defined concentration of dimethyl fumarate was used as the 'High' control to normalise test compound activation responses to.

10 Assay Procedure

U2OS PathHunter eXpress cells were thawed from frozen prior to plating. Following plating, U2OS cells were incubated for 24hrs (37°C/5%CO₂) in commercial kit provided cell medium.

15 Following 24hrs of U2OS incubation, cells were directly treated with an appropriate final concentration of compound, for -GSH conditions, or for +GSH conditions, an intermediate plate containing 6x working concentrations of compound stocks was prepared in a 6mM working concentration of GSH solution (solubilised in sterile PBS). Following a 30 minute compound-GSH pre-incubation (37°C/5%CO₂) for +GSH treatment, plated U2OS cells were incubated with an appropriate final concentration of compound and GSH.

Following compound (+/-GSH) treatment, the U2OS plates were incubated for a further 6 hours (37°C/5%CO₂) before detection reagent from the PathHunter NRF2 commercial kit was prepared and added to test plates according to the manufacturer's instructions. Subsequently, the luminescence signal detection in a microplate reader was measured (PHERAstar®, BMG Labtech).

Percentage activation was calculated by normalising the sample data to the high and low controls used within each plate (+/- DMF). Percentage activation/response was then plotted against compound concentration and the 50% activation concentration (EC₅₀) was determined from the plotted concentration-response curve.

A number of compounds of formula (IW-1) were tested, and the results are shown in Table 5 below. Dimethyl itaconate and dimethyl fumarate were included as comparator compounds. Certain compounds of formula (IW-1) shown in Table 5 exhibited a lower or comparable EC₅₀ and/or a higher E_{max} compared with dimethyl itaconate and/or dimethyl fumarate.

Table 5 – NRF2 activation

Compound	EC ₅₀ (μM)	E _{max} (%)
dimethyl fumarate	5.6	102
dimethyl itaconate	21.4	137
Example 1	8.8	134
Example 2	5.1	268
Example 4	8.3	181
Example 5	5.7	216
Example 14	8.8	189
Example 20	13.5	116
Example 49	15.8	232
Example 50	3.2	225
Example 54	2.8	105
Example 69	14.7	111
Example 75	17.5	143
Example 78	17.7	177
Example 80	21.5	229
Example 81	24.9	110
Example 82	26.5	164
Example 84	6.3	185
Example 85	25.0	163
Example 86	21.0	91
Example 87	34.2	113
Example 88	3.2	139
Example 89	22.4	238
Example 90	29.4	157
Example 91	10.1	73
Example 92	37.8	109
Example 93	36.0	118
Example 94	22.2	193
Example 95	36.5	122
Example 96	21.2	180
Example 98	14.7	193
Example 99	37.6	227
Example 100	48.7	195
Example 101	37.9	186

Compound	EC ₅₀ (μM)	E _{max} (%)
dimethyl fumarate	5.6	102
dimethyl itaconate	21.4	137
Example 102	6.5	191
Example 112	8.9	173
Example 122	17.5	178
Example 125	38.3	116
Example 128	38.0	104
Example 129	5.8	178
Example 130	29.1	164
Example 133	33.3	227
Example 134	20.0	183
Example 135	11.1	157
Example 137	4.2	96
Example 144	2.1	176
Example 145	>100	7
Example 156	47.9	63
Example 157	>100	29
Example 158	72.8	43
Example 159	13.8	86
Example 160	72.6	7
Example 161	5.0	146
Example 162	31.3	164
Example 163	>100	0
Example 164	4.9	168
Example 165	10.9	191
Example 178	14.3	188
Example 182	5.5	188
Example 189	18.0	137
Example 192	11.8	194

Biological Example 6 – Mouse pharmacokinetic studies

5 Pharmacokinetic studies were carried out in 6–8-week-old male C57BL/6 mice having free access to food and water. Intravenous dosing was conducted at 10 mg/kg (5 mL/kg; vehicle: 10% DMSO–90% (25% HP-β-CD in water)) via tail vein injection, with sampling at 3min, 8min, 15min, 30min,

1, 2, 4, 6 and 8 hours, i.e., 9 time points in total (N=3/time point), using semi-serial bleeding for plasma. Oral compound administration, via gavage, was carried out at 100 mg/kg (10 mL/kg; vehicle: 5% DMSO–95% (0.5% HPMC + 0.1% Tween 80 in water)), with sampling at 5min, 15min, 30min, 1, 2, 4, 6, 8 and 24 hours, i.e., 9 time points in total (N=3/time point), using semi-serial

For both intravenous and oral routes, the mice were restrained manually at the designated time points, with ca. 110 µL of blood being taken into K2EDTA tubes via the facial vein. Blood samples were put on ice and centrifuged to obtain plasma samples from which the concentration at each time point was measured by LC-MS/MS.

A number of compounds of formula (IW-1) were tested, and the results are shown in Tables 6 and 7 below. Dimethyl itaconate was included as a comparator compound. All compounds of formula (IW-1) exhibited higher systemic exposures than dimethyl itaconate which was only quantifiable at one timepoint following intravenous dosing and was below the limit of quantification at all timepoints following oral administration.

Table 6 – Parent compound concentrations (ng/mL) following intravenous administration

Compound	Time (h)								
	0.05	0.133	0.25	0.5	1	2	4	6	8
dimethyl itaconate	874	<24	<24	<24	<24	<24	<24	<24	<24
Example 82	17600	8347	2783	752	69	2.2	1.4	1.6	<0.8
Example 84	5575	—*	1034	217	34	6.5	<2.0	<2.0	—
Example 88	42500	23533	12367	6253	2513	200	40	11	4.2
Example 89	27833	12377	7680	2300	430	65	6.8	<4.0	<4.0
Example 90	19233	7160	2023	1597	89	3.6	2.8	1.7	1.2
Example 94	18000	6073	2437	550	42	1.9	1.4	<0.8	<0.8
Example 96	15100	3587	659	169	6.4	3.0	<0.8	<0.8	<0.8
Example 112	63467	40133	36233	23533	13000	3537	1513	424	154
Example 118	3053	161	8.0	2.4	<0.8	<0.8	<0.8	<0.8	<0.8
Example 125	11900	3870	1068	346	38	3.0	<0.8	<0.8	<0.8
Example 129	2920	872	309	96	7.7	<1.6	<1.6	<1.6	<1.6
Example 133	11033	4573	1953	315	33	<8.0	<8.0	<8.0	<8.0
Example 134	31567	7757	2890	4295	74	12	11	1.4	1.7
Example 161	8887	2377	846	343	90	5.1	<4.0	<4.0	<4.0

Example 164	6690	1248	534	211	18	<4.0	<4.0	<4.0	<4.0
Example 169	15600	6433	2803	516	8.6	2.5	1.3	<0.8	<0.8
Example 170	37167	21867	8933	1663	476	66	12	<4.0	<4.0
Example 172	23667	11300	2637	1211	75	9.9	6.1	<4.0	<4.0
Example 175	27467	11700	6110	1193	181	32	<4.0	<4.0	<4.0
Example 178	33367	15500	5677	2850	594	61	8.2	<4.0	<4.0
Example 179	17867	5317	1810	456	13	<4.0	<4.0	<4.0	<4.0
Example 182	40833	17933	6737	2893	642	88	20	6.0	<4.0
Example 192	36633	21433	11273	2907	400	86	26	<4.0	<4.0
Example 193	28833	10677	4040	1450	134	16	4.1	<4.0	<4.0

*Timepoints where no samples were taken are indicated with a dash, “—”.

Table 7 – Parent compound concentrations (ng/mL) following oral administration

Compound	Time (h)								
	0.083	0.25	0.5	1	2	4	6	8	24
Dimethyl itaconate	<24	<24	<24	<24	<24	<24	<24	<24	<24
Example 49	—*	536	843	344	111	12	—	4.5	<1.5
Example 80	—	850	1151	715	173	67	—	<1.5	<1.5
Example 82	27533	18000	6447	3400	1042	568	112	86	<0.8
Example 84	—	9089	5116	3314	1005	368	—	217	<31
Example 86	—	41	943	686	149	19	—	<3.0	<3.0
Example 87	—	35333	15884	8515	1465	198	—	31	<14
Example 88	53900	43633	33767	12683	10527	4105	1947	72	5.5
Example 89	43967	39133	28500	13967	4737	918	582	16	6.8
Example 90	22867	10637	6200	3373	3473	1645	1048	500	1.1
Example 91	—	8863	6235	1920	450	33	—	19	13
Example 94	27833	12563	8217	3113	2137	392	196	90	<0.8
Example 96	15300	4773	3780	1551	810	856	330	443	<0.8
Example 112	79833	64567	72333	49500	31433	21267	6783	12187	25
Example 125	9357	4360	2653	1427	785	427	163	15	<0.8
Example 129	305	1032	109	255	61	13	16	11	3.5
Example 133	9363	9940	4267	1104	527	799	146	101	<8.0
Example 134	17533	3500	7973	1983	856	636	94	62	7.0
Example 161	7023	4340	1900	1265	727	186	108	16	<4.0
Example 164	3793	2973	1859	968	585	381	135	181	<4.0

Example 169	37800	9877	4603	1750	971	215	57	7.7	<0.8
Example 170	55000	38367	40567	10053	4420	4403	441	25	8.1
Example 175	39133	19467	18233	5517	1407	2000	784	231	<4.0
Example 178	67067	27067	27933	11050	3660	1464	2245	639	<4.0
Example 182	65867	46833	27867	13493	5393	1372	1285	417	5.9
Example 192	47000	60667	37900	25167	8737	5440	79	41	6.6
Example 193	52900	45600	31533	8927	2123	920	55	19	5.6

*Timepoints where no samples were taken are indicated with a dash, “—”.

These results reveal that compounds of the invention display improved systemic exposures, as shown by the plasma concentrations of certain compounds of formula (IW-1) in this assay. All the compounds of formula (IW-1) shown in Table 6 exhibited higher systemic exposures compared with dimethyl itaconate when administered intravenously, and all the compounds of formula (IW-1) shown in Table 7 exhibited higher systemic exposures compared with dimethyl itaconate when administered orally.

Biological Example 7 – Hepatocyte stability assay

Defrosted cryo-preserved hepatocytes (viability > 70%) are used to determine the metabolic stability of a compound via calculation of intrinsic clearance (Cl_{int} ; a measure of the removal of a compound from the liver in the absence of blood flow and cell binding). Clearance data are particularly important for *in vitro* work as they can be used in combination with *in vivo* data to predict the half-life and oral bioavailability of a drug.

The metabolic stability in hepatocytes assay involves a time-dependent reaction using both positive and negative controls. The cells must be pre-incubated at 37 °C then spiked with test compound (and positive control); samples taken at pre-determined time intervals are analysed to monitor the change in concentration of the initial drug compound over 60 minutes. A buffer incubation reaction (with no hepatocytes present) acts as a negative control and two cocktail solutions, containing compounds with known high and low clearance values (verapamil/7-hydroxycoumarin and propranolol/diltiazem), act as positive controls.

1. The assay is run with a cell concentration of 0.5×10^6 cells/mL in Leibovitz buffer.
2. All compounds and controls are run in duplicate.
3. Compound concentration is 10µM.
4. All compounds and controls are incubated with both cells and buffer to show turnover is due to hepatic metabolism.

5. All wells on the incubation plate will have 326.7 μL of either cells or buffer added.
6. Prior to assay, cell and buffer-only incubation plates are preincubated for 10 mins at 37 $^{\circ}\text{C}$.
7. The assay is initiated by adding compounds, 3.3 μL of 1mM in 10%DMSO–90%Buffer; final DMSO concentration is 0.1%.
8. Samples are taken at regular timepoints (0, 5, 10, 20, 40, 60 min) until 60 mins.
9. Sample volume is 40 μL and it is added to 160 μL of crash solvent (acetonitrile with internal standard) and stored on ice.
10. At the end of the assay, the crash plates are centrifuged at 3500rpm for 20mins at 4 $^{\circ}\text{C}$.
11. 80 μL of clear supernatant is removed and mixed with 80 μL of deionised water before being analysed by LC-MS/MS.

Raw LC-MS/MS data are exported to, and analysed in, Microsoft Excel for determination of intrinsic clearance. The percentage remaining of a compound is monitored using the peak area of the initial concentration as 100%. Intrinsic clearance and half-life values are calculated using a graph of the natural log of percentage remaining versus the time of reaction in minutes. Half-life (min) and intrinsic clearance (Cl_{int} in $\mu\text{L min}^{-1} 10^{-6}$ cells) values are calculated using the gradient of the graph (the elimination rate constant, k) and Equations 1 and 2.

$$t_{\frac{1}{2}} = \frac{\ln 2}{k} \quad \{\text{Equation 1}\}$$

$$\text{Cl}_{\text{int}} = \left(\frac{\ln 2}{t_{\frac{1}{2}}} \right) \times \left(\frac{350}{0.175} \right) \quad \{\text{Equation 2}\}$$

A number of compounds of formula (IW-1) which were tested in Biological Example 6 were tested in this assay, and the results are shown in Table 8 below. 4-Octyl itaconate was included as a comparator compound.

Table 8 – Hepatocyte stability

Compound	Species	Cl_{int} ($\mu\text{L min}^{-1} 10^{-6}$ cells)	$T_{\frac{1}{2}}$ (min)
4-octyl itaconate	Human	401	4
	Mouse	351	4
Example 49	Human	109	13
	Mouse	138	10
Example 80	Human	243	6
	Mouse	158	9


Compound	Species	Cl _{int} (μL min ⁻¹ 10 ⁻⁶ cells)	T _{1/2} (min)
4-octyl itaconate	Human	401	4
	Mouse	351	4
Example 82	Human	15	91
	Mouse	52	27
Example 84	Human	86	16
	Mouse	220	6
Example 86	Human	44	31
	Mouse	NT*	NT
Example 87	Human	11	136
	Mouse	21	65
Example 88	Human	134	13
	Mouse	297	7
Example 89	Human	29	49
	Mouse	198	13
Example 90	Human	8	183
	Mouse	47	30
Example 91	Human	4	352
	Mouse	29	48
Example 94	Human	16	85
	Mouse	60	23
Example 96	Human	11	126
	Mouse	112	12
Example 112	Human	65	25
	Mouse	255	13
Example 125	Human	9	198
	Mouse	101	16
Example 129	Human	55	108
	Mouse	378	4
Example 133	Human	48	30
	Mouse	107	14
Example 134	Human	27	53
	Mouse	256	7
Example 161	Human	55	22
	Mouse	>460	<3

Compound	Species	Cl _{int} (μL min ⁻¹ 10 ⁶ cells)	T _{1/2} (min)
4-octyl itaconate	Human	401	4
	Mouse	351	4
Example 164	Human	42	33
	Mouse	259	5
Example 169	Human	5	268
	Mouse	38	34
Example 170	Human	12	120
	Mouse	64	20
Example 179	Human	13	129
	Mouse	129	13
Example 182	Human	60	28
	Mouse	187	9
Example 192	Human	32	54
	Mouse	350	5
Example 193	Human	16	109
	Mouse	79	22

*NT means not tested in this assay

These results reveal that compounds of the invention, at least those of Table 8, are expected to have acceptable or improved metabolic stabilities, as shown by their intrinsic clearance (Cl_{int}) and half-life (T_{1/2}) values in this assay. All the compounds of formula (IW-1) shown in Table 8 were more stable, i.e., they exhibited lower intrinsic clearance (Cl_{int}) and longer half-life (T_{1/2}) values compared with 4-octyl itaconate in at least human or mouse species. Preferred compounds exhibited lower intrinsic clearance (Cl_{int}) and longer half-life (T_{1/2}) values compared with 4-octyl itaconate in both human and mouse species.

Biological Example 8 – Metabolites of compounds of formula (IW-1)



Example 112 undergoes hydrolysis in vivo to form Intermediate 8, as evidenced by a mouse pharmacokinetic study — carried out according to the protocol outlined in Biological Example 6 — the data for which are shown in Table 9.

Table 9 – Example 112 and Intermediate 8 concentrations (ng/mL) following oral administration at 100mg/kg to the mouse

Compound	Time (h)								
	0.083	0.25	0.5	1	2	4	6	8	24
Example 112	109300	115667	74200	27900	14000	4883	4024	867	<8
Intermediate 8	18467	19767	12767	4713	2157	719	614	132	BQL

Intermediate 8 was tested in the assay described in Biological Examples 1 and 5 and the results are presented in Table 10. Example 112 is also shown as is dimethyl fumarate and dimethyl itaconate which were used as comparator compounds.

Table 10: Biological assay data for Intermediate 8

Compound	IL-1 β (IC ₅₀)	IL-6 (IC ₅₀)	EC ₅₀ (μ M)	E _{max} (%)
dimethyl fumarate	14.4	9.3	5.6	102
dimethyl itaconate	>100	100.0	21.4	137
Example 112	14.6	NT*	8.9	173
Intermediate 8	56.7	23.7	20.4	165

As shown in Table 10, Intermediate 8 (which is a metabolite of Example 112) exhibited improved cytokine-lowering potencies compared to dimethyl itaconate for IL-1 β and IL-6, and a lower EC₅₀ and a higher E_{max} compared with dimethyl itaconate. Intermediate 8 also displayed a higher E_{max} compared to dimethyl fumarate.

References

The following publication cited in this specification are herein incorporated by reference in their entirety.

- Ackermann et al. *Proc. Soc. Exp. Bio. Med.* **1949**, 72(1), 1-9.
 Andersen J. L. et al. *Nat. Commun.* **2018**, 9, 4344.
 Angiari S. and O'Neill L. A. *Cell Res.* **2018**, 28, 613–615.
 Bagavant G. et al. *Indian J. Pharm. Sci.* **1994**, 56, 80–85.
 Bambouskova M. et al. *Nature* **2018**, 556, 501–504.
 Blewett M. M. et al. *Sci. Sign.* **2016**, 9 (445), rs10; 6.
 Brennan M. S. et al. *PLoS One* **2015**, 10, e0120254.
 Brück J. et al. *Exp. Dermatol.* **2018**, 27, 611–624.
 Cocco M. et al. *J. Med. Chem.* **2014**, 57, 10366–10382.

- Cocco M. *et al. J. Med. Chem.* **2017**, 60, 3656–3671.
- Cordes T. *et al. J. Biol. Chem.* **2016**, 291, 14274–14284.
- Cordes T. *et al. Mol. Metab.* **2020**, 32, 122–135.
- Daly R. *et al. medRxiv* **2019**, 19001594; doi: <https://doi.org/10.1101/19001594>.
- 5 Daniels B. P. *et al. Immunity* **2019**, 50(1), 64–76.e4.
- Dibbert S. *et al. Arch. Dermatol. Res.* **2013**, 305, 447–451.
- ElAzzouny M. *et al. J. Biol. Chem.* **2017**, 292, 4766–4769.
- Gillard G. O. *et al. J. Neuroimmunol.* **2015**, 283, 74–85.
- Gu L. *et al. Immunol. Cell Biol.* **2020** doi:10.1111/imcb.12316.
- 10 Hanke T. *et al. Pharmacol. Therapeut.* **2016**, 157, 163–187.
- Hunt T. *et al. Consortium of Multiple Sclerosis Centers 2015 Annual Meeting*, 27–30 May **2015**, Indianapolis, IN, USA: Poster DX37.
- Kobayashi E. H. *et al. Nat. Commun.* **2016**, 7, 11624.
- Kornberg M. D. *et al. Science* **2018**, 360, 449–453.
- 15 Kulkarni R. A. *et al. Nat. Chem. Biol.* **2019** 10.1038/s41589-018-0217-y.
- Lampropoulou V. *et al. Cell Metab.* **2016**, 24, 158–166.
- Lehmann J. C. U. *et al. J. Invest. Dermatol.* **2007**, 127, 835–845.
- Liao S.-T. *et al. Nat. Commun.* **2019**, 10(1), 5091.
- Liu H. *et al. Cell Commun. Signal.* **2018**, 16, 81.
- 20 McGuire V. A. *et al. Sci. Rep.* **2016**, 6, 31159.
- Michelucci A. *et al. Proc. Natl. Acad. Sci. USA* **2013**, 110, 7820–7825.
- Mills E. A. *et al. Front. Neurol.* **2018**, 9, 5.
- Mills E. L. *et al. Cell* **2016**, 167, 457–470.
- Mills E. L. *et al. Nature* **2018**, 556, 113–117.
- 25 Mrowietz U. *et al. Trends Pharmacol. Sci.* **2018**, 39, 1–12.
- Müller S. *et al. J. Dermatol. Sci.* **2017**, 87, 246–251.
- Murphy M. P. and O'Neill L. A. J. *Cell* **2018**, 174, 780–784.
- O'Neill L. A. J. and Artyomov M. N. *Nat. Rev. Immunol.* **2019** 273–281.
- Olagnier D. *et al. Nat. Commun.* **2018**, 9, 3506.
- 30 Schmidt T. J. *et al. Bioorg. Med. Chem.* **2007**, 15, 333–342.
- Shan Q. *et al. Biochem. Biophys. Res. Commun.* **2019**, 517, 538–544.
- Straub R. H. and Schradin C. *Evol. Med. Public Health* **2016**, 1, 37–51S.
- Straub R. H. and Cutolo M. *Rheumatology* **2016**, 55 (Suppl. 2), ii6–ii14.
- Sun X. *et al., FASEB J.* **2019**, 33, 12929–12940.
- 35 Tang C. *et al. Cell Physiol. Biochem.* **2018**, 51, 979–990.
- Tang C. *et al. Biochem. Biophys. Res. Commun.* **2019**, 508, 921–927.
- Tang H. *et al. Biochem. Biophys. Res. Commun.* **2008**, 375, 562–565.

- Tian *et al.* *Eur. J. Pharmacol.* **2020**, 873, 172989.
van der Reest J. *et al.* *Nat. Commun.* **2018**, 9, 1581.
von Glehn F. *et al.* *Mult. Scler. Relat. Disord.* **2018**, 23, 46–50.
Yi F. *et al.* *Hepatology* **2020**, 873, 172989.
5 Yu X.-H. *et al.* *Immunol. Cell Biol.* **2019**, 97, 134–141.
Zhang S. *et al.* *Bioorg. Med. Chem.* **2012**, 20, 6073–6079.
Zhang D. *et al.* *Int. Immunopharmacol.* **2019**, 77, 105924.
Zhao C. *et al.* *Microb. Pathogen.* **2019**, 133, 103541.
Zhao G. *et al.* *Biochem. Biophys. Res. Commun.* **2014**, 448, 303–307.

10

Miscellaneous

All references referred to in this application, including patent and patent applications, are incorporated herein by reference to the fullest extent possible.

15


Throughout the specification and the claims which follow, unless the context requires otherwise, the word ‘comprise’, and variations such as ‘comprises’ and ‘comprising’, will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps.

20

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without
25 limitation, the following claims.

CLAIMS

1. A compound which is a compound of formula (IW-1):



wherein,

R^A is selected from the group consisting of C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{5-10} spirocycloalkyl and 4–7 membered heterocyclyl; wherein R^A is optionally substituted by one or more substituents selected from the group consisting of oxo, R^{1A} , OR^{2A} , $NR^{2A}R^{3A}$, SR^{2A} , SOR^{9A} , SO_2R^{9A} , $SO_2NR^{2A}R^{3A}$, $C(O)R^{2A}$ and $CONR^{2A}R^{3A}$;

R^{1A} is selected from the group consisting of fluoro, methyl, cyano, $SiR^{4A}R^{5A}R^{6A}$, C_{3-8} cycloalkyl, phenyl and 5-6 membered heteroaryl; wherein methyl, C_{3-8} cycloalkyl, phenyl and 5-6 membered heteroaryl are optionally substituted by R^{7A} and/or R^{8A} ;

R^{4A} , R^{5A} and R^{6A} are independently selected from the group consisting of C_{1-4} alkyl and phenyl; wherein phenyl is optionally substituted by one or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

R^{7A} and R^{8A} are independently selected from the group consisting of oxo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

or, taken together, R^{7A} and R^{8A} form a C_{3-8} cycloalkyl or 4–7 membered heterocyclic ring;

R^{2A} and R^{3A} are independently H, C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{2A} and R^{3A} are independently optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qA}W^A$; or, taken together, R^{2A} and R^{3A} form a 4–7 membered heterocyclic ring optionally independently substituted by one or more substituents selected from the group consisting of C_{1-2} alkyl, hydroxy and oxo;

R^{9A} is C_{1-8} alkyl, C_{3-8} cycloalkyl or phenyl; wherein R^{9A} is optionally substituted by one or more substituents selected from the group consisting of C_{1-8} alkyl, C_{1-4} alkoxy, fluoro, hydroxy, oxo and $-(CH_2)_{qA}W^A$;

qA is 0 or 1;

W^A is selected from the group consisting of C_{3-8} cycloalkyl, phenyl and 5–6 membered heteroaryl; wherein W^A is optionally substituted by one or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, CO_2H , cyano, methanesulfonyl and halo;

wherein

R^B is C_{1-2} alkyl substituted by CO_2H optionally substituted by at least one other substituent selected from the group consisting of halo, trifluoromethyl and methyl;

R^C and R^D are independently selected from the group consisting of H, C_{1-2} alkyl, hydroxy, methoxy and fluoro;

and wherein,

when neither R^A nor R^B contain heteroatoms, the total number of carbon atoms in groups R^A and R^B taken together is at least 6;

or a pharmaceutically acceptable salt and/or solvate thereof;

or a compound selected from the group consisting of:

1-(2-cyanoethyl) 4-octyl 2-methylenesuccinate;

1-(2-(methylsulfonyl)ethyl) 4-octyl 2-methylenesuccinate;

4-octyl 1-(3,3,3-trifluoropropyl) 2-methylenesuccinate;

4-octyl 1-(oxetan-3-yl) 2-methylenesuccinate;

4-octyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;

1-(3-(dimethylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;

4-butyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;

1-(2-cyanoethyl) 4-butyl 2-methylenesuccinate;

1-(2-(2,5-dioxopyrrolidin-1-yl)ethyl) 4-octyl 2-methylenesuccinate;

1-(2-cyanoethyl) 4-methyl 2-methylenesuccinate;

1-(2-cyanoethyl) 4-hexyl 2-methylenesuccinate;

4-methyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;

4-octyl 1-(2-(trifluoromethoxy)ethyl) 2-methylenesuccinate;

4-hexyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;

4-methyl 1-(oxetan-3-yl) 2-methylenesuccinate;

1-(2-(N,N-dimethylsulfamoyl)ethyl) 4-octyl 2-methylenesuccinate;

1-(2-(dimethylamino)ethyl) 4-octyl 2-methylenesuccinate;

1-(3-(methylsulfonyl)propyl) 4-octyl 2-methylenesuccinate;

1-(1-(methylsulfonyl)propan-2-yl) 4-octyl 2-methylenesuccinate;

1-(2-(methylsulfonyl)ethyl) 4-(3-phenoxypropyl) 2-methylenesuccinate;

1-(2-(dimethylamino)-2-oxoethyl) 4-octyl 2-methylenesuccinate;

4-isopropyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;

(S)-4-octyl 1-(tetrahydrofuran-3-yl) 2-methylenesuccinate;

(R)-4-octyl 1-(tetrahydrofuran-3-yl) 2-methylenesuccinate;

4-cyclooctyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;

4-octyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;

1-(1-cyanopropan-2-yl) 4-octyl 2-methylenesuccinate;

1-(1-(methylsulfonyl)piperidin-4-yl) 4-octyl 2-methylenesuccinate;


- 1-(2-methoxyethyl) 4-octyl 2-methylenesuccinate;
 1-(2-cyano-2-methylpropyl) 4-octyl 2-methylenesuccinate;
 1-(1-methoxypropan-2-yl) 4-octyl 2-methylenesuccinate;
 1-((1-cyanocyclopropyl)methyl) 4-octyl 2-methylenesuccinate;
 5 1-(2-methoxypropyl) 4-octyl 2-methylenesuccinate;
 1-(2-methoxy-2-methylpropyl) 4-octyl 2-methylenesuccinate;
 1-(2-morpholinoethyl) 4-octyl 2-methylenesuccinate;
 4-(2-(2-ethoxyethoxy)ethyl) 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 4-butyl 1-(oxetan-3-yl) 2-methylenesuccinate;
 10 4-hexyl 1-(oxetan-3-yl) 2-methylenesuccinate;
 4-butyl 1-(2-tosylethyl) 2-methylenesuccinate;
 4-octyl 1-(2-tosylethyl) 2-methylenesuccinate;
 4-cyclooctyl 1-methyl 2-methylenesuccinate;
 1-methyl 4-octyl 2-methylenesuccinate;
 15 dicyclobutyl 2-methylenesuccinate;
 di(oxetan-3-yl) 2-methylenesuccinate;
 1-cyclobutyl 4-octyl 2-methylenesuccinate;
 1-(1-acetoxyethyl) 4-octyl 2-methylenesuccinate;
 1-(1,1-dioxidothietan-3-yl) 4-octyl 2-methylenesuccinate;
 20 1-(2-(tert-butoxy)-2-oxoethyl) 4-octyl 2-methylenesuccinate;
 1-(1-acetylazetidin-3-yl) 4-octyl 2-methylenesuccinate;
 1-(2-(4-methylpiperazin-1-yl)ethyl) 4-octyl 2-methylenesuccinate;
 1-(2-(1,1-dioxidothiomorpholino)ethyl) 4-octyl 2-methylenesuccinate;
 1-(2-(methylsulfonamido)ethyl) 4-octyl 2-methylenesuccinate;
 25 4-cyclooctyl 1-(1,1-dioxidothietan-3-yl) 2-methylenesuccinate;
 (R)-1-(2-(methylsulfonyl)ethyl) 4-(octan-2-yl) 2-methylenesuccinate;
 1-(1-(methylsulfonyl)propan-2-yl) 4-((R)-octan-2-yl) 2-methylenesuccinate;
 (R)-1-(1,1-dioxidothietan-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
 (R)-1-(1-acetylazetidin-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
 30 4-cyclohexyl 1-(1-(methylsulfonyl)propan-2-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-(1,1-dioxidothietan-3-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 4-cyclooctyl 1-(1-(methylsulfonyl)propan-2-yl) 2-methylenesuccinate;
 1-(1-acetylazetidin-3-yl) 4-cyclooctyl 2-methylenesuccinate;
 35 4-cyclohexyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 (S)-1-(1-acetylazetidin-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
 (S)-1-(1,1-dioxidothietan-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;

- 1-(3-methyloxetan-3-yl) 4-octyl 2-methylenesuccinate;
 4-cyclooctyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
 4-cyclooctyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
 4-cyclooctyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 5 (R)-4-(octan-2-yl) 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 (R)-4-(octan-2-yl) 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
 1-(1-acetylazetidin-3-yl) 4-cyclohexyl 2-methylenesuccinate;
 4-cyclohexyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
 4-hexyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
 10 4-hexyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 1-(2-(1H-tetrazol-5-yl)ethyl) 4-hexyl 2-methylenesuccinate;
 2-(N-methyl-2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetamido)acetic acid;
 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetyl)-L-proline;
 N-methyl-N-(2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)glycine;
 15 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)-L-proline;
 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)glycine;
 N-(2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetyl)-N-methylglycine;
 (2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetyl)-L-proline;
 (S)-N-methyl-N-(2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetyl)glycine;
 20 (S)-(2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetyl)glycine;
 1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl) 4-octyl 2-methylenesuccinate;
 1-(3-morpholino-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 1-(3-(diethylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 1-(3-(methylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 25 1-(2-((N,N-dimethylsulfamoyl)amino)-2-oxoethyl) 4-hexyl 2-methylenesuccinate;
 4-hexyl 1-(2-(methylsulfonamido)-2-oxoethyl) 2-methylenesuccinate;
 4-hexyl 1-(3-(methylsulfonamido)-2-oxoethyl) 2-methylenesuccinate;
 (E)-4-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)but-2-enoic acid;
 3-((2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)ethyl)sulfonyl)propanoic acid;
 30 1-((2H-tetrazol-5-yl)methyl) 4-cyclohexyl 2-methylenesuccinate;
 2-((3-((2-((3-chlorophenyl)sulfonyl)ethoxy)carbonyl)but-3-enoyl)oxy)acetic acid;
 (R)-2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)-2-phenylacetic acid;
 1-(2-(1H-tetrazol-5-yl)ethyl) 4-cyclohexyl 2-methylenesuccinate;
 (S)-1-(2-(1H-tetrazol-5-yl)ethyl) 4-octan-2-yl 2-methylenesuccinate;
 35 1-(2-(1H-tetrazol-5-yl)ethyl) 4-cyclooctyl 2-methylenesuccinate;
 1-(2-((3-chlorophenyl)sulfonyl)-2-methylpropyl) 4-cyclooctyl 2-methylenesuccinate;
 4-cyclooctyl 1-(2-methyl-2-(methylsulfonyl)propyl) 2-methylenesuccinate;
 1-(1-(1H-tetrazol-5-yl)ethyl) 4-cyclooctyl 2-methylenesuccinate;

- 1-((1H-tetrazol-5-yl)methyl) 4-cyclooctyl 2-methylenesuccinate;
 (R)-1-(2-(1H-tetrazol-5-yl)ethyl) 4-octan-2-yl 2-methylenesuccinate;
 (2R,3S)-2-acetamido-3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)butanoic acid;
 4-cyclooctyl 1-(3-(2-ethoxy-2-oxoethyl)oxetan-3-yl) 2-methylenesuccinate;
 5 4-(2-(methylsulfonyl)ethyl) 1-octyl 2-methyl-3-methylenesuccinate;
 1-octyl 4-((S)-tetrahydrofuran-3-yl) 2-methyl-3-methylenesuccinate;
 1-(1-(1H-tetrazol-5-yl)propan-2-yl) 4-((R)-octan-2-yl) 2-methylenesuccinate;
 1-(1-(1H-tetrazol-5-yl)propan-2-yl) 4-((S)-octan-2-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-((2-methyl-2H-tetrazol-5-yl)methyl) 2-methylenesuccinate;
 10 4-cyclohexyl 1-((1-methyl-1H-tetrazol-5-yl)methyl) 2-methylenesuccinate;
 2-((4-((adamantan-2-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 bis((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-methylenesuccinate;
 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-(2-oxaspiro[3.3]heptan-6-yl) 2-
 methylenesuccinate;
 15 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-(oxepan-4-yl) 2-
 methylenesuccinate;
 4-(1-butoxypropan-2-yl) 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-
 methylenesuccinate;
 4-spiro[3.3]heptan-2-yl 1-(3,3,3-trifluoro-2,2-dihydroxypropyl) 2-methylenesuccinate hydrate;(R)-
 20 1-((2H-tetrazol-5-yl)methyl) 4-(octan-2-yl) 2-methylenesuccinate;
 1-(2H-tetrazol-5-yl)methyl 4-cycloheptyl 2-methylenesuccinate;
 1-(2H-tetrazol-5-yl)methyl 4-spiro[3.3]heptan-2-yl 2-methylenesuccinate;
 (S)-1-(2H-tetrazol-5-yl)methyl 4-octan-2-yl 2-methylenesuccinate;
 1-(1-(1H-tetrazol-5-yl)ethyl) 4-((S)-octan-2-yl) 2-methylenesuccinate;
 25 1-(cyclopropyl(1H-tetrazol-5-yl)methyl) 4-((S)-octan-2-yl) 2-methylenesuccinate;
 dicyclohexyl 2-methylenesuccinate; 2-((4-((adamantan-1-yl)oxy)-2-methylene-4-
 oxobutanoyl)oxy)acetic acid; 2-((4-(bicyclo[3.3.1]nonan-9-yloxy)-2-methylene-4-
 oxobutanoyl)oxy)acetic acid;
 1-(3,3-difluorocyclobutyl) 4-octyl 2-methylenesuccinate;
 30 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-((R)-octan-2-yl) 2-
 methylenesuccinate; and
 (R)-4-(octan-2-yl) 1-((3-oxo-2,3-dihydroisoxazol-5-yl)methyl) 2-methylenesuccinate;
 or a pharmaceutically acceptable salt and/or solvate thereof.
- 35 2. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to
 claim 1, which is a compound of formula (IW-1) wherein R^A is selected from the group consisting
 of C₁₋₈ alkyl, C₃₋₈ cycloalkyl and 4-7 membered heterocyclyl.

3. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 2, wherein R^A is C₁₋₈ alkyl.

4. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 3, wherein R^A has the following structure:



5. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 1, which is a compound of formula (IW-1) wherein R^A is C₃₋₈ cycloalkyl.

6. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 5, wherein R^A is cyclobutyl or cyclooctyl.

7. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 6, wherein R^A is cyclobutyl.

8. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 1, which is a compound of formula (IW-1) wherein R^A is 4–7 membered heterocyclyl.

9. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 8, wherein R^A is selected from the group consisting of azetidiny, oxetanyl and thietanyl.

10. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 9, which is a compound of formula (IW-1) wherein R^A is substituted.

11. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 10, wherein R^A is substituted by R^{1A}.

12. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 11, wherein R^A is substituted by one R^{1A}.

13. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 12, which is a compound of formula (IW-1) wherein R^{1A} is selected from the group consisting of fluoro, methyl, cyano, SiR^{4A}R^{5A}R^{6A}, phenyl and 5-6 membered heteroaryl; and in particular is selected from the group consisting of fluoro, methyl, cyano, SiR^{4A}R^{5A}R^{6A} and

phenyl.

14. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 13, wherein R^{1A} is phenyl.

5

15. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 12, which is a compound of formula (IW-1) wherein R^{1A} is substituted by R^{7A} and/or R^{8A} when R^{1A} is methyl, C₃₋₈ cycloalkyl, 4-7 membered heterocyclyl, phenyl or 5-6 membered heteroaryl.

10

16. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 15, wherein R^{1A} is substituted by R^{7A} and R^{8A} is absent.

17. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 16, which is a compound of formula (IW-1) wherein R^{7A} is C₁₋₄ haloalkyl such as CF₃.

18. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 17, which is a compound of formula (IW-1) wherein R^B is C₁₋₂ alkyl substituted by CO₂H.

19. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 17, which is a compound of formula (IW-1) wherein R^B is substituted by CO₂H and at least one other substituent selected from the group consisting of halo, trifluoromethyl and methyl.

20. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 19, which is a compound of formula (IW-1) wherein R^C is H.

21. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 20, which is a compound of formula (IW-1) wherein R^D is H.

22. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 1 which is a compound selected from the group consisting of:

1-(2-cyanoethyl) 4-octyl 2-methylenesuccinate;
 1-(2-(methylsulfonyl)ethyl) 4-octyl 2-methylenesuccinate;
 4-octyl 1-(3,3,3-trifluoropropyl) 2-methylenesuccinate;
 4-octyl 1-(oxetan-3-yl) 2-methylenesuccinate;

- 4-octyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 1-(3-(dimethylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 4-butyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 1-(2-cyanoethyl) 4-butyl 2-methylenesuccinate;
 5 1-(2-(2,5-dioxopyrrolidin-1-yl)ethyl) 4-octyl 2-methylenesuccinate;
 1-(2-cyanoethyl) 4-methyl 2-methylenesuccinate;
 1-(2-cyanoethyl) 4-hexyl 2-methylenesuccinate;
 4-methyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 4-octyl 1-(2-(trifluoromethoxy)ethyl) 2-methylenesuccinate;
 10 4-hexyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 4-methyl 1-(oxetan-3-yl) 2-methylenesuccinate;
 1-(2-(N,N-dimethylsulfamoyl)ethyl) 4-octyl 2-methylenesuccinate;
 1-(2-(dimethylamino)ethyl) 4-octyl 2-methylenesuccinate;
 1-(3-(methylsulfonyl)propyl) 4-octyl 2-methylenesuccinate;
 15 1-(1-(methylsulfonyl)propan-2-yl) 4-octyl 2-methylenesuccinate;
 1-(2-(methylsulfonyl)ethyl) 4-(3-phenoxypropyl) 2-methylenesuccinate;
 1-(2-(dimethylamino)-2-oxoethyl) 4-octyl 2-methylenesuccinate;
 4-isopropyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 (S)-4-octyl 1-(tetrahydrofuran-3-yl) 2-methylenesuccinate;
 20 (R)-4-octyl 1-(tetrahydrofuran-3-yl) 2-methylenesuccinate;
 4-cyclooctyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 4-octyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
 1-(1-cyanopropan-2-yl) 4-octyl 2-methylenesuccinate;
 1-(1-(methylsulfonyl)piperidin-4-yl) 4-octyl 2-methylenesuccinate;
 25 1-(2-methoxyethyl) 4-octyl 2-methylenesuccinate;
 1-(2-cyano-2-methylpropyl) 4-octyl 2-methylenesuccinate;
 1-(1-methoxypropan-2-yl) 4-octyl 2-methylenesuccinate;
 1-((1-cyanocyclopropyl)methyl) 4-octyl 2-methylenesuccinate;
 1-(2-methoxypropyl) 4-octyl 2-methylenesuccinate;
 30 1-(2-methoxy-2-methylpropyl) 4-octyl 2-methylenesuccinate;
 1-(2-morpholinoethyl) 4-octyl 2-methylenesuccinate;
 4-(2-(2-ethoxyethoxy)ethyl) 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 4-butyl 1-(oxetan-3-yl) 2-methylenesuccinate;
 4-hexyl 1-(oxetan-3-yl) 2-methylenesuccinate;
 35 4-butyl 1-(2-tosylethyl) 2-methylenesuccinate;
 4-octyl 1-(2-tosylethyl) 2-methylenesuccinate;
 4-cyclooctyl 1-methyl 2-methylenesuccinate;
 1-methyl 4-octyl 2-methylenesuccinate;

- dicyclobutyl 2-methylenesuccinate;
 di(oxetan-3-yl) 2-methylenesuccinate;
 1-cyclobutyl 4-octyl 2-methylenesuccinate;
 1-(1-acetoxyethyl) 4-octyl 2-methylenesuccinate;
 5 1-(1,1-dioxidothietan-3-yl) 4-octyl 2-methylenesuccinate;
 1-(2-(tert-butoxy)-2-oxoethyl) 4-octyl 2-methylenesuccinate;
 1-(1-acetylazetidin-3-yl) 4-octyl 2-methylenesuccinate;
 1-(2-(4-methylpiperazin-1-yl)ethyl) 4-octyl 2-methylenesuccinate;
 1-(2-(1,1-dioxidothiomorpholino)ethyl) 4-octyl 2-methylenesuccinate;
 10 1-(2-(methylsulfonamido)ethyl) 4-octyl 2-methylenesuccinate;
 4-cyclooctyl 1-(1,1-dioxidothietan-3-yl) 2-methylenesuccinate;
 (R)-1-(2-(methylsulfonyl)ethyl) 4-(octan-2-yl) 2-methylenesuccinate;
 1-(1-(methylsulfonyl)propan-2-yl) 4-((R)-octan-2-yl) 2-methylenesuccinate;
 (R)-1-(1,1-dioxidothietan-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
 15 (R)-1-(1-acetylazetidin-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-(1-(methylsulfonyl)propan-2-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-(1,1-dioxidothietan-3-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-(2-(methylsulfonyl)ethyl) 2-methylenesuccinate;
 4-cyclooctyl 1-(1-(methylsulfonyl)propan-2-yl) 2-methylenesuccinate;
 20 1-(1-acetylazetidin-3-yl) 4-cyclooctyl 2-methylenesuccinate;
 4-cyclohexyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 (S)-1-(1-acetylazetidin-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
 (S)-1-(1,1-dioxidothietan-3-yl) 4-(octan-2-yl) 2-methylenesuccinate;
 25 1-(3-methyloxetan-3-yl) 4-octyl 2-methylenesuccinate;
 4-cyclooctyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
 4-cyclooctyl 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
 4-cyclooctyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 (R)-4-(octan-2-yl) 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 30 (R)-4-(octan-2-yl) 1-(tetrahydro-2H-pyran-4-yl) 2-methylenesuccinate;
 1-(1-acetylazetidin-3-yl) 4-cyclohexyl 2-methylenesuccinate;
 4-cyclohexyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
 4-hexyl 1-(1-(methylsulfonyl)piperidin-4-yl) 2-methylenesuccinate;
 4-hexyl 1-(2-(2-oxopyrrolidin-1-yl)ethyl) 2-methylenesuccinate;
 35 1-(2-(1H-tetrazol-5-yl)ethyl) 4-hexyl 2-methylenesuccinate;
 2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoic acid;
 3-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoic acid;
 3-((4-((4-fluorobenzyl)oxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid;

- 3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid;
 3-((2-methylene-4-(neopentyloxy)-4-oxobutanoyl)oxy)propanoic acid;
 (S)-3-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)propanoic acid;
 3-((4-(hexyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid;
 5 3-((2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoyl)oxy)propanoic acid;
 3-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid;
 (R)-3-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)propanoic acid;
 (S)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid;
 2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 10 2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((2-methylene-4-(neopentyloxy)-4-oxobutanoyl)oxy)acetic acid;
 2-((4-((4-fluorobenzyl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((4-(hexyloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoyl)oxy)acetic acid;
 15 2-((2-methylene-4-oxo-4-(spiro[3.3]heptan-2-yloxy)butanoyl)oxy)acetic acid;
 2-((2-methylene-4-oxo-4-(2-tosylethoxy)butanoyl)oxy)acetic acid;
 2-(N-methyl-2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetamido)acetic acid;
 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)acetyl)-L-proline;
 N-methyl-N-(2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)glycine;
 20 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)-L-proline;
 (2-((2-methylene-4-(octyloxy)-4-oxobutanoyl)oxy)propanoyl)glycine;
 N-(2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetyl)-N-methylglycine;
 (2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)acetyl)-L-proline;
 (S)-N-methyl-N-(2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetyl)glycine;
 25 (S)-(2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetyl)glycine;
 1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl) 4-octyl 2-methylenesuccinate;
 1-(3-morpholino-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 1-(3-(diethylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 1-(3-(methylamino)-3-oxopropyl) 4-octyl 2-methylenesuccinate;
 30 2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)propanoic acid;
 (R)-2-((2-methylene-4-(octan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid;
 2-((4-((4,4-difluorocyclohexyl)methoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((4-(3-ethoxypropoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((4-(bicyclo[2.2.1]heptan-2-yloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 35 2-((4-cyclobutoxy-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 3-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)-2,2-dimethylpropanoic acid;
 1-(2-((N,N-dimethylsulfamoyl)amino)-2-oxoethyl) 4-hexyl 2-methylenesuccinate;
 4-hexyl 1-(2-(methylsulfonamido)-2-oxoethyl) 2-methylenesuccinate;

- 4-hexyl 1-(3-(methylsulfonamido)-2-oxoethyl) 2-methylenesuccinate;
 2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)-3,3,3-trifluoropropanoic acid;
 2-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)-3,3,3-trifluoropropanoic acid;
 (E)-4-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)but-2-enoic acid;
 5 3-((2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)ethyl)sulfonyl)propanoic acid;
 1-((2H-tetrazol-5-yl)methyl) 4-cyclohexyl 2-methylenesuccinate;
 2-((3-((2-((3-chlorophenyl)sulfonyl)ethoxy)carbonyl)but-3-enoyl)oxy)acetic acid;
 (R)-2-((4-(cyclohexyloxy)-2-methylene-4-oxobutanoyl)oxy)-2-phenylacetic acid;
 1-(2-(1H-tetrazol-5-yl)ethyl) 4-cyclohexyl 2-methylenesuccinate;
 10 (S)-1-(2-(1H-tetrazol-5-yl)ethyl) 4-octan-2-yl 2-methylenesuccinate;
 1-(2-(1H-tetrazol-5-yl)ethyl) 4-cyclooctyl 2-methylenesuccinate;
 1-(2-((3-chlorophenyl)sulfonyl)-2-methylpropyl) 4-cyclooctyl 2-methylenesuccinate;
 4-cyclooctyl 1-(2-methyl-2-(methylsulfonyl)propyl) 2-methylenesuccinate;
 1-(1-(1H-tetrazol-5-yl)ethyl) 4-cyclooctyl 2-methylenesuccinate;
 15 1-((1H-tetrazol-5-yl)methyl) 4-cyclooctyl 2-methylenesuccinate;
 (R)-1-(2-(1H-tetrazol-5-yl)ethyl) 4-octan-2-yl 2-methylenesuccinate;
 (2R,3S)-2-acetamido-3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)butanoic acid;
 4-cyclooctyl 1-(3-(2-ethoxy-2-oxoethyl)oxetan-3-yl) 2-methylenesuccinate;
 4-(2-(methylsulfonyl)ethyl) 1-octyl 2-methyl-3-methylenesuccinate;
 20 1-octyl 4-((S)-tetrahydrofuran-3-yl) 2-methyl-3-methylenesuccinate;
 1-(1-(1H-tetrazol-5-yl)propan-2-yl) 4-((R)-octan-2-yl) 2-methylenesuccinate;
 1-(1-(1H-tetrazol-5-yl)propan-2-yl) 4-((S)-octan-2-yl) 2-methylenesuccinate;
 4-cyclohexyl 1-((2-methyl-2H-tetrazol-5-yl)methyl) 2-methylenesuccinate;
 4-cyclohexyl 1-((1-methyl-1H-tetrazol-5-yl)methyl) 2-methylenesuccinate;
 25 3-((4-(cyclooctyloxy)-2-methylene-4-oxobutanoyl)oxy)-4,4,4-trifluorobutanoic acid;
 2-(4-(cycloheptyloxy)-2-methylene-4-oxobutanoyloxy)acetic acid;
 2-(2-methylene-4-(octan-3-yloxy)-4-oxobutanoyloxy)acetic acid;
 2-(2-methylene-4-(octan-4-yloxy)-4-oxobutanoyloxy)acetic acid;
 2-((4-(heptan-4-yloxy)-2-methylene-4-oxobutanoyl)oxy) acetic acid;
 30 2-((4-((adamantan-2-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((4-(1-cyclohexylethoxy)-2-methylene-4-oxobutanoyl)oxy) acetic acid;
 2-((4-(1-cycloheptylethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-(2-methylene-4-oxo-4-(spiro[3.4]octan-2-yloxy)butanoyloxy)acetic acid;
 2-(2-methylene-4-oxo-4-(spiro[3.5]nonan-2-yloxy)butanoyloxy)acetic acid;
 35 2-(2-methylene-4-oxo-4-(spiro[3.5]nonan-7-yloxy)butanoyloxy)acetic acid;
 2-((4-((2,2-dimethylcyclohexyl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 bis((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-methylenesuccinate;

- 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-(2-oxaspiro[3.3]heptan-6-yl) 2-methylenesuccinate;
- 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-(oxepan-4-yl) 2-methylenesuccinate;
- 5 4-(1-butoxypropan-2-yl) 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 2-methylenesuccinate;
- 4-spiro[3.3]heptan-2-yl 1-(3,3,3-trifluoro-2,2-dihydroxypropyl) 2-methylenesuccinate hydrate;
- (*R*)-1-((2H-tetrazol-5-yl)methyl) 4-(octan-2-yl) 2-methylenesuccinate;
- 1-(2H-tetrazol-5-yl)methyl 4-cycloheptyl 2-methylenesuccinate;
- 10 1-(2H-tetrazol-5-yl)methyl 4-spiro[3.3]heptan-2-yl 2-methylenesuccinate;
- (*S*)-1-(2H-tetrazol-5-yl)methyl 4-octan-2-yl 2-methylenesuccinate;
- 1-(1-(1H-tetrazol-5-yl)ethyl) 4-((*S*)-octan-2-yl) 2-methylenesuccinate;
- 1-(cyclopropyl(1H-tetrazol-5-yl)methyl) 4-((*S*)-octan-2-yl) 2-methylenesuccinate;
- dicyclohexyl 2-methylenesuccinate;
- 15 2-((4-(cyclooctyloxy)-3-methyl-2-methylene-4-oxobutanoyl)oxy)acetic acid;
- 2-((2-methylene-4-oxo-4-(2,2,4,4-tetramethylcyclobutoxy)butanoyl)oxy)acetic acid;
- (*S*)-2-(2-methylene-4-(octan-3-yloxy)-4-oxobutanoyloxy)acetic acid;
- 2-((4-(cyclooctyloxy)-3-methoxy-2-methylene-4-oxobutanoyl)oxy)acetic acid;
- 2-((4-((-adamantan-1-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
- 20 (*R*)-2-((4-(heptan-2-yloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
- 2-((2-methylene-4-(nonan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid;
- 2-((2-methylene-4-(nonan-5-yloxy)-4-oxobutanoyl)oxy)acetic acid;
- 2-((4-(1-(3,5-dichlorophenyl)ethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
- 2-((4-((1-(3,5-dichlorophenyl)propan-2-yl)oxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
- 25 (*R*)-2-(2-methylene-4-(octan-3-yloxy)-4-oxobutanoyloxy)acetic acid;
- 2-((2-methylene-4-oxo-4-(((1*R*,2*S*,4*R*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)butanoyl)oxy)acetic acid;
- 2-((4-(1-cyclohexyl-2,2,2-trifluoroethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
- 2-((4-(bicyclo[3.3.1]nonan-9-yloxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
- 30 (*S*)-2-((2-methylene-4-oxo-4-((1,1,1-trifluorooctan-2-yl)oxy)butanoyl)oxy)acetic acid;
- (*R*)-2-((2-methylene-4-(nonan-2-yloxy)-4-oxobutanoyl)oxy)acetic acid;
- (*R*)-2-((4-(1-cyclohexylethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
- 1-(3,3-difluorocyclobutyl) 4-octyl 2-methylenesuccinate;
- 1-((endo)-3-(methylsulfonyl)-3-azabicyclo[3.2.1]octan-8-yl) 4-((*R*)-octan-2-yl) 2-
- 35 methylenesuccinate;
- (*R*)-4-(octan-2-yl) 1-((3-oxo-2,3-dihydroisoxazol-5-yl)methyl) 2-methylenesuccinate;
- (*R*)-4,4,4-trifluoro-3-((2-methylene-4-(((*R*)-octan-2-yl)oxy)-4-oxobutanoyl)oxy)butanoic acid;
- 2-((4-(cyclooctyloxy)-3-hydroxy-2-methylene-4-oxobutanoyl)oxy)acetic acid;

- 2-(3-methylene-5-(4-methylheptan-4-yloxy)-5-oxopent-1-en-2-yloxy)acetic acid;
 2-((4-(1-cyclohexylcyclobutoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((2-methylene-4-((2-methyloctan-2-yl)oxy)-4-oxobutanoyl)oxy)acetic acid;
 2-((2-methylene-4-((2-methylheptan-2-yl)oxy)-4-oxobutanoyl)oxy)acetic acid;
 5 2-((2-methylene-4-oxo-4-(1-pentylcyclobutoxy)butanoyl)oxy) acetic acid;
 2-((2-methylene-4-((2-methylspiro[3.5]nonan-2-yl)oxy)-4-oxobutanoyl)oxy)acetic acid;
 2-((2-methylene-4-oxo-4-(((exo)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)butanoyl)oxy)acetic acid;
 2-((2-methylene-4-oxo-4-((2,2,6,6-tetramethylcyclohexyl)oxy) butanoyl)oxy)acetic acid;
 10 2-((4-(1-(3,5-dichlorophenyl)ethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (Isomer 1);
 2-((4-(1-(3,5-dichlorophenyl)ethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid (Isomer 2);
 (R)-2-((2-methylene-4-oxo-4-(1-(4-(trifluoromethyl)phenyl)ethoxy)butanoyl) oxy) acetic acid);
 (S)-2-((2-methylene-4-oxo-4-(1-(4-(trifluoromethyl)phenyl)ethoxy)butanoyl) oxy) acetic acid);
 2-((4-(1-cyclohexylcyclopropoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 15 (S)-2-((4-(1-cyclohexylethoxy)-2-methylene-4-oxobutanoyl)oxy)acetic acid;
 2-((2-methylene-4-oxo-4-((2,2,4,4-tetramethylpentan-3-yl)oxy)butanoyl) oxy)acetic acid;
 (S)-4,4,4-trifluoro-3-((2-methylene-4-(((R)-octan-2-yl)oxy)-4-oxobutanoyl)oxy)butanoic acid;
 2-((2-methylene-4-oxo-4-(1-pentylcyclopropoxy)butanoyl)oxy) acetic acid; and
 3-((2-methylene-4-oxo-4-(2,2,4,4-tetramethylcyclobutoxy)butanoyl)oxy)propanoic acid;
 20 or a pharmaceutically acceptable salt and/or solvate of any one thereof.

23. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 22.

24. A compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 22 or a pharmaceutical composition according to claim 23 for use as a medicament.

25. A compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 22 or a pharmaceutical composition according to claim 23 for use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response, wherein the inflammatory disease or disease associated with an undesirable immune response is, or is associated with, a disease selected from the group consisting of: psoriasis (including chronic plaque, erythrodermic, pustular, guttate, inverse and nail variants), asthma, chronic obstructive pulmonary disease (COPD, including chronic bronchitis and emphysema), heart failure (including left ventricular failure), myocardial infarction, angina pectoris, other atherosclerosis and/or atherothrombosis-related disorders (including peripheral vascular disease and ischaemic stroke), a mitochondrial and neurodegenerative disease (such as Parkinson's

disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, retinitis pigmentosa or mitochondrial encephalomyopathy), autoimmune paraneoplastic retinopathy, transplantation rejection (including antibody-mediated and T cell-mediated forms), multiple sclerosis, transverse myelitis, ischaemia-reperfusion injury (e.g. during elective surgery such as cardiopulmonary bypass for coronary artery bypass grafting or other cardiac surgery, following percutaneous coronary intervention, following treatment of acute ST-elevation myocardial infarction or ischaemic stroke, organ transplantation, or acute compartment syndrome), AGE-induced genome damage, an inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), primary sclerosing cholangitis (PSC), PSC-autoimmune hepatitis overlap syndrome, non-alcoholic fatty liver disease (non-alcoholic steatohepatitis), rheumatica, granuloma annulare, cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), lupus nephritis, drug-induced lupus, autoimmune myocarditis or myopericarditis, Dressler's syndrome, giant cell myocarditis, post-pericardiotomy syndrome, drug-induced hypersensitivity syndromes (including hypersensitivity myocarditis), eczema, sarcoidosis, erythema nodosum, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorders, MOG (myelin oligodendrocyte glycoprotein) antibody-associated disorders (including MOG-EM), optic neuritis, CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids), diffuse myelinoclastic sclerosis, Addison's disease, alopecia areata, ankylosing spondylitis, other spondyloarthritides (including peripheral spondyloarthritis, that is associated with psoriasis, inflammatory bowel disease, reactive arthritis or juvenile onset forms), antiphospholipid antibody syndrome, autoimmune hemolytic anaemia, autoimmune hepatitis, autoimmune inner ear disease, pemphigoid (including bullous pemphigoid, mucous membrane pemphigoid, cicatricial pemphigoid, herpes gestationis or pemphigoid gestationis, ocular cicatricial pemphigoid), linear IgA disease, Behçet's disease, celiac disease, Chagas disease, dermatomyositis, diabetes mellitus type I, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome and its subtypes (including acute inflammatory demyelinating polyneuropathy, AIDP, acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), pharyngeal-cervical-brachial variant, Miller-Fisher variant and Bickerstaff's brainstem encephalitis), progressive inflammatory neuropathy, Hashimoto's disease, hidradenitis suppurativa, inclusion body myositis, necrotising myopathy, Kawasaki disease, IgA nephropathy, Henoch-Schonlein purpura, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura (TTP), Evans' syndrome, interstitial cystitis, mixed connective tissue disease, undifferentiated connective tissue disease, morphea, myasthenia gravis (including MuSK antibody positive and seronegative variants), narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, psoriatic arthritis, polymyositis, primary biliary cholangitis (also known as primary biliary cirrhosis), rheumatoid arthritis, palindromic rheumatism, schizophrenia, autoimmune (meningo-)encephalitis syndromes, scleroderma, Sjogren's syndrome, stiff person syndrome, polymyalgia rheumatica, giant cell arteritis (temporal arteritis), Takayasu arteritis,

polyarteritis nodosa, Kawasaki disease, granulomatosis with polyangiitis (GPA; formerly known as Wegener's granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome), microscopic polyarteritis/polyangiitis, hypocomplementaemic urticarial vasculitis, hypersensitivity vasculitis, cryoglobulinemia, thromboangiitis obliterans (Buerger's disease), vasculitis, leukocytoclastic vasculitis, vitiligo, acute disseminated encephalomyelitis, adrenoleukodystrophy, Alexander's disease, Alper's disease, Baló concentric sclerosis or Marburg disease, cryptogenic organising pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia), Canavan disease, central nervous system vasculitic syndrome, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic inflammatory demyelinating polyneuropathy (CIDP), diabetic retinopathy, globoid cell leukodystrophy (Krabbe disease), graft-versus-host disease (GVHD) (including acute and chronic forms, as well as intestinal GVHD), hepatitis C (HCV) infection or complication, herpes simplex viral infection or complication, human immunodeficiency virus (HIV) infection or complication, lichen planus, monomelic amyotrophy, cystic fibrosis, pulmonary arterial hypertension (PAH, including idiopathic PAH), lung sarcoidosis, idiopathic pulmonary fibrosis, paediatric asthma, atopic dermatitis, allergic dermatitis, contact dermatitis, allergic rhinitis, rhinitis, sinusitis, conjunctivitis, allergic conjunctivitis, keratoconjunctivitis sicca, dry eye, xerophthalmia, glaucoma, macular oedema, diabetic macular oedema, central retinal vein occlusion (CRVO), macular degeneration (including dry and/or wet age related macular degeneration, AMD), post-operative cataract inflammation, uveitis (including posterior, anterior, intermediate and pan uveitis), iridocyclitis, scleritis, corneal graft and limbal cell transplant rejection, gluten sensitive enteropathy (coeliac disease), dermatitis herpetiformis, eosinophilic esophagitis, achalasia, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, aortitis and periaortitis, autoimmune retinopathy, autoimmune urticaria, Behcet's disease, (idiopathic) Castleman's disease, Cogan's syndrome, IgG4-related disease, retroperitoneal fibrosis, juvenile idiopathic arthritis including systemic juvenile idiopathic arthritis (Still's disease), adult-onset Still's disease, ligneous conjunctivitis, Mooren's ulcer, pityriasis lichenoides et varioliformis acuta (PLEVA, also known as Mucha-Habermann disease), multifocal motor neuropathy (MMN), paediatric acute-onset neuropsychiatric syndrome (PANS) (including paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)), paraneoplastic syndromes (including paraneoplastic cerebellar degeneration, Lambert-Eaton myasthenic syndrome, limbic encephalitis, brainstem encephalitis, opsoclonus myoclonus ataxia syndrome, anti-NMDA receptor encephalitis, thymoma-associated multiorgan autoimmunity), perivenous encephalomyelitis, reflex sympathetic dystrophy, relapsing polychondritis, sperm & testicular autoimmunity, Susac's syndrome, Tolosa-Hunt syndrome, Vogt-Koyanagi-Harada Disease, anti-synthetase syndrome, autoimmune enteropathy, immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX), microscopic colitis, autoimmune lymphoproliferative syndrome

(ALPS), autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APEX), gout, pseudogout, amyloid (including AA or secondary amyloidosis), eosinophilic fasciitis (Shulman syndrome) progesterone hypersensitivity (including progesterone dermatitis), familial Mediterranean fever (FMF), tumour necrosis factor (TNF) receptor-associated periodic fever syndrome (TRAPS), hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS), PAPA (pyogenic arthritis, pyoderma gangrenosum, severe cystic acne) syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), deficiency of the interleukin-36-receptor antagonist (DITRA), cryopyrin-associated periodic syndromes (CAPS) (including familial cold autoinflammatory syndrome [FCAS], Muckle-Wells syndrome, neonatal onset multisystem inflammatory disease [NOMID]), NLRP12-associated autoinflammatory disorders (NLRP12AD), periodic fever aphthous stomatitis (PFAPA), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), Majeed syndrome, Blau syndrome (also known as juvenile systemic granulomatosis), macrophage activation syndrome, chronic recurrent multifocal osteomyelitis (CRMO), familial cold autoinflammatory syndrome, mutant adenosine deaminase 2 and monogenic interferonopathies (including Aicardi-Goutières syndrome, retinal vasculopathy with cerebral leukodystrophy, spondyloenchondrodysplasia, STING [stimulator of interferon genes]-associated vasculopathy with onset in infancy, proteasome associated autoinflammatory syndromes, familial chilblain lupus, dyschromatosis symmetrica hereditaria), Schnitzler syndrome; familial cylindromatosis, congenital B cell lymphocytosis, OTULIN-related autoinflammatory syndrome, type 2 diabetes mellitus, insulin resistance and the metabolic syndrome (including obesity-associated inflammation), atherosclerotic disorders (e.g. myocardial infarction, angina, ischaemic heart failure, ischaemic nephropathy, ischaemic stroke, peripheral vascular disease, aortic aneurysm), renal inflammatory disorders (e.g. diabetic nephropathy, membranous nephropathy, minimal change disease, crescentic glomerulonephritis, acute kidney injury, renal transplantation).

26. Use of a compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 22 or a pharmaceutical composition according to claim 23 in the manufacture of a medicament for treating or preventing an inflammatory disease or a disease associated with an undesirable immune response, wherein the inflammatory disease or disease associated with an undesirable immune response is, or is associated with, a disease selected from the group consisting of: psoriasis (including chronic plaque, erythrodermic, pustular, guttate, inverse and nail variants), asthma, chronic obstructive pulmonary disease (COPD, including chronic bronchitis and emphysema), heart failure (including left ventricular failure), myocardial infarction, angina pectoris, other atherosclerosis and/or atherothrombosis-related disorders (including peripheral vascular disease and ischaemic stroke), a mitochondrial and neurodegenerative disease (such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, retinitis pigmentosa or mitochondrial encephalomyopathy),


autoimmune paraneoplastic retinopathy, transplantation rejection (including antibody-mediated and T cell-mediated forms), multiple sclerosis, transverse myelitis, ischaemia-reperfusion injury (e.g. during elective surgery such as cardiopulmonary bypass for coronary artery bypass grafting or other cardiac surgery, following percutaneous coronary intervention, following treatment of acute ST-elevation myocardial infarction or ischaemic stroke, organ transplantation, or acute compartment syndrome), AGE-induced genome damage, an inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), primary sclerosing cholangitis (PSC), PSC-autoimmune hepatitis overlap syndrome, non-alcoholic fatty liver disease (non-alcoholic steatohepatitis), rheumatica, granuloma annulare, cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), lupus nephritis, drug-induced lupus, autoimmune myocarditis or myopericarditis, Dressler's syndrome, giant cell myocarditis, post-pericardiotomy syndrome, drug-induced hypersensitivity syndromes (including hypersensitivity myocarditis), eczema, sarcoidosis, erythema nodosum, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorders, MOG (myelin oligodendrocyte glycoprotein) antibody-associated disorders (including MOG-EM), optic neuritis, CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids), diffuse myelinoclastic sclerosis, Addison's disease, alopecia areata, ankylosing spondylitis, other spondyloarthritides (including peripheral spondyloarthritis, that is associated with psoriasis, inflammatory bowel disease, reactive arthritis or juvenile onset forms), antiphospholipid antibody syndrome, autoimmune hemolytic anaemia, autoimmune hepatitis, autoimmune inner ear disease, pemphigoid (including bullous pemphigoid, mucous membrane pemphigoid, cicatricial pemphigoid, herpes gestationis or pemphigoid gestationis, ocular cicatricial pemphigoid), linear IgA disease, Behçet's disease, celiac disease, Chagas disease, dermatomyositis, diabetes mellitus type I, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome and its subtypes (including acute inflammatory demyelinating polyneuropathy, AIDP, acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), pharyngeal-cervical-brachial variant, Miller-Fisher variant and Bickerstaff's brainstem encephalitis), progressive inflammatory neuropathy, Hashimoto's disease, hidradenitis suppurativa, inclusion body myositis, necrotising myopathy, Kawasaki disease, IgA nephropathy, Henoch-Schonlein purpura, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura (TTP), Evans' syndrome, interstitial cystitis, mixed connective tissue disease, undifferentiated connective tissue disease, morphea, myasthenia gravis (including MuSK antibody positive and seronegative variants), narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, psoriatic arthritis, polymyositis, primary biliary cholangitis (also known as primary biliary cirrhosis), rheumatoid arthritis, palindromic rheumatism, schizophrenia, autoimmune (meningo-)encephalitis syndromes, scleroderma, Sjogren's syndrome, stiff person syndrome, polymyalgia rheumatica, giant cell arteritis (temporal arteritis), Takayasu arteritis, polyarteritis nodosa, Kawasaki disease, granulomatosis with polyangiitis (GPA; formerly known as Wegener's granulomatosis),

eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome), microscopic polyarteritis/polyangiitis, hypocomplementaemic urticarial vasculitis, hypersensitivity vasculitis, cryoglobulinemia, thromboangiitis obliterans (Buerger's disease), vasculitis, leukocytoclastic vasculitis, vitiligo, acute disseminated encephalomyelitis, 5 adrenoleukodystrophy, Alexander's disease, Alper's disease, Baló concentric sclerosis or Marburg disease, cryptogenic organising pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia), Canavan disease, central nervous system vasculitic syndrome, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic inflammatory demyelinating polyneuropathy (CIDP), diabetic retinopathy, globoid cell 10 leukodystrophy (Krabbe disease), graft-versus-host disease (GVHD) (including acute and chronic forms, as well as intestinal GVHD), hepatitis C (HCV) infection or complication, herpes simplex viral infection or complication, human immunodeficiency virus (HIV) infection or complication, lichen planus, monomelic amyotrophy, cystic fibrosis, pulmonary arterial hypertension (PAH, including idiopathic PAH), lung sarcoidosis, idiopathic pulmonary fibrosis, paediatric asthma, 15 atopic dermatitis, allergic dermatitis, contact dermatitis, allergic rhinitis, rhinitis, sinusitis, conjunctivitis, allergic conjunctivitis, keratoconjunctivitis sicca, dry eye, xerophthalmia, glaucoma, macular oedema, diabetic macular oedema, central retinal vein occlusion (CRVO), macular degeneration (including dry and/or wet age related macular degeneration, AMD), post-operative cataract inflammation, uveitis (including posterior, anterior, intermediate and pan uveitis), 20 iridocyclitis, scleritis, corneal graft and limbal cell transplant rejection, gluten sensitive enteropathy (coeliac disease), dermatitis herpetiformis, eosinophilic esophagitis, achalasia, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, aortitis and periaortitis, autoimmune retinopathy, autoimmune urticaria, Behcet's disease, (idiopathic) Castleman's disease, Cogan's syndrome, IgG4-related disease, 25 retroperitoneal fibrosis, juvenile idiopathic arthritis including systemic juvenile idiopathic arthritis (Still's disease), adult-onset Still's disease, ligneous conjunctivitis, Mooren's ulcer, pityriasis lichenoides et varioliformis acuta (PLEVA, also known as Mucha-Habermann disease), multifocal motor neuropathy (MMN), paediatric acute-onset neuropsychiatric syndrome (PANS) (including paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)), 30 paraneoplastic syndromes (including paraneoplastic cerebellar degeneration, Lambert-Eaton myasthenic syndrome, limbic encephalitis, brainstem encephalitis, opsoclonus myoclonus ataxia syndrome, anti-NMDA receptor encephalitis, thymoma-associated multiorgan autoimmunity), perivenous encephalomyelitis, reflex sympathetic dystrophy, relapsing polychondritis, sperm & testicular autoimmunity, Susac's syndrome, Tolosa-Hunt syndrome, 35 Vogt-Koyanagi-Harada Disease, anti-synthetase syndrome, autoimmune enteropathy, immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX), microscopic colitis, autoimmune lymphoproliferative syndrome (ALPS), autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APEX), gout, pseudogout, amyloid (including AA or secondary

- amyloidosis), eosinophilic fasciitis (Shulman syndrome) progesterone hypersensitivity (including progesterone dermatitis), amilial Mediterranean fever (FMF), tumour necrosis factor (TNF) receptor-associated periodic fever syndrome (TRAPS), hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS), PAPA (pyogenic arthritis, pyoderma gangrenosum, severe cystic acne) syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), deficiency of the interleukin-36-receptor antagonist (DITRA), cryopyrin-associated periodic syndromes (CAPS) (including familial cold autoinflammatory syndrome [FCAS], Muckle-Wells syndrome, neonatal onset multisystem inflammatory disease [NOMID]), NLRP12-associated autoinflammatory disorders (NLRP12AD), periodic fever aphthous stomatitis (PFAPA), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), Majeed syndrome, Blau syndrome (also known as juvenile systemic granulomatosis), macrophage activation syndrome, chronic recurrent multifocal osteomyelitis (CRMO), familial cold autoinflammatory syndrome, mutant adenosine deaminase 2 and monogenic interferonopathies (including Aicardi-Goutières syndrome, retinal vasculopathy with cerebral leukodystrophy, spondyloenchondrodysplasia, STING [stimulator of interferon genes]-associated vasculopathy with onset in infancy, proteasome associated autoinflammatory syndromes, familial chilblain lupus, dyschromatosis symmetrica hereditaria), Schnitzler syndrome; familial cylindromatosis, congenital B cell lymphocytosis, OTULIN-related autoinflammatory syndrome, type 2 diabetes mellitus, insulin resistance and the metabolic syndrome (including obesity-associated inflammation), atherosclerotic disorders (e.g. myocardial infarction, angina, ischaemic heart failure, ischaemic nephropathy, ischaemic stroke, peripheral vascular disease, aortic aneurysm), renal inflammatory disorders (e.g. diabetic nephropathy, membranous nephropathy, minimal change disease, crescentic glomerulonephritis, acute kidney injury, renal transplantation).
27. The compound or pharmaceutical composition according to any one of claims 1 to 23, for use in combination with a further therapeutic agent, such as a corticosteroid (glucocorticoid), retinoid (e.g. acitretin, isotretinoin, tazarotene), anthralin, vitamin D analogue (e.g. calcitriol, calcipotriol), calcineurin inhibitors (e.g. tacrolimus, pimecrolimus), phototherapy or photochemotherapy (e.g. psoralen ultraviolet irradiation, PUVA) or other form of ultraviolet light irradiation therapy, ciclosporine, a thiopurine (e.g. azathioprine, 6-mercaptopurine), methotrexate, an anti-TNF α agents (e.g. infliximab, etanercept, adalimumab, certolizumab, golimumab or a biosimilar), phosphodiesterase-4 (PDE4) inhibition (e.g. apremilast, crisaborole), anti-IL-17 agent (e.g. brodalumab, ixekizumab, secukinumab), anti-IL12/IL-23 agent (e.g. ustekinumab, briakinumab), anti-IL-23 agent (e.g. guselkumab, tildrakizumab), JAK (Janus Kinase) inhibitor (e.g. tofacitinib, ruxolitinib, baricitinib, filgotinib, upadacitinib), plasma exchange, intravenous immune globulin (IVIG), cyclophosphamide, anti-CD20 B cell depleting agent (e.g. rituximab, ocrelizumab, ofatumumab, obinutuzumab), anthracycline analogue (e.g. mitoxantrone), cladribine, sphingosine 1-phosphate receptor modulator or sphingosine analogue (e.g.

fingolimod, siponimod, ozanimod, etrasimod), interferon beta preparation (including interferon beta 1b/1a), glatiramer, anti-CD3 therapy (e.g. OKT3), anti-CD52 targeting agent (e.g. alemtuzumab), leflunomide, teriflunomide, gold compound, laquinimod, potassium channel blocker (e.g. dalfampridine/4-aminopyridine), mycophenolic acid, mycophenolate mofetil, purine analogue (e.g. pentostatin), mTOR (mechanistic target of rapamycin) pathway inhibitor (e.g. sirolimus, everolimus), anti-thymocyte globulin (ATG), IL-2 receptor (CD25) inhibitor (e.g. basiliximab, daclizumab), anti-IL-6 receptor or anti-IL-6 agent (e.g. tocilizumab, siltuximab), Bruton's tyrosine kinase (BTK) inhibitor (e.g. ibrutinib), tyrosine kinase inhibitor (e.g. imatinib), ursodeoxycholic acid, hydroxychloroquine, chloroquine, B cell activating factor (BAFF, also known as BLyS, B lymphocyte stimulator) inhibitor (e.g. belimumab, blisibimod), other B cell targeted therapy including a fusion protein targeting both APRIL (A Proliferation-Inducing Ligand) and BLyS (e.g. atacicept), PI3K inhibitor including pan-inhibitor or one targeting the p110 δ and/or p110 γ containing isoforms (e.g. idelalisib, copanlisib, duvelisib), an interferon α receptor inhibitor (e.g. anifrolumab, sifalimumab), T cell co-stimulation blocker (e.g. abatacept, belatacept), thalidomide and its derivatives (e.g. lenalidomide), dapsone, clofazimine, a leukotriene antagonist (e.g. montelukast), theophylline, anti-IgE therapy (e.g. omalizumab), an anti-IL-5 agent (e.g. mepolizumab, reslizumab), a long-acting muscarinic agent (e.g. tiotropium, aclidinium, umeclidinium), a PDE4 inhibitor (e.g. roflumilast), riluzole, a free radical scavenger (e.g. edaravone), a proteasome inhibitor (e.g. bortezomib), a complement cascade inhibitor including one directed against C5 (e.g. eculizumab), immunoadsor, antithymocyte globulin, 5-aminosalicylates and their derivatives (e.g. sulfasalazine, balsalazide, mesalamine), an anti-integrin agent including one targeting $\alpha 4\beta 1$ and/or $\alpha 4\beta 7$ integrins (e.g. natalizumab, vedolizumab), an anti-CD11- α agent (e.g. efalizumab), a non-steroidal anti-inflammatory drug (NSAID) including a salicylate (e.g. aspirin), a propionic acid (e.g. ibuprofen, naproxen), an acetic acid (e.g. indomethacin, diclofenac, etodolac), an oxicam (e.g. meloxicam) a fenamate (e.g. mefenamic acid), a selective or relatively selective COX-2 inhibitor (e.g. celecoxib, etoricoxib, valdecoxib and etodolac, meloxicam, nabumetone), colchicine, an IL-4 receptor inhibitor (e.g. dupilumab), topical/contact immunotherapy (e.g. diphenylcyclopropenone, squaric acid dibutyl ester), anti-IL-1 receptor therapy (e.g. anakinra), IL-1 β inhibitor (e.g. canakinumab), IL-1 neutralising therapy (e.g. rilonacept), chlorambucil, a specific antibiotic with immunomodulatory properties and/or ability to modulate NRF2 (e.g. tetracyclines including minocycline, clindamycin, macrolide antibiotics), anti-androgenic therapy (e.g. cyproterone, spironolactone, finasteride), pentoxifylline, ursodeoxycholic acid, obeticholic acid, fibrate, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, a VEGF (vascular endothelial growth factor) inhibitor (e.g. bevacizumab, ranibizumab, pegaptanib, aflibercept), pirfenidone or mizoribine.

28. A compound which is:




wherein:

$R^{A'}$ is a protected derivative of R^A , or $R^{A'}$ is R^A wherein R^A is selected from the group consisting of C_{3-8} cycloalkyl, C_{5-10} spirocycloalkyl and 4–7 membered heterocyclyl, wherein R^A is optionally substituted as defined in any one of claims 1 to 17, or R^A is C_{1-8} alkyl which is substituted by one or more substituents as defined in any one of claims 1 to 17;


R^C and R^D are as defined in any one of claims 1 to 22;

or a salt thereof.

29. A compound which is selected from the group consisting of:



; and



;

wherein:

R^B is as defined in any one of claims 1 to 22;

R^C and R^D are as defined in any one of claims 1 to 22; and

PG is an oxygen protecting group;

or a salt thereof.

30. The compound or salt according to claim 28 selected from the group consisting of:

4-(cyclooctyloxy)-2-methylene-4-oxobutanoic acid;

2-methylene-4-oxo-4-(3-phenoxypropoxy)butanoic acid;

4-(2-(2-ethoxyethoxy)ethoxy)-2-methylene-4-oxobutanoic acid; and

4-((4-fluorobenzyl)oxy)-2-methylene-4-oxobutanoic acid;

or a salt of any one thereof.